1
00:00:13,780 --> 00:00:14,514
>> YES, THANKING.

2
00:00:14,581 --> 00:00:16,816
THANK YOU VERY MUCH.

3
00:00:16,883 --> 00:00:19,853
SO, WELCOME.

4
00:00:19,919 --> 00:00:21,121
SEEMS LIKE FOREVER SINCE WE'VE

5
00:00:21,187 --> 00:00:22,822
BEEN TOGETHER.

6
00:00:22,889 --> 00:00:28,194
I LOOK FORWARD TO AN IN-PERSON

7
00:00:28,261 --> 00:00:28,995
MEETING, HOPEFULLY SOON.

8
00:00:29,062 --> 00:00:30,497
AS COMMITTEE MEMBERS I WANT TO

9
00:00:30,563 --> 00:00:34,701
REMIND YOU THAT YOU MUST ABSENT

10
00:00:34,768 --> 00:00:36,736
YOURSELF DURING SPECIFIC

11
00:00:36,803 --> 00:00:38,438
DISCUSSIONS WHENEVER YOU'RE

12
00:00:38,505 --> 00:00:39,372
PARTICIPATION AND DELIBERATIONS

13
00:00:39,439 --> 00:00:41,875
OR A PARTICULAR PRODUCT,

14
00:00:41,941 --> 00:00:43,476
PROGRAM, OR ANY OTHER SPECIFIC

15
00:00:43,543 --> 00:00:46,446
MATTER CONSTITUTES A CONFLICT OF

16
00:00:46,513 --> 00:00:50,383
INTEREST, OR CREATES THE

17
00:00:50,450 --> 00:00:50,950
APPEARANCE OF 1.

18
00:00:51,017 --> 00:00:52,719
WE ALL KNOW WHEN WE'RE IN

19
00:00:52,786 --> 00:00:53,653
CONFLICT, SO PLEASE, IT'S REALLY

20
00:00:53,720 --> 00:00:55,655
UP TO YOU TO LET US KNOW IF YOU

21
00:00:55,722 --> 00:00:58,425
FEEL LIKE YOU'RE IN CONFLICT.

22
00:00:58,491 --> 00:00:59,459
IT'S INCUMBENT UPON EACH AND

23
00:00:59,526 --> 00:01:03,763
EVERY 1 OF US TO ADVISE THE

24
00:01:03,830 --> 00:01:05,732
EXECUTIVE SECRETARY

25
00:01:05,799 --> 00:01:06,966
DR. CHRISTOPHER KANE, AND

26
00:01:07,033 --> 00:01:07,834
ABSTAIN FROM WHETHER

27
00:01:07,901 --> 00:01:09,002
PARTICIPATION IN THE DISCUSSION

28
00:01:09,068 --> 00:01:13,740
OR ACTION  REGARDING THAT MATTE.

29
00:01:13,807 --> 00:01:16,609
IN KEEPING IN POLICIES GOVERNING

30
00:01:16,676 --> 00:01:19,412
CONFLICT OF INTEREST BASED ON

31
00:01:19,479 --> 00:01:20,980
FINANCIAL HOLDINGS OF SPECIAL

32
00:01:21,047 --> 00:01:21,915
GOVERNMENT EMPLOYEES WHICH

33
00:01:21,981 --> 00:01:24,918
CATEGORY INCLUDES ALL MEMBERS OF

34
00:01:24,984 --> 00:01:26,186
THIS COMMITTEE, WE REALLY MUST

35
00:01:26,252 --> 00:01:31,124
DEPEND ON YOU TO VOLUNTARILY

36
00:01:31,191 --> 00:01:32,058
ABSENT YOURSELF DURING ALL

37
00:01:32,125 --> 00:01:34,127
DISCUSSIONS OF MATTERS THAT

38
00:01:34,194 --> 00:01:35,495
WOULD CONCEIVABLY IMPACT THE

39
00:01:35,562 --> 00:01:37,697
STATUS OF THOSE HOLDINGS AND WE

40
00:01:37,764 --> 00:01:44,103
TRUST YOUR JUDGMENT IN THESE

41
00:01:44,170 --> 00:01:44,370
INSTANCES.

42
00:01:44,437 --> 00:01:46,339
WE ALL ARE VERY MUCH COGNIZANT

43
00:01:46,406 --> 00:01:48,508
OF THESE SORTS OF THINGS SO

44
00:01:48,575 --> 00:01:50,810
PLEASE LET DR. KANE KNOW IF

45
00:01:50,877 --> 00:01:51,878
THERE ARE ANY ISSUES.

46
00:01:51,945 --> 00:01:54,147
MEMBERS OF THE PUBLIC WHO MAY

47
00:01:54,214 --> 00:01:57,317
WISH TO EXPRESS VIEWS REGARDING

48
00:01:57,383 --> 00:01:58,651
ANY ITEMS DISCUSSED DURING

49
00:01:58,718 --> 00:02:00,820
TODAY'S MEETING MAY DO SO BY

50
00:02:00,887 --> 00:02:03,590
WRITING DR. CAIN, THE EXECUTIVE

51
00:02:03,656 --> 00:02:04,724
COMMITTEE WITHIN 10 DAYS AFTER

52
00:02:04,791 --> 00:02:06,025
THE MEETING AND ANY WRITTEN

53
00:02:06,092 --> 00:02:07,760
STATEMENTS BY MEMBERS OF THE

54
00:02:07,827 --> 00:02:11,931
PUBLIC WILL RECEIVE CAREFUL

55
00:02:11,998 --> 00:02:12,265
CONSIDERATION.

56
00:02:12,332 --> 00:02:14,067
BY LAW A QUORUM OF COMMITTEE

57
00:02:14,133 --> 00:02:15,802
MEMBERS IS REQUIRED FOR INSTANCE

58
00:02:15,869 --> 00:02:19,806
IN WHICH A VOTE OCCURS.

59
00:02:19,873 --> 00:02:21,441
DURING TODAY'S MEETING A MINIMUM

60
00:02:21,508 --> 00:02:23,810
OF 8 APPOINTED MEMBERS MUST BE

61
00:02:23,877 --> 00:02:25,111
PRESENT TO VOICE THEIR VOTES

62
00:02:25,178 --> 00:02:29,616
SINCE WE CANNOT PREDICT THE TIME

63
00:02:29,682 --> 00:02:31,017
OR OCCURRENCE OR EMOTION, YOUR

64
00:02:31,084 --> 00:02:34,120
PRESENCE AND A MUST FOR AUGUST

65
00:02:34,187 --> 00:02:34,821
SEGMENT ANDS MEETINGS.

66
00:02:34,888 --> 00:02:37,190
SO CHRIS, DO WE HAVE A QUORUM.

67
00:02:37,257 --> 00:02:39,125
>> WE HAVE ACHIEVED A QUORUM.

68
00:02:39,192 --> 00:02:39,425
>> GREAT.

69
00:02:39,492 --> 00:02:43,696
THANK YOU VERY MUCH.

70
00:02:43,763 --> 00:02:46,332
I NOW--OUR MINUTES ARE ENCLOSED,

71
00:02:46,399 --> 00:02:47,200
HOPEFULLY YOU'VE ALL HAD A

72
00:02:47,267 --> 00:02:50,537
CHANCE TO TAKE A LOOK AT THEM.

73
00:02:50,603 --> 00:02:51,905
ARE THERE ANY CORRECTIONS OR ANY

74
00:02:51,971 --> 00:02:54,707
ISSUES WITH THE MINUTES AND IF

75
00:02:54,774 --> 00:02:56,609
NOT, I WOULD LIKE A MOTION TO

76
00:02:56,676 --> 00:02:58,912
APPROVE THE MINUTES OF THE

77
00:02:58,978 --> 00:03:07,020
OCTOBER 19th 2023 MEETING.

78
00:03:07,086 --> 00:03:07,320
>> SECOND.

79
00:03:07,387 --> 00:03:09,789
>> THANK YOU.

80
00:03:09,856 --> 00:03:10,890
THANKS.

81
00:03:10,957 --> 00:03:11,724
OKAY.

82
00:03:11,791 --> 00:03:13,893
SO THOSE MINUTES--ALL THOSE IN

83
00:03:13,960 --> 00:03:15,728
FAVOR, JUST RAISE YOUR HAND?

84
00:03:15,795 --> 00:03:19,165
ANYONE OPPOSED TO THE APPROVAL

85
00:03:19,232 --> 00:03:19,732
OF THE MINUTES?

86
00:03:19,799 --> 00:03:21,000
THANK YOU VERY MUCH.

87
00:03:21,067 --> 00:03:23,436
I WOULD ALSO LIKE TO CONFIRM THE

88
00:03:23,503 --> 00:03:25,939
FUTURE MEETING DATES AND CALL

89
00:03:26,005 --> 00:03:27,574
YOUR ATTENTION TO THE MEETINGS

90
00:03:27,640 --> 00:03:28,641
LISTED IN THE AGENDA.

91
00:03:28,708 --> 00:03:32,512
YOU CAN SEE THE LIST AND THE

92
00:03:32,579 --> 00:03:34,213
FNLAC MEETING IN JULY IS

93
00:03:34,280 --> 00:03:35,748
CURRENTLY PLANNED AS AN

94
00:03:35,815 --> 00:03:37,350
IN-PERSON MEETING SO IT WILL BE

95
00:03:37,417 --> 00:03:39,485
FUN FOR ALL OF US TO ACTUALLY

96
00:03:39,552 --> 00:03:40,720
GET TO SEE ETCH - OTHER IN

97
00:03:40,787 --> 00:03:43,156
PERSON AS WE'VE BEEN LOOKING AT

98
00:03:43,222 --> 00:03:44,357
OUR LITTLE SQUARES OF PICTURES

99
00:03:44,424 --> 00:03:45,959
FOR TOO MANY MEETINGS.

100
00:03:46,025 --> 00:03:52,765
SO, WE LOOK FORWARD TO THAT.

101
00:03:52,832 --> 00:03:54,167
AND WITH THAT, UNLESS THERE'S

102
00:03:54,233 --> 00:03:56,002
ANY OTHER BUSINESS, WE WILL GO

103
00:03:56,069 --> 00:03:58,404
DIRECTLY TO THE NCI DIRECTOR'S

104
00:03:58,471 --> 00:04:04,911
REPORT AND DR. RATHMELL.

105
00:04:04,978 --> 00:04:06,145
>> GREAT, THANK YOU VERY MUCH.

106
00:04:06,212 --> 00:04:07,847
IT'S NICE TO BE HERE, I'M ALSO

107
00:04:07,914 --> 00:04:09,349
LOOKING FORWARD TO MEETING YOU

108
00:04:09,415 --> 00:04:10,149
ALL IN PERSON.

109
00:04:10,216 --> 00:04:11,618
I WANT TO TART BY THANKING

110
00:04:11,684 --> 00:04:13,219
EVERYONE FOR THE TIME AND EFFORT

111
00:04:13,286 --> 00:04:14,621
AND FOR BEING HERE AND THANK YOU

112
00:04:14,687 --> 00:04:18,124
FOR THE PEOPLE WATCHING ONLINE

113
00:04:18,191 --> 00:04:19,792
AS WELL, I THINK WE'RE REALLY

114
00:04:19,859 --> 00:04:22,095
TRYING TO OPEN UP THE DOORS TO

115
00:04:22,161 --> 00:04:23,296
COMMUNICATION AND SO, THIS IS

116
00:04:23,363 --> 00:04:27,133
HOW WE DO IT BEST.

117
00:04:27,200 --> 00:04:28,401
I'M REALLY THRILLED TO BE IN

118
00:04:28,468 --> 00:04:31,938
THIS ROLE AND HEARING FROM ALL

119
00:04:32,005 --> 00:04:33,706
OF YOU, PARTICULARLY AT THE

120
00:04:33,773 --> 00:04:34,707
FREDERICK NATIONAL LAB.

121
00:04:34,774 --> 00:04:37,610
THIS IS A UNIQUE RESOURCE THAT

122
00:04:37,677 --> 00:04:39,112
DOES INCREDIBLE AND IMPORTANT

123
00:04:39,178 --> 00:04:40,380
WORK IN THE PROGRESS AGAINST

124
00:04:40,446 --> 00:04:41,681
CANCER AND YOUR INPUT IS

125
00:04:41,748 --> 00:04:45,251
INVALENTINED AUTOMOBILE.

126
00:04:45,318 --> 00:04:47,887
SO NEXT SLIDE WILL--SORRYI HOPE

127
00:04:47,954 --> 00:04:50,823
IT'S NOT TOO LONG, THERE'S SOME

128
00:04:50,890 --> 00:04:51,991
MECHANICAL SOUND THAT DECIDED TO

129
00:04:52,058 --> 00:04:53,226
JOIN ME IN MY ROOM.

130
00:04:53,292 --> 00:04:55,094
SO IT IS WHAT IT IS.

131
00:04:55,161 --> 00:04:57,497
SO TODAY'S TALK, I WILL GIVE YOU

132
00:04:57,563 --> 00:04:58,564
A BRIEF INTRODUCTION TO WHO I

133
00:04:58,631 --> 00:05:00,099
AM, HOW I THINK SO YOU CAN START

134
00:05:00,166 --> 00:05:03,136
TO GET TO KNOW ME A LITTLE BIT

135
00:05:03,202 --> 00:05:03,670
AS WELL.

136
00:05:03,736 --> 00:05:05,438
TOPIC OF THE DAY AROUND HERE IS

137
00:05:05,505 --> 00:05:06,639
BUDGET AND WE'LL TALK A LITTLE

138
00:05:06,706 --> 00:05:07,907
BIT ABOUT THE BUDGET OUTLOOK,

139
00:05:07,974 --> 00:05:09,776
JUST SO YOU KNOW WHERE THAT ALL

140
00:05:09,842 --> 00:05:11,077
STANDS AND THEN TALK ABOUT

141
00:05:11,144 --> 00:05:13,379
RESEARCH HIGHLIGHTS AND

142
00:05:13,446 --> 00:05:14,514
HOPEFULLY HAVE TIME FOR SOME

143
00:05:14,580 --> 00:05:18,317
QUESTION AND ANSWER AS WELL.

144
00:05:18,384 --> 00:05:18,985
SO NEXT SLIDE.

145
00:05:19,052 --> 00:05:23,156
OKAY, SO A BIT ABOUT ME, SO I AM

146
00:05:23,222 --> 00:05:24,357
ORIGINALLY FROM THE MIDWEST,

147
00:05:24,424 --> 00:05:25,992
GREW UP IN NEBRASKA AND IOWA, I

148
00:05:26,059 --> 00:05:30,963
WENT ON TO DO MY MD-Ph.D.,

149
00:05:31,030 --> 00:05:31,898
Ph.D. IN BIOPHYSICS AT

150
00:05:31,964 --> 00:05:33,533
STANFORD, I'M A SCIENTIST THAT'S

151
00:05:33,599 --> 00:05:34,967
INTERESTED IN MOLECULAR PATHWAYS

152
00:05:35,034 --> 00:05:35,268
AND CANCER.

153
00:05:35,334 --> 00:05:37,970
I'M ALSO A CLINICIAN, MEDICAL

154
00:05:38,037 --> 00:05:39,505
ONCOLOGIST AND I SEE--MY FOCUS

155
00:05:39,572 --> 00:05:41,374
HAS BEEN ON KIDNEY CANCER

156
00:05:41,441 --> 00:05:41,741
PATIENTS.

157
00:05:41,808 --> 00:05:44,243
I ALSO FOUND A PASSION EARLY IN

158
00:05:44,310 --> 00:05:47,613
MY CAREER AT UNC CHAPEL HILL IN

159
00:05:47,680 --> 00:05:49,449
EDUCATION WORKING WITH THE

160
00:05:49,515 --> 00:05:50,950
MD-Ph.D. PROGRAM AND ASSOCIATE

161
00:05:51,017 --> 00:05:51,918
DIRECTOR FOR EDUCATION AND

162
00:05:51,984 --> 00:05:55,088
TRAINING IN THAT CANCER CENTER.

163
00:05:55,154 --> 00:05:57,056
THAT GOT ME AND PUTTING ALL THAT

164
00:05:57,123 --> 00:06:00,193
TOGETHER, THE 3 LEGS OF THE

165
00:06:00,259 --> 00:06:01,127
ACADEMIC TRIANGLE RESEARCH,

166
00:06:01,194 --> 00:06:03,663
CLINICAL AND EDUCATION ON TO THE

167
00:06:03,730 --> 00:06:05,064
ADMIN TRAITIVE PATH AND LED ME

168
00:06:05,131 --> 00:06:08,568
TO MOVE TO VANDERBILT 8 YEARS

169
00:06:08,634 --> 00:06:11,604
AGO WHERE I WAS HEMEATOLOGY AND

170
00:06:11,671 --> 00:06:12,672
DIVISION ONCOLOGY CHIEF AND THEN

171
00:06:12,739 --> 00:06:15,174
4 YEARS AGO MOVED INTO CHAIRING

172
00:06:15,241 --> 00:06:15,908
THE DEPARTMENT OF MEDICINE JUST

173
00:06:15,975 --> 00:06:18,244
IN TIME FOR THE PANDEMIC SO I

174
00:06:18,311 --> 00:06:21,881
LEARNED LOTS OF GOOD OPERATIONAL

175
00:06:21,948 --> 00:06:22,815
SKILLS ACTUALLY ENOUGH THAT

176
00:06:22,882 --> 00:06:25,151
PROMPTED ME TO GO INTO LEARNING

177
00:06:25,218 --> 00:06:28,421
MORE ABOUT MANAGEMENT AND

178
00:06:28,488 --> 00:06:30,456
ADMINISTRATION AND TO GET A

179
00:06:30,523 --> 00:06:32,191
MASTERS DEGREE IN 2022 IN THE

180
00:06:32,258 --> 00:06:35,128
OWENS SCHOOL OF BUSINESS.

181
00:06:35,194 --> 00:06:37,196
SO WITH THAT, WITH SOME

182
00:06:37,263 --> 00:06:38,698
EXPERIENCES IN MY CAREER THAT

183
00:06:38,765 --> 00:06:40,600
HAVE TAUGHT ME THE VALUE IN

184
00:06:40,666 --> 00:06:41,934
ADVOCACY AND IN LEADERSHIP AND

185
00:06:42,001 --> 00:06:45,404
IN TEAMS, WHICH IS THE

186
00:06:45,471 --> 00:06:48,574
BASKETBALL PLAYER ANALOGY THERE,

187
00:06:48,641 --> 00:06:50,243
I THINK I'M SERVING VERY WELL.

188
00:06:50,309 --> 00:06:51,778
AS I MOVED INTO THE ROLE, THE

189
00:06:51,844 --> 00:06:53,079
STAFF ARE AMAZING AND I'M REALLY

190
00:06:53,146 --> 00:06:54,647
HAVING A GOOD TIME LOOKING AT

191
00:06:54,714 --> 00:06:56,582
THE WHOLE LANDSCAPE OF THE NCI.

192
00:06:56,649 --> 00:06:59,619
SO WHAT DO I VALUE, I REALLY

193
00:06:59,685 --> 00:07:01,020
VALUE LISTENING AND OPENNESS.

194
00:07:01,087 --> 00:07:05,191
THIS IS A GREAT FORUM TO

195
00:07:05,258 --> 00:07:06,459
EXCHANGE INFORMATION AND

196
00:07:06,526 --> 00:07:08,194
THROUGHOUT--I WILL BE WITH YOU

197
00:07:08,261 --> 00:07:10,029
ALL DAY LONG AND WE'LL BE

198
00:07:10,096 --> 00:07:11,764
LISTENING TO THE PRESENTATIONS

199
00:07:11,831 --> 00:07:12,665
AND YOUR COMMENTS AS WELL AS

200
00:07:12,732 --> 00:07:14,167
QUESTIONS THAT YOU ASK, I REALLY

201
00:07:14,233 --> 00:07:18,004
WANT TO KNOW WHAT IS ON PEOPLE'S

202
00:07:18,070 --> 00:07:18,337
MINDS.

203
00:07:18,404 --> 00:07:20,640
I REALLY VALUE TEAM WORK AND

204
00:07:20,706 --> 00:07:21,240
COLLABORATION, THE BASKETBALL

205
00:07:21,307 --> 00:07:23,209
ANALOGY THERE, I LIKE TO USE

206
00:07:23,276 --> 00:07:24,477
BASKETBALL TO YOU KNOW DIVE INTO

207
00:07:24,544 --> 00:07:29,248
ALL OF THE COMPONENTS ABOUT

208
00:07:29,315 --> 00:07:30,416
DEFINITION AND EVERYONE KNOWS

209
00:07:30,483 --> 00:07:32,084
THEIR PART ON THE TEAM, THE

210
00:07:32,151 --> 00:07:32,785
DIVERSITY THAT'S REQUIRED TO

211
00:07:32,852 --> 00:07:34,220
MAKE A GOOD TEAM AND GET IN THE

212
00:07:34,287 --> 00:07:35,521
ZONE AND EXECUTE IN THE FINAL

213
00:07:35,588 --> 00:07:36,823
MINUTES OF THE GAME.

214
00:07:36,889 --> 00:07:40,459
I'M VERY EXCITED TO PUT MY

215
00:07:40,526 --> 00:07:42,228
BRACKET TOGETHER IN A WEEK OR

216
00:07:42,295 --> 00:07:42,562
SO.

217
00:07:42,628 --> 00:07:44,430
AND I REALLY LIKE SOLVING

218
00:07:44,497 --> 00:07:50,002
COMPLEX PROBLEMS, THIS CAN BE

219
00:07:50,069 --> 00:07:50,636
UNTANGLING COMPLICATED MECHANISM

220
00:07:50,703 --> 00:07:55,741
IN A CELL TO WORKING ON A SYSTEM

221
00:07:55,808 --> 00:08:00,313
WIDE OPERATIONAL CHALLENGE.

222
00:08:00,379 --> 00:08:02,715
AND SO, I'M HAVING A GREAT TIME

223
00:08:02,782 --> 00:08:04,784
IN GOVERNMENT REALLY WORKING AT

224
00:08:04,851 --> 00:08:05,418
UNTANGLING THINGS.

225
00:08:05,484 --> 00:08:08,054
SO THAT'S WHO I AM.

226
00:08:08,120 --> 00:08:11,157
LET'S SEE, SO I THOUGHT I WOULD

227
00:08:11,224 --> 00:08:13,125
TELL A LITTLE BIT OF A DIFFERENT

228
00:08:13,192 --> 00:08:14,894
STORY FROM SOME OF THE OTHER

229
00:08:14,961 --> 00:08:17,063
OVERVIEW PRESENTATIONS I'VE

230
00:08:17,129 --> 00:08:17,263
DONE.

231
00:08:17,330 --> 00:08:20,967
LOOKING AT WHERE THE PIVOTAL

232
00:08:21,033 --> 00:08:22,468
EVENTS IN MY CAREER AS A

233
00:08:22,535 --> 00:08:25,538
SCIENTIST OR A CLINICIAN THAT

234
00:08:25,605 --> 00:08:27,740
REALLY COULD TIE WELL TO THE

235
00:08:27,807 --> 00:08:29,308
FREDERICK NATIONAL LAB.

236
00:08:29,375 --> 00:08:30,943
AND I REALIZE THAT A BIG PIVOT

237
00:08:31,010 --> 00:08:34,280
FOR ME WAS THE CANCER GENOME

238
00:08:34,347 --> 00:08:36,182
ATLAS WHICH RELIED HEAVRY ON

239
00:08:36,249 --> 00:08:39,585
RESOURCES OF THE FREDERICK

240
00:08:39,652 --> 00:08:40,019
NATIONAL LAB.

241
00:08:40,086 --> 00:08:41,821
I WAS AT UNC CHAPEL HILL AT THE

242
00:08:41,888 --> 00:08:43,923
TIME WHICH WAS DOING THE

243
00:08:43,990 --> 00:08:45,324
TRANSCRIPT ANALYSIS AND WAS

244
00:08:45,391 --> 00:08:46,926
INVOLVED AS A TISSUE SOURCE SITE

245
00:08:46,993 --> 00:08:48,961
ACROSS THE BOARD BUT WAS VERY

246
00:08:49,028 --> 00:08:51,430
LUCKY TO BE TAPPED TO BE A

247
00:08:51,497 --> 00:08:52,999
LEADER FOR THE 3 DIFFERENT

248
00:08:53,065 --> 00:08:53,733
KIDNEY CANCER PROJECTS.

249
00:08:53,799 --> 00:08:55,902
I WOULD SAY THOSE PROJECTS

250
00:08:55,968 --> 00:08:58,070
REALLY FOR ME HELPED ME SEE

251
00:08:58,137 --> 00:09:00,072
KIDNEY CANCER IN A DIFFERENT

252
00:09:00,139 --> 00:09:01,774
WAY, REALLY TOOK US IN A

253
00:09:01,841 --> 00:09:03,276
DIFFERENT DIRECTION TO WHAT WE

254
00:09:03,342 --> 00:09:04,810
WERE STUDYING IN THE KIDNEY

255
00:09:04,877 --> 00:09:06,979
CANCER ARENA AND WHAT I'VE SHOWN

256
00:09:07,046 --> 00:09:08,547
HERE IS IN OF THE LANDMARK

257
00:09:08,614 --> 00:09:10,683
PAPERS THAT CAME FROM THE CANCER

258
00:09:10,750 --> 00:09:11,984
GENOME ATLAS THAT WE WERE PART

259
00:09:12,051 --> 00:09:14,287
OF OR HAD THE OPPORTUNITY TO

260
00:09:14,353 --> 00:09:17,390
HELP LEAD AND THE TRAINEES OF MY

261
00:09:17,456 --> 00:09:19,692
LAB WHO ALL--THEIR CAREERS WERE

262
00:09:19,759 --> 00:09:21,160
ALSO SHAPED BY THEIR EXPERIENCE

263
00:09:21,227 --> 00:09:24,897
OF BEING MAJOR PARTS OF THE

264
00:09:24,964 --> 00:09:26,432
CANCER DENOAM ATLAS AND

265
00:09:26,499 --> 00:09:27,400
DIFFERENT PROJECTS ON THIS, SO

266
00:09:27,466 --> 00:09:29,568
EACH OF THEM HAD AN OPPORTUNITY

267
00:09:29,635 --> 00:09:33,005
TO COME OF AGE, TO BE

268
00:09:33,072 --> 00:09:35,041
CONTRIBUTING ON A PEER TO PEER

269
00:09:35,107 --> 00:09:36,309
LEVEL ON A REALLY IMPORTANT PART

270
00:09:36,375 --> 00:09:38,945
OF EACH OF THESE PROJECTS.

271
00:09:39,011 --> 00:09:41,614
SO, THIS IS AN EXAMPLE, AND I

272
00:09:41,681 --> 00:09:42,915
HAVE JUST AN EXAMPLE, TO PUSH

273
00:09:42,982 --> 00:09:44,684
THE BUTTON AND MOVE THE SLIDE.

274
00:09:44,750 --> 00:09:47,386
CAN YOU MOVE THE SLIDE,A HEAD OF

275
00:09:47,453 --> 00:09:49,789
WHAT THE TCGA, YOU KNOW YOU ALL

276
00:09:49,855 --> 00:09:51,991
PROBABLY USE THE TCGA OR WERE

277
00:09:52,058 --> 00:09:53,960
INVOLVED IN IT, YOU KNOW THE

278
00:09:54,026 --> 00:09:57,964
REAL VALUE IN SCIENCE, A

279
00:09:58,030 --> 00:09:58,631
NATIONWIDE EFFORT GALVANIZED

280
00:09:58,698 --> 00:10:00,533
AROUND THIS, I THINK THE ABILITY

281
00:10:00,599 --> 00:10:02,935
TO SEE TUMORS FOR THEIR MORE

282
00:10:03,002 --> 00:10:03,869
COMPLETE IDENTITY AS WE GAVE

283
00:10:03,936 --> 00:10:05,671
THEM A WHOLE MOLECULAR CONTEXT,

284
00:10:05,738 --> 00:10:07,606
A LOT MORE COLLABORATIONS, I

285
00:10:07,673 --> 00:10:09,442
KNOW, BUT I KNOW THIS WAS TRUE

286
00:10:09,508 --> 00:10:10,977
FOR EVERYONE STARTED TO WORK

287
00:10:11,043 --> 00:10:12,244
WITH DIFFERENT PEOPLE AND

288
00:10:12,311 --> 00:10:14,080
DIFFERENT KINDS OF PEOPLE,

289
00:10:14,146 --> 00:10:15,414
DISCOVERING NEW AREAS OF WORK,

290
00:10:15,481 --> 00:10:18,517
WE OPENED TONS AND TONS OF DOORS

291
00:10:18,584 --> 00:10:20,720
AND THAT'S JUST ACCELERATES AND

292
00:10:20,786 --> 00:10:21,954
MOVES CANCER RESEARCH FORWARD

293
00:10:22,021 --> 00:10:23,356
AND DEVELOPED A GENERATION OF

294
00:10:23,422 --> 00:10:25,858
SCIENTISTS WHO EXPECT THIS AS

295
00:10:25,925 --> 00:10:26,058
WELL.

296
00:10:26,125 --> 00:10:27,426
SO WITH THAT EXAMPLE, GO AHEAD

297
00:10:27,493 --> 00:10:31,697
TO THE NEXT SLIDE.

298
00:10:31,764 --> 00:10:34,100
I THOUGHT I WOULD JUST KIND OF

299
00:10:34,166 --> 00:10:35,301
SET THAT STAGE THAT THIS IS THE

300
00:10:35,368 --> 00:10:37,169
KIND OF THING THAT WE CAN DO

301
00:10:37,236 --> 00:10:38,604
WITH A FEDERALLY FUNDED RESEARCH

302
00:10:38,671 --> 00:10:41,440
AND DEVELOPMENT CENTER ASK WHERE

303
00:10:41,507 --> 00:10:42,708
IT HAS REALLY SHINED.

304
00:10:42,775 --> 00:10:43,909
I HAVE GREAT EXAMPLES WE WILL

305
00:10:43,976 --> 00:10:46,445
GIVE LATER IN THE TALK, ABOUT TO

306
00:10:46,512 --> 00:10:48,514
LET YOU KNOW, THIS IS--YOU

307
00:10:48,581 --> 00:10:50,282
PROBABLY KNOW MORE THAN ME, THIS

308
00:10:50,349 --> 00:10:52,051
IS A BIG CONTRACT ORGANIZATION,

309
00:10:52,118 --> 00:10:56,822
WE ARE IN THE MIDDLE OF THE

310
00:10:56,889 --> 00:10:57,790
RECOMPETE FOR THIS CONTRACT.

311
00:10:57,857 --> 00:10:59,592
YOU WILL HEAR MORE ABOUT THAT A

312
00:10:59,658 --> 00:11:01,093
LITTLE BIT LATER ON THIS

313
00:11:01,160 --> 00:11:02,828
AFTERNOON WITH THE NEGOTIATIONS

314
00:11:02,895 --> 00:11:05,331
ACTIVELY GOING SO THAT WE CAN

315
00:11:05,398 --> 00:11:07,500
MOVE THIS INTO ITS NEXT PHASE.

316
00:11:07,566 --> 00:11:10,803
ALL RIGHT, NEXT SLIDE.

317
00:11:10,870 --> 00:11:13,806
OKAY, LET'S TALK ABOUT BUDGETS.

318
00:11:13,873 --> 00:11:14,373
SO NEXT SLIDE.

319
00:11:14,440 --> 00:11:18,577
SO THIS IS WHEREY --WHERE WE ARE

320
00:11:18,644 --> 00:11:21,313
TODAY, SO WE HAVE AVERTED SHUT

321
00:11:21,380 --> 00:11:22,715
DOWNS OVER AND OVER AGAIN

322
00:11:22,782 --> 00:11:23,816
INCLUDING LAST FRIDAY AND NOW

323
00:11:23,883 --> 00:11:25,084
HALF OF THE BUDGET HAS BEEN

324
00:11:25,151 --> 00:11:27,386
PASSED BUT WE ARE IN THE SECOND

325
00:11:27,453 --> 00:11:27,720
HALF.

326
00:11:27,787 --> 00:11:29,722
I HAVE A SLIDE ON THAT IN JUST A

327
00:11:29,789 --> 00:11:32,358
SECOND EMPLOY BUT WE'RE LOOKING

328
00:11:32,425 --> 00:11:34,427
AT MARCH 22nd AS OUR NEXT

329
00:11:34,493 --> 00:11:35,628
DEADLINE, THIS WILL BE FULLY

330
00:11:35,694 --> 00:11:37,963
HALFWAY THROUGH OUR FISCAL YEAR,

331
00:11:38,030 --> 00:11:38,564
WITHOUT A BUDGET.

332
00:11:38,631 --> 00:11:41,067
WE'VE BEEN WORKING ON A SET OF

333
00:11:41,133 --> 00:11:43,135
INTERIM GRANT POLICIES THAT WERE

334
00:11:43,202 --> 00:11:45,004
BASED ON THE ASSUMPTION THAT OUR

335
00:11:45,071 --> 00:11:46,972
BUDGET WOULD LIKE BE LIKE LAST

336
00:11:47,039 --> 00:11:48,774
YEAR, WE WILL MAKE FINAL,A

337
00:11:48,841 --> 00:11:50,476
JUSTMENTS AS SOON AS WE KNOW

338
00:11:50,543 --> 00:11:51,644
WHAT OUR APPROPRIATIONS WILL BE.

339
00:11:51,710 --> 00:11:53,012
I WILL SAY I'M VERY EXCITED TO

340
00:11:53,079 --> 00:11:54,947
BE ABLE TO NOT JUST TALK ABOUT

341
00:11:55,014 --> 00:11:57,249
WHAT WE MIGHT DO OR MIGHT NOT

342
00:11:57,316 --> 00:11:59,118
DO, TO WHAT WILL WE BE ABLE TO

343
00:11:59,185 --> 00:12:03,189
DO WHEN WE HAVE A BUDGET TO WORK

344
00:12:03,255 --> 00:12:03,756
WITH.

345
00:12:03,823 --> 00:12:04,924
NEXT SLIDE.

346
00:12:04,990 --> 00:12:06,225
YEAH, THIS JUST GETS A LITTLE

347
00:12:06,292 --> 00:12:09,795
BIT INTO THE WEEDS OF THIS SO

348
00:12:09,862 --> 00:12:12,631
MARCH 8th WAS THE FIRST ISSUE

349
00:12:12,698 --> 00:12:14,467
OF APPROPRIATION BILLS AND THEY

350
00:12:14,533 --> 00:12:16,769
WERE PASSED SO NOW WE'RE LOOKING

351
00:12:16,836 --> 00:12:17,503
AT MARCH 22nd.

352
00:12:17,570 --> 00:12:19,672
WE'RE STILL LUMPED IN WITH

353
00:12:19,738 --> 00:12:20,272
HOMELAND SECURITY, DEFENSE, ET

354
00:12:20,339 --> 00:12:20,506
CETERA.

355
00:12:20,573 --> 00:12:23,642
SO WE WILL BE WATCHING THIS VERY

356
00:12:23,709 --> 00:12:25,144
CLOSELY, AND YOU KNOW REALLY,

357
00:12:25,211 --> 00:12:30,883
WOOING TOGETHER TO MAKE SURE

358
00:12:30,950 --> 00:12:31,684
THAT APPROPRIATORS KNOW HOW

359
00:12:31,750 --> 00:12:34,887
IMPORTANT IT IS TO SUPPORT

360
00:12:34,954 --> 00:12:35,354
CANCER RESEARCH.

361
00:12:35,421 --> 00:12:36,522
I WILL SAY I'VE BEEN DOING ALL

362
00:12:36,589 --> 00:12:42,294
THAT I CAN TO REALLY SUPPORT

363
00:12:42,361 --> 00:12:43,496
THEIR KNOWLEDGE OF WHATIA GOING

364
00:12:43,562 --> 00:12:44,930
ON AT THE NCI.

365
00:12:44,997 --> 00:12:46,532
I'VE BEEN MEETING WITH PEOPLE,

366
00:12:46,599 --> 00:12:50,102
TRYING TO INSURE THAT WE HAVE

367
00:12:50,169 --> 00:12:51,036
GREAT RELATIONSHIPS AND

368
00:12:51,103 --> 00:12:51,604
UNDERSTANDING.

369
00:12:51,670 --> 00:12:53,873
I CAN SAY THAT EVERYONE THAT I

370
00:12:53,939 --> 00:12:55,641
HAVE MET WITH HAS BEEN

371
00:12:55,708 --> 00:12:57,943
SUPPORTIVE AND HOPEFULLY WE WILL

372
00:12:58,010 --> 00:12:59,645
HAVE A BUDGET TO SUPPORT THE

373
00:12:59,712 --> 00:13:04,316
IMPORTANT WORK THAT WE DO HERE.

374
00:13:04,383 --> 00:13:06,752
NEXT SLIDE.

375
00:13:06,819 --> 00:13:08,254
OKAY, SO WHEREVER WE SPEND OUR

376
00:13:08,320 --> 00:13:09,822
MONEY IS IN THIS VARIETY OF

377
00:13:09,889 --> 00:13:10,256
THINGS.

378
00:13:10,322 --> 00:13:14,260
WE HAVE ABOUT 3-QUARTERS OF OUR

379
00:13:14,326 --> 00:13:17,696
FUNDINGS THAT WE THE NCI TO DO

380
00:13:17,763 --> 00:13:20,633
RESEARCH, GRANT CENTERS, ET

381
00:13:20,699 --> 00:13:22,668
CETERA, ABOUT A QUARTER STAYS IN

382
00:13:22,735 --> 00:13:23,302
THE INTRAMURAL PROGRAM,

383
00:13:23,369 --> 00:13:25,771
INCLUDING THE SUPPORT FOR THE

384
00:13:25,838 --> 00:13:26,438
WHOLE GRANTS ADMINITRATION

385
00:13:26,505 --> 00:13:32,778
PROCESS IS IN THAT PART AS WELL

386
00:13:32,845 --> 00:13:35,548
SO, IT'S A LOT OF KNCHT

387
00:13:35,614 --> 00:13:36,949
COMPETING FORCES, ALL OF WHICH

388
00:13:37,016 --> 00:13:39,718
NEED TO BE MANAGED SO THAT WE

389
00:13:39,785 --> 00:13:42,721
HAVE GREAT PORTFOLIO AND THE

390
00:13:42,788 --> 00:13:44,490
FNLAC IS PART OF THAT.

391
00:13:44,557 --> 00:13:44,924
NEXT SLIDE.

392
00:13:44,990 --> 00:13:48,460
SO WHAT WOULD IT COST TO DO THIS

393
00:13:48,527 --> 00:13:51,297
WORK IN SO OUR APPROPRIATION

394
00:13:51,363 --> 00:13:52,464
LAST YEAR WAS 7.3 BILLION

395
00:13:52,531 --> 00:13:55,301
DOLLARS AND AS YOU KNOW THAT

396
00:13:55,367 --> 00:13:57,937
REALLY JUST COVERS THE WORK THAT

397
00:13:58,003 --> 00:13:58,537
WE'RE DOING.

398
00:13:58,604 --> 00:14:01,140
I THINK 1 THING I DIDN'T POINT

399
00:14:01,207 --> 00:14:02,675
OUT ON THAT SLIDE BEFORE WAS

400
00:14:02,741 --> 00:14:04,610
EVERY YEAR, THERE ARE INCREASED

401
00:14:04,677 --> 00:14:06,845
COSTS, NO MATTER WHAT WE DO,

402
00:14:06,912 --> 00:14:08,347
THERE'S ALWAYS INCREASED COST OF

403
00:14:08,414 --> 00:14:10,216
ABOUT A HUNDRED MILLION DOLLARS

404
00:14:10,282 --> 00:14:11,417
IN MANDATORY EXPENSES JUST TO

405
00:14:11,483 --> 00:14:13,485
KEEP FUNDING AT THE CURRENT RATE

406
00:14:13,552 --> 00:14:17,623
OF OUR GRANTS IS AN INCREASED

407
00:14:17,690 --> 00:14:18,157
250 MILLION.

408
00:14:18,224 --> 00:14:19,291
IN THE INTRAMURAL PROGRAM ALONE,

409
00:14:19,358 --> 00:14:25,264
THE INCREASE IN COST OF LIVING

410
00:14:25,331 --> 00:14:27,633
ADJUSTMENT WAS OVER

411
00:14:27,700 --> 00:14:28,467
40 MILLION-DOLLAR.

412
00:14:28,534 --> 00:14:29,068
SO IT'S--IT'SAN EXPENSIVE

413
00:14:29,134 --> 00:14:30,135
BUSINESS AND WE WILL LIKE TO DO

414
00:14:30,202 --> 00:14:32,204
MORE, SO WE HAVE THE OPPORTUNITY

415
00:14:32,271 --> 00:14:34,373
EVERY YEAR TO PROVIDE

416
00:14:34,440 --> 00:14:35,641
PROFESSIONAL JUDGMENT OF WHAT

417
00:14:35,708 --> 00:14:36,942
WOULD IT COST TO DO THE WORK

418
00:14:37,009 --> 00:14:39,278
THAT WE ARE WANTING TO BE ABLE

419
00:14:39,345 --> 00:14:40,679
TO DO, THIS IS NOT EVERYTHING WE

420
00:14:40,746 --> 00:14:42,147
DO BUT OF THE THINGS THAT ARE

421
00:14:42,214 --> 00:14:43,749
EXPECTED OF US.

422
00:14:43,816 --> 00:14:45,684
AND FY24, THAT PROFESSIONAL

423
00:14:45,751 --> 00:14:47,419
JUDGMENT WAS 9.9 BILLION

424
00:14:47,486 --> 00:14:48,954
DOLLARS, THE PRESIDENT

425
00:14:49,021 --> 00:14:50,155
RECOMMENDED 7.8.

426
00:14:50,222 --> 00:14:52,124
WE'RE STILL WAITING TILL

427
00:14:52,191 --> 00:14:57,129
MARCH 22nd OR HOPEFULLY BEFORE

428
00:14:57,196 --> 00:14:58,464
THAT TO KNOW.

429
00:14:58,530 --> 00:15:02,468
BASED ON THE EXPECTATION OF A

430
00:15:02,534 --> 00:15:04,436
9.9 BILLION DOLLAR BUDGET, WE

431
00:15:04,503 --> 00:15:06,939
LOOKED AT WHAT WOULD IT COST TO

432
00:15:07,006 --> 00:15:08,841
TO GROW AT THAT KIND OF RATE AND

433
00:15:08,907 --> 00:15:10,142
THAT WOULD BE LISTEN BILLION

434
00:15:10,209 --> 00:15:11,777
DOLLARS, WE'RE WAITING TO SEE

435
00:15:11,844 --> 00:15:12,578
THE PRESIDENT'S PROPOSAL WILL

436
00:15:12,645 --> 00:15:14,480
COME OUT SOON AND OF COURSE,

437
00:15:14,546 --> 00:15:18,317
FY25 WILL BE WATCHING VERY

438
00:15:18,384 --> 00:15:18,550
CLOSELY.

439
00:15:18,617 --> 00:15:23,856
SO THIS IS WHERE WE ARE.

440
00:15:23,922 --> 00:15:25,157
THANK YOU FOR MOVING THE SLIDE.

441
00:15:25,224 --> 00:15:28,394
WHAT WOULD WE DO IF WE HAD THE

442
00:15:28,460 --> 00:15:29,561
FUNDINGS THAT WE'VE PROPOSED IN

443
00:15:29,628 --> 00:15:30,929
THE PROFESSIONAL JUDGMENT, WE

444
00:15:30,996 --> 00:15:34,266
WOULD REALLY PUSH HARD ON CANCER

445
00:15:34,333 --> 00:15:35,000
CLINICAL TRIALS, REALLY

446
00:15:35,067 --> 00:15:36,402
REVOLUTIONIZING THE WORK WE DO

447
00:15:36,468 --> 00:15:38,003
THERE, GETTING THINGS OUT INTO

448
00:15:38,070 --> 00:15:38,971
THE ENVIRONMENT, ACTUALLY

449
00:15:39,038 --> 00:15:40,973
LOOKING AT ENVIRONMENTAL EFFECTS

450
00:15:41,040 --> 00:15:42,107
ON CANCER RISK.

451
00:15:42,174 --> 00:15:43,509
DOING MORE WITH DATA, MOVERRING

452
00:15:43,575 --> 00:15:45,377
MORE DATA INTO THE CLOUD AND

453
00:15:45,444 --> 00:15:50,316
INTEGRATING DATA SETS TOGETHER

454
00:15:50,382 --> 00:15:52,551
AND UNRAVELING MORE OF THE

455
00:15:52,618 --> 00:15:53,252
INTRICACIES OF CANCER.

456
00:15:53,319 --> 00:15:55,020
SO WITH A FLAT BUDGET, IT'S

457
00:15:55,087 --> 00:16:00,726
REALLY NOT FLAT, THAT'S THE NEXT

458
00:16:00,793 --> 00:16:00,926
SLIDE.

459
00:16:00,993 --> 00:16:03,362
SORRY, GO AHEAD TO THE NEXT

460
00:16:03,429 --> 00:16:03,562
SLIDE.

461
00:16:03,629 --> 00:16:05,497
OH, SORRY, I SKIPPED A SLIDE.

462
00:16:05,564 --> 00:16:06,932
NO, GO AHEAD TO THE 1 WITH THE

463
00:16:06,999 --> 00:16:07,166
GRAPHS.

464
00:16:07,232 --> 00:16:10,669
I FORGOT ABOUT THAT SLIDE.

465
00:16:10,736 --> 00:16:14,306
SO WE'VE BEEN VERY FORTUNATE TO

466
00:16:14,373 --> 00:16:16,809
BE INCREASING OUR BUDGET OR OUR

467
00:16:16,875 --> 00:16:17,676
APPROPRIATION YEAR OVER YEAR AS

468
00:16:17,743 --> 00:16:20,245
YOU CAN SEE ON THE GRAPH ON THE

469
00:16:20,312 --> 00:16:23,349
LEFT AND THE AFFECT THEN IS THE

470
00:16:23,415 --> 00:16:24,550
EXPECT AGZ THAT WE WILL CONTINUE

471
00:16:24,616 --> 00:16:26,485
TO GROW MORE AWARD ANDS CONTINUE

472
00:16:26,552 --> 00:16:27,686
TO GROW THE WHOLE INTRAIZ OF

473
00:16:27,753 --> 00:16:28,620
CANCER RESEARCH FOR THE ENTIRE

474
00:16:28,687 --> 00:16:30,689
UNITED STATES AND THAT HAS BEEN

475
00:16:30,756 --> 00:16:31,790
TRUE, YEAR OVER YEAR, I JUST

476
00:16:31,857 --> 00:16:34,093
WANT TO MAKE SURE THAT THAT'S

477
00:16:34,159 --> 00:16:35,594
VERY CLEAR, THAT'S ALL THERE IN

478
00:16:35,661 --> 00:16:38,530
THE BLUE AND YOU CAN SEE THAT

479
00:16:38,597 --> 00:16:41,734
THAT'S RISEN YEAR OVER YEAR.

480
00:16:41,800 --> 00:16:43,936
WITH EVERY YEAR, THE SIZE OF THE

481
00:16:44,002 --> 00:16:45,471
GRANTS GO UP, SO THE NUMBER OF

482
00:16:45,537 --> 00:16:46,705
DOLLARS THAT GOES INTO EACH

483
00:16:46,772 --> 00:16:50,042
GRANT GETS MORE AND MORE AND SO

484
00:16:50,109 --> 00:16:51,210
TO CONTINUE THIS TRAJECTORY, IT

485
00:16:51,276 --> 00:16:52,978
DOESN'T TAKE AN ECONOMICS DEGREE

486
00:16:53,045 --> 00:16:58,250
TO KNOW THIS WILL COST MORE

487
00:16:58,317 --> 00:17:00,586
COMPARED TO WHAT WE HAD THE YEAR

488
00:17:00,652 --> 00:17:00,819
BEFORE.

489
00:17:00,886 --> 00:17:04,723
NEXT SLIDE.

490
00:17:04,790 --> 00:17:06,125
SO WE'RE EXPECTING OR MODELING

491
00:17:06,191 --> 00:17:07,960
ON A FLAT BUDGET, BUT A FLAT

492
00:17:08,026 --> 00:17:11,330
BUDGET AS A SAID IS NOT TRULY

493
00:17:11,397 --> 00:17:12,331
FLAT.

494
00:17:12,398 --> 00:17:15,901
THERE ARE MANDATORY EXTENSE

495
00:17:15,968 --> 00:17:17,770
PENSS THAT INCREASE, INCREASE TO

496
00:17:17,836 --> 00:17:18,604
COSTS AND RPG POOLS AND WHAT

497
00:17:18,670 --> 00:17:21,407
WILL HAVE TO GIVE, TELLING YOU

498
00:17:21,473 --> 00:17:24,276
THE LEVERS WE HAVE TO PULL, OF

499
00:17:24,343 --> 00:17:25,544
COURSE HOLD THE PAY LINE AND

500
00:17:25,611 --> 00:17:30,749
LOOK AT THAT AS A LEVER WHICH I

501
00:17:30,816 --> 00:17:34,086
HOPE TO BE ABLE TO MAINTAIN,

502
00:17:34,153 --> 00:17:38,957
OTHER PROJECTS IN THE INTRAMURAL

503
00:17:39,024 --> 00:17:41,059
PROGRAM AND IN THE EXTRAMURAL

504
00:17:41,126 --> 00:17:42,995
PROGRAM AS LWE'RE LOOKING AT

505
00:17:43,061 --> 00:17:45,464
BUDGET REDUCKS AND CONTRACT

506
00:17:45,531 --> 00:17:46,732
UTILIZEITION THAT'S DIFFERENT

507
00:17:46,799 --> 00:17:47,933
CONTRACTORS THAT THAN THE

508
00:17:48,000 --> 00:17:48,767
FREDERICK CONTRACT BUT THIS IS

509
00:17:48,834 --> 00:17:50,536
AN AREA THAT WE'RE REALLY

510
00:17:50,602 --> 00:17:51,470
FOCUSING ON BECAUSE CONTRACT

511
00:17:51,537 --> 00:17:53,105
WORK CAN BE MORE EXPENSIVE THAN

512
00:17:53,172 --> 00:17:55,374
TRANSLATIONAL RESEARCH DEGZAL

513
00:17:55,441 --> 00:17:56,775
HIRES:  AND WE ARE CURRENTLY

514
00:17:56,842 --> 00:17:58,110
JUST SO YOU KNOW WHERE THINGS

515
00:17:58,177 --> 00:18:01,113
ARE AT THE NCI, WE HAVE PAUSED

516
00:18:01,180 --> 00:18:03,182
HIRING FOR THE MOMENT.

517
00:18:03,248 --> 00:18:06,151
SO THAT WE CAN GET A REAL GOOD

518
00:18:06,218 --> 00:18:07,920
LOOK AT WHAT WE'RE DOING IN

519
00:18:07,986 --> 00:18:08,487
TERMS OF HIRING.

520
00:18:08,554 --> 00:18:18,030
ALL RIGHT, NEXT SLIDE.

521
00:18:18,096 --> 00:18:19,064
OKAY, IF YOU WANT MORE

522
00:18:19,131 --> 00:18:20,466
INFORMATION ABOUT THE BUDGET, WE

523
00:18:20,532 --> 00:18:22,434
TRY TO BE AS TRANSPARENT ABOUT

524
00:18:22,501 --> 00:18:24,069
THE FUNDS WE GET AND WHERE THEY

525
00:18:24,136 --> 00:18:24,236
GO.

526
00:18:24,303 --> 00:18:26,305
THERE ARE SEVERAL GOOD RESOURCES

527
00:18:26,371 --> 00:18:27,506
ONLINE AND INCLUDING GOOD VIDEOS

528
00:18:27,573 --> 00:18:30,342
IF YOU WANT TO TAKE A LOOK, THIS

529
00:18:30,409 --> 00:18:30,909
IS THAT CONTENT.

530
00:18:30,976 --> 00:18:34,313
ALL RIGHT, NEXT SLIDE.

531
00:18:34,379 --> 00:18:37,850
OKAY, SO THAT'S BUDGET.

532
00:18:37,916 --> 00:18:38,917
LET'S TALK ABOUT--A LITTLE BIT

533
00:18:38,984 --> 00:18:40,219
MORE HOW WE'RE MAKING DECISIONS

534
00:18:40,285 --> 00:18:41,553
AND THINKING ABOUT THINGS HERE

535
00:18:41,620 --> 00:18:42,387
AT THE NCI.

536
00:18:42,454 --> 00:18:44,456
SO THE NATIONAL CANCER PLAN WAS

537
00:18:44,523 --> 00:18:48,594
INTRODUCED ALMOST EXACTLY A YEAR

538
00:18:48,660 --> 00:18:50,295
AGO AS A CONCEPTUAL FRAMEWORK TO

539
00:18:50,362 --> 00:18:51,430
THINK ABOUT THE WAY THAT WE

540
00:18:51,497 --> 00:18:55,868
THINK ABOUT CANCER WITH 8 GOALS,

541
00:18:55,934 --> 00:18:57,803
PREVENTING CANCER, DETECTING

542
00:18:57,870 --> 00:18:58,837
CANCERS EARLY, DEVELOPING

543
00:18:58,904 --> 00:19:00,372
TREATMENTS AND DELIVERING

544
00:19:00,439 --> 00:19:04,409
OPTIMAL CARE, MAXIMIZE DATA

545
00:19:04,476 --> 00:19:05,110
UTILITY, ELIMINATE INEQUITS,

546
00:19:05,177 --> 00:19:06,411
OPTIMIZE THE WORKFORCE, AND

547
00:19:06,478 --> 00:19:07,446
ENGAGE EVERY PERSON.

548
00:19:07,513 --> 00:19:09,748
WITH THESE WHOLISTIC GOALS BEING

549
00:19:09,815 --> 00:19:10,949
HOW WE MAKE THE ADVANCED

550
00:19:11,016 --> 00:19:12,217
PROGRESS WE WANT TO MAKE THIS

551
00:19:12,284 --> 00:19:14,887
END CANCER AS WE KNOW IT.

552
00:19:14,953 --> 00:19:17,456
IT TIES CLOSELY TO THE CANCER

553
00:19:17,523 --> 00:19:19,424
MOONSHOT, IT WAS REVIEWED BY THE

554
00:19:19,491 --> 00:19:20,592
PRESIDENT'S CANCER PANEL WHICH

555
00:19:20,659 --> 00:19:23,529
GAVE AN ASSESSMENT FOR EACH GOAL

556
00:19:23,595 --> 00:19:27,366
AND A SERIES OF RECOMMENDATIONS

557
00:19:27,432 --> 00:19:27,799
AS WELL.

558
00:19:27,866 --> 00:19:28,867
NEXT SLIDE.

559
00:19:28,934 --> 00:19:30,102
SO THE CANCER MOONSHOT, HOW DOES

560
00:19:30,168 --> 00:19:32,771
THIS TIE TO THE CANCER MOONSHOT

561
00:19:32,838 --> 00:19:34,606
WITH A ROADMAP LIKE THE NATIONAL

562
00:19:34,673 --> 00:19:35,741
CANCER PLAN, WE KNOW WHAT WE

563
00:19:35,807 --> 00:19:37,142
NEED TO DO TO MOVE FORWARD.

564
00:19:37,209 --> 00:19:40,779
YOU THINK ABOUT THIS LIKE A GAME

565
00:19:40,846 --> 00:19:41,847
PLAN AND A BASKETBALL GAME BUT

566
00:19:41,914 --> 00:19:43,148
THE MOON SHOT IS WHERE WE NEED

567
00:19:43,215 --> 00:19:44,483
TO BE, THE SCORE WE NEED TO

568
00:19:44,550 --> 00:19:47,786
ACHIEVE TO WIN AT THE END, THE

569
00:19:47,853 --> 00:19:49,454
GOAL THAT WE'RE AIMING TOWARD IS

570
00:19:49,521 --> 00:19:52,424
REDUCING U.S. CANCER MORTALITY

571
00:19:52,491 --> 00:19:57,930
BY 50%, BY 20  2047 AND IMPROVIG

572
00:19:57,996 --> 00:19:59,097
THE EXPERIENCE OF PEOPLE AND

573
00:19:59,164 --> 00:20:00,299
THEIR FAMILIES LIVING WITH

574
00:20:00,365 --> 00:20:01,500
CANCER AND SURVIVING CANCER.

575
00:20:01,567 --> 00:20:07,673
SO ENDING CAPSER AS --CANCER ASE

576
00:20:07,739 --> 00:20:08,040
KNOW IT.

577
00:20:08,106 --> 00:20:09,841
TALK ABOUT THE WINS.

578
00:20:09,908 --> 00:20:11,410
IT IS REMARKABLY POWERFUL TO

579
00:20:11,476 --> 00:20:15,247
HAVE ADVOCACY LIKE WE HAVE FROM

580
00:20:15,314 --> 00:20:18,450
THE WHITE HOUSE AND THE BACKING

581
00:20:18,517 --> 00:20:19,651
TO REALLY BE--TRYING TO DO BOLD

582
00:20:19,718 --> 00:20:21,186
THINGS IN A CANCER ARENA, THAT

583
00:20:21,253 --> 00:20:23,822
IS WHERE I'M HERE AND WHY I'M

584
00:20:23,889 --> 00:20:24,790
REALLY EXCITED ABOUT THIS.

585
00:20:24,856 --> 00:20:27,092
SO WE'VE BEEN DOING THESE TALKS

586
00:20:27,159 --> 00:20:31,196
WITH BIG RECENT WINS, THERE ARE

587
00:20:31,263 --> 00:20:32,497
MULTIPLE AND THERE'S ALWAYS A

588
00:20:32,564 --> 00:20:33,632
HUNDRED DIFFERENT THINGS WE

589
00:20:33,699 --> 00:20:37,169
COULD CHOOSE FROM TO TALK ABOUT

590
00:20:37,235 --> 00:20:38,670
HOW AMAZING THE SCIENCE IS, BUT

591
00:20:38,737 --> 00:20:40,405
I THOUGHT WE WOULD PULL

592
00:20:40,472 --> 00:20:41,473
SPECIFICALLY TO LOOK AT WEENKS

593
00:20:41,540 --> 00:20:44,376
THAT HAVE COME FROM THE

594
00:20:44,443 --> 00:20:48,380
FREDERICK NATIONAL LAB.

595
00:20:48,447 --> 00:20:51,016
SO, FIRST, JUST THE RAS PROJECT,

596
00:20:51,083 --> 00:20:51,249
RIGHT?

597
00:20:51,316 --> 00:20:53,251
NOW REALLY COWL MIN 8ING WITH A

598
00:20:53,318 --> 00:20:57,055
FIRST IN CLASS DIRECT INHIBITOR

599
00:20:57,122 --> 00:20:58,457
OF KRAS G12 C, THAT'S BEEN

600
00:20:58,523 --> 00:21:00,125
DEVELOPED WITH THE RAS

601
00:21:00,192 --> 00:21:05,097
INITIATIVE AND IN CLINICAL

602
00:21:05,163 --> 00:21:06,431
TRIALS.

603
00:21:06,498 --> 00:21:10,802
AND CLEARED FDA IN MORE CLINICAL

604
00:21:10,869 --> 00:21:11,837
TRIALS--EXCUSE ME.

605
00:21:11,903 --> 00:21:14,139
WE'RE ALSO SEEING MORE

606
00:21:14,206 --> 00:21:15,407
RANDOMIZED CLINICAL TRIALS ON

607
00:21:15,474 --> 00:21:16,475
HPV VACCINE IN PARTICULAR AND

608
00:21:16,541 --> 00:21:20,679
THIS WAS JUST PUBLISHED, A LARGE

609
00:21:20,746 --> 00:21:22,848
COLLABORATION LOOKING AT SINGLE

610
00:21:22,914 --> 00:21:24,583
DOSING OF HPV WHICH COULD BE A

611
00:21:24,650 --> 00:21:26,451
GAME CHANGER IN TERMS OF GETTING

612
00:21:26,518 --> 00:21:28,420
MORE VACCINE INTO MORE PATIENTS

613
00:21:28,487 --> 00:21:31,790
AND REDUCING THE GLOBAL IMPACT

614
00:21:31,857 --> 00:21:34,393
OF HPV-DRIVEN CANCERS.

615
00:21:34,459 --> 00:21:38,063
WE ALSO HAVE A NUMBER OF BIG

616
00:21:38,130 --> 00:21:39,765
DATA INITIATIVES, REALLY FITTING

617
00:21:39,831 --> 00:21:41,767
WITH THE MAXIMIZING DATA UTILITY

618
00:21:41,833 --> 00:21:43,368
GOAL OF THE NATIONAL CANCER

619
00:21:43,435 --> 00:21:47,105
PLAN, BUT LOOKING AT AI OF FOR

620
00:21:47,172 --> 00:21:48,373
ENDOMEETRIAL CANCER SO THIS IS A

621
00:21:48,440 --> 00:21:50,776
GREAT TIEWPT TO LACK AT AN

622
00:21:50,842 --> 00:21:52,611
UNDERSERVED CANCER THAT HAS

623
00:21:52,678 --> 00:21:53,445
TRADITIONALLY HAD A PRETTY POOR

624
00:21:53,512 --> 00:21:55,447
OUTCOME AND BE ABLE TO CLOSE

625
00:21:55,514 --> 00:21:57,649
GAPS THAT ARE RELATIVE TO

626
00:21:57,716 --> 00:21:59,985
DISPARITIES AS WELL AS MAJOR

627
00:22:00,052 --> 00:22:00,652
SOURCE OF MORTALITY.

628
00:22:00,719 --> 00:22:02,854
YOU WILL HEAR MORE ABOUT THE AI

629
00:22:02,921 --> 00:22:06,625
WORK LATER IN THE PRESENTATIONS

630
00:22:06,692 --> 00:22:07,025
TODAY.

631
00:22:07,092 --> 00:22:09,261
WE ALSO HAVE NEW COLLABORATIONS

632
00:22:09,327 --> 00:22:11,797
ON ANTIBODY AND DRUG CONJUGATES,

633
00:22:11,863 --> 00:22:14,800
REALLY A NEW FRONTIER IN

634
00:22:14,866 --> 00:22:16,068
DEVELOPING BIOPHARMACEUTICAL

635
00:22:16,134 --> 00:22:17,703
ANDS THIS WHERE FREDERICK

636
00:22:17,769 --> 00:22:19,104
NATIONAL LAB CAN REALLY SHINE,

637
00:22:19,171 --> 00:22:20,405
MAKING NEW TREATMENTS WITH FEWER

638
00:22:20,472 --> 00:22:22,340
SIDE EFFECTS THAT CAN TARGET

639
00:22:22,407 --> 00:22:25,877
SOME OF THE MORE RECALCITRANT

640
00:22:25,944 --> 00:22:30,415
CANCERS AND THE FIRST ADC

641
00:22:30,482 --> 00:22:31,817
TARGETING THE C-PROTEIN IS

642
00:22:31,883 --> 00:22:33,085
MOVING INTO CLINICAL TRIALS

643
00:22:33,151 --> 00:22:34,453
WITHIN THE NEXT YEAR OR SO AND

644
00:22:34,519 --> 00:22:36,154
YOU WILL HEAR MORE ABOUT THIS IN

645
00:22:36,221 --> 00:22:36,955
THE NEXT PRESENTATION.

646
00:22:37,022 --> 00:22:39,057
AND THEN I ALSO WANT TO JUST

647
00:22:39,124 --> 00:22:40,258
POINT OUT THAT FREDERICK

648
00:22:40,325 --> 00:22:43,395
NATIONAL LABS IS PARTNERING WITH

649
00:22:43,462 --> 00:22:45,263
THE AMERICAN CANCER SOCIETY AND

650
00:22:45,330 --> 00:22:47,232
CANCER RESEARCH UK TO PUT

651
00:22:47,299 --> 00:22:49,901
TOGETHER THE FIRST U.S. BLACK IN

652
00:22:49,968 --> 00:22:50,469
CANCER MEETING.

653
00:22:50,535 --> 00:22:52,437
THIS IS HAPPENING IN UNI.

654
00:22:52,504 --> 00:22:55,006
I AM REALLY EXCITED THAT THIS IS

655
00:22:55,073 --> 00:22:55,941
KNOW INITIATIVE THAT FREDERICK

656
00:22:56,007 --> 00:22:57,375
NATIONAL LAB IS TAKING ON, THE

657
00:22:57,442 --> 00:22:59,444
BLACK IN CANCER MOVEMENT WAS

658
00:22:59,511 --> 00:23:02,748
TART AS A SOCIAL MEDIA EFFORT

659
00:23:02,814 --> 00:23:05,450
AND HAS REALLY GALVANIZED AND

660
00:23:05,517 --> 00:23:08,954
GOTTEN MORE INVESTIGATORS

661
00:23:09,020 --> 00:23:10,055
ATTRACTED TO CONSIDERING THE

662
00:23:10,122 --> 00:23:10,856
CAREER IN CANCER.

663
00:23:10,922 --> 00:23:13,358
WE NEED A DIVERSE TALENT POOL

664
00:23:13,425 --> 00:23:16,361
AND AN ONGOING DEVELOPED

665
00:23:16,428 --> 00:23:17,929
PIPELINE TO REALLY HAVE THE

666
00:23:17,996 --> 00:23:18,663
INVESTIGATORS AND THE

667
00:23:18,730 --> 00:23:20,165
RESEARCHERS AND ALL THE TALENT

668
00:23:20,232 --> 00:23:22,567
THAT CAN BE BROUGHT TO BEAR FOR

669
00:23:22,634 --> 00:23:25,971
CANCER AND SO EFFORTS LIKE THIS

670
00:23:26,037 --> 00:23:27,506
CAN REALLY MAKE A DIFFERENCE.

671
00:23:27,572 --> 00:23:29,875
ALL RIGHT, NEXT SLIDE.

672
00:23:29,941 --> 00:23:31,643
AND THEN I JUST WANTED TO POINT

673
00:23:31,710 --> 00:23:34,079
OUT, AS YOU KNOW, WE ARE A PART

674
00:23:34,146 --> 00:23:35,747
OF THE CANCER GRANT CHALLENGES,

675
00:23:35,814 --> 00:23:38,283
THIS IS A PARTNERSHIP WITH

676
00:23:38,350 --> 00:23:39,885
CANCER RESEARCH UK, AND AN

677
00:23:39,951 --> 00:23:40,986
OPPORTUNITY TO REALLY THINK BIG,

678
00:23:41,052 --> 00:23:45,123
WHAT ARE INTEREST REALLY BIG

679
00:23:45,190 --> 00:23:47,526
BOLD OPPORTUNITIES TO DIVE IN

680
00:23:47,592 --> 00:23:48,660
AND INVESTIGATORS FROM AROUND

681
00:23:48,727 --> 00:23:50,629
THE WORLD CREATE LARGE TEAMS,

682
00:23:50,695 --> 00:23:52,664
KIND OF COMING BACK TO WHERE THE

683
00:23:52,731 --> 00:23:54,132
POWER IS IN TEAM SCIENCE AND

684
00:23:54,199 --> 00:23:55,467
THERE ARE 5 TEAMS THAT ARE

685
00:23:55,534 --> 00:23:59,538
WORKING ON 4 PROJECTS, THE 4

686
00:23:59,604 --> 00:24:01,540
CHALLENGES ARE, REDUCING CANCER

687
00:24:01,606 --> 00:24:02,340
INIQUITIES, UNDERSTANDING

688
00:24:02,407 --> 00:24:03,909
MECHANISMS OF EARLY ONSET

689
00:24:03,975 --> 00:24:05,043
CANCERS, DEVELOPING DRUGS FOR

690
00:24:05,110 --> 00:24:07,245
SOLID TUMORS IN CHILDREN AND

691
00:24:07,312 --> 00:24:10,549
BROADENING KNOWLEDGE OF HOW

692
00:24:10,615 --> 00:24:12,050
T-CELLS RECOGNIZE CANCER CELLS.

693
00:24:12,117 --> 00:24:15,320
SO ALL TRULY IMPORTANT AWARDS.

694
00:24:15,387 --> 00:24:18,056
EACH TWEAM RECEIVES $25 MILLION

695
00:24:18,123 --> 00:24:20,058
OVER 5 YEARS AND WE'RE REALLY

696
00:24:20,125 --> 00:24:21,259
EXPECTING AND LOOKING FORWARD TO

697
00:24:21,326 --> 00:24:25,330
REALLY MOVING THE NEEDLE.

698
00:24:25,397 --> 00:24:25,864
NEXT SLIDE.

699
00:24:25,931 --> 00:24:27,566
THIS IS MY LAST SLIDE.

700
00:24:27,632 --> 00:24:28,433
JUST CLOSING THOUGHTS.

701
00:24:28,500 --> 00:24:30,335
THIS IS A CHALLENGING YEAR, AND

702
00:24:30,402 --> 00:24:32,070
THERE ARE MORE CHALLENGES TO

703
00:24:32,137 --> 00:24:34,840
COME, WE CERTAINLY UP TO THOSE

704
00:24:34,906 --> 00:24:37,142
CHALLENGES AND YOU KNOW BY BEING

705
00:24:37,209 --> 00:24:37,843
GOOD SCIENTISTS, RIGOROUS,

706
00:24:37,909 --> 00:24:39,411
HONEST AND THOUGHTFUL AND

707
00:24:39,477 --> 00:24:41,246
PRIORITIZING WELL, USING ALL OF

708
00:24:41,313 --> 00:24:42,113
OUR RESOURCES TO THEIR BEST

709
00:24:42,180 --> 00:24:43,281
PURPOSE THAT, IS WHY IT'S SO

710
00:24:43,348 --> 00:24:45,984
VALUABLE TO HAVE A BOARD LIKE

711
00:24:46,051 --> 00:24:46,952
THIS, REALLY WORKING WITH US AND

712
00:24:47,018 --> 00:24:48,253
THINKING ABOUT THE WORK THAT WE

713
00:24:48,320 --> 00:24:49,688
DO SO WE CAN END CANCER AS WEB

714
00:24:49,754 --> 00:24:51,356
CONNECTED KNOW IT, USING THE

715
00:24:51,423 --> 00:24:52,490
NATIONAL CANCER PLAN AS OUR

716
00:24:52,557 --> 00:24:55,794
ROADMAP AND I WILL ADD AND THE

717
00:24:55,861 --> 00:24:56,761
MOON SHOT IS OUR GOAL.

718
00:24:56,828 --> 00:24:59,097
SO I WANT TO JUST THANK YOU.

719
00:24:59,164 --> 00:25:00,365
I SHARED MY THOUGHTS.

720
00:25:00,432 --> 00:25:04,569
I AM COUNTING ON YOU TO PROVIDE

721
00:25:04,636 --> 00:25:06,538
WISE AND CANDID INSIGHTS AND

722
00:25:06,605 --> 00:25:08,340
LOOKING FORWARD TO THE REST OF

723
00:25:08,406 --> 00:25:09,007
THE MEETING.

724
00:25:09,074 --> 00:25:14,946
I AM HAPPY TO TAKE ANY

725
00:25:15,013 --> 00:25:15,247
QUESTIONS.

726
00:25:15,313 --> 00:25:16,514
NTHANK YOU SO MUCH, IT WAS GREAT

727
00:25:16,581 --> 00:25:19,484
TO HEAR FROM YOU.

728
00:25:19,551 --> 00:25:30,028
ARE THERE QUESTIONS FROM THE

729
00:25:33,331 --> 00:25:33,632
COMMITTEE?

730
00:25:33,698 --> 00:25:35,033
>> I ACTUALLY HAD A QUESTION

731
00:25:35,100 --> 00:25:37,235
BUTIME HAVING A HARD TIME COMING

732
00:25:37,302 --> 00:25:38,270
OFF MUTE.

733
00:25:38,336 --> 00:25:38,637
>> HEY,.

734
00:25:38,703 --> 00:25:40,038
>> NICE TO SEE AND

735
00:25:40,105 --> 00:25:41,506
CONGRATULATIONS, I'M REAL LE

736
00:25:41,573 --> 00:25:42,607
EXCITED YOU'RE IN THIS POSITION

737
00:25:42,674 --> 00:25:47,579
AND I'M VERY, VERY EXCITED ABOUT

738
00:25:47,646 --> 00:25:48,813
THE FOCUS ON ENDOMIRROR IMAGE

739
00:25:48,880 --> 00:25:49,814
TRI OLDER PEOPLE CANCER AND

740
00:25:49,881 --> 00:25:51,883
BLACK IN CANCER AND I JUST WAS

741
00:25:51,950 --> 00:25:53,518
WONDERING HOW MUCH IS THAT

742
00:25:53,585 --> 00:25:54,152
INFORMATION BEING DISSEMINATED

743
00:25:54,219 --> 00:25:55,987
AND HOW CAN MORE OF US JOIN IN

744
00:25:56,054 --> 00:25:58,490
THESE EFFORTS WHO MAY NOT BE AS

745
00:25:58,556 --> 00:26:00,759
MUCH AS WARE OF WHERE THE

746
00:26:00,825 --> 00:26:05,096
PROCESS IS AND HOW WE CAN GET

747
00:26:05,163 --> 00:26:05,797
INVOLVED.

748
00:26:05,864 --> 00:26:06,798
>> OH, THAT'S--SO, YOU KNOW,

749
00:26:06,865 --> 00:26:08,900
IT'S ON WEBSITES AND BEING

750
00:26:08,967 --> 00:26:10,068
DISSEMINATED BUT WE CAN DO MORE.

751
00:26:10,135 --> 00:26:12,570
SO IF THE WORD IS NOT OUT, WE'LL

752
00:26:12,637 --> 00:26:15,707
WORK ON PUSHING IT OUT A LITTLE

753
00:26:15,774 --> 00:26:16,141
BIT FURTHER.

754
00:26:16,207 --> 00:26:17,709
I TRIED TO BE MUCH MORE ACTIVE

755
00:26:17,776 --> 00:26:18,810
IN SOCIAL MEDIA, IN PARTICULAR

756
00:26:18,877 --> 00:26:21,713
TALKING ABOUT THIS TODAY, THIS

757
00:26:21,780 --> 00:26:24,215
WILL LIKELY BE PUT THERE, BUT

758
00:26:24,282 --> 00:26:26,751
WE'LL GET THE WORD OUT.

759
00:26:26,818 --> 00:26:29,788
NYEAH, I'M HEADED TO OUR

760
00:26:29,854 --> 00:26:33,358
NATIONAL SOCIETY OF GYNECOLOGIC

761
00:26:33,425 --> 00:26:35,193
MEETING THAT'S HAPPENING WEEK SO

762
00:26:35,260 --> 00:26:36,861
I'M HAPPY TO AMPLIFY AS WELL, SO

763
00:26:36,928 --> 00:26:38,730
THANK YOU NOKAY, WE WILL GET YOU

764
00:26:38,797 --> 00:26:41,166
SOME MATERIALS.

765
00:26:41,232 --> 00:26:44,169
>> LINDA?

766
00:26:44,235 --> 00:26:46,104
>> ACTUALLY, A SIMILAR POINT.

767
00:26:46,171 --> 00:26:47,605
MY DEPARTMENT SUPPORTS

768
00:26:47,672 --> 00:26:48,340
FINANCIALLY AND COMMUNICATIONS

769
00:26:48,406 --> 00:26:50,875
WISE BLACK IN UMPIRESUNOLOGY AND

770
00:26:50,942 --> 00:26:52,277
BLACK IN MICRO, AND IT'S GREAT

771
00:26:52,344 --> 00:26:53,778
THAT BLACK IN CANCER IS GETTING

772
00:26:53,845 --> 00:26:55,613
UNDER WAY BUT THESE ARE REALLY

773
00:26:55,680 --> 00:26:56,681
GREAT DPRASES ROOTS EFFORTS BY

774
00:26:56,748 --> 00:27:00,785
THE PEOPLE IN THE FIELDS BUT I

775
00:27:00,852 --> 00:27:05,323
WONDER IF NIH MIGHT BE ABLE TO

776
00:27:05,390 --> 00:27:06,157
PROVIDE SUPPORT FOR CROSS

777
00:27:06,224 --> 00:27:08,927
GREWSING THEM AND ALLOWING CROSS

778
00:27:08,994 --> 00:27:09,627
DISCIPLINARY WORK AND

779
00:27:09,694 --> 00:27:12,564
INDIVIDUALS WHO WORK AT

780
00:27:12,630 --> 00:27:13,398
INTERSECTIONS TO BENEFIT FROM

781
00:27:13,465 --> 00:27:16,067
MORE THAN 1 OF THESE.

782
00:27:16,134 --> 00:27:18,336
>> YEAH, I LOVE THAT IDEA.

783
00:27:18,403 --> 00:27:24,142
AND I THINK THAT, YOU KNOW FIRST

784
00:27:24,209 --> 00:27:25,210
THAT PROBABLY HAPPENS NATURALLY

785
00:27:25,276 --> 00:27:26,978
BECAUSE THERE ARE CANCER

786
00:27:27,045 --> 00:27:27,946
IMMUNOLOGISTS, ET CETERA BUT

787
00:27:28,013 --> 00:27:29,381
DOING THAT WITH MORE INTENG,

788
00:27:29,447 --> 00:27:35,587
THAT'S A GREAT IDEA.

789
00:27:35,653 --> 00:27:36,221
>> JOHN?

790
00:27:36,287 --> 00:27:41,259
>> CONGRATULESS ULES--CONGRATTUN

791
00:27:41,326 --> 00:27:43,328
YOUR ASHES POINTMENT.

792
00:27:43,395 --> 00:27:44,963
THE SLIDE WHERE YOU SHOWED THE

793
00:27:45,030 --> 00:27:47,766
PLOTS AND THE NUMBER OF GRANTS

794
00:27:47,832 --> 00:27:49,401
GOING UP OVER TIME, CAN YOU

795
00:27:49,467 --> 00:27:50,935
COMMENT, IS THE R-GRANT

796
00:27:51,002 --> 00:27:52,437
MECHANISM GOING UP AS THE SAME

797
00:27:52,504 --> 00:27:53,905
PACE AS THE OVERALL PACE OR

798
00:27:53,972 --> 00:27:57,008
DIFFERENT?

799
00:27:57,075 --> 00:28:00,545
I WOULD ARGUE THAT THAT'S OUR

800
00:28:00,612 --> 00:28:01,646
BROADEST MOST EFFECTIVE

801
00:28:01,713 --> 00:28:02,814
SCIENTIFICALLY DIVERSE POOL OF

802
00:28:02,881 --> 00:28:04,682
ACTIVITIES AND THAT'S WHERE THE

803
00:28:04,749 --> 00:28:05,950
PRIORITY SHOULD BE.

804
00:28:06,017 --> 00:28:08,019
>> YEAH, I AGREE COMPLETELY.

805
00:28:08,086 --> 00:28:09,854
I WENT OVER THAT SLIDE QUICKLY,

806
00:28:09,921 --> 00:28:12,724
THERE WAS A YELLOW BAR ON THAT

807
00:28:12,791 --> 00:28:15,326
SLIDE AND THOSE WERE RO-1S SO

808
00:28:15,393 --> 00:28:19,697
THEY ARE INCREASING AT A SIMILAR

809
00:28:19,764 --> 00:28:20,765
RATE, AND CHAIRMAN AS A

810
00:28:20,832 --> 00:28:24,769
DEPARTMENT THAT REALLY LIVED ON

811
00:28:24,836 --> 00:28:25,837
RO-1s AND SO, HAVE TO MYSELF

812
00:28:25,904 --> 00:28:29,707
AND I GET THAT, THIS IS--THAT'S

813
00:28:29,774 --> 00:28:35,346
OUR BREAD AND BUTTER AND

814
00:28:35,413 --> 00:28:39,884
ABSOLUTELY SUPPORTIVE OF THAT.

815
00:28:39,951 --> 00:28:40,685
>> [INDISCERNIBLE]

816
00:28:40,752 --> 00:28:42,921
>> CONGRATULATIONS ON YOUR

817
00:28:42,987 --> 00:28:43,288
APPOINTMENT.

818
00:28:43,354 --> 00:28:49,761
IN LIGHT OF THE NEW INSTITUTE,

819
00:28:49,828 --> 00:28:50,829
ARP-H, AND AWARDS FOR CANCER CAN

820
00:28:50,895 --> 00:28:52,497
YOU SPEAK TO WHAT IF ANY IMPACT

821
00:28:52,564 --> 00:28:57,268
IT'S BEEN HAVING ON THE NCI

822
00:28:57,335 --> 00:29:00,338
PORTFOLIO AND JUST WITH NCI WARD

823
00:29:00,405 --> 00:29:03,007
ANDS NEW FUNDING OPPORTUNITIES?

824
00:29:03,074 --> 00:29:03,942
>> YEAH, THAT'S A GREAT

825
00:29:04,008 --> 00:29:04,309
QUESTION.

826
00:29:04,375 --> 00:29:07,579
I'M NOT SURE IT'S HAVING AN

827
00:29:07,645 --> 00:29:11,316
IMPACT ON OUR PORTFOLIO, YET, I

828
00:29:11,382 --> 00:29:13,818
THINK THAT WHERE IT'S HAVING ITS

829
00:29:13,885 --> 00:29:15,487
BIGGEST IMPACT IS IN ENCOURAGING

830
00:29:15,553 --> 00:29:17,355
US TO THINK ABOUT WHAT KINDS OF

831
00:29:17,422 --> 00:29:22,727
PROJECTS ARE READY FOR THAT SORT

832
00:29:22,794 --> 00:29:24,429
OF DARP A LIKE ACCELERATION AND

833
00:29:24,496 --> 00:29:25,964
THEY HAVE SEVERAL PROGGENTS THAT

834
00:29:26,030 --> 00:29:27,165
THEY'VE ANNOUNCED THAT ARE

835
00:29:27,232 --> 00:29:29,334
SQUARELY IN THE CANCER SPACE, I

836
00:29:29,400 --> 00:29:31,469
THINK IT'S GREAT, IT IS LARGELY

837
00:29:31,536 --> 00:29:32,504
NCI INVESTIGATORS THAT ARE

838
00:29:32,570 --> 00:29:34,372
LOOKING TO THIS, AND I SUSPECT

839
00:29:34,439 --> 00:29:36,007
THAT AS THESE PROJECTS MATURE,

840
00:29:36,074 --> 00:29:37,442
THEY WILL COME BACK INTO THE

841
00:29:37,509 --> 00:29:39,444
NCI, SO WE'RE LOOKINGA THE THIS

842
00:29:39,511 --> 00:29:43,114
AS A VERY SYMBIOTIC

843
00:29:43,181 --> 00:29:43,448
RELATIONSHIP.

844
00:29:43,515 --> 00:29:44,649
SO I'M REALLY EXCITED TO SEE

845
00:29:44,716 --> 00:29:52,624
WHAT COMES FROM THIS WORK.

846
00:29:52,690 --> 00:29:53,725
>> AND LAST, RODNEY?

847
00:29:53,791 --> 00:29:57,629
>> THANK YOU.

848
00:29:57,695 --> 00:29:58,563
WELCOME EMPLOY [INDISCERNIBLE]

849
00:29:58,630 --> 00:30:01,499
MANY THING VS HAPPENED SO IT'S

850
00:30:01,566 --> 00:30:03,034
GREAT TO SEE THAT.

851
00:30:03,101 --> 00:30:06,671
I WAS TRYING TO FIGURE IT OUT

852
00:30:06,738 --> 00:30:11,743
THIS GRANT CHALLENGE PROJECTS

853
00:30:11,809 --> 00:30:13,578
ALIGNMENT WITH NCI AND FOUND

854
00:30:13,645 --> 00:30:16,247
THEY'RE IN LINE WITH THE

855
00:30:16,314 --> 00:30:19,517
FREDERICK LABS, SO, I THINK ALL

856
00:30:19,584 --> 00:30:21,586
FED RAKE LABS CAN BE

857
00:30:21,653 --> 00:30:23,421
CHARACTERIZATION AND SCALE UP

858
00:30:23,488 --> 00:30:25,790
INTO A CLINICAL TRANSLATION

859
00:30:25,857 --> 00:30:27,458
PROGRAM, SO, DO YOU HAVE ANY

860
00:30:27,525 --> 00:30:28,359
THOUGHTS ON THAT?

861
00:30:28,426 --> 00:30:31,829
I KNOW YOU'RE JUST STARTING,

862
00:30:31,896 --> 00:30:33,231
TAKE THE TEAM SCIENCE AND ALL

863
00:30:33,298 --> 00:30:35,066
THESE, HOW WOULD THAT FIT IN

864
00:30:35,133 --> 00:30:36,701
YOUR PHILOSOPHY AND YOUR

865
00:30:36,768 --> 00:30:37,669
THINKING?

866
00:30:37,735 --> 00:30:38,703
>> YEAH, I'M NOT QUITE SURE I

867
00:30:38,770 --> 00:30:40,438
BEING HEAR ALL THE QUESTION BUT

868
00:30:40,505 --> 00:30:43,074
I THINK YOU WERE ASKING ABOUT

869
00:30:43,141 --> 00:30:44,108
THE CANCER GRANT CHALLENGES AND

870
00:30:44,175 --> 00:30:46,311
HOW THEY INTERSECT WITH THE FED

871
00:30:46,377 --> 00:30:47,712
RICK NATIONAL LAB IN.

872
00:30:47,779 --> 00:30:48,046
>> RIGHT.

873
00:30:48,112 --> 00:30:49,280
>> I DON'T KNOW OFF THE TOP OF

874
00:30:49,347 --> 00:30:51,482
MY HEAD AND I DON'T KNOW IF DINA

875
00:30:51,549 --> 00:30:53,084
OR ANYONE ELSE WANTS TO COMMENT

876
00:30:53,151 --> 00:30:54,953
IF THERE ARE CURRENT CONNECTIONS

877
00:30:55,019 --> 00:30:56,821
BUT THERE CERTAINLY BEING BE, I

878
00:30:56,888 --> 00:30:58,990
WILL IMAGINE IT'S A NATURAL

879
00:30:59,057 --> 00:31:02,493
EXTENSION FOR THE RIGHT KIND OF

880
00:31:02,560 --> 00:31:02,860
PROJECT.

881
00:31:02,927 --> 00:31:03,795
SO I WOULD ACTUALLY HOPE THAT

882
00:31:03,861 --> 00:31:08,600
PEOPLE WOULD SEE IT AS AN

883
00:31:08,666 --> 00:31:08,900
OPPORTUNITY.

884
00:31:08,967 --> 00:31:10,935
>> THANK YOU.

885
00:31:11,002 --> 00:31:11,236
>> CAROL.

886
00:31:11,302 --> 00:31:18,610
NYES, THANK YOU VERY MUCH.

887
00:31:18,676 --> 00:31:20,612
AND CONGRATULATIONS, CAROL BULT

888
00:31:20,678 --> 00:31:23,248
FROM THE NCI LAB, I WAS EXCITED

889
00:31:23,314 --> 00:31:24,782
TO SEE THE AI RESEARCH

890
00:31:24,849 --> 00:31:26,551
APPROACHES TO DIAGNOSIS AND THAT

891
00:31:26,618 --> 00:31:28,086
IS A RAPIDLY, RAPIDLY MOVING

892
00:31:28,152 --> 00:31:31,823
FIELD AND I'M WONDERING IF THERE

893
00:31:31,889 --> 00:31:35,426
ARE PARTNERSHIPS WITH INDUSTRY

894
00:31:35,493 --> 00:31:37,495
PARTNERS IN THAT SPACE WITH

895
00:31:37,562 --> 00:31:42,267
FREDERICK NATIONAL LAB

896
00:31:42,333 --> 00:31:42,600
INVESTIGATORS?

897
00:31:42,667 --> 00:31:43,401
>> I CAN'T ANSWER SPECIFICALLY

898
00:31:43,468 --> 00:31:48,840
THE LAST PART OF THAT QUESTION,

899
00:31:48,906 --> 00:31:50,808
YOU KNOW, WITH ACCURACY BUT MY

900
00:31:50,875 --> 00:31:52,443
SENSE OF EVERY PROJECT THAT I

901
00:31:52,510 --> 00:31:55,079
KNOW IN THE AI SPACE TENDS TO

902
00:31:55,146 --> 00:31:59,017
HAVE A GOOD COLLABORATION--THIS

903
00:31:59,083 --> 00:32:02,053
IS LIKE A RIPE SPACE FOR

904
00:32:02,120 --> 00:32:03,655
PUBLIC-PRIVATE PARTNERSHIPS.

905
00:32:03,721 --> 00:32:04,722
>> YEAH, IT REALLY IS.

906
00:32:04,789 --> 00:32:06,124
>> YEAH, THIS STUFF IS MOVING SO

907
00:32:06,190 --> 00:32:10,295
FAST IN BOTH SPACES REALLY

908
00:32:10,361 --> 00:32:10,528
QUICKLY.

909
00:32:10,595 --> 00:32:10,795
>> OKAY.

910
00:32:10,862 --> 00:32:15,033
THANK YOU VERY MUCH.

911
00:32:15,099 --> 00:32:15,533
>> THANK YOU.

912
00:32:15,600 --> 00:32:18,169
>> AND I THINK WE WILL MOVE ON

913
00:32:18,236 --> 00:32:20,004
WITH ANY OTHER QUESTIONS, WE ARE

914
00:32:20,071 --> 00:32:22,407
RIGHT ON SCHEDULE ANDON TIME.

915
00:32:22,473 --> 00:32:25,843
THIS IS THIS IS A PRESENTATION

916
00:32:25,910 --> 00:32:30,581
BY DR. YOVANDICH, TALKS ABOUT

917
00:32:30,648 --> 00:32:31,449
THE BIOPHARMACEUTICAL

918
00:32:31,516 --> 00:32:35,019
DEVELOPMENT AND PRODECLARATION

919
00:32:35,086 --> 00:32:35,353
AT THE FNLCR.

920
00:32:35,420 --> 00:32:37,622
>> THANK YOU VERY MUCH, I WOULD

921
00:32:37,689 --> 00:32:43,294
LIKE TO THANK DR. RATHMELL AND

922
00:32:43,361 --> 00:32:44,529
DOROSHOW, FOR THE OPPORTUNITY TO

923
00:32:44,595 --> 00:32:49,801
GIVE A PRESENTATION ON DCTD'S

924
00:32:49,867 --> 00:32:50,501
DEVELOPMENT OF

925
00:32:50,568 --> 00:32:51,402
BIOPHARMACEUTICALS AND

926
00:32:51,469 --> 00:32:55,373
PRODUCTION AT THE FED RICK

927
00:32:55,440 --> 00:32:56,040
NATIONAL LAB--FEDDERRIC NATIONAL

928
00:32:56,107 --> 00:32:57,408
LAB AND I THINK YOU SHOULD BE

929
00:32:57,475 --> 00:33:04,549
ABLE TO SEE THE SCREEN NOW, IS

930
00:33:04,615 --> 00:33:05,216
THAT CORRECT?

931
00:33:05,283 --> 00:33:08,286
>> YES, YOU ARE VISIBLE.

932
00:33:08,353 --> 00:33:08,853
>> GREAT.

933
00:33:08,920 --> 00:33:09,120
THANK YOU.

934
00:33:09,187 --> 00:33:09,320
OKAY.

935
00:33:09,387 --> 00:33:10,755
SO HERE ARE THE SET OF TOPICS

936
00:33:10,822 --> 00:33:12,657
THAT I WILL BE GOING OVER IN THE

937
00:33:12,724 --> 00:33:16,294
PRESENTATION, I WILL GIVE A

938
00:33:16,361 --> 00:33:22,367
BRIEF HISTORY AND OVERVIEW OF

939
00:33:22,433 --> 00:33:24,268
DCTK'S APPROACH TO DEVELOPING

940
00:33:24,335 --> 00:33:24,702
BIOPHARMACEUTICALS.

941
00:33:24,769 --> 00:33:26,170
PROVIDE CAPABILITY AND IT IS

942
00:33:26,237 --> 00:33:28,539
HIGHLIGHT RECENT ACCOMPLISHMENTS

943
00:33:28,606 --> 00:33:29,540
OF THE BIOPHARMACEUTICAL

944
00:33:29,607 --> 00:33:32,043
DEVELOPMENT PROGRAM HERE AT THE

945
00:33:32,110 --> 00:33:33,578
FREDERICK NATIONAL LAB.

946
00:33:33,644 --> 00:33:35,480
AND DESCRIBE OR HIGHLIGHT SOME

947
00:33:35,546 --> 00:33:38,049
OF THE RECENT SUPPORT THAT THE

948
00:33:38,116 --> 00:33:41,119
BDP IS PROVIDING FOR THE CELL

949
00:33:41,185 --> 00:33:43,521
THERAPY FIELD AND MORE RECENTLY

950
00:33:43,588 --> 00:33:45,456
THE CANCER ADAPTIVE CELL THERAPY

951
00:33:45,523 --> 00:33:46,724
INITIATIVE THAT'S BEEN SET UP

952
00:33:46,791 --> 00:33:48,393
AND THEN I WILL WIND UP THE

953
00:33:48,459 --> 00:33:50,228
PRESENTATION WITH AN OVERVIEW OF

954
00:33:50,294 --> 00:33:52,864
ACCESS, HOW FOLKS CAN ACCESS THE

955
00:33:52,930 --> 00:33:54,732
BDP AS WELL AS RECENT

956
00:33:54,799 --> 00:34:00,071
COLLABORATION OPPORTUNITIES THAT

957
00:34:00,138 --> 00:34:02,106
HAVE COME UP.

958
00:34:02,173 --> 00:34:05,243
SO WHY DOES DCTD SUPPORT

959
00:34:05,309 --> 00:34:05,843
BIOPHARMACEUTICAL DEVELOPMENT?

960
00:34:05,910 --> 00:34:08,079
WE WANT TO ROUGH ATOM VIED

961
00:34:08,146 --> 00:34:09,680
RESOURCES THROUGH THE COMMUNITY,

962
00:34:09,747 --> 00:34:11,549
FILL GAPS AND FOSTER DEVELOPMENT

963
00:34:11,616 --> 00:34:13,151
OF NEW BIOTECHNOLOGIES AND WE

964
00:34:13,217 --> 00:34:14,185
WANT TO DISSEMINATE THE

965
00:34:14,252 --> 00:34:16,320
KNOWLEDGE WE'VE AGAINED AND

966
00:34:16,387 --> 00:34:17,755
SHARE THAT WITH ANY UNIQUE

967
00:34:17,822 --> 00:34:23,628
RESOURCES WE HAVE WITH NIH

968
00:34:23,694 --> 00:34:23,895
PARTNERS.

969
00:34:23,961 --> 00:34:25,296
SO A BRIEF HISTORY AND OVERVIEW

970
00:34:25,363 --> 00:34:27,865
OF OUR APPROACH TO

971
00:34:27,932 --> 00:34:28,466
BIOPHARMACEUTICAL DEVELOPMENT,

972
00:34:28,533 --> 00:34:29,834
WE'VE ACTUALLY BEEN ARK ROUND

973
00:34:29,901 --> 00:34:31,469
SINCE THE 70S, THE ORIGINAL

974
00:34:31,536 --> 00:34:33,538
PROGRAM WAS THE BIOLOGICAL

975
00:34:33,604 --> 00:34:34,839
RESPONSE MODIFIERS PROGRAM AND

976
00:34:34,906 --> 00:34:39,277
IT WAS THEN IN THE DIVISION OF

977
00:34:39,343 --> 00:34:41,913
CANCER THERAPY, THE BRMP

978
00:34:41,979 --> 00:34:45,082
SUPPORTED A LOT OF THE EARLY

979
00:34:45,149 --> 00:34:47,518
CLINICAL STUDIES WITH INTERFORON

980
00:34:47,585 --> 00:34:50,888
AND IRPT LUKEIN 2, THIS WAS

981
00:34:50,955 --> 00:34:52,590
MOSTLY DONE THRAW CONTRACTS AND

982
00:34:52,657 --> 00:34:53,458
GRANT ANDS CLINICAL TRIAL

983
00:34:53,524 --> 00:34:54,659
SUPPORT THAT ARE PROVIDED TO THE

984
00:34:54,725 --> 00:34:57,228
CLINICAL CENTER AS WELL AS A

985
00:34:57,295 --> 00:34:58,529
SATELLITE CLINICAL SITE HERE IN

986
00:34:58,596 --> 00:35:00,264
FREDERICK AT THE TIME.

987
00:35:00,331 --> 00:35:03,267
THE PROGRAM SUPPORTED A LOT OF

988
00:35:03,334 --> 00:35:04,502
ACQUISITION OF MONOCLONAL

989
00:35:04,569 --> 00:35:05,937
ANTIBODIES, MOVED IN SOME OF THE

990
00:35:06,003 --> 00:35:10,308
EARLY VERSIONS OF TUMOR VACCINE

991
00:35:10,374 --> 00:35:12,477
STRATEGIES, ONCO LYTIC VIRUS AND

992
00:35:12,543 --> 00:35:15,313
BACTERIA AND NOW IN CELL AND

993
00:35:15,379 --> 00:35:16,848
GENE THERAPIES.

994
00:35:16,914 --> 00:35:19,951
SO BIOLOGICS AS MOST FOLKS KNOW

995
00:35:20,017 --> 00:35:22,920
HAS EVOLVED QUIT SIGNIFICANT LYE

996
00:35:22,987 --> 00:35:25,456
THE LAST 10-20 YEARS STARTING

997
00:35:25,523 --> 00:35:28,092
WITH CRUDE ISOLATES AND

998
00:35:28,159 --> 00:35:29,327
EXTRACTS, WORKING INTO RECOMBIN

999
00:35:29,393 --> 00:35:30,628
ANT PROTEIN AND PURIFICATION

1000
00:35:30,695 --> 00:35:33,831
PRODUCTION, THEN WITH THE ADVENT

1001
00:35:33,898 --> 00:35:39,270
OF CLINICALLY ACTIVE AND

1002
00:35:39,337 --> 00:35:42,273
SUCCESSFUL ANTIBODY THERAPIES.

1003
00:35:42,340 --> 00:35:43,808
AS DR. RATHMELL MENINGED WE ARE

1004
00:35:43,875 --> 00:35:47,211
NOW MOVING INTO THE CONJUGATE

1005
00:35:47,278 --> 00:35:48,045
AGENTS AND ANTIBODIES, AND

1006
00:35:48,112 --> 00:35:50,348
THERE'S BEEN A NUMBER OF

1007
00:35:50,414 --> 00:35:51,883
SUCCESSFUL VIRUS PRODUCTS AND

1008
00:35:51,949 --> 00:35:52,817
VIRUS-LIKE PARTICLE ANDS A LOT

1009
00:35:52,884 --> 00:35:55,520
OF THE FIELD AND MOVING INTO

1010
00:35:55,586 --> 00:35:56,621
BACTERIAL BASED THERAPIES AS

1011
00:35:56,687 --> 00:36:01,959
WELL AND MORE RECENTLY, WITH THE

1012
00:36:02,026 --> 00:36:09,166
SUCCESS OF TILL THERAPIES AND

1013
00:36:09,233 --> 00:36:10,535
AUTOLOGOUS THERAPIES WE ARE NOW

1014
00:36:10,601 --> 00:36:17,141
MOVING INTO A TERRITORY OF

1015
00:36:17,208 --> 00:36:18,142
ENGINEERED CELLS AND BIOLOGY.

1016
00:36:18,209 --> 00:36:19,911
SO WHAT ARE THE TYPICAL

1017
00:36:19,977 --> 00:36:21,746
MILESTONES, HOW DO WE DEVELOP

1018
00:36:21,812 --> 00:36:24,348
AND APPROACH THE TRANSLATION OF

1019
00:36:24,415 --> 00:36:24,615
BIOLOGICS.

1020
00:36:24,682 --> 00:36:25,950
FIRST IS IT WHAT YOU THINK IT

1021
00:36:26,017 --> 00:36:26,117
IS?

1022
00:36:26,183 --> 00:36:28,085
WE DO A LOT OF PRECLINICAL

1023
00:36:28,152 --> 00:36:30,555
TESTING OF THE MATERIAL TO

1024
00:36:30,621 --> 00:36:35,192
ANALYZE THE STARTING MATERIALS

1025
00:36:35,259 --> 00:36:38,496
FOR YEEN SUITABILITY, WE APPLY

1026
00:36:38,563 --> 00:36:41,866
WHAT WE CALL SSISQF, THAT STAND

1027
00:36:41,933 --> 00:36:43,734
FORS DETERMINING SAFETY, IESHES

1028
00:36:43,801 --> 00:36:44,635
DENTITY, STRENGTH OR POTENT

1029
00:36:44,702 --> 00:36:46,037
STATE ENSEL OF THE AGENT,

1030
00:36:46,103 --> 00:36:48,606
QUALITY OF THE MATERIAL AS WELL

1031
00:36:48,673 --> 00:36:50,408
AS THE PURITY OF THE MATERIAL.

1032
00:36:50,474 --> 00:36:51,742
NEXT QUESTION IS CAN WE MAKE

1033
00:36:51,809 --> 00:36:53,811
ENOUGH IN THIS IS WHERE THE

1034
00:36:53,878 --> 00:36:58,215
PROCESS DEVELOPMENT STAGE COMES

1035
00:36:58,282 --> 00:37:01,218
IN FOR SCALE ASK FEASIBILITY,

1036
00:37:01,285 --> 00:37:03,521
ASSAY DEVELOPMENT AS WELL AS

1037
00:37:03,588 --> 00:37:05,356
STANDARD OPERATING PROCEDURES

1038
00:37:05,423 --> 00:37:06,190
AND FORMULATION STABILITY.

1039
00:37:06,257 --> 00:37:07,925
THE NEXT STEP IS TO GENERATE

1040
00:37:07,992 --> 00:37:09,594
ENOUGH REFERENCE MATERIAL AND

1041
00:37:09,660 --> 00:37:13,364
THIS DOESN'T ONLY APPLY TO THE

1042
00:37:13,431 --> 00:37:15,800
BIOLOGIC CANDIDATE BUT ALSO TO

1043
00:37:15,866 --> 00:37:17,535
THE STARTING MATERIALS, THE

1044
00:37:17,602 --> 00:37:18,703
PRODUCTION MATERIALS, THE CELL

1045
00:37:18,769 --> 00:37:22,773
BANKS AND THE VIRUS BANKS.

1046
00:37:22,840 --> 00:37:24,976
OTHER THAN THE SET TESTING

1047
00:37:25,042 --> 00:37:26,477
SPECIFICATIONS, THIS IS WHERE

1048
00:37:26,544 --> 00:37:29,046
THE QC GROUP STEPS IN FOR

1049
00:37:29,113 --> 00:37:30,114
DEVELOPING ANALYTICAL QUAL

1050
00:37:30,181 --> 00:37:31,382
IIVESS FOR PRODUCT RELEASE, WE

1051
00:37:31,449 --> 00:37:34,218
ALSO DO SOME FORCED DEGRADATION

1052
00:37:34,285 --> 00:37:37,421
STUDIES TO INFORM THE UPCOMING

1053
00:37:37,488 --> 00:37:38,589
STABILITY PROGRAM, AND THEN THE

1054
00:37:38,656 --> 00:37:41,726
NEXT BIG QUESTION IS, CAN WE

1055
00:37:41,792 --> 00:37:43,194
MAKE THE CLINICAL LOT?

1056
00:37:43,260 --> 00:37:45,596
THIS WHERE THE DRESS REHEARSAL

1057
00:37:45,663 --> 00:37:48,733
COMES THROUGH, WE DO A PILOT

1058
00:37:48,799 --> 00:37:50,001
MANUFACTURING OR ENGINEERING

1059
00:37:50,067 --> 00:37:51,535
LINE AS ITS SOMETIMES CALLED TO

1060
00:37:51,602 --> 00:37:53,371
PRODUCE MATERIAL THAT CAN BE

1061
00:37:53,437 --> 00:37:55,906
USED FOR REFERENCE STANDARDS AS

1062
00:37:55,973 --> 00:37:59,210
WELL AS FOR THE DIRECT IND

1063
00:37:59,276 --> 00:38:01,278
TOXICOLOGY AND FUTURE ED

1064
00:38:01,345 --> 00:38:01,812
CREDIBILITY STUDIES.

1065
00:38:01,879 --> 00:38:03,881
THE NEXT STEP IS TO LOOK AT

1066
00:38:03,948 --> 00:38:05,016
PRECLINICAL SAFETY STUDIES THIS

1067
00:38:05,082 --> 00:38:10,721
WILL BE PART OF SUPPORT FOR AN

1068
00:38:10,788 --> 00:38:12,256
I&  D FINDINGINGS, RANGE STUDIES

1069
00:38:12,323 --> 00:38:14,325
AND TOXICOLOGY AND DISTRIBUTION,

1070
00:38:14,392 --> 00:38:18,763
THE LAST BIG STEP IS THE

1071
00:38:18,829 --> 00:38:19,196
MANUFACTURING.

1072
00:38:19,263 --> 00:38:21,565
THIS INVOLVES QC AND QA RELEASE,

1073
00:38:21,632 --> 00:38:22,967
ALTHOUGH THE REGULATORY

1074
00:38:23,034 --> 00:38:28,572
DOCUMENTATION ASSOCIATE WIDE THE

1075
00:38:28,639 --> 00:38:29,206
BIOLOGIC [INDISCERNIBLE].

1076
00:38:29,273 --> 00:38:32,877
AND THEN LAST BUT NOT LEAST THIS

1077
00:38:32,943 --> 00:38:34,245
IS REALTIME SUSTAINABLE, THIS IS

1078
00:38:34,311 --> 00:38:37,148
A SUBSET OF TESTS THAT ARE USED

1079
00:38:37,214 --> 00:38:40,217
AND DESIGNED TO DETECT

1080
00:38:40,284 --> 00:38:43,287
DEGRADATION AND CONTAMINATION

1081
00:38:43,354 --> 00:38:45,790
AND THEN SOMETIME AMONG THESE

1082
00:38:45,856 --> 00:38:47,191
LAST FEW POINTS WE HIGHLIGHT AND

1083
00:38:47,258 --> 00:38:47,825
RECOMMEND THAT EVERYBODY REACH

1084
00:38:47,892 --> 00:38:50,594
OUT TO THE FDA FOR PREI&  D

1085
00:38:50,661 --> 00:38:51,962
MEETING TO MAKE SURE THEY'RE ON

1086
00:38:52,029 --> 00:38:54,665
THE RIGHT PATH FOR SUCCESSFUL I

1087
00:38:54,732 --> 00:38:54,799
D.

1088
00:38:54,865 --> 00:38:57,735
>> SO WHAT WE DO, AS THE

1089
00:38:57,802 --> 00:38:59,737
PROJECTS COME IN AS WE SET UP A

1090
00:38:59,804 --> 00:39:02,039
SET OF GENERIC QUESTIONNAIRES,

1091
00:39:02,106 --> 00:39:03,541
OR GENERATED IRBIC GENERAL

1092
00:39:03,607 --> 00:39:06,644
QUESTIONS FOR BIOLOGICS TO GAUGE

1093
00:39:06,711 --> 00:39:07,311
THE DEVELOPMENTAL READINESS OF

1094
00:39:07,378 --> 00:39:07,978
THE AGENT.

1095
00:39:08,045 --> 00:39:10,381
IT ADDRESSES THAT SISQP, I

1096
00:39:10,448 --> 00:39:12,817
MENTIONED EARLIER AND CONTAINS

1097
00:39:12,883 --> 00:39:16,554
SPECIFIC QUESTIONS FOR A VERY

1098
00:39:16,620 --> 00:39:17,521
SPECIFIC BIOLOGICS THAT PERTAINS

1099
00:39:17,588 --> 00:39:19,857
TO BECOMING A PROTEIN, VIRUSES,

1100
00:39:19,924 --> 00:39:24,462
PEPTIDES AND CELL PRODUCTS.

1101
00:39:24,528 --> 00:39:26,430
ALL RIGHT, SO TO GO OVER THE

1102
00:39:26,497 --> 00:39:28,032
CAPABILITIES AND RECENT

1103
00:39:28,099 --> 00:39:29,967
ACCOMPLISHMENTS OF THE

1104
00:39:30,034 --> 00:39:30,634
PHARMACEUTICAL DEVELOPMENT

1105
00:39:30,701 --> 00:39:33,370
PROGRAM, WE SET UP THE BDP IN

1106
00:39:33,437 --> 00:39:35,005
THE EARLY NIEND 90S IN

1107
00:39:35,072 --> 00:39:37,775
FREDERICK, TO PROVIDE TECHNICAL

1108
00:39:37,842 --> 00:39:38,676
EXPERTISE THAT'S NOT READILY

1109
00:39:38,743 --> 00:39:39,443
AVAILABLE IN THE COMMERCIAL

1110
00:39:39,510 --> 00:39:45,716
MARKET AND THIS FITS NICELY WITH

1111
00:39:45,783 --> 00:39:48,519
THE MISSION OF--THE BDP CONDUCKS

1112
00:39:48,586 --> 00:39:49,787
FEASIBILITY STUDIES ON PROJECT

1113
00:39:49,854 --> 00:39:50,387
CANDIDATES.

1114
00:39:50,454 --> 00:39:51,989
THEY DEVELOP MANUFACTURING

1115
00:39:52,056 --> 00:39:53,724
PROCESSES AND ASSAYS   PERFORM

1116
00:39:53,791 --> 00:39:56,460
THE GMP MANUFACTURING INCLUDING

1117
00:39:56,527 --> 00:39:58,229
FILL AND FINISH AND PRODUCT

1118
00:39:58,295 --> 00:39:58,562
RELEASE.

1119
00:39:58,629 --> 00:40:02,466
THEY ALSO PRODUCE AND SUBMIT ALL

1120
00:40:02,533 --> 00:40:04,668
THE DOCUMENTATION REQUIRED FOR

1121
00:40:04,735 --> 00:40:05,970
FDA AND REGULATORY FILINGS AND

1122
00:40:06,036 --> 00:40:08,839
THEY'VE SET UP A VERY NICELY

1123
00:40:08,906 --> 00:40:10,775
STREAMLINED PROCESS, FOR TECH

1124
00:40:10,841 --> 00:40:12,276
TRANSFER, OF EVERYTHING THAT

1125
00:40:12,343 --> 00:40:13,744
THEY'VE WORKED ON AS

1126
00:40:13,811 --> 00:40:14,678
COMMERCIALENTITY IS COME INTO

1127
00:40:14,745 --> 00:40:17,782
PLAY AND TAKE OVER THE PRODUCT

1128
00:40:17,848 --> 00:40:18,349
FOR FURTHER DEVELOPMENT.

1129
00:40:18,415 --> 00:40:20,651
THEY ALSO HAVE A VERY SOLID GENE

1130
00:40:20,718 --> 00:40:22,987
TRAINING PROGRAM FOR THEIR STAFF

1131
00:40:23,053 --> 00:40:24,622
AS WELL AS EXTERNAL PARTNERS,

1132
00:40:24,688 --> 00:40:28,092
TOO, SINCE THE LATE 90S THEY

1133
00:40:28,159 --> 00:40:29,426
PRODUCED MORE THAN 260

1134
00:40:29,493 --> 00:40:29,994
INVESTIGATIONAL AGENTINGS.

1135
00:40:30,060 --> 00:40:31,362
AS YOU SEE FROM THE PIE CHART

1136
00:40:31,428 --> 00:40:33,998
THERE, AS A BREAK DOWN OF THE

1137
00:40:34,064 --> 00:40:36,867
NATURE OF THE BIOLOGICS, THE

1138
00:40:36,934 --> 00:40:38,602
RECOMBIN ANT PROTEINS OR

1139
00:40:38,669 --> 00:40:40,271
PEPTIDES FOLLOWED CLOSELY AND

1140
00:40:40,337 --> 00:40:41,405
INCREASINGLY BY CELLULAR

1141
00:40:41,472 --> 00:40:42,540
PRODUCTS THAT WILL GET TO YOU

1142
00:40:42,606 --> 00:40:46,277
LATER IN THE PRESENTATION ALONG

1143
00:40:46,343 --> 00:40:47,344
WITH MONOCLONAL ANTIBODIES,

1144
00:40:47,411 --> 00:40:52,850
VIRAL VECTORS AND VIRUS LIKE

1145
00:40:52,917 --> 00:40:54,585
PARTICLES.

1146
00:40:54,652 --> 00:40:57,488
SO THE BDP, HERE IS--HERE AT THE

1147
00:40:57,555 --> 00:41:00,291
ADVANCED TECHNOLOGY RESEARCH

1148
00:41:00,357 --> 00:41:03,060
FACILITY IN FREDERICK, IT IS IN

1149
00:41:03,127 --> 00:41:06,730
2 WINGS OF THE FACILITY HERE AND

1150
00:41:06,797 --> 00:41:09,834
MULTIPRODUCT PILOT FACILITY FOR

1151
00:41:09,900 --> 00:41:10,868
MAKING BIOPHARMACEUTICALS AND

1152
00:41:10,935 --> 00:41:15,039
CELLULAR PRODUCTS AND THE OVER

1153
00:41:15,105 --> 00:41:17,341
ALL SIZE IS ABOUT 66,000 SQUARE

1154
00:41:17,408 --> 00:41:19,476
FEET AND A THIRD OF WHICH IS THE

1155
00:41:19,543 --> 00:41:20,711
GMP MANUFACTURING AREA.

1156
00:41:20,778 --> 00:41:22,580
THAT AREA CONTAINS SEPARATE SETS

1157
00:41:22,646 --> 00:41:25,716
OF ROOMS OR TRAINS FOR

1158
00:41:25,783 --> 00:41:28,118
PRODUCTION FROM EUKARYOTIC CELLS

1159
00:41:28,185 --> 00:41:29,854
OR PROPROKARYOTIC CELLS LIKE

1160
00:41:29,920 --> 00:41:30,788
E.COLI PRODUCTION AND PURE IIVES

1161
00:41:30,855 --> 00:41:36,427
AND THEN A SEPARATE SET OF

1162
00:41:36,493 --> 00:41:38,429
FILL/FINISH VIAL BLAIBLING AND

1163
00:41:38,495 --> 00:41:39,897
INSPECTION, UP TO 10,000 USING

1164
00:41:39,964 --> 00:41:42,666
OUR AUTOMATED FILLER AND THEN UP

1165
00:41:42,733 --> 00:41:44,668
TO 2500 FOR MANUEL FILLED.

1166
00:41:44,735 --> 00:41:47,738
THE FACILITY HAS A

1167
00:41:47,805 --> 00:41:48,205
SELF-CONTAINED VIRUS

1168
00:41:48,272 --> 00:41:50,140
MANUFACTURING SUITE RUN ON ITS

1169
00:41:50,207 --> 00:41:51,642
OWN AIR HANDLER ANDS RUNNING

1170
00:41:51,709 --> 00:41:52,843
WITH SEPARATE ENTERS AND

1171
00:41:52,910 --> 00:41:56,847
CHANGING ROOMS AND THEN RECENTLY

1172
00:41:56,914 --> 00:41:58,949
WE RENOVATED SOME R&D SPACES, AS

1173
00:41:59,016 --> 00:42:02,019
WELL AS OFFICE SPACE TO PROVIDE

1174
00:42:02,086 --> 00:42:03,587
4 NEW GMP CELL THERAPY SUITES

1175
00:42:03,654 --> 00:42:05,289
AND THEN THE REST OF THE

1176
00:42:05,356 --> 00:42:07,091
FACILITY IS MADE UP OF LABS FOR

1177
00:42:07,157 --> 00:42:08,692
THE QC GROUP FOR PROCESS

1178
00:42:08,759 --> 00:42:10,060
DEVELOPMENT AND FOR WAREHOUSING

1179
00:42:10,127 --> 00:42:14,131
PRODUCT ANDS RAW MATERIALS.

1180
00:42:14,198 --> 00:42:16,166
SO THIS IS JUST A SAMPLING OF

1181
00:42:16,233 --> 00:42:18,135
SOME OF THE STATE-OF-THE-ART

1182
00:42:18,202 --> 00:42:19,570
EQUIPMENT THAT THE BDP HAS

1183
00:42:19,637 --> 00:42:21,839
STARTING GOING FROM LEFT TO

1184
00:42:21,906 --> 00:42:22,740
RIGHT HERE.

1185
00:42:22,806 --> 00:42:25,876
WE'VE SWITCHED OVER TO

1186
00:42:25,943 --> 00:42:27,077
DISPOSABLE BIOREAGHTORS HERE UP

1187
00:42:27,144 --> 00:42:29,613
TO 200 LITERS THAT WE CAN GROW,

1188
00:42:29,680 --> 00:42:31,382
SHOW CELLS OR 293 CELLS THAT ARE

1189
00:42:31,448 --> 00:42:33,150
PRODUCING RECOMBIN ANT PROTEINS

1190
00:42:33,217 --> 00:42:35,586
AND ANTIBODIES, AND THEN DOWN

1191
00:42:35,653 --> 00:42:38,322
BELOW THERE, THERE'S THE

1192
00:42:38,389 --> 00:42:43,627
FERMENTERS FOR THE E.COLI AND

1193
00:42:43,694 --> 00:42:44,228
[INDISCERNIBLE] FERMENTATION,

1194
00:42:44,295 --> 00:42:46,864
SCALES WITH BE PRODUCED THERE

1195
00:42:46,931 --> 00:42:51,001
ANDOR WORKFORCE FOR PURIFICATION

1196
00:42:51,068 --> 00:42:52,303
IS THE ACTIVE SKID SEEN IN THE

1197
00:42:52,369 --> 00:42:53,938
TOP ALONG WITH A PACKED COLUMN

1198
00:42:54,004 --> 00:42:55,906
USED IN THE PURIFICATION

1199
00:42:55,973 --> 00:42:56,240
PROCESS.

1200
00:42:56,307 --> 00:43:01,345
DOWN AT THE BOTTOM WE HAVE 1 OF

1201
00:43:01,412 --> 00:43:02,313
MANY NEXT QUANT MULTICELL

1202
00:43:02,379 --> 00:43:04,148
SORTERS THAT ARE USED TO

1203
00:43:04,214 --> 00:43:06,016
QUANTIFY AND SORT CELL PROTEINS

1204
00:43:06,083 --> 00:43:09,320
AND THEN OUR WORK HOUSE FOR CELL

1205
00:43:09,386 --> 00:43:11,055
THERAPY PRODUCTION AND A NICE

1206
00:43:11,121 --> 00:43:14,191
CLOSED SYSTEM FOR ISOLATING,

1207
00:43:14,258 --> 00:43:15,793
TRANSDUCING AND EXPANDING CELL

1208
00:43:15,859 --> 00:43:16,327
PROD UBIQUITINNATIONS.

1209
00:43:16,393 --> 00:43:18,595
UP THERE IN THE UPPER RIGHT HAND

1210
00:43:18,662 --> 00:43:21,432
CORNER AND JUST 1 EXAMPLE OF

1211
00:43:21,498 --> 00:43:23,534
MANY PIECES OF QC EQUIPMENT THAT

1212
00:43:23,600 --> 00:43:29,006
WE UTILIZE, THIS IS AN ADJUVANT

1213
00:43:29,073 --> 00:43:31,809
HPLC, FOR DETERMINING THE SISQP,

1214
00:43:31,875 --> 00:43:32,776
OF THE BIOLOGICAL PRODUCTS AND

1215
00:43:32,843 --> 00:43:35,879
THEN DOWN AT THE BOTTOM IS A

1216
00:43:35,946 --> 00:43:36,914
BRAND NEW SEMIAUTOFILLING

1217
00:43:36,981 --> 00:43:40,351
MACHINE THAT REPLACES OUR OLD

1218
00:43:40,417 --> 00:43:41,852
FLEXICON THAT HAS JUST BEEN

1219
00:43:41,919 --> 00:43:43,721
INSTALLED OVER THE LAST FEW

1220
00:43:43,787 --> 00:43:45,689
MONTHS AND HANDLES THOSE

1221
00:43:45,756 --> 00:43:49,560
AUTOMATED FILLS, UP TO 10 MILL

1222
00:43:49,626 --> 00:43:50,160
VIALS.

1223
00:43:50,227 --> 00:43:57,434
SO, THE BDP FOLLOWS WILL CODE

1224
00:43:57,501 --> 00:44:08,012
CODE OF FEDERAL RELATIONS, 21

1225
00:44:15,753 --> 00:44:17,121
CFR211, THIS PERTAINS--DOING ALL

1226
00:44:17,187 --> 00:44:18,889
THE GMP PRODUCTION AND THE

1227
00:44:18,956 --> 00:44:20,057
PRODUCT CONTROLS ASSOCIATE WIDE

1228
00:44:20,124 --> 00:44:24,495
THAT AND THE FINISH ASPECTS, THE

1229
00:44:24,561 --> 00:44:25,863
GENERATION AND MAINTENANCE AND

1230
00:44:25,929 --> 00:44:27,464
REPORTS ARE ALSO INCLUDED YOU

1231
00:44:27,531 --> 00:44:32,002
SHOULD THAT CODE OF FEDERAL

1232
00:44:32,069 --> 00:44:33,170
REGULATIONS AND BECAUSE THEY

1233
00:44:33,237 --> 00:44:35,205
FOCUS ON EARLY STAGE

1234
00:44:35,272 --> 00:44:37,508
DEVELOPMENT, SO FOR PHASE 1,

1235
00:44:37,574 --> 00:44:40,744
MAYBE PHASE 2, OR CERTAIN LYE

1236
00:44:40,811 --> 00:44:42,212
NONPIVOTAL CLINICAL TRIALS, THEY

1237
00:44:42,279 --> 00:44:44,048
HAVE ESTABLISHED A QUALITY

1238
00:44:44,114 --> 00:44:46,784
MANUEL THAT DRIEBS HOW THEY WILL

1239
00:44:46,850 --> 00:44:50,154
ADHERE TO 21 CFR211 BUT WITH AT

1240
00:44:50,220 --> 00:44:51,422
THE LEVEL THAT IS PHASE

1241
00:44:51,488 --> 00:44:54,925
APPROPRIATE AND THE FDA ACCEPTS

1242
00:44:54,992 --> 00:44:57,327
THIS FOR EARLY PHASE DEVELOPMENT

1243
00:44:57,394 --> 00:44:57,828
OF PRODUCTS.

1244
00:44:57,895 --> 00:44:59,263
DIGGING INTO A BIT MORE DETAIL

1245
00:44:59,329 --> 00:45:01,365
ON THIS, ON THE QUALITY SYSTEMS

1246
00:45:01,432 --> 00:45:03,567
WITH REGARDS TO ORGANIZATION AND

1247
00:45:03,634 --> 00:45:05,436
PERSONNEL, THE BDP PERSONNEL ARE

1248
00:45:05,502 --> 00:45:07,271
VERY HIGHLY TRAINED AND GO

1249
00:45:07,337 --> 00:45:11,708
THROUGH GMP TRAINING EVERY YEAR.

1250
00:45:11,775 --> 00:45:13,377
EACH PERSON HAS THEIR OWN

1251
00:45:13,444 --> 00:45:14,711
TRAINING CURRICULUM BASED ON

1252
00:45:14,778 --> 00:45:16,313
WHICH DEPARTMENT THEY'RE IN AND

1253
00:45:16,380 --> 00:45:23,353
JOB FUNCTION AND SPBTS QA AND QC

1254
00:45:23,420 --> 00:45:25,289
PROVIDE REGULATORY AND OVERSIGHT

1255
00:45:25,355 --> 00:45:27,157
AND VENTERS AND ALSO INTERNAL

1256
00:45:27,224 --> 00:45:29,460
AUDITING OF THE INTERNAL

1257
00:45:29,526 --> 00:45:31,862
DEVELOPMENT PROGRAMS AND THE

1258
00:45:31,929 --> 00:45:36,066
DEVELOPMENT GROUP AND THE

1259
00:45:36,133 --> 00:45:38,435
MANUFACTURING LABS HERE.

1260
00:45:38,502 --> 00:45:41,271
AS REQUIRED BY 21 CFR211 THE QA

1261
00:45:41,338 --> 00:45:43,073
GROUP HAS AN INDEPENDENT

1262
00:45:43,140 --> 00:45:44,041
REPORTING STRUCTURE THAN THE

1263
00:45:44,108 --> 00:45:47,111
REST OF THE MANUFACTURING AND

1264
00:45:47,177 --> 00:45:49,413
DEVELOPMENT GROUP AT BDP.

1265
00:45:49,480 --> 00:45:52,783
WITH REGARDS TO DOCUMMATION

1266
00:45:52,850 --> 00:45:54,685
THERE'S STANDARD OPERATING

1267
00:45:54,751 --> 00:45:56,887
PROCEDURES FOR EVERY ASPECT OF

1268
00:45:56,954 --> 00:45:58,889
THE PROGRAM INCLUDING

1269
00:45:58,956 --> 00:46:00,224
MANUFACTURING, QC TESTING,

1270
00:46:00,290 --> 00:46:01,959
FACILITY OPERATIONS, EQUIM

1271
00:46:02,025 --> 00:46:06,630
OPERATIONS, AND ENVIRONMENTAL

1272
00:46:06,697 --> 00:46:08,532
MONITORING THERE ARE MASTER

1273
00:46:08,599 --> 00:46:09,133
PRODUCTIONS RECORDS FOR EACH

1274
00:46:09,199 --> 00:46:10,534
PRODUCT AND THEN DURING THE

1275
00:46:10,601 --> 00:46:11,735
MANUFACTURING RUN A BATCH

1276
00:46:11,802 --> 00:46:14,004
PRODUCTION RECORD IS COMPLETED

1277
00:46:14,071 --> 00:46:16,440
UNTIL THAT FOR APPROPRIATE DOCK

1278
00:46:16,507 --> 00:46:18,175
ULTIMATELIATION, QC TEST REPORTS

1279
00:46:18,242 --> 00:46:21,578
ARE GENERATED ACCORDING TO 21

1280
00:46:21,645 --> 00:46:23,947
CFR 211 AND THE PRODUCTS ALL

1281
00:46:24,014 --> 00:46:25,482
INCLUDE MASTER SPECIFICATIONS

1282
00:46:25,549 --> 00:46:28,018
AND CERTIFICATES OF ANALYSIS

1283
00:46:28,085 --> 00:46:29,153
ASSOCIATED WITH THEM.

1284
00:46:29,219 --> 00:46:32,256
THE UTILIZED MASTER CONTROL AS

1285
00:46:32,322 --> 00:46:33,290
OUR VALIDATED ELECTRONIC

1286
00:46:33,357 --> 00:46:34,091
DOCUMENT MANAGEMENT SYSTEM THAT

1287
00:46:34,158 --> 00:46:36,360
HOLDS ALL OF THE SOPs,

1288
00:46:36,426 --> 00:46:40,097
TRAINING RECORDS AND MASTER

1289
00:46:40,164 --> 00:46:41,031
PRODUCTION RECORDS.

1290
00:46:41,098 --> 00:46:43,700
WITH REGARDS TO FACILITIES AND

1291
00:46:43,767 --> 00:46:46,203
EQUIPMENT, THE FACILITY BEFORE

1292
00:46:46,270 --> 00:46:47,571
CONSTRUCTION WAS INITIATED IN

1293
00:46:47,638 --> 00:46:49,840
2011 WENT THROUGH AN FDA REVIEW

1294
00:46:49,907 --> 00:46:51,942
AND A TYPE-C MEETING SO WE GO

1295
00:46:52,009 --> 00:46:54,411
BUY-IN ON THE FDAOT DESIGN

1296
00:46:54,478 --> 00:46:57,848
FACILITY, ALL THE UTILITIES AND

1297
00:46:57,915 --> 00:47:00,017
STERILIZATION ARE UNDERGO RECERT

1298
00:47:00,083 --> 00:47:02,186
IVENGZ EACH YEAR.

1299
00:47:02,252 --> 00:47:02,786
QUANTITATIVE INSTRUMENTATION,

1300
00:47:02,853 --> 00:47:05,255
ALSO ARE ON ANY CALIBRATION

1301
00:47:05,322 --> 00:47:06,089
PROGRAM, REGULAR CALIBRATION

1302
00:47:06,156 --> 00:47:09,293
PROGRAM AND THEN PRODUCT CONTACT

1303
00:47:09,359 --> 00:47:09,960
EQUIPMENT AND VALIDATED, REALLY

1304
00:47:10,027 --> 00:47:12,563
DON'T HAVE THE RESOURCES TO DO

1305
00:47:12,629 --> 00:47:13,430
COMPLETE VALIDATION ON EVERY

1306
00:47:13,497 --> 00:47:15,766
SINGLE PIECE OF EQUIPMENT, SO WE

1307
00:47:15,832 --> 00:47:17,467
UTILIZE A RISK BASED APPROACH,

1308
00:47:17,534 --> 00:47:19,836
BASED ON PRODUCT SAFETY AND

1309
00:47:19,903 --> 00:47:20,871
QUALITY IMPACT ASSESSMENT.

1310
00:47:20,938 --> 00:47:23,040
THE AUTOMATED PHONE EQUIPMENT IS

1311
00:47:23,106 --> 00:47:26,543
REVALIDATED WITHIN 6 MONTHS OF A

1312
00:47:26,610 --> 00:47:27,511
PRODUCT FILL.

1313
00:47:27,578 --> 00:47:30,981
WITH REGARDS TO MANUFACTURING,

1314
00:47:31,048 --> 00:47:32,849
RAW MATERIALS ARE ASSIGNED PART

1315
00:47:32,916 --> 00:47:34,451
NUMBERS,A CORDING TO

1316
00:47:34,518 --> 00:47:39,256
REGULATIONS, THEY EACH HAVE

1317
00:47:39,323 --> 00:47:42,259
THEIR OWN SET OF PRODUCT CONTENT

1318
00:47:42,326 --> 00:47:44,094
AND THEN WHAT'S INTERESTING IS

1319
00:47:44,161 --> 00:47:46,396
THAT RECEIVING NUMBERS ARE

1320
00:47:46,463 --> 00:47:48,065
ASSIGNED TO EACH PACKAGE THAT'S

1321
00:47:48,131 --> 00:47:48,599
RECEIVED.

1322
00:47:48,665 --> 00:47:51,668
O IF WE ORDER A RAW--SO IF WE

1323
00:47:51,735 --> 00:47:53,503
ORDER A RAW MATERIAL OF THE SAME

1324
00:47:53,570 --> 00:47:55,038
VENDOR OF THE SAME MANUFACTURING

1325
00:47:55,105 --> 00:47:57,140
LOT BUT IT'S RECEIVED ON 2

1326
00:47:57,207 --> 00:47:59,409
SEPARATE DAYS, EACH 1 OF THOSE

1327
00:47:59,476 --> 00:48:01,311
ARE--EACH 1 OF THOSE SHIPMENTS

1328
00:48:01,378 --> 00:48:02,579
RECEIVE A SEPARATE NUMBER FOR

1329
00:48:02,646 --> 00:48:04,481
APPROPRIATE TRACKING IS REQUIRED

1330
00:48:04,548 --> 00:48:05,148
BY THE REGULATION.

1331
00:48:05,215 --> 00:48:09,319
ALL OF OUR FACILITIES AND AREA

1332
00:48:09,386 --> 00:48:10,821
CLEARANCES ARE   PERFORMED BY QA

1333
00:48:10,887 --> 00:48:13,156
AND BATCH PRODUCTION RECORDS AS

1334
00:48:13,223 --> 00:48:16,193
I MENTIONED EARLIER, DOCUMENT A

1335
00:48:16,260 --> 00:48:18,829
PRODUCTION PROCESS, THE FULL

1336
00:48:18,895 --> 00:48:20,464
FINISH AND CRITICAL GENE

1337
00:48:20,530 --> 00:48:22,766
MANUFACTURING STEPS INCLUDE AN

1338
00:48:22,833 --> 00:48:25,235
IN-PERSON QA OBSERVATION TO

1339
00:48:25,302 --> 00:48:28,805
MONITOR AND ASSURE THAT STEPS

1340
00:48:28,872 --> 00:48:30,707
ARE BEING CONDUCTED AS

1341
00:48:30,774 --> 00:48:31,074
INSTRUCTED.

1342
00:48:31,141 --> 00:48:33,477
QA REVIEWS THESE COMPLETED BATCH

1343
00:48:33,543 --> 00:48:35,178
PRODUCTIONS RECORDS AND RELEASES

1344
00:48:35,245 --> 00:48:37,547
PRODUCTS FOR CLINICAL USE AND

1345
00:48:37,614 --> 00:48:39,249
THE REGULATORY GROUP GENERATES

1346
00:48:39,316 --> 00:48:40,917
THE CHEMISTRY MATERIALS AND

1347
00:48:40,984 --> 00:48:44,021
CONTROL, DOCUMENT FOR REGULATORY

1348
00:48:44,087 --> 00:48:44,354
FILING.

1349
00:48:44,421 --> 00:48:45,656
SO NOW MIEWFING INTO WHAT I

1350
00:48:45,722 --> 00:48:47,291
WOULD LIKE TO HIGHLIGHT SOME OF

1351
00:48:47,357 --> 00:48:49,026
THE RECENT CAPABILITIES, THAT

1352
00:48:49,092 --> 00:48:51,428
THE BDP HAS ESTABLISHED AND SOME

1353
00:48:51,495 --> 00:48:53,163
FOLKS IN THIS COMMITTEE HAVE

1354
00:48:53,230 --> 00:48:55,699
HEARD SOME PRESENTATIONS ON

1355
00:48:55,766 --> 00:48:58,235
THIS, BUT ABOUT 5 OR 6 YEARS AGO

1356
00:48:58,302 --> 00:49:02,606
OR SO, WE ASK BDP TO SET UP A

1357
00:49:02,673 --> 00:49:06,576
CAPABILITY TO DEVELOP AND

1358
00:49:06,643 --> 00:49:07,311
MANUFACTURE AHATOLOGIOUS KARKS-T

1359
00:49:07,377 --> 00:49:08,545
CELL PROD UBIQUITINNATIONS AND

1360
00:49:08,612 --> 00:49:09,713
THEY DID THAT SUCCESSFULLY AND

1361
00:49:09,780 --> 00:49:11,381
FOR THE LAST FEW YEARS WE'VE

1362
00:49:11,448 --> 00:49:12,249
BEEN SUPPORTING CLINICAL TRIALS

1363
00:49:12,316 --> 00:49:14,685
WITH THE NUMBER OF NEW CLINICAL

1364
00:49:14,751 --> 00:49:15,485
TRIALS COMING ONLINE PRETTY SOON

1365
00:49:15,552 --> 00:49:20,424
THAT WILL BE SUPPORTING.

1366
00:49:20,490 --> 00:49:22,159
SO WHAT THIS CAPABILITY

1367
00:49:22,225 --> 00:49:24,594
ENCOMPASSES IS 5 GMP SUITES, 2

1368
00:49:24,661 --> 00:49:26,363
ARE FLEXIBLE FOR VIRUS

1369
00:49:26,430 --> 00:49:27,097
MANUFACTURING, INCORPORATE

1370
00:49:27,164 --> 00:49:27,764
CLOSED MANUFACTURING SYSTEMS

1371
00:49:27,831 --> 00:49:37,974
LIKE THE PRODIGY EQUIPMENT I

1372
00:49:38,041 --> 00:49:39,176
SHOWED EARLIER, PROCESS

1373
00:49:39,242 --> 00:49:40,877
VALIDATIONS ARE ESTABLISHED TO,A

1374
00:49:40,944 --> 00:49:43,613
SURE QUALITY HIGH QUALITY AND

1375
00:49:43,680 --> 00:49:48,685
STERILITY OF THE PRODUCT.

1376
00:49:48,752 --> 00:49:49,619
PROCESS QUALIFICATION IS

1377
00:49:49,686 --> 00:49:51,054
ESTABLISHED AS WELL, AND WHAT

1378
00:49:51,121 --> 00:49:53,023
THIS DOES IS ALLOWED FOR A VERY

1379
00:49:53,090 --> 00:49:54,191
RAPID PRODUCT RELEASE AS YOU CAN

1380
00:49:54,257 --> 00:49:57,694
SEE FROM THE DIAGRAM THERE WITH

1381
00:49:57,761 --> 00:50:02,799
TEABED WITHIN 10 WEEKS OR SO THE

1382
00:50:02,866 --> 00:50:05,035
BDP AND FOR THE STARTING

1383
00:50:05,102 --> 00:50:05,535
MATERIAL.

1384
00:50:05,602 --> 00:50:08,805
THE BDP IS ALSO ESTABLISHED

1385
00:50:08,872 --> 00:50:09,973
SHIPPING AND PRODUCT WAS

1386
00:50:10,040 --> 00:50:13,443
LOGISTICS THAT ARE CAPABLE OF

1387
00:50:13,510 --> 00:50:14,478
SUPPORTING MULTICENTERRED TRIALS

1388
00:50:14,544 --> 00:50:16,546
WITH THE BDP BEING THE CENTRAL

1389
00:50:16,613 --> 00:50:18,181
MANUFACTURING SITE AND WHAT THIS

1390
00:50:18,248 --> 00:50:21,151
ENDS UP BEING OR PRODUCING IS A

1391
00:50:21,218 --> 00:50:22,119
REALLY GOOD QUALITY

1392
00:50:22,185 --> 00:50:24,654
MANUFACTURING PROCESS TO ADD

1393
00:50:24,721 --> 00:50:26,123
RIGOR AND REPRODUCIBILITY TO THE

1394
00:50:26,189 --> 00:50:26,990
CLINICAL RESEARCH PROGRAM

1395
00:50:27,057 --> 00:50:28,592
THEY'RE SUPPORTING.

1396
00:50:28,658 --> 00:50:30,127
AND BY SUPPORTING MULTISITE

1397
00:50:30,193 --> 00:50:31,428
CLINICAL TRIALS, IT REALLY

1398
00:50:31,495 --> 00:50:33,730
BENEFIT, IT REALLY HAS A

1399
00:50:33,797 --> 00:50:37,434
POSITIVE IMPACT ON RURAL RATES

1400
00:50:37,501 --> 00:50:39,836
OF THESE TRIALS.

1401
00:50:39,903 --> 00:50:42,305
SO ASSOCIATED WITH THE CELL

1402
00:50:42,372 --> 00:50:43,673
THERAPY PLATFORM ESTABLISHMENT,

1403
00:50:43,740 --> 00:50:46,109
THE BDP HAS ALSO ESTABLISHED

1404
00:50:46,176 --> 00:50:48,745
PLATFORMS FOR PRODUCING GMP

1405
00:50:48,812 --> 00:50:49,946
GRADE LENTIVIRUS AND GAMMA VIRUS

1406
00:50:50,013 --> 00:50:51,047
THAT ARE USED FOR ENGINEERING

1407
00:50:51,114 --> 00:50:55,585
THE CELL PROD YOUS.

1408
00:50:55,652 --> 00:51:02,025
LENTIVIRUS PLATFORM CONSISTS OF

1409
00:51:02,092 --> 00:51:05,629
HEK293 CELL BRAINK AND IT'S A

1410
00:51:05,695 --> 00:51:07,030
TRANSVEKS PROCESS ALONG WITH THE

1411
00:51:07,097 --> 00:51:09,733
YEEN OF PLASMA THAT'S EXPRESSING

1412
00:51:09,800 --> 00:51:11,601
THE CAR CONSTRUCT, THE

1413
00:51:11,668 --> 00:51:15,305
LENTIVIRUS PLATFORM INCLUDES A

1414
00:51:15,372 --> 00:51:16,640
CHROMATOGRAPHY AND AFFAIRS TEAM

1415
00:51:16,706 --> 00:51:18,675
LEADERRER FILTRATION STEP TO

1416
00:51:18,742 --> 00:51:19,609
INCREASE CONCENTRATION AND

1417
00:51:19,676 --> 00:51:21,778
PURITY OF THE VECTOR.

1418
00:51:21,845 --> 00:51:23,947
THIS IS A SUSPENSION BASED

1419
00:51:24,014 --> 00:51:26,616
CULTURE THAT IS CURRENTLY AT THE

1420
00:51:26,683 --> 00:51:31,188
10 LITER SCALE WHICH, YOU KNOW

1421
00:51:31,254 --> 00:51:32,856
SATISFIES OUR SAFETY HERE AT THE

1422
00:51:32,923 --> 00:51:34,257
FREDERICK NATIONAL LAB AS WELL

1423
00:51:34,324 --> 00:51:38,562
AS MEETS THE CLINICAL NEED FOR

1424
00:51:38,628 --> 00:51:39,296
MANUFACTURING FOR--AT LEAST 1

1425
00:51:39,362 --> 00:51:41,264
PHASE 1 TRIAL, IF NOT 2.

1426
00:51:41,331 --> 00:51:44,134
BUT BECAUSE THE CELLS ARE IN

1427
00:51:44,201 --> 00:51:45,902
SUSPENSION PLATFORM, THIS IS A

1428
00:51:45,969 --> 00:51:47,070
SCALABLE PROCESS, SO IF MORE

1429
00:51:47,137 --> 00:51:48,672
MATERIAL IS NEEDED OR IT NEEDS

1430
00:51:48,738 --> 00:51:51,107
TO BE TECH TRANSFERRED TO

1431
00:51:51,174 --> 00:51:52,175
COMMERCIAL ENTITY, THAT CAN

1432
00:51:52,242 --> 00:51:54,945
EASILY SCALE UP PRODUCTION, NOW

1433
00:51:55,011 --> 00:51:59,115
AGAIN A RETROVIRUS, PRODUCTION

1434
00:51:59,182 --> 00:52:00,617
PLATFORM, RETROVIRUSES ARE MORE

1435
00:52:00,684 --> 00:52:02,118
LABEL THAN LENTIVIRUSES SO THEY

1436
00:52:02,185 --> 00:52:03,320
CAN'T STAND THE CHROMATOGRAPHY

1437
00:52:03,386 --> 00:52:05,288
TEPS SO THIS PURIFICATION

1438
00:52:05,355 --> 00:52:07,591
PROCESS, IT'S A TRANSIENT

1439
00:52:07,657 --> 00:52:09,159
TRANSFECTION BASED PROCESS, 10

1440
00:52:09,226 --> 00:52:10,126
LITER SCALE, SUSPENSION CELL

1441
00:52:10,193 --> 00:52:12,662
LINE THAT, YOU KNOW THAT IS AS

1442
00:52:12,729 --> 00:52:15,065
PRODUCED BY JUST CLARIFYING

1443
00:52:15,131 --> 00:52:17,367
SUPER 98ENT AND THEN

1444
00:52:17,434 --> 00:52:22,506
CONCENTRATING THE YIELD OF THE

1445
00:52:22,572 --> 00:52:26,176
LENDY VIRUSES RANGES FROM

1446
00:52:26,243 --> 00:52:27,310
10-SEVENTH, TO 1 TIMES TO THE

1447
00:52:27,377 --> 00:52:31,715
NINTH IN THE LINE, AND THE

1448
00:52:31,781 --> 00:52:32,449
RETROVIRUS PRODUCTIVITY IS

1449
00:52:32,516 --> 00:52:33,783
SOMEWHERE BETWEEN 5 TIMES TO THE

1450
00:52:33,850 --> 00:52:37,287
SIXTH AND 5 TIMES TO THE SEVENTH

1451
00:52:37,354 --> 00:52:38,088
TRANSDUCTION UNITS   PERMILL

1452
00:52:38,154 --> 00:52:41,191
BASED ON THE INDICATOR LINE.

1453
00:52:41,258 --> 00:52:43,693
SO ANOTHER RECENT TECHNOLOGY AND

1454
00:52:43,760 --> 00:52:48,798
CAPABILITY BDP HAS STOOD UP IS

1455
00:52:48,865 --> 00:52:49,966
CRSPR CELL BASED ENGINEERING.

1456
00:52:50,033 --> 00:52:51,635
THEY'VE BEEN ABE TO SOURCE ALL

1457
00:52:51,701 --> 00:52:54,104
THE STARTING MATERIALS FROM GMP

1458
00:52:54,170 --> 00:52:55,605
COMPLIANT SOURCES INCLUDING THE

1459
00:52:55,672 --> 00:52:58,375
GUIDE RNAs, THAT THE CAS 9

1460
00:52:58,441 --> 00:53:01,244
PROTEIN AND THE DNA TEMPLATE

1461
00:53:01,311 --> 00:53:04,481
THAT'S USED FOR INTRODUCING IN

1462
00:53:04,548 --> 00:53:05,282
THIS CASE, PARSIGNIFYQUENCE OR

1463
00:53:05,348 --> 00:53:06,483
ANYTHING ELSE THAT NEEDS TO BE

1464
00:53:06,550 --> 00:53:10,086
INTRODUCED INTO THE CELLS.

1465
00:53:10,153 --> 00:53:11,555
SO IT'S AN ELECTROPRORATION

1466
00:53:11,621 --> 00:53:13,957
BASED PROCESSION AND THE BDP HAS

1467
00:53:14,024 --> 00:53:16,726
BEEN ABLE TO DEMON TRAIT

1468
00:53:16,793 --> 00:53:18,295
EFFICIENT, ENDOGENOUS PC R KNOCK

1469
00:53:18,361 --> 00:53:22,666
OUT GREATER THAN 98% AT BOTH OF

1470
00:53:22,732 --> 00:53:26,336
THOSE SITES AND EFFICIENCY OF

1471
00:53:26,403 --> 00:53:28,104
WHAT UP TO 40% WHICH IS GOOD

1472
00:53:28,171 --> 00:53:28,738
CONSIDERING THE RECENT REPORTS

1473
00:53:28,805 --> 00:53:31,575
IN THE FIELD OF THE AVERAGE

1474
00:53:31,641 --> 00:53:33,577
AROUND 15-TBEPT% WITH TWEAKS TO

1475
00:53:33,643 --> 00:53:38,315
THE BDP'S GODDEN UP TO 40%

1476
00:53:38,381 --> 00:53:38,949
KNOCK-IN EFFICIENCY.

1477
00:53:39,015 --> 00:53:42,719
I WANT TO HIGHLIGHT A FEW OF THE

1478
00:53:42,786 --> 00:53:43,653
SUCCESSFUL COMMERCIALIZATION AND

1479
00:53:43,720 --> 00:53:44,354
PRODUCT LICENSURES THAT HAVE

1480
00:53:44,421 --> 00:53:50,594
COME OUT OF THE BDP, SO WE'VE

1481
00:53:50,660 --> 00:53:51,428
GOT [INDISCERNIBLE] WHICH HAS

1482
00:53:51,494 --> 00:53:53,296
BEEN PULLED FROM THE MARKET BUT

1483
00:53:53,363 --> 00:53:54,598
THIS WAS THE FIRST PRODUCT THAT

1484
00:53:54,664 --> 00:54:01,571
THE BDP SAW GO-2

1485
00:54:01,638 --> 00:54:04,074
COMMERCIALIZEITIONS ANTICD TOXIN

1486
00:54:04,140 --> 00:54:07,410
FOR HAIRY CELL LEUKEMIA,UNE

1487
00:54:07,477 --> 00:54:12,649
TUXIN FOR PEDIATRIC

1488
00:54:12,716 --> 00:54:13,316
NEUROBLASTOMA, LERAPOLTUREV, IS

1489
00:54:13,383 --> 00:54:15,585
IN THE LATE STAGES OF

1490
00:54:15,652 --> 00:54:18,888
COMMERCIALIZATION AND THAT IS

1491
00:54:18,955 --> 00:54:20,523
RECOMBIN ANT POLIO VIRUS

1492
00:54:20,590 --> 00:54:22,726
PROVIDED BY THE PROGRAMS HERE

1493
00:54:22,792 --> 00:54:26,563
THAT IS DEVELOPED BY ISTARI, FOR

1494
00:54:26,630 --> 00:54:29,199
GLUE MARIOUS O BLASTOMA,

1495
00:54:29,265 --> 00:54:30,266
MELANOMA, NONMUSCLE INVASIVE

1496
00:54:30,333 --> 00:54:31,768
BLADDER CANCER AND THEN ANOTHER

1497
00:54:31,835 --> 00:54:36,806
PRODUCT INITIALLY DEVELOPED HERE

1498
00:54:36,873 --> 00:54:41,745
IS ANSELAMIMAB, IT TARGETS THE

1499
00:54:41,811 --> 00:54:45,849
GAMMA LIKE CHAIN THAT'S IN

1500
00:54:45,915 --> 00:54:48,785
AMYLOID PLAQUES FOR PRIMARY

1501
00:54:48,852 --> 00:54:51,388
AMYLOIDOSEIS AND THAT'S BY

1502
00:54:51,454 --> 00:54:51,655
ALEXION.

1503
00:54:51,721 --> 00:54:52,956
SO NOW I WANT TO HIGHLIGHT AND

1504
00:54:53,023 --> 00:54:53,957
GO INTO MORE DETAIL ON THE

1505
00:54:54,024 --> 00:54:55,025
SUPPORT EXPOSURE TO RADIATIONS

1506
00:54:55,091 --> 00:54:59,562
THAT THE BDP IS PROVIDING FOR

1507
00:54:59,629 --> 00:55:01,998
THE CELL THERAPY COMMUNITY AND

1508
00:55:02,065 --> 00:55:05,769
FOR THE CANCER CELL THERAPY

1509
00:55:05,835 --> 00:55:06,269
ADOPTIVE NETWORK.

1510
00:55:06,336 --> 00:55:08,738
SO WHEN THEY TOAD UP THEIR

1511
00:55:08,805 --> 00:55:10,106
MANUFACTURING PLATFORM AND

1512
00:55:10,173 --> 00:55:12,942
CAPABILITY, 1 OF THE FIRST TASKS

1513
00:55:13,009 --> 00:55:17,213
WAS TO SUPPORT A MULTISITE

1514
00:55:17,280 --> 00:55:19,416
CLINICAL TRIAL FOR RELAPSE OR

1515
00:55:19,482 --> 00:55:22,719
FACTORY AML, YOUNG ADULT ANDS IN

1516
00:55:22,786 --> 00:55:23,253
CHILDREN.

1517
00:55:23,319 --> 00:55:26,523
THIS IS A I&  D SPONSORED BY THE

1518
00:55:26,589 --> 00:55:27,457
NATIONAL MARROW DONOR PROGRAM

1519
00:55:27,524 --> 00:55:29,793
AND THE PRIMARY STUDY PI IS AT

1520
00:55:29,859 --> 00:55:31,761
THE CENTER FOR CANCER RESEARCH.

1521
00:55:31,828 --> 00:55:36,866
AND SO TO DATE, THE BDP HAS

1522
00:55:36,933 --> 00:55:39,302
PRODUCED 26 PRODUCTS,

1523
00:55:39,369 --> 00:55:41,471
SUCCESSFULLY, AND HAVE SUPPORTED

1524
00:55:41,538 --> 00:55:43,406
THE CLINICAL TRIAL UP TO THE

1525
00:55:43,473 --> 00:55:44,674
MAXIMUM TOLERATED DOSE AS YOU

1526
00:55:44,741 --> 00:55:48,378
SEE THERE, 10 TO THE SEVENTH

1527
00:55:48,445 --> 00:55:49,546
CELL KILOGRAM, UNFORTUNATELY,

1528
00:55:49,612 --> 00:55:50,714
ALTHOUGH THE MANUFACTURING WAS

1529
00:55:50,780 --> 00:55:53,083
VERY SUCCESSFUL LEER AT THE BDP,

1530
00:55:53,149 --> 00:55:58,121
THIS ARM OF THE STUDY DID WAS

1531
00:55:58,188 --> 00:56:03,426
HALTED FOR FUTILITY BUT THE

1532
00:56:03,493 --> 00:56:04,761
CLINICAL PROGRAM KD--SALLY XA

1533
00:56:04,828 --> 00:56:08,531
HAS BEEN ABLE TO FILE AN I&  D

1534
00:56:08,598 --> 00:56:09,933
AMENDMENT TO ADD AN ALOE

1535
00:56:09,999 --> 00:56:11,234
GENERATED AIC ARM TO THE STUDY

1536
00:56:11,301 --> 00:56:14,437
WHICH WILL USE CELLS FROM

1537
00:56:14,504 --> 00:56:16,072
HEALTHY HLA MATCHED DONORS FROM

1538
00:56:16,139 --> 00:56:17,707
AML PATIENT ANDS THE BDP WILL

1539
00:56:17,774 --> 00:56:21,344
MANUFACTURE FOR THAT ARM

1540
00:56:21,411 --> 00:56:21,945
SHORTLY.

1541
00:56:22,011 --> 00:56:24,481
ANOTHER MULTISITE TRIAL THAT IS

1542
00:56:24,547 --> 00:56:30,086
ONGOING AND SPONSORED BY DCTD,

1543
00:56:30,153 --> 00:56:31,821
THROUGH INITIALLY THE PICN, AND

1544
00:56:31,888 --> 00:56:33,323
NOW IT'S TRANSITIONED OVER TO

1545
00:56:33,389 --> 00:56:36,893
THE PET CTN NETWORK, SO THIS BPI

1546
00:56:36,960 --> 00:56:39,829
IS ROSIE CAP LANAT CCR AND THIS

1547
00:56:39,896 --> 00:56:45,335
IS A GD2 TARGETED CAR-T FOR

1548
00:56:45,401 --> 00:56:46,936
OSTEOSARCOMA OR NEUROBLASTOMA.

1549
00:56:47,003 --> 00:56:49,672
THE BDP HAS MANUFACTURED PRODUCT

1550
00:56:49,739 --> 00:56:50,974
FOR THE FIRST DOSE LEVEL, IT WAS

1551
00:56:51,040 --> 00:56:56,079
DETERMINED THAT THIS WAS THE

1552
00:56:56,146 --> 00:57:00,283
BTD, AND THE NEXT STEP WAS TO GO

1553
00:57:00,350 --> 00:57:02,852
DOWN AND ONCE THE TRANSFER HAS

1554
00:57:02,919 --> 00:57:04,220
BEEN SUCCESSFULLY MOVED TO PEP

1555
00:57:04,287 --> 00:57:05,622
CTN THEN THEY WILL RESUME

1556
00:57:05,688 --> 00:57:10,760
MANUFACTURING FOR THIS MULTISITE

1557
00:57:10,827 --> 00:57:10,960
TRIAL.

1558
00:57:11,027 --> 00:57:16,432
OKAY AND NOW KIND OF OUR LATEST

1559
00:57:16,499 --> 00:57:19,636
AND MUCH MORE VERY CHALLENGING

1560
00:57:19,702 --> 00:57:21,471
STEP IN CELL THERAPY WORLD AND

1561
00:57:21,538 --> 00:57:24,808
SUPPORT FOR THE RECENTLY FUNDED

1562
00:57:24,874 --> 00:57:26,643
CANCER ADOPTIVE CELL THERAPY

1563
00:57:26,709 --> 00:57:29,245
NETWORK OR CAN ACT.

1564
00:57:29,312 --> 00:57:31,681
THIS NETWORK HAS BEEN SET UP TO

1565
00:57:31,748 --> 00:57:33,817
FOSTER INNOVATION AND PROMOTE

1566
00:57:33,883 --> 00:57:36,319
EARLY STAGE CLINICAL TESTING OF

1567
00:57:36,386 --> 00:57:38,855
NOVEL IMMUNO CELL BASED THERAPY

1568
00:57:38,922 --> 00:57:40,590
FOR SOLID TUMORS IN ADULTS AND

1569
00:57:40,657 --> 00:57:42,258
PEDIATRIC PATIENT ANDS IT REALLY

1570
00:57:42,325 --> 00:57:44,227
LEVERAGES OUR RESOURCES HERE AT

1571
00:57:44,294 --> 00:57:46,963
THE FREDERICK NATIONAL LAB

1572
00:57:47,030 --> 00:57:47,864
INCLUDING THE BIOPHARMACEUTICAL

1573
00:57:47,931 --> 00:57:49,566
DEVELOPMENT PROGRAM TO SUPPORT

1574
00:57:49,632 --> 00:57:50,233
THESE IMRANTS.

1575
00:57:50,300 --> 00:57:52,435
SO YOU KNOW THE GOALS STATED

1576
00:57:52,502 --> 00:57:54,404
THERE DEVELOP AND ENHANCE

1577
00:57:54,470 --> 00:57:55,805
CELLULAR PRODUCTS, EITHER

1578
00:57:55,872 --> 00:57:57,207
GENETICALLY MODIFIED OR THRAW

1579
00:57:57,273 --> 00:57:58,274
OTHER MANIPULATIONS FOR

1580
00:57:58,341 --> 00:58:00,276
TREATMENT OF ADULLS AND

1581
00:58:00,343 --> 00:58:01,511
PEDIATRIC SOLID TUMORS, SUPPORT

1582
00:58:01,578 --> 00:58:04,113
EARLY PHASE CLENICAL TRIALS,

1583
00:58:04,180 --> 00:58:05,648
EXPLORE IMAGING AND BIOMARKER

1584
00:58:05,715 --> 00:58:06,182
DEVELOPMENT, EXPAND OUR

1585
00:58:06,249 --> 00:58:07,483
UNDERSTANDING OF THE MECHANISMS

1586
00:58:07,550 --> 00:58:10,920
OF ACTION AS WELL AS RESISTANCE

1587
00:58:10,987 --> 00:58:13,723
MECHANISMS THAT SPRING UP AND

1588
00:58:13,790 --> 00:58:15,959
EVALUATE STRATEGIES TO MODULATE

1589
00:58:16,025 --> 00:58:17,026
THE IMMUNOSUPPRESSIVE TUMOR

1590
00:58:17,093 --> 00:58:17,660
MICROENVIRONMENT.

1591
00:58:17,727 --> 00:58:20,263
SO I KIND OF AMPLIFIED THE

1592
00:58:20,330 --> 00:58:22,665
BUBBLE FOR THE IC N CORE BECAUSE

1593
00:58:22,732 --> 00:58:24,667
IT PERTAINS TO THE SUPPORT THAT

1594
00:58:24,734 --> 00:58:26,202
THE BDP IS PROVIDING TO THIS

1595
00:58:26,269 --> 00:58:28,304
NETWORK BUT JUST TO GIVE YOU AN

1596
00:58:28,371 --> 00:58:29,606
UPDATE, THIS NETWORK IS IN THE

1597
00:58:29,672 --> 00:58:30,406
PRACTICES ASSESSES OF BEING

1598
00:58:30,473 --> 00:58:32,775
ESTABLISHED SO RIGHT NOW WE HAVE

1599
00:58:32,842 --> 00:58:35,578
FUNDED THE 4 DARK BLUE BUBBLES,

1600
00:58:35,645 --> 00:58:38,815
THE 4 ADULT UG3 GRANTS AND THE

1601
00:58:38,882 --> 00:58:39,382
U24 COORDINATING CENTER.

1602
00:58:39,449 --> 00:58:43,953
WE ARE IN THE PROCESS OF

1603
00:58:44,020 --> 00:58:45,455
REVIEWING, GRANT REVIEWING FOR

1604
00:58:45,521 --> 00:58:47,156
THE PEDIATRIC INDICATIONS AND

1605
00:58:47,223 --> 00:58:49,359
HOPE TO GET AT LEAST 1 IF NOT 2

1606
00:58:49,425 --> 00:58:53,663
OF THOSE GRANTS FUNDED IN THE

1607
00:58:53,730 --> 00:58:58,635
NEXT 6 TO 8 MONTHS AND A SERIES

1608
00:58:58,701 --> 00:59:02,839
OF OF SUPLEMS ARE ANTICIPATED TO

1609
00:59:02,906 --> 00:59:04,507
BRING IN P30, P50 CANCER

1610
00:59:04,574 --> 00:59:14,717
TRUSTEES AFFILIATES INTO THE

1611
00:59:14,784 --> 00:59:15,518
NETWORK.

1612
00:59:15,585 --> 00:59:18,388
SO RIGHT NOW OF THE 4 GRANTS, 3

1613
00:59:18,454 --> 00:59:21,524
OF THOSE ARE USING THE LAB,

1614
00:59:21,591 --> 00:59:23,626
IMMUNE CELL CORE, THE BDP IS

1615
00:59:23,693 --> 00:59:26,629
PART OF THAT CORE, OR THE ICN

1616
00:59:26,696 --> 00:59:26,829
CORE.

1617
00:59:26,896 --> 00:59:30,767
THE CRITERIA ARE IF GETTING BDP

1618
00:59:30,833 --> 00:59:32,735
SUPPORT OR ICN SUPPORT IS THAT

1619
00:59:32,802 --> 00:59:34,404
THE APPLICANTS HAPPENED TO HAVE

1620
00:59:34,470 --> 00:59:36,372
PLANNED A MULTISITE CLINICAL

1621
00:59:36,439 --> 00:59:38,174
TRIAL CAN LEVERAGED THE

1622
00:59:38,241 --> 00:59:40,510
LOGISTICS CAPABILITIES OF THE

1623
00:59:40,576 --> 00:59:43,680
BDP FOR CELL THERAPY

1624
00:59:43,746 --> 00:59:47,216
DISTRIBUTION PRODUCTS AND SO WE

1625
00:59:47,283 --> 00:59:51,587
HAVE THE 3 GRANTEES LISTED HERE,

1626
00:59:51,654 --> 00:59:54,023
MASSACHUSETTS GENERAL IS

1627
00:59:54,090 --> 00:59:56,326
DEVELOPING A CAR TSTRATEGY THAT

1628
00:59:56,392 --> 00:59:57,961
TARGETS MESOTHELIUM AS WELL AS

1629
00:59:58,027 --> 01:00:05,168
EXPRESSING A DUAL TARGETING

1630
01:00:05,234 --> 01:00:07,603
AGENT THAT TARGETS FIBROBLASTS

1631
01:00:07,670 --> 01:00:09,706
ACTIVATING PROTEIN AND CD3 TO

1632
01:00:09,772 --> 01:00:18,281
RECRUIT BI STANDERS T-CELLS,

1633
01:00:18,348 --> 01:00:20,249
BEATRIZ CARRENO, HAS AT THE

1634
01:00:20,316 --> 01:00:21,884
UNIVERSITY OF PENNSYLVANIA, HAS

1635
01:00:21,951 --> 01:00:25,855
A VERY CHALLENGING PROJECT THAT

1636
01:00:25,922 --> 01:00:29,325
INVOLVES TCR T-CELL STRATEGY

1637
01:00:29,392 --> 01:00:33,162
TARGETING USING MKRAS, AND THE

1638
01:00:33,229 --> 01:00:37,166
HLA 1101 AND IT INVOLVES CRSPR

1639
01:00:37,233 --> 01:00:38,601
BASE YEEN KNOCK OUT AS WELL AS

1640
01:00:38,668 --> 01:00:40,903
YET TO BE DETERMINED EXHAUSTION

1641
01:00:40,970 --> 01:00:42,071
MARKER KNOCK OUT AND

1642
01:00:42,138 --> 01:00:44,140
INTORPERATION OF A MYELOID CHECK

1643
01:00:44,207 --> 01:00:47,010
POINT INHIBITOR OF THE FORM OF

1644
01:00:47,076 --> 01:00:49,012
AN FCFV, SO THIS 1 WILL BE

1645
01:00:49,078 --> 01:00:49,846
XROAMLY CHALLENGING FOR THE

1646
01:00:49,912 --> 01:00:51,547
PROGRAM AND THEN LAST BUT NOT

1647
01:00:51,614 --> 01:00:59,956
LEAST IS A RECENT FUNDED GRANTEE

1648
01:01:00,023 --> 01:01:01,824
PRASAD, ADUSUMILLI, WITH

1649
01:01:01,891 --> 01:01:03,426
MEMORIAL SLOAN KETTERRING, THIS

1650
01:01:03,493 --> 01:01:07,430
IS DEVELOPING A CAR SPECIFIC

1651
01:01:07,497 --> 01:01:09,065
MESOTHELIN, AND INCORPORATING CO

1652
01:01:09,132 --> 01:01:11,501
STIMLATTORY FACTORS AS WELL AS

1653
01:01:11,567 --> 01:01:12,769
PD1 DOMINANT NEGATIVE RECEPTOR

1654
01:01:12,835 --> 01:01:14,604
AND EXPRESSION FOR CHECK POINT

1655
01:01:14,670 --> 01:01:16,205
BLOCKADE, BUT THE REQUIREMENT

1656
01:01:16,272 --> 01:01:18,074
FROM THE ICN CORE AND THE BDP

1657
01:01:18,141 --> 01:01:19,976
FOR THIS IS JUST THE VIRAL

1658
01:01:20,043 --> 01:01:21,277
VECTOR THAT'S USED FOR

1659
01:01:21,344 --> 01:01:24,647
EXPRESSING THE CAR CONSTRUCT.

1660
01:01:24,714 --> 01:01:26,616
SO THE BDP TASK AREAS THAT ARE

1661
01:01:26,682 --> 01:01:29,152
PART OF THIS ICN CORE INCLUDE

1662
01:01:29,218 --> 01:01:32,088
GUIDANCE ON QUALITY SYSTEMS AND

1663
01:01:32,155 --> 01:01:32,822
REGULATORY AFFAIRS, INCLUDING

1664
01:01:32,889 --> 01:01:35,324
THE DEVELOPMENT AND

1665
01:01:35,391 --> 01:01:37,493
STANDARDIZATION OF ASSAYS FOR

1666
01:01:37,560 --> 01:01:40,063
DETERMINING PRODUCT CRITICAL

1667
01:01:40,129 --> 01:01:41,097
QUALITY ATTRIBUTES, PROVIDING

1668
01:01:41,164 --> 01:01:43,232
REAGENTS AND SOPs TO THE NET,

1669
01:01:43,299 --> 01:01:44,133
AND PROVOIDING REGULATORY

1670
01:01:44,200 --> 01:01:45,034
GUIDANCE, TIMES IN THE FORM,

1671
01:01:45,101 --> 01:01:48,204
MAYBE IN THE FORM OF GMP AUDITS

1672
01:01:48,271 --> 01:01:51,340
OR,A CYSTANCE WITH REGULATORY

1673
01:01:51,407 --> 01:01:51,808
FILINGS.

1674
01:01:51,874 --> 01:01:52,675
BUT THE--REALLY THE MEAT AND

1675
01:01:52,742 --> 01:01:54,010
BONES OF THE SUPPORT HERE COME

1676
01:01:54,077 --> 01:01:56,813
FROM THE CAPABILITY TO SUPPORT

1677
01:01:56,879 --> 01:01:58,314
MULTITRIAL GMP PRODUCTION,

1678
01:01:58,381 --> 01:02:02,218
INCLUDES DEVELOPMENT OF THE

1679
01:02:02,285 --> 01:02:03,319
NOVEL PRODUCTION TECHNOLOGIES

1680
01:02:03,386 --> 01:02:05,755
AND VIRAL VECTORS AND CELL

1681
01:02:05,822 --> 01:02:08,091
PRODUCTS FOR THE MULTISITE

1682
01:02:08,157 --> 01:02:08,324
TRIALS.

1683
01:02:08,391 --> 01:02:13,429
OKAY, SO ACCESS TO THE BDP FROM

1684
01:02:13,496 --> 01:02:15,631
THE INTRAMURAL COMMUNITY IS FROM

1685
01:02:15,698 --> 01:02:16,899
THE NCI DEVELOPMENTAL

1686
01:02:16,966 --> 01:02:18,768
THERAPEUTICS PROGRAM OR NEXT,

1687
01:02:18,835 --> 01:02:20,069
AND UNFORTUNATELY I WON'T GO

1688
01:02:20,136 --> 01:02:24,841
INTO DETAILS ON THE ADC THAT

1689
01:02:24,907 --> 01:02:25,475
DR. RATHMELL, MENTIONED EARLIER

1690
01:02:25,541 --> 01:02:26,843
BUT THIS IS THE MECH INFORM BY

1691
01:02:26,909 --> 01:02:29,112
WHICH THAT PROJECT IS IN THE

1692
01:02:29,178 --> 01:02:30,079
PORTFOLIO THROUGH THE NEXT PART.

1693
01:02:30,146 --> 01:02:32,181
SO NEXT A LOT OF FOLKS HERE ARE

1694
01:02:32,248 --> 01:02:34,951
FAMILIAR WITH IT'S NOT A GRANT,

1695
01:02:35,017 --> 01:02:37,753
NO FUNDED IS PROVIDED TO THE

1696
01:02:37,820 --> 01:02:38,955
APPLICANT, RATHER IT ALLOWS

1697
01:02:39,021 --> 01:02:41,924
APPLICATIONSLICANTS ON ACCESS TO

1698
01:02:41,991 --> 01:02:43,759
OUR RESOURCES HERE INCLUDING THE

1699
01:02:43,826 --> 01:02:44,827
BDP, IT DOES REQUIRE A CLEAR

1700
01:02:44,894 --> 01:02:47,130
PATH TO THE CLINIC OR PATIENT

1701
01:02:47,196 --> 01:02:48,264
BENEFIT AND THE APPLICANT

1702
01:02:48,331 --> 01:02:50,199
BECOMES A KEY MEMBER OF THE

1703
01:02:50,266 --> 01:02:52,034
PROJECT TEAM AND INVOLVED IN THE

1704
01:02:52,101 --> 01:02:53,102
PLANNING AND IMPLEMENTATION AND

1705
01:02:53,169 --> 01:02:55,071
ALSO HOUSE GETS FULL ACCESS TO

1706
01:02:55,138 --> 01:02:56,506
THE DATA GENERATED BY OUR

1707
01:02:56,572 --> 01:02:57,740
CONTRACTORS ISSUES THE NEXT

1708
01:02:57,807 --> 01:03:00,109
PROGRAM ALSO OFFERS A

1709
01:03:00,176 --> 01:03:01,777
PRECONSULTATION SERVICE NOT ONLY

1710
01:03:01,844 --> 01:03:02,845
TO PERSPECTIVE APPLICANTS ABOUT

1711
01:03:02,912 --> 01:03:07,683
YOU TO ANYBODY WHO IS IN THE

1712
01:03:07,750 --> 01:03:09,318
EARLY STAGES OF I&  D PLANNING

1713
01:03:09,385 --> 01:03:12,054
AND NEEDS GUIDANCE ON WHAT KINDS

1714
01:03:12,121 --> 01:03:13,389
OF TOXICOLOGY STUDIES, SOME MAY

1715
01:03:13,456 --> 01:03:15,258
BE REQUIRED, TESTING FOR THE

1716
01:03:15,324 --> 01:03:16,292
CLINICAL PRODUCT AND THAT SORT

1717
01:03:16,359 --> 01:03:19,362
OF THING, SO IT'S BEEN A VERY

1718
01:03:19,428 --> 01:03:20,329
SUCCESSFUL SERVICE THAT'S MADE

1719
01:03:20,396 --> 01:03:24,133
AVAILABLE THROUGH THE NEXT

1720
01:03:24,200 --> 01:03:24,400
PROGRAM.

1721
01:03:24,467 --> 01:03:25,935
ALL RIGHT, I WANT TO HIGHLIGHT

1722
01:03:26,002 --> 01:03:27,303
THE RECENT COLLABORATIONS THAT

1723
01:03:27,370 --> 01:03:30,506
THE BDP HAS HAD WITH VARIOUS

1724
01:03:30,573 --> 01:03:38,281
ENTITIES, YOU KNOW 1 THING

1725
01:03:38,347 --> 01:03:39,115
THAT'S--THAT BCTD SUPPORTS WITH

1726
01:03:39,182 --> 01:03:42,251
THE REST OF NCI AND NIH IS THAT

1727
01:03:42,318 --> 01:03:44,020
WHEN THERE'S EXCESS CAPACITY

1728
01:03:44,086 --> 01:03:45,988
OUTSIDE OF DCT, PRIORITIES HERE,

1729
01:03:46,055 --> 01:03:49,125
THAT THE BDP CAN BE ACCESSED BY

1730
01:03:49,192 --> 01:03:51,394
OTHER AGENCIES, OTHER INSTITUTES

1731
01:03:51,460 --> 01:03:53,796
AND HAVE HAD A NUMBER OF

1732
01:03:53,863 --> 01:03:57,500
COLLABORATIONS WITH NCATS AND

1733
01:03:57,567 --> 01:04:00,803
CCR, AND DIVISION CANCER BIOLOGY

1734
01:04:00,870 --> 01:04:02,271
ANDY PREVENT PROGRAM TO DEVELOP

1735
01:04:02,338 --> 01:04:05,174
SOME OF THEIR AGENTS FOR THEIR

1736
01:04:05,241 --> 01:04:06,475
EXTRAMURAL COLLABORATORS.

1737
01:04:06,542 --> 01:04:07,843
SO 1 OF THE RECENT SUCCESSES

1738
01:04:07,910 --> 01:04:10,346
WE'VE HAD IS WITH

1739
01:04:10,413 --> 01:04:20,223
YEFERSON--JEFFERSON  JEFF KOWENE

1740
01:04:20,289 --> 01:04:23,226
HAD A NOVEL EBV VACCINE

1741
01:04:23,292 --> 01:04:24,660
CANDIDATES ARE 2 CANDIDATES

1742
01:04:24,727 --> 01:04:26,095
THESE ARE BASED ON THE NANO

1743
01:04:26,162 --> 01:04:27,396
PARTICLE THAT CAN BE

1744
01:04:27,463 --> 01:04:29,098
IBT--INTEGRATE CORPORATED WITH

1745
01:04:29,165 --> 01:04:31,567
ANTIIENS AND IN HIS CASE HE WAS

1746
01:04:31,634 --> 01:04:35,304
ABLE TO SUCCESSFULLY INCORPORATE

1747
01:04:35,371 --> 01:04:40,743
THE EGP3 FICT ANTIGEN AS WELL AS

1748
01:04:40,810 --> 01:04:44,413
COMBO ANTIGEN EBV GHGLGP42, BUT

1749
01:04:44,480 --> 01:04:45,948
BEFORE THAT THE PROJECT TARTED

1750
01:04:46,015 --> 01:04:46,782
EARLIER IN PROCESS DEVELOPMENT

1751
01:04:46,849 --> 01:04:49,418
AND SCALE UP AND NEVER

1752
01:04:49,485 --> 01:04:51,053
MANUFACTURING AND ANALYTICAL

1753
01:04:51,120 --> 01:04:52,355
DEVELOPMENT, THE BDP PRODUCED

1754
01:04:52,421 --> 01:04:53,956
BOTH OF THESE PRODUCTS AS WELL

1755
01:04:54,023 --> 01:04:59,362
AS THE CLINICAL TRIAL AND

1756
01:04:59,428 --> 01:05:00,896
CURRENTLY THE EBC 350 AND IN

1757
01:05:00,963 --> 01:05:02,398
CLINICAL TRIAL ANDS ONCE SAFETY

1758
01:05:02,465 --> 01:05:04,066
IS DEMON TRAITED THERE, THE PLAN

1759
01:05:04,133 --> 01:05:13,776
IS TO INCORPORATE THE SECOND

1760
01:05:13,843 --> 01:05:16,646
NANO PARTICLE, THE GBHL32 FOR

1761
01:05:16,712 --> 01:05:18,047
CLINICAL TRIAL.

1762
01:05:18,114 --> 01:05:21,050
WE'VE ALSO STARTED A MEMORANDUM

1763
01:05:21,117 --> 01:05:22,551
OF UNDERSTANDING BETWEEN COREE

1764
01:05:22,618 --> 01:05:25,021
AND NCI, WE HAD A VISITOR FROM

1765
01:05:25,087 --> 01:05:26,055
THE KOREAN NATIONAL KANSZER

1766
01:05:26,122 --> 01:05:29,492
CENTER TO TOUR AND MEET WITH BDP

1767
01:05:29,558 --> 01:05:30,559
STAFF, THEY'RE VERY INTERESTED

1768
01:05:30,626 --> 01:05:34,964
IN GETTING UP TO SPEED ON CELL

1769
01:05:35,031 --> 01:05:36,832
THERAPIES AND CANCER VACCINES

1770
01:05:36,899 --> 01:05:39,568
TECHNOLOGIES AND SETTING UP A

1771
01:05:39,635 --> 01:05:40,870
DBP LIKE PROGRAM OVER THERE, SO

1772
01:05:40,936 --> 01:05:42,872
WE'VE ALREADY HAD A NUMBER OF

1773
01:05:42,938 --> 01:05:44,740
DISCUSSIONS WITH THE

1774
01:05:44,807 --> 01:05:45,808
REPRESENTATIVES, EXCHANGED A

1775
01:05:45,875 --> 01:05:47,777
NUMBER OF SOPs ALREADY AND

1776
01:05:47,843 --> 01:05:49,278
TALKING ABOUT POTENTIAL

1777
01:05:49,345 --> 01:05:50,346
COLLABORATIONS THAT MIGHT

1778
01:05:50,413 --> 01:05:53,616
INCLUDE A VISITOR COMING FROM

1779
01:05:53,683 --> 01:05:58,554
KOREA AND HOSTED BY THE DCTD OR

1780
01:05:58,621 --> 01:06:00,156
SERIES OF VISITORRING TO TAG

1781
01:06:00,222 --> 01:06:02,091
ALONG WITH THE BDP STAFF AND

1782
01:06:02,158 --> 01:06:07,263
UNDERSTAND HOW THE PROGRAM

1783
01:06:07,330 --> 01:06:07,463
WORKS.

1784
01:06:07,530 --> 01:06:08,698
BDP WAS ALSO INVITED TO

1785
01:06:08,764 --> 01:06:11,067
CONTRIBUTE TO THE HEALTH AND

1786
01:06:11,133 --> 01:06:14,036
ENVIRONMENTAL SCIENCES INSTITUTE

1787
01:06:14,103 --> 01:06:16,339
OR HESI, THEY'RE CELL THERAPY

1788
01:06:16,405 --> 01:06:18,741
TRACKS CIRCULATION AND SAFETY

1789
01:06:18,808 --> 01:06:20,109
COMMITTEE, CT-TRACKS THEIR

1790
01:06:20,176 --> 01:06:24,480
EFFORTS TO ADDRESS THE ISSUES

1791
01:06:24,547 --> 01:06:27,016
WITH REGARDS TO SAFETY AND

1792
01:06:27,083 --> 01:06:29,819
REGULATORY OR IPSC, OR INCLUESS

1793
01:06:29,885 --> 01:06:30,486
PLURIPOTENT STEM CELL THERAPIES

1794
01:06:30,553 --> 01:06:32,855
THAT ARE ON THE FOREFRONT.

1795
01:06:32,922 --> 01:06:36,325
AND THE BDP HAD EXPERIENCE WITH

1796
01:06:36,392 --> 01:06:37,159
IPSC, ASSESSMENT, DEVELOPMENT,

1797
01:06:37,226 --> 01:06:42,164
AS PART OF THEIR CRSPR-BASED

1798
01:06:42,231 --> 01:06:45,034
TECHNOLOGY DEVELOPMENT EFFORTS

1799
01:06:45,101 --> 01:06:47,103
IN RECENT YEARS AND SO IT'S BEEN

1800
01:06:47,169 --> 01:06:49,105
GENERATING SAFETY DATA IN ARE

1801
01:06:49,171 --> 01:06:50,906
ALIGNMENT WITH THE CT TRACKS

1802
01:06:50,973 --> 01:06:51,474
EFFORTS.

1803
01:06:51,540 --> 01:06:53,642
THEY ARE INCORPORATING THEIR

1804
01:06:53,709 --> 01:06:57,613
DIGITAL DROP OF PSR ASSAY, FOR

1805
01:06:57,680 --> 01:07:00,149
THE DETECTION OF

1806
01:07:00,216 --> 01:07:00,716
UNDIFFERENTIATED PLURIPOTENT

1807
01:07:00,783 --> 01:07:03,085
CELLS WHICH WAS IS A POTENTIAL

1808
01:07:03,152 --> 01:07:04,553
SIGNIFICANT SAFETY CONCERN FOR

1809
01:07:04,620 --> 01:07:06,722
THESE PRODUCTS IN THE FUTURE.

1810
01:07:06,789 --> 01:07:11,827
AND THEN, THE BDP AND US HERE IN

1811
01:07:11,894 --> 01:07:14,397
THE BRB AND ACT ARE INVOLVED

1812
01:07:14,463 --> 01:07:16,699
WITH NIST AND THEIR FLOW

1813
01:07:16,766 --> 01:07:17,366
CYTOMETRY CONSORTIUM.

1814
01:07:17,433 --> 01:07:19,502
THEY HAVE 2 WORKS GROUPS THAT

1815
01:07:19,568 --> 01:07:28,344
PERTAIN TO BDP ACTIVITIES, , THE

1816
01:07:28,411 --> 01:07:30,146
ASSAY GROUP FOR QUANTITATIVE

1817
01:07:30,212 --> 01:07:31,680
ASSAYS AND COMMONLY USED FOR

1818
01:07:31,747 --> 01:07:33,582
CELL AND GENE THERAPY AND GENE

1819
01:07:33,649 --> 01:07:35,484
DELIVERY SYSTEMS WORKING GROUP,

1820
01:07:35,551 --> 01:07:38,187
TO DEVELOP MEASUREMENT SOLUTIONS

1821
01:07:38,254 --> 01:07:39,855
AND STANDARDS FOR GENE DELIVERY

1822
01:07:39,922 --> 01:07:42,057
SYSTEMS BOTH VIRAL AND NONI HAVE

1823
01:07:42,124 --> 01:07:42,591
VALENTINED.

1824
01:07:42,658 --> 01:07:44,560
THE BDP, ALSO PROVIDES JUST

1825
01:07:44,627 --> 01:07:46,896
ABOUT ALL OF THEIR S. O. P.s,

1826
01:07:46,962 --> 01:07:48,397
THOSE THAT ARE NOT PRODUCT

1827
01:07:48,464 --> 01:07:50,232
SPECIFIC, ON THEIR WEBSITE, AND

1828
01:07:50,299 --> 01:07:51,901
THEY'RE FREE FOR DOWNLOAD,

1829
01:07:51,967 --> 01:07:56,272
THERE'S MORE THAN 300 SOPs FOR

1830
01:07:56,338 --> 01:07:58,040
MANUFACTURING, TESTING, QUALITY

1831
01:07:58,107 --> 01:07:58,974
SYSTEMS, CELL THERAPY THAT HAVE

1832
01:07:59,041 --> 01:08:01,777
BEEN ESTABLISHED AND HAD BEEN

1833
01:08:01,844 --> 01:08:03,212
VERY HELPFUL TO INDUSTRY AS WELL

1834
01:08:03,279 --> 01:08:05,614
AS ACADEMIC TRUSTEESS FOR

1835
01:08:05,681 --> 01:08:06,816
ESTABLISHING PROCEDURES AND

1836
01:08:06,882 --> 01:08:10,653
PROCESSES AND THEIR FACILITY.

1837
01:08:10,719 --> 01:08:12,488
AND THEN LASTLY, I WANTED TO

1838
01:08:12,555 --> 01:08:16,459
WIND UP THE PRESENTATION, TO

1839
01:08:16,525 --> 01:08:20,162
DESCRIBE A RARE OPPORTUNITY THAT

1840
01:08:20,229 --> 01:08:23,732
WE GET HERE IN BRB AND THE BDP

1841
01:08:23,799 --> 01:08:25,267
TO SEE SOME IMPACT THAT THE WORK

1842
01:08:25,334 --> 01:08:29,338
THAT WE DO HAS ON PATIENTS AND

1843
01:08:29,405 --> 01:08:33,509
YOUR COORDINATION OF SHAH AND

1844
01:08:33,576 --> 01:08:34,677
CRR AND [INDISCERNIBLE] IN MY

1845
01:08:34,743 --> 01:08:36,378
GROUP, WE WERE ABLE TO HOST A

1846
01:08:36,445 --> 01:08:40,816
VISIT BY 2 FAMILIES, THE

1847
01:08:40,883 --> 01:08:41,517
[INDISCERNIBLE] FAMILIES,

1848
01:08:41,584 --> 01:08:43,486
THEY'RE VERY ACTIVE FAMILIES FOR

1849
01:08:43,552 --> 01:08:47,823
PEDIATRIC CANCER RESEARCH AND

1850
01:08:47,890 --> 01:08:50,459
THE SANDY FAMILY VISITED WITH

1851
01:08:50,526 --> 01:08:53,195
THEIR SON, WHO IS THERE IN THE

1852
01:08:53,262 --> 01:08:55,397
CENTER PHOTO IN THE WHITE SHIRT

1853
01:08:55,464 --> 01:09:03,372
HERE, HE WAS ACTUALLY TREATED BY

1854
01:09:03,439 --> 01:09:05,207
NIRALI, AND SO TO BE ABLE TO

1855
01:09:05,274 --> 01:09:08,410
HOST THEM AND SHOW THEM HOW A

1856
01:09:08,477 --> 01:09:09,945
CAR T-CELL THERAPY IS MADE AND

1857
01:09:10,012 --> 01:09:12,448
WHAT GOES INTO THE TESTING AND

1858
01:09:12,515 --> 01:09:20,389
PRODUCTION OF IT WAS VERY

1859
01:09:20,456 --> 01:09:21,323
FULFILLING.

1860
01:09:21,390 --> 01:09:24,326
GAVIN LINDBORG, IS ALSO VERY

1861
01:09:24,393 --> 01:09:26,495
AVID ADVOCATE AND HIS SON EVAN

1862
01:09:26,562 --> 01:09:29,231
LOST HIS BALGT TO NEUROBLASTOMA

1863
01:09:29,298 --> 01:09:31,400
AND HE WAS VERY, VERY STRONG

1864
01:09:31,467 --> 01:09:35,604
CERTAINTIER OF THE BDP AND SO IT

1865
01:09:35,671 --> 01:09:37,940
REALLY PROVIDED US AND THE BDP

1866
01:09:38,007 --> 01:09:39,275
FOLKS WITH POSITIVE FEEDBACK

1867
01:09:39,341 --> 01:09:43,646
THAT WE DON'T NORMALLY GET FROM

1868
01:09:43,712 --> 01:09:44,647
ACTUAL THERAPY--ACTUAL OUTCOMES

1869
01:09:44,713 --> 01:09:45,614
OF THE THERAPIES THAT WE MAKE.

1870
01:09:45,681 --> 01:09:48,317
SO WITH THAT I WOULD LIKE TO

1871
01:09:48,384 --> 01:09:49,118
ACKNOWLEDGE THE BDP, THIS IS

1872
01:09:49,184 --> 01:09:53,822
JUST A PORTION OF THE BDP STAFF

1873
01:09:53,889 --> 01:09:56,025
THAT ARE INVOLVED IN THE

1874
01:09:56,091 --> 01:09:57,192
DAY-TO-DAY OPERATIONS HERE, MY

1875
01:09:57,259 --> 01:09:59,962
STAFF AND THE BRD, MICHELLE,

1876
01:10:00,029 --> 01:10:06,435
RAY, YEANY AND KASHA,

1877
01:10:06,502 --> 01:10:08,971
DR. DOROSHOW, AND STEVE,

1878
01:10:09,038 --> 01:10:10,139
HIGHFILL, AND THEY'VE ALL BEEN

1879
01:10:10,205 --> 01:10:12,474
VERY HELPFUL IN HELPING US STAND

1880
01:10:12,541 --> 01:10:16,478
UP OUR CELL THERAPY

1881
01:10:16,545 --> 01:10:17,046
CAPABILITIES.

1882
01:10:17,112 --> 01:10:20,583
NIRALI, AND RESOURCESY AND JEFF

1883
01:10:20,649 --> 01:10:22,885
WITH THEIR HELP FROM CCR AND

1884
01:10:22,952 --> 01:10:23,252
NIAID.

1885
01:10:23,319 --> 01:10:28,657
>> THANK YOU JASON WHAT AN

1886
01:10:28,724 --> 01:10:30,593
INCREDIBLE ARRAY OF THANKS THAT

1887
01:10:30,659 --> 01:10:34,730
YOU HAVE GOING ON FOR FOLKS

1888
01:10:34,797 --> 01:10:35,831
AROUND THE COUNTRY.

1889
01:10:35,898 --> 01:10:37,733
THANK YOU FOR THAT.

1890
01:10:37,800 --> 01:10:38,067
ANGELLA?

1891
01:10:38,133 --> 01:10:42,271
>> THANK YOU FOR THIS VERY COMP

1892
01:10:42,338 --> 01:10:43,806
REHONSIVE PRESENTATION, NOW WITH

1893
01:10:43,872 --> 01:10:45,074
THE SUCCESSES OF THE RNA

1894
01:10:45,140 --> 01:10:50,012
VACCINES AND ALL THE EXCITEMENT

1895
01:10:50,079 --> 01:10:53,549
ABOUT CRISPR TECHNOLOGIES, RNA

1896
01:10:53,616 --> 01:10:55,084
REALLY AS A BIOLOGIC IS MOVING

1897
01:10:55,150 --> 01:10:58,854
MORE INTO THE SPOTLIGHT, HAS THE

1898
01:10:58,921 --> 01:10:59,788
BDP CONTEMPLATED MOVING INTO

1899
01:10:59,855 --> 01:11:00,389
THIS SPACE.

1900
01:11:00,456 --> 01:11:02,791
ON YOUR PIE CHART, I REALLY SAW

1901
01:11:02,858 --> 01:11:11,233
ONLY A VERY SMALL SECTION AND

1902
01:11:11,300 --> 01:11:13,769
THAT WAS DEVOTED TO VECTORS, AND

1903
01:11:13,836 --> 01:11:15,804
60% PROTEINS SO WHAT ARE THE

1904
01:11:15,871 --> 01:11:16,038
PLANS?

1905
01:11:16,105 --> 01:11:17,072
>> WE ACTUALLY, WITHIN THE NEXT

1906
01:11:17,139 --> 01:11:19,742
PROGRAM, WE DO HAVE AN ACTIVE

1907
01:11:19,808 --> 01:11:23,145
PROJECT, IT IS RNA NANO PARTICLE

1908
01:11:23,212 --> 01:11:25,614
BASED THAT THE BDP IS

1909
01:11:25,681 --> 01:11:27,282
LEARNING--NOW WE DON'T HAVE THE

1910
01:11:27,349 --> 01:11:30,219
CAPABILITIES IN THE FACILITY

1911
01:11:30,285 --> 01:11:32,621
HERE FOR SYNTHESIZING RNA

1912
01:11:32,688 --> 01:11:34,890
CONSTRUBTS OR THE MATERIALS THAT

1913
01:11:34,957 --> 01:11:39,895
GO INTO DEVELOPING THE NANO

1914
01:11:39,962 --> 01:11:42,398
PARTICLES, BUT BECAUSE OF THE

1915
01:11:42,464 --> 01:11:44,333
BIOMEDICAL CAPABILITIES TO

1916
01:11:44,400 --> 01:11:45,100
SUBCONTRACT OR TECHNICAL

1917
01:11:45,167 --> 01:11:47,269
EXPERTISE, A LOT OF THIS WORK IS

1918
01:11:47,336 --> 01:11:48,337
BEING DONE OUTSOURCED AND WE'RE

1919
01:11:48,404 --> 01:11:50,272
IN EARLY STAGES OF THAT

1920
01:11:50,339 --> 01:11:54,043
PARTICULAR PROJECT BUT, YES, WE

1921
01:11:54,109 --> 01:11:55,277
ARE CERTAINLY MOVING INTO THAT

1922
01:11:55,344 --> 01:12:01,050
FIELD AND WE RECENTLY HAD A FEW

1923
01:12:01,116 --> 01:12:03,218
DISCUSSIONS WITH DR. SINGER ON

1924
01:12:03,285 --> 01:12:05,854
SOME OF THE NEED OUT THERE IN

1925
01:12:05,921 --> 01:12:10,325
THE COMMUNITY FOR RNA BASED

1926
01:12:10,392 --> 01:12:11,960
VACCINES AND THERAPY ANDS WE'RE

1927
01:12:12,027 --> 01:12:14,029
CERTAINLY WILLING TO COLLABORATE

1928
01:12:14,096 --> 01:12:17,566
WITH INVESTIGATORS AS THESE NEW

1929
01:12:17,633 --> 01:12:20,869
IDEAS COME IN.

1930
01:12:20,936 --> 01:12:21,904
>> I BELIEVE TIM?

1931
01:12:21,970 --> 01:12:23,338
>> YEAH, JASON THAT WAS A NICE

1932
01:12:23,405 --> 01:12:24,073
PRESENTATION.

1933
01:12:24,139 --> 01:12:24,873
MY QUESTION IS ACTUALLY BASED

1934
01:12:24,940 --> 01:12:29,645
OFF OF WHAT WAS JUST ASKED, AND

1935
01:12:29,712 --> 01:12:31,480
THAT IS, YOU KNOW FOR MY

1936
01:12:31,547 --> 01:12:33,348
INTERACTION WITH A FIELD SO FAR

1937
01:12:33,415 --> 01:12:35,117
AND PARTLY STIMULATED BY THE

1938
01:12:35,184 --> 01:12:38,487
SUCCESSFUL PARTY OF VACCINES, IS

1939
01:12:38,554 --> 01:12:41,824
THAT THE FACT THAT THERE'S A

1940
01:12:41,890 --> 01:12:44,026
CERTAIN LACK OF ACCESSIBILITY TO

1941
01:12:44,093 --> 01:12:45,060
DELIVERY VEHICLES NOW FOR

1942
01:12:45,127 --> 01:12:46,962
VACCINES AND ALL SORTS OF

1943
01:12:47,029 --> 01:12:47,429
RNAs.

1944
01:12:47,496 --> 01:12:48,964
IN FACT, YOU KNOW JUST FROM MY

1945
01:12:49,031 --> 01:12:50,432
KNOWLEDGE OF BEING ON VARIOUS

1946
01:12:50,499 --> 01:12:54,169
BOARDS AND STUFF, ACCESS TO

1947
01:12:54,236 --> 01:12:55,771
LIPID NANO PARTICLES ITSELF IS

1948
01:12:55,838 --> 01:12:57,539
OFTEN WRAPPED UP IN ALL SORTS OF

1949
01:12:57,606 --> 01:13:00,776
IP ISSUE ANDS THAT'S REALLY BEEN

1950
01:13:00,843 --> 01:13:03,078
A MAJOR, MAJOR ACHILLES' HEEL IN

1951
01:13:03,145 --> 01:13:06,682
PUSHING FORWARD A LOT OF

1952
01:13:06,749 --> 01:13:10,319
CLINICAL TRIALS, SO I'M

1953
01:13:10,385 --> 01:13:13,088
WONDERING IF YOU OR THE FNLAC

1954
01:13:13,155 --> 01:13:14,456
LEADERSHIP HAVE THOUGHT ABOUT,

1955
01:13:14,523 --> 01:13:16,225
YOU KNOW NOT JUST NANO PARTICLES

1956
01:13:16,291 --> 01:13:20,963
BUT OTHER TYPES OF PLATFORMS TO

1957
01:13:21,029 --> 01:13:23,966
ENHANCE ACCESS FOR THE FIELD

1958
01:13:24,032 --> 01:13:27,469
THAT SORT OF PERHAPS ALLOWS 1 TO

1959
01:13:27,536 --> 01:13:29,605
NOT BE SO WRAPPED UP IN TERMS OF

1960
01:13:29,671 --> 01:13:34,710
IP ISSUES AND SO FORTH.

1961
01:13:34,777 --> 01:13:35,844
>> YEAH, THE SHORT ANSWER IS

1962
01:13:35,911 --> 01:13:37,045
YES, WE HAVE CONSIDERED IT AND

1963
01:13:37,112 --> 01:13:38,914
IT'S BEEN A NUMBER OF

1964
01:13:38,981 --> 01:13:39,481
DISCUSSIONS.

1965
01:13:39,548 --> 01:13:42,217
I THINK THE CHALLENGE IS AND I

1966
01:13:42,284 --> 01:13:45,154
THINK THIS IS A BIGGER QUESTION

1967
01:13:45,220 --> 01:13:47,189
ON THE OUTSIDE OF MY OFFICE AND

1968
01:13:47,256 --> 01:13:48,590
THE BDP, BUT YOU KNOW IT'S LIKE

1969
01:13:48,657 --> 01:13:52,995
YOU SAID, HOW DO WE SET UP

1970
01:13:53,061 --> 01:13:54,763
WHETHER IT'S A CORE CAPABILITY

1971
01:13:54,830 --> 01:13:58,700
HERE AT THE FREDERICK NATIONAL

1972
01:13:58,767 --> 01:14:01,804
LAB OR A--LIKE I SPOKE AND WHEEL

1973
01:14:01,870 --> 01:14:05,073
TYPE OF MODEL WHERE IN THE

1974
01:14:05,140 --> 01:14:06,742
NATIONAL LAB SUPPORTS EXPERT

1975
01:14:06,809 --> 01:14:08,811
SITES TO PRODUCE THESE, BUT,

1976
01:14:08,877 --> 01:14:14,616
YEAH, YOU'RE RIGHT, THE IP ARE

1977
01:14:14,683 --> 01:14:15,184
VERY CHALLENGING.

1978
01:14:15,250 --> 01:14:16,919
I CAN TELL YOU WITH THE CURRENT

1979
01:14:16,985 --> 01:14:18,120
PROJECT THAT WE'RE WORKING ON, A

1980
01:14:18,187 --> 01:14:21,723
LOT OF THE LEAD TIME THAT WE'VE

1981
01:14:21,790 --> 01:14:25,394
SPENT IS IN ESTABLISHING THE

1982
01:14:25,460 --> 01:14:26,461
APPROPRIATE MTAs AND CDAs IN

1983
01:14:26,528 --> 01:14:31,366
PLACE SO THAT WE CAN ACCESS

1984
01:14:31,433 --> 01:14:31,967
THOSE, THOSE PROPRIETARY

1985
01:14:32,034 --> 01:14:39,775
REAGENTS AND IT HAS BEEN VERY

1986
01:14:39,842 --> 01:14:40,075
CHALLENGING.

1987
01:14:40,142 --> 01:14:40,576
>> RODNEY IN.

1988
01:14:40,642 --> 01:14:45,547
>> JASON YOU HAVE A BIG

1989
01:14:45,614 --> 01:14:47,883
FOOTPRINT, 66,000, SQUARE FOOT

1990
01:14:47,950 --> 01:14:49,218
AND 22,000 SQUARE FOOT IN

1991
01:14:49,284 --> 01:14:51,553
MANUFACTURING SO A LOT GOING ON.

1992
01:14:51,620 --> 01:14:58,026
SO THE CELL THERAPY, THE CELLS

1993
01:14:58,093 --> 01:14:59,928
AUTOLOGOUS, ARE ALL MOVING

1994
01:14:59,995 --> 01:15:02,064
FORWARD AND HEAVY ARE THESE

1995
01:15:02,130 --> 01:15:04,333
TOOLS AND QC, QA AND FACILITIES

1996
01:15:04,399 --> 01:15:09,271
AND PARAMOUNT EMPLOY IN TERMS OF

1997
01:15:09,338 --> 01:15:11,440
THE ACADEMIC RESEARCH OR

1998
01:15:11,506 --> 01:15:13,375
INSTITUTIONAL RESEARCH ON THE

1999
01:15:13,442 --> 01:15:18,714
PHASE 1 IS WITH THE SPACE OF THE

2000
01:15:18,780 --> 01:15:21,149
FNLAC WILL BE BOTH

2001
01:15:21,216 --> 01:15:25,754
[INDISCERNIBLE] AND NCI USE THAT

2002
01:15:25,821 --> 01:15:27,289
FACILITY TO ACCELERATE THE EARLY

2003
01:15:27,356 --> 01:15:27,923
CLINICAL STUDIES.

2004
01:15:27,990 --> 01:15:32,728
SO THE QUESTION REALLY IS THAT

2005
01:15:32,794 --> 01:15:35,497
HAVE YOU THOUGHT ABOUT GIVING

2006
01:15:35,564 --> 01:15:36,665
THE GOVERNMENT FACILITIES, AND

2007
01:15:36,732 --> 01:15:40,903
THAT'S ALSO GO TO NCI.

2008
01:15:40,969 --> 01:15:42,838
IT'S REALLY THE IP ISSUES IS 1

2009
01:15:42,905 --> 01:15:46,041
THING, ANOTHER IS GETTING ACCESS

2010
01:15:46,108 --> 01:15:50,479
TO IN OF THE REAGENT, RIGHT IN

2011
01:15:50,545 --> 01:15:51,847
SO ASSAY INSTITUTIONAL PRACTICE,

2012
01:15:51,914 --> 01:15:55,250
I THINK WE'RE CLEAR ON WHAT WE

2013
01:15:55,317 --> 01:15:56,618
CAN STUDY, EVEN THOUGH THERE

2014
01:15:56,685 --> 01:15:57,219
MIGHT BE RECONTRADICTIONS.

2015
01:15:57,286 --> 01:15:58,720
SO THE QUESTION IS HOW DO YOU

2016
01:15:58,787 --> 01:16:01,523
BALANCE BETWEEN SCIENCE

2017
01:16:01,590 --> 01:16:04,993
QUESTIONS VERSUS COMMERCIAL

2018
01:16:05,060 --> 01:16:05,460
INTEREST?

2019
01:16:05,527 --> 01:16:08,697
AND MAYBE IT'S FOR DR. RATHMELL,

2020
01:16:08,764 --> 01:16:10,098
TO CONSIDER EMPLOY YOU KNOW

2021
01:16:10,165 --> 01:16:12,701
THERE ARE ISSUES, OBVIOUSLY.

2022
01:16:12,768 --> 01:16:15,370
YOU CANNOT STOP US IF YEAR NOT

2023
01:16:15,437 --> 01:16:16,972
DEVELOPING ASSAY WORK, IF IT IS

2024
01:16:17,039 --> 01:16:17,940
HIGH PRIORITY FOR SCIENTIFIC

2025
01:16:18,006 --> 01:16:22,544
QUESTIONS, WE CAN THINK ABOUT A

2026
01:16:22,611 --> 01:16:24,179
WAY TO ADVANCE IT.

2027
01:16:24,246 --> 01:16:25,213
THAT'S FIRST QUESTION.

2028
01:16:25,280 --> 01:16:27,516
SECOND QUESTION REALLY IS COME

2029
01:16:27,582 --> 01:16:30,519
TO THE ISSUES OF ASSAYS TO YOUR

2030
01:16:30,585 --> 01:16:30,986
PROGRAM.

2031
01:16:31,053 --> 01:16:34,289
SO I UNDERSTAND THE ENTRY MAY BE

2032
01:16:34,356 --> 01:16:36,458
MIXED PROGRAM OR ANY OTHER ENTRY

2033
01:16:36,525 --> 01:16:39,528
THAT I'M NOT AWARE OF,

2034
01:16:39,594 --> 01:16:41,163
UNDERSTAND NCI HAS A NEXT

2035
01:16:41,229 --> 01:16:43,131
PROGRAM TO LOAD UP OTHER ISSUES

2036
01:16:43,198 --> 01:16:45,100
COULD BE THAT OF THE BIG

2037
01:16:45,167 --> 01:16:49,438
PROJECTS THAT WE TALK ABOUT,

2038
01:16:49,504 --> 01:16:50,372
RIGHT, GRANT-CHALLENGED PRODUCTS

2039
01:16:50,439 --> 01:16:57,879
HOW DO WE INTERFACE WHAT ARE THE

2040
01:16:57,946 --> 01:16:58,947
SAFE GUARD AND A LOT OF PEOPLE

2041
01:16:59,014 --> 01:17:08,290
ASK YOU HOW DO WE MANAGE THAT

2042
01:17:08,357 --> 01:17:08,523
ACCESS?

2043
01:17:08,590 --> 01:17:12,427
>> SO THAT IS A GREAT QUESTION,

2044
01:17:12,494 --> 01:17:13,996
A COUPLE IN THERE AND I WILL

2045
01:17:14,062 --> 01:17:15,530
MAKE AN ATTEMPT TO AT LEAST

2046
01:17:15,597 --> 01:17:17,065
PROVIDE, YOU KNOW MY PERSPECTIVE

2047
01:17:17,132 --> 01:17:23,638
ON SOME OF THOSE ASPECTS WITH

2048
01:17:23,705 --> 01:17:26,908
REGARDS TO THE BALANCING OF THE

2049
01:17:26,975 --> 01:17:29,311
SCIENCE WITH THE PRODUCTION, YOU

2050
01:17:29,378 --> 01:17:33,749
KNOW IT'S VERY EXPENSIVE, GMP

2051
01:17:33,815 --> 01:17:34,783
DEVELOPMENT PRODUCTION IS

2052
01:17:34,850 --> 01:17:36,218
EXTREMELY EXPENSIVE AND WHAT WE

2053
01:17:36,284 --> 01:17:39,921
HAVE TO BALANCE AT LEAST FROM MY

2054
01:17:39,988 --> 01:17:41,556
GROUP AND MY DIRECTIVE OF OUR

2055
01:17:41,623 --> 01:17:45,093
GROUP HERE IS THAT, YOU KNOW,

2056
01:17:45,160 --> 01:17:47,062
THE SCIENCE COMES INTO US PRETTY

2057
01:17:47,129 --> 01:17:49,364
MUCH WELL ESTABLISHED AND SO,

2058
01:17:49,431 --> 01:17:52,667
YOU KNOW OUR GROUP DOES NOT DO

2059
01:17:52,734 --> 01:17:55,070
THE--WE'RE NOT LOOKING AT

2060
01:17:55,137 --> 01:17:56,171
MULTILE CANDIDATES AND

2061
01:17:56,238 --> 01:17:57,239
CHARACTERIZING THOSE, WE REALLY

2062
01:17:57,305 --> 01:17:59,608
WANT TO FOCUS JUST ON THAT

2063
01:17:59,674 --> 01:18:01,877
VALLEY OF DEATH TRANSLATIONAL

2064
01:18:01,943 --> 01:18:06,415
PART OF THE DEVELOPMENT PROCESS.

2065
01:18:06,481 --> 01:18:08,417
SO THERE DEFINITELY NEED TO BE

2066
01:18:08,483 --> 01:18:10,118
OTHER FASSETS AND CERTAINLY THE

2067
01:18:10,185 --> 01:18:12,287
OTHER NATIONAL LAB CAN SUPPORT

2068
01:18:12,354 --> 01:18:13,488
THOSE FACETS OF THE SCIENCE

2069
01:18:13,555 --> 01:18:15,323
COMOPPOSITE BEHAVIORIAL

2070
01:18:15,390 --> 01:18:19,194
PHENOTYPENTS OF IT.

2071
01:18:19,261 --> 01:18:19,861
--COMPONENTS OF IT.

2072
01:18:19,928 --> 01:18:21,430
ONE MODEL THAT I THINK WILL WORK

2073
01:18:21,496 --> 01:18:24,499
OUT REALLY WELL IS THE CAN-ACT

2074
01:18:24,566 --> 01:18:26,701
INITIATIVE WHERE IT'S A

2075
01:18:26,768 --> 01:18:27,436
COMBINATION OF GRANT-FUNDED

2076
01:18:27,502 --> 01:18:29,037
RESEARCH WHERE THAT'S WHERE THE

2077
01:18:29,104 --> 01:18:30,439
SCIENCE OCCURS IS AT THESE

2078
01:18:30,505 --> 01:18:31,840
EN--STRATEGIESITUTES BUT THEN

2079
01:18:31,907 --> 01:18:34,743
THERE'S A VERY, VERY CLOSE

2080
01:18:34,810 --> 01:18:36,178
INTERACTION BETWEEN THE

2081
01:18:36,244 --> 01:18:38,580
TRANSLATIONAL COMPONENT HERE AT

2082
01:18:38,647 --> 01:18:40,982
THE BDP AND THEIR--YOU KNOW

2083
01:18:41,049 --> 01:18:41,950
THEIR SCIENTIFIC DEVELOPMENT SO

2084
01:18:42,017 --> 01:18:44,319
THAT IT WILL HOPEFULLY

2085
01:18:44,386 --> 01:18:45,387
TRANSITION VERY PATHOGENLY AND

2086
01:18:45,454 --> 01:18:47,022
QUICKLY INTO A CLINICAL TRIAL.

2087
01:18:47,089 --> 01:18:48,457
AND SO I THINK THAT THAT MIGHT

2088
01:18:48,523 --> 01:18:51,026
BE A REALLY GOOD MODEL FOR THESE

2089
01:18:51,093 --> 01:18:56,731
KINDS OF EFFORTS GOING FORWARD.

2090
01:18:56,798 --> 01:18:57,399
>> OKAY, I BELIEVE PLOSES ORDER

2091
01:18:57,466 --> 01:19:03,705
OF MICRONS, YOU HAD YOUR HAND U

2092
01:19:03,772 --> 01:19:03,839
P.

2093
01:19:03,905 --> 01:19:04,606
>> YEAH, THANKS.

2094
01:19:04,673 --> 01:19:06,641
YAISON THAT WAS AN AMAZING

2095
01:19:06,708 --> 01:19:07,843
PRESENTATION, KUDOS TO YOUR WORK

2096
01:19:07,909 --> 01:19:08,376
FOR ALL THIS.

2097
01:19:08,443 --> 01:19:12,247
I SAW A LOT OF CAR T-CELL WORK

2098
01:19:12,314 --> 01:19:16,485
BUT ARE YOU STARTING ANY CAR

2099
01:19:16,551 --> 01:19:17,119
IMPLEMENTATION TRIALS NWE WANT

2100
01:19:17,185 --> 01:19:18,753
TO BUT IT GETS BACK TO THE

2101
01:19:18,820 --> 01:19:19,688
PREVIOUS DISCUSSION, YOU KNOW

2102
01:19:19,754 --> 01:19:22,290
WE'RE DRIIVE MORE ON WHAT'S THE

2103
01:19:22,357 --> 01:19:23,258
NEED AT THE MOMENT.

2104
01:19:23,325 --> 01:19:25,527
SO WE WOULD HAVE LOVED TO HAVE

2105
01:19:25,594 --> 01:19:28,296
GOTTEN 1 OF THE CAN-ACT GRANTEES

2106
01:19:28,363 --> 01:19:31,600
THAT HAD A CART NK THAT WE COULD

2107
01:19:31,666 --> 01:19:34,069
WORK ON BUT THAT SPECIFIC NEED

2108
01:19:34,136 --> 01:19:35,704
EITHER THROUGH THAT MECHANISM OR

2109
01:19:35,770 --> 01:19:38,440
THROUGH THE NEXT PROGRAM, IT

2110
01:19:38,507 --> 01:19:39,407
HASN'T SURFACED YET BUT WE'RE

2111
01:19:39,474 --> 01:19:41,910
WILLING TO JUMP ON IT WHEN IT

2112
01:19:41,977 --> 01:19:45,046
COMES TO IT

2113
01:19:45,113 --> 01:19:46,681
>> BUT YOU HAVE THE FACILITIES

2114
01:19:46,748 --> 01:19:48,517
TO DO IT, IT'S JUST GROWING THE

2115
01:19:48,583 --> 01:19:50,952
DIFFERENT CELL TYPE IN.

2116
01:19:51,019 --> 01:19:51,720
>> ABSOLUTELY.

2117
01:19:51,786 --> 01:19:52,954
YES, IT'S GETTING FAMILIAR WITH

2118
01:19:53,021 --> 01:19:54,723
THE MARKERS AND ASSAY

2119
01:19:54,789 --> 01:20:00,862
DEVELOPMENT AND TYPES.

2120
01:20:00,929 --> 01:20:01,463
YEAH.

2121
01:20:01,530 --> 01:20:01,930
>> ALLYSON?

2122
01:20:01,997 --> 01:20:02,264
>> AWESOME.

2123
01:20:02,330 --> 01:20:04,633
IF I CAN FIGURE OUT HOW ON

2124
01:20:04,699 --> 01:20:06,168
UNMUTE MYSELF.

2125
01:20:06,234 --> 01:20:07,269
ANYWAY, JASON I'M REALLY EXCITED

2126
01:20:07,335 --> 01:20:11,306
ABOUT THE FACT THAT YOU FOLKS

2127
01:20:11,373 --> 01:20:13,074
ARE SUPPORTING EFFORTS THAT HAVE

2128
01:20:13,141 --> 01:20:14,809
CLINICAL TRIALS AT MULTIPLE

2129
01:20:14,876 --> 01:20:15,377
LOCATIONS.

2130
01:20:15,443 --> 01:20:17,546
THAT IS A TREMENDOUS KNOWLEDGE

2131
01:20:17,612 --> 01:20:22,617
IN TERMS OF SUPPLY CHAIN THAT

2132
01:20:22,684 --> 01:20:23,952
WILL BE REALLY IMPORTANT FOR THE

2133
01:20:24,019 --> 01:20:25,320
FIELD MOVING FORWARD, CAN YOU

2134
01:20:25,387 --> 01:20:26,721
COMMENT ON THAT A LITTLE BIT?

2135
01:20:26,788 --> 01:20:29,925
ARE YOU DOING A FAIR ARK MOUNT

2136
01:20:29,991 --> 01:20:34,062
OF FRESH IN, FRESH OUT,

2137
01:20:34,129 --> 01:20:36,131
CRYOPRESERVED IN HOW ARE YOU

2138
01:20:36,198 --> 01:20:38,300
ADDRESSING THE UNIQUE AND

2139
01:20:38,366 --> 01:20:39,034
IMPORTANT CHALLENGINGS OF

2140
01:20:39,100 --> 01:20:40,769
SCALING UP THESE THERAPIES TO

2141
01:20:40,835 --> 01:20:43,238
MULTIMEL CLINICAL SITES IN.

2142
01:20:43,305 --> 01:20:43,705
>> YES, THANK YOU.

2143
01:20:43,772 --> 01:20:44,973
THAT IS A GREAT QUESTION.

2144
01:20:45,040 --> 01:20:46,741
AND THAT IS 1 OF THE GOALS OF

2145
01:20:46,808 --> 01:20:48,176
THE CAN-ACT NETWORK AS WELL AS

2146
01:20:48,243 --> 01:20:49,778
STANDING UP THIS CAPABILITY IS

2147
01:20:49,844 --> 01:20:52,113
THE CENTRALIZED MANUFACTURING

2148
01:20:52,180 --> 01:20:55,383
AND LOGISTICS ESTABLISHMENT AND

2149
01:20:55,450 --> 01:20:57,419
VERY WELL CONTROLLED REPEATABLE,

2150
01:20:57,485 --> 01:20:59,988
ROBUST MANUFACTURING AND

2151
01:21:00,055 --> 01:21:01,089
ANALYTICAL PROCESSES.

2152
01:21:01,156 --> 01:21:02,691
SO, TO THAT END, WHAT WE'VE

2153
01:21:02,757 --> 01:21:05,227
STOOD UP SO FAR AND IT'S BEEN

2154
01:21:05,293 --> 01:21:13,001
SUCCESSFUL IS A CRYOPRESERVED

2155
01:21:13,068 --> 01:21:14,736
BASE LOGISTICS PROCESS WITH ALL

2156
01:21:14,803 --> 01:21:15,670
THE DOCUMENTATION AND THAT SORT

2157
01:21:15,737 --> 01:21:19,074
OF THING THAT'S BEEN VERY

2158
01:21:19,140 --> 01:21:22,911
SUCCESSFUL AND GRANTED THIS IS

2159
01:21:22,978 --> 01:21:25,180
JUST WITH CAR-T PROUCTS.

2160
01:21:25,247 --> 01:21:30,452
SO WE CAN HANDLE FROZENPHORESIS,

2161
01:21:30,518 --> 01:21:31,086
ACCORDING TO CERTAIN PROTOCOLS,

2162
01:21:31,152 --> 01:21:33,054
IT AM CANS OUT WELL, CELLS

2163
01:21:33,121 --> 01:21:34,322
TRANSDUCE WELL, THAT SAID,

2164
01:21:34,389 --> 01:21:35,724
THINGS MIGHT BE COMPLETELY

2165
01:21:35,790 --> 01:21:38,260
FLIPPED ON THEIR HEAD IF IT WAS

2166
01:21:38,326 --> 01:21:42,063
A DENDRITIC CELL BASED THERAPY

2167
01:21:42,130 --> 01:21:42,931
OR NK-CELL BASED THERAPY SO I

2168
01:21:42,998 --> 01:21:44,299
THINK WE WILL HAVE TO DEAL WITH

2169
01:21:44,366 --> 01:21:46,468
THAT BRIDGE WHEN WE GET TO IT.

2170
01:21:46,534 --> 01:21:47,936
>> YOU KNOW 1 THYME WE TALKED A

2171
01:21:48,003 --> 01:21:50,005
LOT ABOUT IN THESE ADVISORY

2172
01:21:50,071 --> 01:21:51,640
BOARDS AND HOW PEOPLE DON'T KNOW

2173
01:21:51,706 --> 01:21:53,174
ALL THE GOOD THINGS THAT ARE

2174
01:21:53,241 --> 01:21:54,209
HAPPENING AT THE FREDERICK

2175
01:21:54,276 --> 01:21:57,412
NATIONAL LABS AND IT WOULD BE

2176
01:21:57,479 --> 01:21:59,047
GREAT IF WE COULD HAVE SOME SORT

2177
01:21:59,114 --> 01:22:00,582
OF WORKSHOP OR SYMPOSIUM OR

2178
01:22:00,649 --> 01:22:01,750
SOMETHING JUST TO TALK ABOUT

2179
01:22:01,816 --> 01:22:04,152
SOME OF THESE CONTRIBUTIONS THAT

2180
01:22:04,219 --> 01:22:07,188
THE BDP HAS BEEN MAKING THAT I

2181
01:22:07,255 --> 01:22:09,190
THINK ARE IMPORTANT TO

2182
01:22:09,257 --> 01:22:09,491
DISSEMINATE.

2183
01:22:09,557 --> 01:22:11,593
JUST THROWING THAT OUT THERE.

2184
01:22:11,660 --> 01:22:13,361
BECAUSE THERE IS A LOT OF

2185
01:22:13,428 --> 01:22:16,398
EXPERTISE THAT COULD REALLY HELP

2186
01:22:16,464 --> 01:22:17,465
THE FIELD MOVE FORWARD AND THAT

2187
01:22:17,532 --> 01:22:23,705
MAY NOT BE GETTING OUT THERE.

2188
01:22:23,772 --> 01:22:26,541
>> GOOD POINT ALLYSON, SO

2189
01:22:26,608 --> 01:22:26,775
RODNEY?

2190
01:22:26,841 --> 01:22:30,545
>> SO I JUST WANT TO TACK ON TO

2191
01:22:30,612 --> 01:22:35,850
SAY THAT CELLS CNC,

2192
01:22:35,917 --> 01:22:36,885
MANUFACTURING AND PRESERVING

2193
01:22:36,951 --> 01:22:38,286
REENTRY REQUAL IIVES ALL THESE

2194
01:22:38,353 --> 01:22:44,392
ARE VERY, VERY IMPORTANT FOR THE

2195
01:22:44,459 --> 01:22:46,795
INDUSTRY MEMBERS, IT'S SO

2196
01:22:46,861 --> 01:22:48,863
IMPORTANT ABOUT QUALITY

2197
01:22:48,930 --> 01:22:50,231
ASSURANCE, AND SO HOW DO YOU

2198
01:22:50,298 --> 01:22:52,434
START THEM, HOW DO YOU VERIFY

2199
01:22:52,500 --> 01:22:55,737
ENTRY, AND SO ALL THIS KNOWLEDGE

2200
01:22:55,804 --> 01:22:57,772
CAN BE PUT TOGETHER FROM THE

2201
01:22:57,839 --> 01:23:01,276
CENTRAL LAB AS WELL AS THAT OF

2202
01:23:01,343 --> 01:23:05,480
INDUSTRY WHO WOULD BE WILLING TO

2203
01:23:05,547 --> 01:23:09,517
SHOW THOSE.

2204
01:23:09,584 --> 01:23:10,885
>> YEAH, I THANK YOU.

2205
01:23:10,952 --> 01:23:12,687
I AGREE AND THAT IS THE

2206
01:23:12,754 --> 01:23:13,121
INTENTION.

2207
01:23:13,188 --> 01:23:13,421
>> TIM IN.

2208
01:23:13,488 --> 01:23:16,658
>> JUST A QUICK QUESTION, JASON.

2209
01:23:16,725 --> 01:23:19,661
I THINK A YEAR AND A HALF OR 2

2210
01:23:19,728 --> 01:23:21,863
AGO WE HAD AN UPDATE ON THE

2211
01:23:21,930 --> 01:23:23,998
LEVEL OF UTILITY ON GMP VECTOR

2212
01:23:24,065 --> 01:23:26,968
PRODUCK, I KNOW IT WAS A VERY,

2213
01:23:27,035 --> 01:23:28,603
VERY HIGH DEMAND AT THAT POINT

2214
01:23:28,670 --> 01:23:33,742
AND WE WERE TALKING ABOUT IN

2215
01:23:33,808 --> 01:23:34,943
FNLAC A COMMITTEE ON HOW YOU

2216
01:23:35,009 --> 01:23:37,245
WOULD DEAL WITH THE INCREASE IN

2217
01:23:37,312 --> 01:23:37,479
DEMAND.

2218
01:23:37,545 --> 01:23:40,248
HOW IS IT GOING SO FAR?

2219
01:23:40,315 --> 01:23:41,449
I'M CURIOUS?

2220
01:23:41,516 --> 01:23:42,350
>> YEAH, YEAH, NO.

2221
01:23:42,417 --> 01:23:42,584
WELL.

2222
01:23:42,650 --> 01:23:45,453
THERE IS AGAIN A LOT OF CONTROLS

2223
01:23:45,520 --> 01:23:51,025
TO GET TO THE BDP, AND THE--THE

2224
01:23:51,092 --> 01:23:53,628
DEMAND AS FAR AS WE'RE HEARING,

2225
01:23:53,695 --> 01:23:55,730
NOT ONLY FROM THESE CAN-ACT

2226
01:23:55,797 --> 01:23:57,365
APPLICANTS BUT THE NEXT

2227
01:23:57,432 --> 01:23:59,000
APPLICANTS AND GENERAL

2228
01:23:59,067 --> 01:24:00,034
CONSULTATIONS THAT WE'VE

2229
01:24:00,101 --> 01:24:06,775
PARTICIPATED IN IS THAT YES, THE

2230
01:24:06,841 --> 01:24:10,678
AVAILABILITY TO GMP GRADE

2231
01:24:10,745 --> 01:24:12,414
RETROVIRUS LENTIVIRUS VECTORS,

2232
01:24:12,480 --> 01:24:14,916
EVEN NUCLEIC ACIDS, THE PLAZ

2233
01:24:14,983 --> 01:24:16,885
MIDS MIDS IN RNA AS YOU

2234
01:24:16,951 --> 01:24:17,719
MENTIONED EARLIER IS QUITE

2235
01:24:17,786 --> 01:24:19,154
STRAINED AND TO THAT EPPED, LIKE

2236
01:24:19,220 --> 01:24:21,356
I SAID, WE'VE GOT A COUPLE OF

2237
01:24:21,423 --> 01:24:24,626
SUITES HERE THAT ARE AVAILABLE

2238
01:24:24,692 --> 01:24:25,894
FOR MANUFACTURING, YOU KNOW, WE

2239
01:24:25,960 --> 01:24:28,029
CAN DO 2 PRODUCTS SAME

2240
01:24:28,096 --> 01:24:29,297
ULTIMATELY TAINIOUSLY IF WE HAD

2241
01:24:29,364 --> 01:24:29,964
THE APPROPRIATE THROW A FOOTBALL

2242
01:24:30,031 --> 01:24:33,301
SET UP FOR DOING THAT.

2243
01:24:33,368 --> 01:24:35,003
SO WE HAVE THE CAPABILITY TO

2244
01:24:35,069 --> 01:24:37,205
HELP ALLEVIATE SOME OF THIS NEED

2245
01:24:37,272 --> 01:24:39,507
IN THE COMMUNITY AND IN FACT,

2246
01:24:39,574 --> 01:24:43,478
JUST IN THE LAST YEAR, I THINK

2247
01:24:43,545 --> 01:24:46,047
WE MADE 2 OR 3ULENTYY VIRUS

2248
01:24:46,114 --> 01:24:49,717
PRODUCTS AND 1 OR 2 RETROVIRUS

2249
01:24:49,784 --> 01:24:51,586
PROD UBTS FOR OUR COLLABORATORS

2250
01:24:51,653 --> 01:24:55,190
IN THE NEXT PROGRAM OR OVER AT

2251
01:24:55,256 --> 01:24:55,857
CCR.

2252
01:24:55,924 --> 01:24:56,124
>> OKAY.

2253
01:24:56,191 --> 01:24:59,494
SO WE'RE NOW SCHEDULED FOR A

2254
01:24:59,561 --> 01:25:00,862
BREAK.

2255
01:25:00,929 --> 01:25:07,035
DO WE GO TILL DR. KANE--GIVE ME

2256
01:25:07,101 --> 01:25:09,637
SOME ADVICE, TO 2:50 OR SINCE

2257
01:25:09,704 --> 01:25:10,638
WE'RE AHEAD 2:45?

2258
01:25:10,705 --> 01:25:11,773
>> YEAH, I SUSPECT THERE MAY BE

2259
01:25:11,840 --> 01:25:15,543
A LOT OF INTEREST IN THE AI, SO

2260
01:25:15,610 --> 01:25:20,181
LET'S RECONVENE AT 2:45 P.M.

2261
01:25:20,248 --> 01:25:21,316
>> OKAY.

2262
01:25:21,382 --> 01:25:21,850
>> EASTERN TIME.

2263
01:25:21,916 --> 01:25:24,285
>> ALL RIGHT, SEE EVERYBODY

2264
01:25:24,352 --> 01:25:24,285
BACK.

2265
01:25:24,285 --> 01:25:26,754
SO NOW THESE WILL BE QUITE

2266
01:25:26,821 --> 01:25:29,457
INTERESTING, PRESENTATION ON AI

2267
01:25:29,524 --> 01:25:31,326
DRIVEN MULTISCALE INVESTIGATION

2268
01:25:31,392 --> 01:25:35,763
OF THE RAS-RAF ACTIVATION LIFE

2269
01:25:35,830 --> 01:25:43,371
CYCLE PROJECT, DR. STREITZ, AND

2270
01:25:43,438 --> 01:25:50,612
DR. NISSLEY,

2271
01:25:50,678 --> 01:25:54,015
>> THANK YOU, I WILL DO A QUICK

2272
01:25:54,082 --> 01:25:56,384
OVERVIEW, OF THE COLLABORATION,

2273
01:25:56,451 --> 01:26:00,021
WE ARE IN ITS SECOND YEAR OF 5

2274
01:26:00,088 --> 01:26:02,657
YEAR PERIOD, BETWEEN THE NCI AND

2275
01:26:02,724 --> 01:26:03,391
THE DOE.

2276
01:26:03,458 --> 01:26:06,294
THIS IS LAB RAARE TOYS NOT ONLY

2277
01:26:06,361 --> 01:26:09,931
WITH FNLAC AND AGERON, OAK RIDGE

2278
01:26:09,998 --> 01:26:11,266
AND LOS ALOE PHOSPHORYLATED,

2279
01:26:11,332 --> 01:26:12,500
NATIONAL LAB RAARE TOYS.

2280
01:26:12,567 --> 01:26:14,402
NOW THE 3 PROGGENTS WE WILL TALK

2281
01:26:14,469 --> 01:26:18,239
ABOUT TODAY ARE SHOWN ON THE

2282
01:26:18,306 --> 01:26:20,108
RIGHT IN CARTOON FORM, WHICH

2283
01:26:20,174 --> 01:26:21,843
FRED AND I WILL DESCRIBE AS

2284
01:26:21,910 --> 01:26:26,381
LOOKING AT THE MECHANISM OF AN

2285
01:26:26,447 --> 01:26:29,317
IMPORTANT BIOLOGICAL ACTIVITY

2286
01:26:29,384 --> 01:26:30,785
THAT ISN'T COMPLETELY

2287
01:26:30,852 --> 01:26:31,252
UNDERSTOOD.

2288
01:26:31,319 --> 01:26:37,425
IMPROVE IS AT A PRECLINICAL

2289
01:26:37,492 --> 01:26:40,094
SCALE AND THEN MOSAIC IS AT A

2290
01:26:40,161 --> 01:26:40,795
POPULATION SCALE.

2291
01:26:40,862 --> 01:26:41,896
AGAIN, PREDOMINANTLY AND I WILL

2292
01:26:41,963 --> 01:26:43,665
TELL YOU ABOUT OUR PROJECT

2293
01:26:43,731 --> 01:26:46,134
SHORTLY BUT THE IMPROVED PROJECT

2294
01:26:46,200 --> 01:26:47,669
AIMS TO EVALUATE IMPROVED DEEP

2295
01:26:47,735 --> 01:26:49,904
LEARNING MODELS OF DRUG RESPONSE

2296
01:26:49,971 --> 01:26:51,306
USING STANDARDIZED AND TESTING

2297
01:26:51,372 --> 01:26:55,743
DATA SETS AND THE MOSAIC PROJECT

2298
01:26:55,810 --> 01:26:58,179
APPLIES DEEP LEARNING MODELS AND

2299
01:26:58,246 --> 01:27:00,348
POPULATION BASED CANCER DATA,

2300
01:27:00,415 --> 01:27:02,250
THIS DATA SET TO--FOR

2301
01:27:02,317 --> 01:27:03,885
SURVEILLANCE AND ALSO TO MODEL

2302
01:27:03,952 --> 01:27:06,955
CANCER OUTCOMES IN REALTIME.

2303
01:27:07,021 --> 01:27:10,425
AND THEN A CROSS CUT, ACROSS

2304
01:27:10,491 --> 01:27:11,759
THESE--ALL THE NCI DOE PROJECTS

2305
01:27:11,826 --> 01:27:13,928
AND KNOWN AS CANDLE AND CANDLE

2306
01:27:13,995 --> 01:27:18,700
IS AN OPEN SOURCE DEEP LEARNING

2307
01:27:18,766 --> 01:27:20,401
METHODOLOGIES AND SET UP

2308
01:27:20,468 --> 01:27:23,137
CAPABILITIES, THAT'S AVAILABLE

2309
01:27:23,204 --> 01:27:25,139
ON GIT HUB AND HAS BEEN DESIGNED

2310
01:27:25,206 --> 01:27:27,842
AND ABLE TO WORK IN THIS TYPE OF

2311
01:27:27,909 --> 01:27:30,979
SPACE AND THAT WAS--CANDLE WAS

2312
01:27:31,045 --> 01:27:32,347
RECENTLY WON AN ARK WARD AS

2313
01:27:32,413 --> 01:27:34,782
SEVERAL OF THE CAPABILITIES THAT

2314
01:27:34,849 --> 01:27:37,585
WE'LL DESCRIBE AND THE OTHER

2315
01:27:37,652 --> 01:27:39,253
PROJECT TEAMS WILL DRIEB TODAY.

2316
01:27:39,320 --> 01:27:41,456
SO I WITHOUT FURTHER ADO, FRED

2317
01:27:41,522 --> 01:27:51,232
AND I WILL GET STARTED ON OUR

2318
01:27:51,299 --> 01:27:56,704
PROJECT.

2319
01:27:56,771 --> 01:27:57,705
>> GOOD AFTERNOON.

2320
01:27:57,772 --> 01:28:01,542
YOU'RE NOT IN PRESENTER DWIGHT.

2321
01:28:01,609 --> 01:28:03,511
>> OH, YOU'RE RIGHT THERE.  WE

2322
01:28:03,578 --> 01:28:03,878
GO.

2323
01:28:03,945 --> 01:28:14,422
>> SO THE ADMIRAL PROJECT,

2324
01:28:15,056 --> 01:28:17,392
CLEVERLY NAMED AI DRIVEN

2325
01:28:17,458 --> 01:28:21,195
MULTISCALE INVESTIGATION OF

2326
01:28:21,262 --> 01:28:21,929
RAS-RAF ACTIVATION LIFE CYCLE,

2327
01:28:21,996 --> 01:28:24,432
THE POINT OF THIS PROJECT IS TO

2328
01:28:24,499 --> 01:28:25,366
INVESTIGATE THIS CRITICAL PIECE

2329
01:28:25,433 --> 01:28:27,402
OF BIOLOGY WITH A PIECE OF

2330
01:28:27,468 --> 01:28:28,569
TECHNOLOGY, A COMPUTING

2331
01:28:28,636 --> 01:28:29,370
TECHNOLOGY WHICH CURRENTLY

2332
01:28:29,437 --> 01:28:31,305
DOESN'T EXIST WHICH ENABLING US

2333
01:28:31,372 --> 01:28:34,709
TO JUMP BEYOND THE LIMITATIONS

2334
01:28:34,776 --> 01:28:37,311
OF CLASSICAL NORTH DYNAMICS AND

2335
01:28:37,378 --> 01:28:40,048
DYNAMICS THAT ARE LIMITED TO

2336
01:28:40,114 --> 01:28:42,950
PEEK SECONDS OR NANO SECONDS OR

2337
01:28:43,017 --> 01:28:44,652
MICROSECONDS, OR MILLI SECONDS

2338
01:28:44,719 --> 01:28:46,854
BUT THE BIOLOGY WE'RE INTERESTED

2339
01:28:46,921 --> 01:28:47,922
IN HAPPENS OVER SECONDS OR

2340
01:28:47,989 --> 01:28:49,290
MINUTES AND THIS IS AN ATTEMPT

2341
01:28:49,357 --> 01:28:50,825
TO BUILD THAT KIND OF CAPABILITY

2342
01:28:50,892 --> 01:28:52,627
WHERE YOU HAVE THE RESOLUTION

2343
01:28:52,694 --> 01:29:03,237
YOU WANT OVER THE TIME SCALE YOU

2344
01:29:04,138 --> 01:29:04,806
NEED.

2345
01:29:04,872 --> 01:29:07,942
AND THIS WAS TOAD UP WITH THE

2346
01:29:08,009 --> 01:29:10,645
NCEYE RAS INISSUIAATIVE WHICH WE

2347
01:29:10,712 --> 01:29:12,046
LEAD HERE AT THE FED RICK

2348
01:29:12,113 --> 01:29:13,347
NATIONAL LAB, AND THE GOALS OF

2349
01:29:13,414 --> 01:29:15,817
THAT WHEN THIS STARTED 10IERS

2350
01:29:15,883 --> 01:29:17,652
AGO, THERE WEREN'T ANY

2351
01:29:17,719 --> 01:29:18,986
THERAPEUTIC OPTIONS FOR CANCERS

2352
01:29:19,053 --> 01:29:21,122
THAT ARE RESPONSIBLE FOR 20-30%

2353
01:29:21,189 --> 01:29:22,590
OF CANCERS AND SOME OF THE--1 OF

2354
01:29:22,657 --> 01:29:26,828
THE GOALS OF THE PROGRAM WAS TO

2355
01:29:26,894 --> 01:29:27,962
DRIVE MECHANISTIC INSIGHTS INTO

2356
01:29:28,029 --> 01:29:31,499
THE BIOLOGY OF THIS.

2357
01:29:31,566 --> 01:29:33,234
SO WE'VE--YOU KNOW CAN PUT

2358
01:29:33,301 --> 01:29:35,470
TOGETHER A TEAM HERE THAT HAS

2359
01:29:35,536 --> 01:29:38,339
GENERATED LOTS OF DATA, STRONG

2360
01:29:38,406 --> 01:29:38,973
EXPERIMENTAL CAPABILITIES, SOME

2361
01:29:39,040 --> 01:29:40,908
OF THEM ARE SHOWN AT THE TOP AND

2362
01:29:40,975 --> 01:29:47,782
HAVE COLLABORATED WITH THE DOE.

2363
01:29:47,849 --> 01:29:50,051
>> SO [INDISCERNIBLE] BRINGS TO

2364
01:29:50,118 --> 01:29:53,154
THIS COLLABORATION, AND DOE, BUT

2365
01:29:53,221 --> 01:29:55,156
THEY BRING HIGH COMPUTING KALE,

2366
01:29:55,223 --> 01:29:57,892
AND ARGUABLILY THE PREMIER

2367
01:29:57,959 --> 01:30:01,329
COMPUTING STATION IN THE WORLD

2368
01:30:01,395 --> 01:30:02,396
AND CERTAINLY IN THE COUNTRY IN

2369
01:30:02,463 --> 01:30:04,499
TERMS OF THE MACHINE ANDS CAPE

2370
01:30:04,565 --> 01:30:06,000
ANLT THAT IS PRESENT THERE.

2371
01:30:06,067 --> 01:30:08,169
ALONG WITH MEAS MACHINES WHICH

2372
01:30:08,236 --> 01:30:12,206
ARE TYPICAL LYE A

2373
01:30:12,273 --> 01:30:13,608
MEDICAL--TYPICALLY A MILLION

2374
01:30:13,674 --> 01:30:15,543
TIMES MORE THAN THIS MACHINE,

2375
01:30:15,610 --> 01:30:16,978
THE PERSONNEL WITH ADVANCE TO

2376
01:30:17,044 --> 01:30:19,046
ACTUALLY UTILIZE THAT AND THEY

2377
01:30:19,113 --> 01:30:21,449
WILL BE USING THESE TIGHT COUPLE

2378
01:30:21,516 --> 01:30:23,651
WITH THE COLLEAGUES AT FREDERICK

2379
01:30:23,718 --> 01:30:26,554
TO DO MOLECULAR DISCIPLINARY

2380
01:30:26,621 --> 01:30:27,121
DYNAMIC

2381
01:30:27,188 --> 01:30:27,822
STIMULATION, TO VERIFY THIS

2382
01:30:27,889 --> 01:30:30,558
EXPERIMENT TO LOOK AT THIS

2383
01:30:30,625 --> 01:30:32,927
PARTICULAR RATHER DIFFICULT

2384
01:30:32,994 --> 01:30:34,428
PROBLEM IN RAS BIOLOGY.

2385
01:30:34,495 --> 01:30:37,932
>> AND SO JUST GOING QUICKLY

2386
01:30:37,999 --> 01:30:39,200
OVER THE BIOLOGY THAT WE'RE

2387
01:30:39,267 --> 01:30:45,039
STUDYING, THIS IS A CARTOON OF

2388
01:30:45,106 --> 01:30:46,107
THE RAS-RAF ACTIVATION AS WE

2389
01:30:46,174 --> 01:30:48,009
CALL TIT'S A MEMBRANE, - IT IS A

2390
01:30:48,075 --> 01:30:50,678
BINARY SWITCH WHEN ON, ENGAGES

2391
01:30:50,745 --> 01:30:53,014
EFFECTORS, THE PRIMARY EFFECTOR

2392
01:30:53,080 --> 01:30:55,516
OF MAP K-SIGNALING IS THE RAF

2393
01:30:55,583 --> 01:30:58,853
KINASE, IT EXISTS IN AN

2394
01:30:58,920 --> 01:31:00,221
AUTOINHIBITTED FORM AND THAT

2395
01:31:00,288 --> 01:31:02,557
AUTOINHIBITION IS RELEASED WHEN

2396
01:31:02,623 --> 01:31:04,625
COMPONENTS OF RAF KINASE

2397
01:31:04,692 --> 01:31:06,928
INTERACT WITH RAS AND

2398
01:31:06,994 --> 01:31:07,829
CONSEQUENTIALLY THE MEMBRANE

2399
01:31:07,895 --> 01:31:12,166
RESULTING IN SERIES OF

2400
01:31:12,233 --> 01:31:12,567
DEPHOSPHORYLATION,

2401
01:31:12,633 --> 01:31:14,302
REARRANGEMENTS WITH CHAPERON

2402
01:31:14,368 --> 01:31:15,570
PROTEINS KNOWN AS 1433

2403
01:31:15,636 --> 01:31:20,408
STRICTURAL CHANGES AND THEN,

2404
01:31:20,474 --> 01:31:21,442
CLUSTERING OR COLOCALIZATION OF

2405
01:31:21,509 --> 01:31:24,011
THE MEMBRANE SO THAT 2 RAFs

2406
01:31:24,078 --> 01:31:25,980
CAN DIMERIZE AT THE KINASE

2407
01:31:26,047 --> 01:31:29,750
DOMAIN AND RESULT IN AN ACTIVE

2408
01:31:29,817 --> 01:31:31,185
SIGNALING PLATFORM SO THAT THE

2409
01:31:31,252 --> 01:31:33,454
KINASE AND ACTIVATED AND SIGNAL

2410
01:31:33,521 --> 01:31:38,526
IS PROPAGATED DOWN THROUGH THE

2411
01:31:38,593 --> 01:31:38,860
CASCADE.

2412
01:31:38,926 --> 01:31:40,795
SO YOU KNOW WE'RE INTERESTED IN

2413
01:31:40,862 --> 01:31:42,864
THIS FOR BEYOND JUST THE BIOLOGY

2414
01:31:42,930 --> 01:31:44,398
ISSUES WE BELIEVE THAT MULTIPLE

2415
01:31:44,465 --> 01:31:45,700
STEPS HERE, THERE ARE

2416
01:31:45,766 --> 01:31:46,334
THERAPEUTIC POSSIBILITIES THAT

2417
01:31:46,400 --> 01:31:47,702
IF THE STRUCTURE AND THE

2418
01:31:47,768 --> 01:31:48,703
MECHANISM WERE UNDERSTAND

2419
01:31:48,769 --> 01:31:54,909
BETTER, WE MIGHT BE ABLE TO

2420
01:31:54,976 --> 01:31:56,444
EXPLOIT TO PERTURB ONCOGENIC

2421
01:31:56,510 --> 01:31:56,711
SIGNALING.

2422
01:31:56,777 --> 01:31:58,679
THE FIRST STAGE OF THIS PROJECT,

2423
01:31:58,746 --> 01:32:00,648
JUST THE FIRST 5 YEARS WAS TO

2424
01:32:00,715 --> 01:32:02,650
ACTUALLY BUILD A MODEL TO BETTER

2425
01:32:02,717 --> 01:32:04,518
UNDERSTAND RAS IN THE CONTEXT OF

2426
01:32:04,585 --> 01:32:05,586
A REALISTIC MEMBRANE, THAT WAS

2427
01:32:05,653 --> 01:32:07,688
REFERRED TO AS PILOT 2.

2428
01:32:07,755 --> 01:32:13,861
AND WHAT WE WILL  WILL DESCRIBEU

2429
01:32:13,928 --> 01:32:15,029
TODAY IS WHAT FOLLOWED ON FROM

2430
01:32:15,096 --> 01:32:15,229
THAT.

2431
01:32:15,296 --> 01:32:17,732
BUT AS A PILOT IN THESE 2, WE

2432
01:32:17,798 --> 01:32:20,368
DID THESE SIMULATIONS IN THE 8

2433
01:32:20,434 --> 01:32:22,203
LIPID MEMBRANE, SCALE, MORE FOR

2434
01:32:22,270 --> 01:32:23,437
SIMULATION THAN HAD EVER BEEN

2435
01:32:23,504 --> 01:32:25,172
DONE BEFORE AND WAS BIOLOGICALLY

2436
01:32:25,239 --> 01:32:26,974
AND AT THAT TIMISTICALLY

2437
01:32:27,041 --> 01:32:29,277
RELEVANT EMPLOY WE IDENTIFIED

2438
01:32:29,343 --> 01:32:31,679
FINGERPRINTS OR CONCENTRATIONS

2439
01:32:31,746 --> 01:32:33,014
OF SPECIFIC LIPIDS AROUND RAS,

2440
01:32:33,080 --> 01:32:38,286
THIS IS JUST THE DENSITY

2441
01:32:38,352 --> 01:32:40,554
REPRESENTATIONS OF THE DIFFERENT

2442
01:32:40,621 --> 01:32:43,758
LIPIDS, AND RAS IS SHOWN HERE IN

2443
01:32:43,824 --> 01:32:48,262
BLACK, AND WE WERE ABLE TO

2444
01:32:48,329 --> 01:32:48,763
IDENTIFY FINGERPRINTS OR

2445
01:32:48,829 --> 01:32:52,466
CONFIGURURATIONS OF THE LIPIDS

2446
01:32:52,533 --> 01:32:54,235
THAT RAS PREFERRED OR RAS

2447
01:32:54,302 --> 01:32:55,503
CREATED WHEN IT AGGREGATED.

2448
01:32:55,569 --> 01:32:57,772
AND WE REFER TO THOSE AS LOW,

2449
01:32:57,838 --> 01:33:00,942
AVERAGE AND HIGH RAS FINGERPRINT

2450
01:33:01,008 --> 01:33:03,844
ANDS WE WERE ABLE TO

2451
01:33:03,911 --> 01:33:04,512
RECAPITULATE THAT EXPERIMENTALLY

2452
01:33:04,578 --> 01:33:06,547
SHOWN ON THE BOTTOM RIGHT BY

2453
01:33:06,614 --> 01:33:08,115
DOING SPR BIEBDING EXPERIMENTS

2454
01:33:08,182 --> 01:33:12,219
AND COULD SHOW THAT IF WE

2455
01:33:12,286 --> 01:33:12,820
RECONSITUTED THE LIPID

2456
01:33:12,887 --> 01:33:13,554
FINGERPRINTS THAT WERE

2457
01:33:13,621 --> 01:33:15,723
ASSOCIATED WITH HIGH RAS

2458
01:33:15,790 --> 01:33:18,259
BIEBDING OR ACCUMULATION OF RAS

2459
01:33:18,326 --> 01:33:24,598
AND ANTICLUSTERS WE COULD GET

2460
01:33:24,665 --> 01:33:25,366
STRONGER BINDING INVITRO.

2461
01:33:25,433 --> 01:33:26,968
SO AS I SAID AT THE OUTSET, 1 OF

2462
01:33:27,034 --> 01:33:29,270
THE THINGS WE NOTED AS WE WERE

2463
01:33:29,337 --> 01:33:30,471
FINISHING PILOT 2 AND HAVING

2464
01:33:30,538 --> 01:33:32,006
BUILT THAT CAPABILITY TO DO THE

2465
01:33:32,073 --> 01:33:35,910
HUNDREDS OF THOUSANDS OF

2466
01:33:35,977 --> 01:33:36,978
SIMULATIONS CORRELATED

2467
01:33:37,044 --> 01:33:38,546
SIMULATIONS THAT LED TO THE

2468
01:33:38,612 --> 01:33:39,947
RESULTS THAT DWIGHT JUST

2469
01:33:40,014 --> 01:33:41,248
PRESENTED IS THAT WE WANTED TO

2470
01:33:41,315 --> 01:33:44,819
BE ABLE TO GET MORE AROUND THE

2471
01:33:44,885 --> 01:33:47,088
ACTIVATION LIFE CYCLE THAT

2472
01:33:47,154 --> 01:33:48,089
DWIGHT DESCRIBES BECAUSE OF THE

2473
01:33:48,155 --> 01:33:50,124
TIME FRAME INVOEVERRED, MUCH

2474
01:33:50,191 --> 01:33:52,626
LONGER TIME, WE NEEDED A

2475
01:33:52,693 --> 01:33:57,064
DIFFERENT APPROACH, AND THAT

2476
01:33:57,131 --> 01:33:59,133
APPROACH IS ADMIRRALL, WHICH WE

2477
01:33:59,200 --> 01:34:01,435
WILL SPEND A BIT OF MORE TIME

2478
01:34:01,502 --> 01:34:04,238
SPEAKING ON BUT FIRST, A LITTLE

2479
01:34:04,305 --> 01:34:04,638
MORE CARTOON FORM.

2480
01:34:04,705 --> 01:34:06,107
>> THIS REPRESENTS THE PROCESS,

2481
01:34:06,173 --> 01:34:08,776
WHEN THAT RAS IS GDP BOUND IN

2482
01:34:08,843 --> 01:34:11,245
THE UPPER LEFT, IT'S INACTIVE

2483
01:34:11,312 --> 01:34:12,380
CONFIGURURATION, WHEN IT'S GTP

2484
01:34:12,446 --> 01:34:15,049
BOUND IT'S IN ACTIVE

2485
01:34:15,116 --> 01:34:16,217
CONFIGURURATION AND COMBINED 2

2486
01:34:16,283 --> 01:34:19,453
EFFECTORS SUCH AS THE RAS-RAF

2487
01:34:19,520 --> 01:34:20,321
KINASE, WHICH THE DIFFERENT

2488
01:34:20,388 --> 01:34:22,056
DOMAINS ARE SHOWN HERE.

2489
01:34:22,123 --> 01:34:25,459
ENGAGEMENT OF THE RAS BINDING

2490
01:34:25,526 --> 01:34:27,461
DOMAIN RBD RESULTS IN PARTIAL

2491
01:34:27,528 --> 01:34:28,763
LOOSENING OF THIS COMPLEX AND

2492
01:34:28,829 --> 01:34:31,599
EVENTUAL MOVEMENT OF THE CRD

2493
01:34:31,665 --> 01:34:33,234
INTO THE MEMBRANE AND YOU CAN

2494
01:34:33,300 --> 01:34:35,636
SEE THAT ASSOCIATED WITH THIS

2495
01:34:35,703 --> 01:34:38,072
BINDING TO RAS AND REARRANGEMENT

2496
01:34:38,139 --> 01:34:40,541
THAT THERE'S A RELEASE OF SOME

2497
01:34:40,608 --> 01:34:43,511
COMPONENTS OF RAF ARE OPENING

2498
01:34:43,577 --> 01:34:44,311
UP, THERE'S PROBABLY

2499
01:34:44,378 --> 01:34:45,146
DEPHOSPHORYLATION STEPS THAT ARE

2500
01:34:45,212 --> 01:34:46,947
ASSOCIATE WIDE THAT, BUT THERE'S

2501
01:34:47,014 --> 01:34:49,550
LARGE DOMAIN MOVEMENT, AND

2502
01:34:49,617 --> 01:34:50,684
REARRANGEMENT DOMAINS AND THESE

2503
01:34:50,751 --> 01:34:52,720
ARE THE TYPE OF THINGS THAT ARE

2504
01:34:52,787 --> 01:34:54,688
HARD TO CAPTURE EXPERIMENTALLY,

2505
01:34:54,755 --> 01:34:57,825
AND SO PART OF THE RATIONAL FOR

2506
01:34:57,892 --> 01:34:59,493
THIS PROJECT IS TO TRY TO MODEL

2507
01:34:59,560 --> 01:35:03,464
SOME OF THESE THINGS

2508
01:35:03,531 --> 01:35:04,098
COMPUTATIONALLY, AND THEN

2509
01:35:04,165 --> 01:35:05,800
ASSOCIATE WIDE THAT, WE HAVE

2510
01:35:05,866 --> 01:35:07,568
INPUTS SUCH AS STRUCTURES THAT

2511
01:35:07,635 --> 01:35:09,503
WE'VE GENERATED HERE WITHIN THE

2512
01:35:09,570 --> 01:35:11,605
RAS INITIATIVE OR NCI, THIS JUST

2513
01:35:11,672 --> 01:35:14,842
SHOWS R,A S BOUND TO THE RBD AND

2514
01:35:14,909 --> 01:35:17,778
CRD OF THE RAF KINASE, WE HAVE A

2515
01:35:17,845 --> 01:35:18,846
PLETHORA OF EXPERIMENTAL

2516
01:35:18,913 --> 01:35:21,015
APPROACHES, YOU KNOW INCLUDING

2517
01:35:21,082 --> 01:35:22,416
LOOKING AT SIGNALING IN LIVE

2518
01:35:22,483 --> 01:35:25,953
CELLS, TO LOOK AT BINDING AND

2519
01:35:26,020 --> 01:35:28,689
ACTIVATION OF DEFINITE ONCOGENIC

2520
01:35:28,756 --> 01:35:33,094
MUTANTS OF RAS OR PERMIAITATIONS

2521
01:35:33,160 --> 01:35:35,863
OF RASE MODEL BETWEEN DIFFERENT

2522
01:35:35,930 --> 01:35:37,531
RASs AND RAF, AND WHAT HELPED

2523
01:35:37,598 --> 01:35:39,100
EARLIER THAT WAS GENERATED

2524
01:35:39,166 --> 01:35:41,068
EENTLY WITHIN THE LAST YEAR OR 2

2525
01:35:41,135 --> 01:35:43,070
THAT CAME OUT OF THE MORRISON

2526
01:35:43,137 --> 01:35:46,640
LAB AND CCR THAT SHOWED THIS

2527
01:35:46,707 --> 01:35:48,776
AUTOINHIBITTED COMPLEX SHOWING

2528
01:35:48,843 --> 01:35:50,911
DOWN AT THE BOTTOM 1433, AND

2529
01:35:50,978 --> 01:35:52,646
THEN THE RAS BYPASSING DOMAIN

2530
01:35:52,713 --> 01:35:54,748
AND THE CRD DOMAINS ALONG WITH

2531
01:35:54,815 --> 01:35:59,887
THE KINASE DOMAIN IN THE

2532
01:35:59,954 --> 01:36:02,189
INHIBITING COMPLEX, AND HELPFUL

2533
01:36:02,256 --> 01:36:04,391
IN PUSHING US FORWARD, SOME

2534
01:36:04,458 --> 01:36:05,426
EXPERIMENTAL APPROACHES JUST TO

2535
01:36:05,493 --> 01:36:08,529
SHOW HOW WE INTEND TO YOU KNOW

2536
01:36:08,596 --> 01:36:11,165
IN PARALLEL VALIDATE PREDICTIONS

2537
01:36:11,232 --> 01:36:13,701
FROM THE STIMULATIONS ARE SHOWN

2538
01:36:13,767 --> 01:36:14,935
ON THE LEFT.

2539
01:36:15,002 --> 01:36:17,938
AND THAT AN AUTOINHIBIT THE

2540
01:36:18,005 --> 01:36:19,673
COMPLEX APPOINTED BINDING TO

2541
01:36:19,740 --> 01:36:30,184
RAS, ITSELF, WILL COME UP

2542
01:36:31,485 --> 01:36:32,653
WITH--WELL, WE WON'T WORRY ABOUT

2543
01:36:32,720 --> 01:36:33,988
THAT FOR NOW.

2544
01:36:34,054 --> 01:36:39,093
IF RAF BINDS TO RAS AND RELEASES

2545
01:36:39,160 --> 01:36:41,996
2 FLOORS INDICATED HERE WITH A

2546
01:36:42,062 --> 01:36:43,831
GREEN AND RED STAR WOULD MOVE

2547
01:36:43,898 --> 01:36:45,132
FURTHER APART AND IF YOU SET

2548
01:36:45,199 --> 01:36:49,570
THOSE UP SO THAT THOSE WERE SET

2549
01:36:49,637 --> 01:36:52,173
UP FOR FLUORESCENCE ENERGY

2550
01:36:52,239 --> 01:36:53,674
TRANSFER OR FRET, YOU CAN

2551
01:36:53,741 --> 01:36:54,875
IMAGINE THAT SIGNAL WOULD

2552
01:36:54,942 --> 01:36:55,109
CHANGE.

2553
01:36:55,176 --> 01:36:57,211
SO THAT'S 1 WAY WE COULD LOOK AT

2554
01:36:57,278 --> 01:36:58,245
ACTIVATION OR DOMAIN MOVEMENT.

2555
01:36:58,312 --> 01:37:01,115
WE ALSO HAVE THE ABILITY TO

2556
01:37:01,182 --> 01:37:03,284
COLLABORATE WITH OTHERS AND LOOK

2557
01:37:03,350 --> 01:37:04,885
AT THE NEUTRON REFLECTIVITY

2558
01:37:04,952 --> 01:37:10,724
SHOWN HERE ON THE RIGHT.

2559
01:37:10,791 --> 01:37:12,927
IN THE BUT TITLED PANEL, YOU SEE

2560
01:37:12,993 --> 01:37:15,496
THE EXPECT RUM YOU GET FROM RAS

2561
01:37:15,563 --> 01:37:17,364
WHEN IT'S SITTING ON A MEMBRANE

2562
01:37:17,431 --> 01:37:19,200
WHICH IS SIDE WAYS IN IN DIAGRAM

2563
01:37:19,266 --> 01:37:21,635
AND THERE'S AN AVERAGE DISTANCE

2564
01:37:21,702 --> 01:37:23,170
TO THIS CENTER TO THE MOLECULE,

2565
01:37:23,237 --> 01:37:25,506
WHEN YOU ADD RAFOT LEFT, CAN YOU

2566
01:37:25,573 --> 01:37:27,408
SEE THAT RAS MOVES CLOSER TO THE

2567
01:37:27,474 --> 01:37:29,476
MEMBRANE AND WE CAN NOW SEE

2568
01:37:29,543 --> 01:37:31,111
DENSITY THAT'S ASSOCIATE WIDE

2569
01:37:31,178 --> 01:37:32,513
THE RAF KINASE ITSELF, SO THESE

2570
01:37:32,580 --> 01:37:34,715
ARE JUST EXAMPLES OF SOME OF THE

2571
01:37:34,782 --> 01:37:36,684
MANY TYPES OF EXPERIMENTAL

2572
01:37:36,750 --> 01:37:39,119
APPROACHES WE HAVE TO LOOK AT

2573
01:37:39,186 --> 01:37:42,856
THIS IN PARALLEL WITH THE

2574
01:37:42,923 --> 01:37:43,490
COMPUTATIONAL APPROACHES.

2575
01:37:43,557 --> 01:37:45,726
>> SO I HOPE YOU CAN APPRECIATE

2576
01:37:45,793 --> 01:37:47,027
HOW DIFFICULT SOME OF THE

2577
01:37:47,094 --> 01:37:48,862
EXPERIMENTS ARE IN ORDER TO GET

2578
01:37:48,929 --> 01:37:51,198
WHAT IS SOME OF THE BASIC PIECES

2579
01:37:51,265 --> 01:37:52,766
OF INFORMATION, LIKE THE

2580
01:37:52,833 --> 01:37:53,467
STRUCTURAL COMPONENTS BUT WE

2581
01:37:53,534 --> 01:37:55,002
WANT TO FIND OUT THE DYNAMICS,

2582
01:37:55,069 --> 01:37:56,570
WE WANT TO SEE HOW IT GETS FROM

2583
01:37:56,637 --> 01:37:58,906
THE FIRST STATE, WHAT I WILL

2584
01:37:58,973 --> 01:38:00,441
CALLITATE A, MARKED WITH THE

2585
01:38:00,507 --> 01:38:02,309
LEFT ARROW THERE, TOITATE B, THE

2586
01:38:02,376 --> 01:38:03,510
RIGHT ARROW AND THESE ARE STATES

2587
01:38:03,577 --> 01:38:05,379
THAT WE CAN ACTUALLY HAVE

2588
01:38:05,446 --> 01:38:06,513
EXPERIMENTAL CONFIRMATION FROM,

2589
01:38:06,580 --> 01:38:08,015
THE WORK THAT DWIGHT JUST

2590
01:38:08,082 --> 01:38:08,449
DESCRIBED.

2591
01:38:08,515 --> 01:38:09,683
HOW DOES IT GET FROM THERE, FROM

2592
01:38:09,750 --> 01:38:10,651
1 TO THE OTHER.

2593
01:38:10,718 --> 01:38:13,320
THIS IS WHAT WE CAN'T MODEL WITH

2594
01:38:13,387 --> 01:38:14,922
THE SINGLE DYNAMIC SIMULATION,

2595
01:38:14,989 --> 01:38:16,924
IT'S TOO LARGE, EVEN FOR THE

2596
01:38:16,991 --> 01:38:18,325
LARGEST COMPUTER ON EARTH, IT'S

2597
01:38:18,392 --> 01:38:19,860
TOO LARGE, SO THE APPROACH WE'RE

2598
01:38:19,927 --> 01:38:22,596
TAKING MOW IS USING MACHINE

2599
01:38:22,663 --> 01:38:25,199
LEARNING TO DEVELOP A SUITABLE

2600
01:38:25,266 --> 01:38:27,534
LATENT SPACE AND A LATENT SPACE

2601
01:38:27,601 --> 01:38:33,040
IS A REDUCED ORDER SPACE, LOWER

2602
01:38:33,107 --> 01:38:33,674
DIMENSIONAL SPACE.

2603
01:38:33,741 --> 01:38:35,276
YOU COULD THINK OF THAT AS LIKE

2604
01:38:35,342 --> 01:38:37,911
TAKING A PHOTOGRAPH OF 3

2605
01:38:37,978 --> 01:38:38,979
DIMENSIONAL SCENE AND THEN

2606
01:38:39,046 --> 01:38:40,614
CAPTURING THAT ON A 2

2607
01:38:40,681 --> 01:38:42,916
DIMENSIONAL PIECE OF FILM,

2608
01:38:42,983 --> 01:38:44,318
THAT'S SORT OF--THAT'S A FUNNY

2609
01:38:44,385 --> 01:38:46,854
WAY SORT OF LIKE A LATENT SPACE.

2610
01:38:46,920 --> 01:38:48,622
ONE THING WE CAN DO WITH CERTAIN

2611
01:38:48,689 --> 01:38:50,024
TYPES OF LATENT SPACES AND

2612
01:38:50,090 --> 01:38:51,425
YOU'VE SEEN A LOT OF THIS

2613
01:38:51,492 --> 01:38:54,261
WRITTEN ABOUT IN THE OPEN PRESS

2614
01:38:54,328 --> 01:38:55,896
IS YOU CAN ONCE YOU FIGURE OUT

2615
01:38:55,963 --> 01:38:57,965
HOW TO CREATE A SPACE, YOU CAN

2616
01:38:58,032 --> 01:38:59,033
PLAY IT BACKWARDS WHICH MEANS

2617
01:38:59,099 --> 01:39:00,701
YOU CAN TAKE A SPOT IN THE

2618
01:39:00,768 --> 01:39:03,470
LATENT SPACE AND TURN IT INTO A

2619
01:39:03,537 --> 01:39:04,838
CONFIGURURATION, YOU CAN DO

2620
01:39:04,905 --> 01:39:05,673
GENERATIVE WORK.

2621
01:39:05,739 --> 01:39:08,842
SO THE INTENT HERE IS FOR US TO

2622
01:39:08,909 --> 01:39:13,147
LEARN A LATENT SPACE THAT HAS A

2623
01:39:13,213 --> 01:39:14,782
CLUSTER IN THAT SPACE THAT

2624
01:39:14,848 --> 01:39:15,949
REPRESENTS THE FIRST STAGE WHICH

2625
01:39:16,016 --> 01:39:18,952
IS HERE SHOWN, RED, AND THAT

2626
01:39:19,019 --> 01:39:20,754
REPRESENTS THE SECOND STATE

2627
01:39:20,821 --> 01:39:21,722
WHICH IS HERE SHOWN ORANGE.

2628
01:39:21,789 --> 01:39:22,823
WE DON'T KNOW WHAT HAPPENS IN

2629
01:39:22,890 --> 01:39:24,224
THE MIDDLE BUT RATHER THAN TRY

2630
01:39:24,291 --> 01:39:26,093
TO EXPLORE THAT IN REAL SPACE,

2631
01:39:26,160 --> 01:39:27,261
USE THE LATENT SPACE TO

2632
01:39:27,328 --> 01:39:30,431
GENERATE, GO INTO THE NEXT

2633
01:39:30,497 --> 01:39:34,702
SLIDE, SO WE WILL SET UP A LOOP

2634
01:39:34,768 --> 01:39:37,004
THAT ATTEMPTS--ATTEMPTS A NEW

2635
01:39:37,071 --> 01:39:38,939
CONFIGURURATION, VALIDATES IT

2636
01:39:39,006 --> 01:39:40,441
WITH THE HIGH PERFORMANCE

2637
01:39:40,507 --> 01:39:41,642
DYNAMICS CODE AND IF IT'S GOOD

2638
01:39:41,709 --> 01:39:44,745
WE KEEP IT AND IF IT'S NOT GOOD,

2639
01:39:44,812 --> 01:39:46,647
WE DON'T KEEP IT AND IF WE KEEP

2640
01:39:46,714 --> 01:39:48,382
DOING THIS LOOP, SO IN THIS WAY,

2641
01:39:48,449 --> 01:39:50,718
WE LEARN NOW DOTS AND NEW SPACES

2642
01:39:50,784 --> 01:39:52,119
IN THE LATENT SPACE WE DIDN'T

2643
01:39:52,186 --> 01:39:55,556
KNOW BEFORE, THESE WERE VALID

2644
01:39:55,622 --> 01:39:56,390
CONFIGURATIONS AND IF WE

2645
01:39:56,457 --> 01:39:57,958
CONTINUE THIS LOOP, WE WILL FILL

2646
01:39:58,025 --> 01:40:02,930
THIS SPACE IN THE LATENT SPACE

2647
01:40:02,996 --> 01:40:04,098
BETWEEN THE 2 FIGURURATIONS, THE

2648
01:40:04,164 --> 01:40:05,065
FOLDED AND THE UNFOLDED STATE

2649
01:40:05,132 --> 01:40:07,501
AND WE CAN PAUSE IT NOW A PATH

2650
01:40:07,568 --> 01:40:09,236
THAT CONNECTS THISEMMA WE

2651
01:40:09,303 --> 01:40:10,637
COULDN'T HAVE SEEN SINGLY BUT

2652
01:40:10,704 --> 01:40:12,306
NOW WE KNOW WHERE THE PATH IS,

2653
01:40:12,373 --> 01:40:13,374
WE HAVE A REACTION COORDINATE

2654
01:40:13,440 --> 01:40:16,510
AND WE CAN GO BACK AND VALIDATE

2655
01:40:16,577 --> 01:40:17,144
THAT TRAJECTORY.

2656
01:40:17,211 --> 01:40:21,715
GO AHEAD AND GO TO THE NEXT

2657
01:40:21,782 --> 01:40:22,483
SLIDE.

2658
01:40:22,549 --> 01:40:23,684
THIS IS BUILDINGOT TECHNOLOGY WE

2659
01:40:23,751 --> 01:40:28,255
CREATED OUT OF PILOT 2 TO

2660
01:40:28,322 --> 01:40:28,956
INITIATE, RUN, ANALYZE, CLOSE

2661
01:40:29,022 --> 01:40:32,092
AND YOU KNOW HARVEST THE DATA

2662
01:40:32,159 --> 01:40:33,026
FROM LITERALLY HUNDREDS OF

2663
01:40:33,093 --> 01:40:34,995
THOUSANDS AND WE'RE XEBTING

2664
01:40:35,062 --> 01:40:36,296
CLOSE TO A MILLION STIMULATIONS

2665
01:40:36,363 --> 01:40:38,065
IN ORDER TO DO THE PROCESS THAT

2666
01:40:38,132 --> 01:40:39,333
I JUST DESCRIBED TO YOU.

2667
01:40:39,400 --> 01:40:41,869
ALL OF THAT HAS TO GET MAPPED ON

2668
01:40:41,935 --> 01:40:43,570
TO A VERY COMPLICATED COMPUTER,

2669
01:40:43,637 --> 01:40:44,938
ALL THE DAILY BASIS THEA HAS TO

2670
01:40:45,005 --> 01:40:46,573
BE THE RIGHT SPOT AT THE RIGHT

2671
01:40:46,640 --> 01:40:48,442
TIME AND THAT'S ALL MANAGED WITH

2672
01:40:48,509 --> 01:40:51,478
WHAT WE CALL MIMI, OUR

2673
01:40:51,545 --> 01:40:53,647
MULTISCALED MACHINE LEARNING

2674
01:40:53,714 --> 01:40:54,882
MODELING INFRASTRUCTURE THAT

2675
01:40:54,948 --> 01:40:58,652
WE'VE NOW UPGRADED TO FIT INTO

2676
01:40:58,719 --> 01:41:02,156
THIS GENERATIVE MODELING WE'RE

2677
01:41:02,222 --> 01:41:07,294
USING FOR ADMIRRAL.

2678
01:41:07,361 --> 01:41:10,964
OKAY, YES, YEAH, NO, GO BACK 1

2679
01:41:11,031 --> 01:41:12,132
PLEASE, AND I'LL EXPLAIN JUST A

2680
01:41:12,199 --> 01:41:13,867
LITTLE BIT MORE HOW THIS WORKS.

2681
01:41:13,934 --> 01:41:16,069
BECAUSE YOU SEE THE PINK, BLUE,

2682
01:41:16,136 --> 01:41:19,173
GREEN AND PURPLE ARE DIFFERENT

2683
01:41:19,239 --> 01:41:20,541
LAYERS IN THE MODEL.

2684
01:41:20,607 --> 01:41:22,409
THE PINK LAYER IS THE COURSES

2685
01:41:22,476 --> 01:41:27,047
SAMPLE AND THAT'S WHERE WE'RE

2686
01:41:27,114 --> 01:41:29,850
ACTUALLY GENERATING PROTEIN

2687
01:41:29,917 --> 01:41:31,251
CONFIRMATIONS THAT WE'RE GOING

2688
01:41:31,318 --> 01:41:33,854
TO VALIDATE.

2689
01:41:33,921 --> 01:41:37,057
THE BLUE MODEL INCORPORATES THE

2690
01:41:37,124 --> 01:41:39,426
LIPID AROUND THE PROTEIN

2691
01:41:39,493 --> 01:41:40,928
CONFIRMATION WHICH IS JUST A

2692
01:41:40,994 --> 01:41:43,163
GUEST, NOW WE WILL PUT A LIPPED

2693
01:41:43,230 --> 01:41:45,432
AROUND IT AND NOW WE WILL MODEL

2694
01:41:45,499 --> 01:41:48,035
IT USING COARSE GRAIN SIMULATION

2695
01:41:48,101 --> 01:41:48,936
FULLY ANIMALISTIC MODELS WITH

2696
01:41:49,002 --> 01:41:50,337
THE CORE KREEN WHERE THE CORE

2697
01:41:50,404 --> 01:41:51,839
SCREEN MAY NOT BE COMPLETELY

2698
01:41:51,905 --> 01:41:52,873
CORRECT AND THEN THAT

2699
01:41:52,940 --> 01:41:56,210
INFORMATION GETS FED BACK UP AND

2700
01:41:56,276 --> 01:41:56,944
YOU RATHER, RINSE, REPEAT AND

2701
01:41:57,010 --> 01:41:59,046
YOU DO IT OVER AND OVER AGAIN AS

2702
01:41:59,112 --> 01:42:01,215
YOU FIND THE SPOTS THAT ALLOW TO

2703
01:42:01,281 --> 01:42:02,816
YOU CONNECT THE PATH THAT YOU

2704
01:42:02,883 --> 01:42:05,152
WOULD NOT HAVE EVER SEEN, THAT'S

2705
01:42:05,219 --> 01:42:06,653
ADMIRAL IN A NUT SHELL.

2706
01:42:06,720 --> 01:42:09,957
THE CODE IS BASED ON THIS MEDIA

2707
01:42:10,023 --> 01:42:11,592
FRAMEWORK AND A NUMBER OF VERY

2708
01:42:11,658 --> 01:42:13,227
SPECIALIZED CODES THAT HAVE BEEN

2709
01:42:13,293 --> 01:42:15,162
WRITTEN TO HANDLE THIS PROCESS,

2710
01:42:15,229 --> 01:42:17,331
THEY'RE ALL HIGHLY SCALABLE

2711
01:42:17,397 --> 01:42:20,868
CODES AND THEY'RE ALL AVAILABLE

2712
01:42:20,934 --> 01:42:24,438
OPEN DOMAIN, THE MUMMI

2713
01:42:24,505 --> 01:42:25,572
FRAMEWORK, THE DDCMD, THE

2714
01:42:25,639 --> 01:42:27,541
MULTIDISCIPLINARY MEDICARE AND

2715
01:42:27,608 --> 01:42:29,843
MEDICAIDICS CODE, MAR TIPY

2716
01:42:29,910 --> 01:42:31,144
PARAMETERS WHICH WE CAN COLLAB 8

2717
01:42:31,211 --> 01:42:33,380
WITH THE FOLKS WHO DEVELOP THE

2718
01:42:33,447 --> 01:42:34,548
MARTINI PARAMETERS, ALL THE WAY

2719
01:42:34,615 --> 01:42:36,750
TO THE CODE THAT IS USED TO DO

2720
01:42:36,817 --> 01:42:38,118
THE MANAGEMENT OF THE COMPUTER

2721
01:42:38,185 --> 01:42:43,824
ITSELF, ALL OF THAT IS OPEN

2722
01:42:43,891 --> 01:42:44,157
DOMAIN.

2723
01:42:44,224 --> 01:42:45,592
>> IN ADDITION MUCH OF THIS DATA

2724
01:42:45,659 --> 01:42:48,428
HAS BEEN PLACED ON THE CANCER

2725
01:42:48,495 --> 01:42:49,963
.GOV SITE AND IT'S A SITE THAT'S

2726
01:42:50,030 --> 01:42:52,933
SET UP FOR ALL THESE

2727
01:42:53,000 --> 01:42:54,568
COLLABORATIONS OR PROGECS TO

2728
01:42:54,635 --> 01:42:58,539
SHARE DATAS AND CAPABILITIES.

2729
01:42:58,605 --> 01:43:01,708
THIS HAS BEEN A HIGHLY

2730
01:43:01,775 --> 01:43:02,809
COLLABORATIVE INTERACTIVE

2731
01:43:02,876 --> 01:43:03,944
PROJECT MULTIDISCIPLINARY ACROSS

2732
01:43:04,011 --> 01:43:09,416
MULTIPLE   LABS AND INITYS, I

2733
01:43:09,483 --> 01:43:11,885
THINK IT'S BEEN A REAL BOOM FOR

2734
01:43:11,952 --> 01:43:15,289
THE FNLAC AND TO INTERACT WITH

2735
01:43:15,355 --> 01:43:21,795
PEOPLE FROM LIVER MORE WHO ARE

2736
01:43:21,862 --> 01:43:22,563
MORE COMPUTATIONALLY BASED.

2737
01:43:22,629 --> 01:43:25,899
>> IT'S BEEN AN EXTRAORDINARILY

2738
01:43:25,966 --> 01:43:26,767
COLLABORATIVE PROCESS, WHICH MET

2739
01:43:26,833 --> 01:43:28,268
THE PREMISE OF THE ORIGINAL

2740
01:43:28,335 --> 01:43:30,237
PROJECTS WHICH WAS THAT THE D.

2741
01:43:30,304 --> 01:43:33,740
O. E. WAS GOING TO BRING VERY

2742
01:43:33,807 --> 01:43:37,611
HIGH PERM FORMANCE COMPUTING TO

2743
01:43:37,678 --> 01:43:39,513
HELP WITH THE DEEP COMLICATED

2744
01:43:39,580 --> 01:43:41,982
BIOLOGY THAT NCI IS DEALING WITH

2745
01:43:42,049 --> 01:43:43,116
AND THE CHALLENGING BIOLOGY IS

2746
01:43:43,183 --> 01:43:44,518
GOING TO INFORM AND COMPUTE IN

2747
01:43:44,585 --> 01:43:46,920
THE D. O. E. AND I THINK BOTH OF

2748
01:43:46,987 --> 01:43:48,522
THOSE HAVE HAPPENED.

2749
01:43:48,589 --> 01:43:50,490
NAGREED AND JUST 1 FINAL SIDE,

2750
01:43:50,557 --> 01:43:52,225
TO REMIND EVERYONE THAT BIOLOGY

2751
01:43:52,292 --> 01:43:53,660
IS COMPLICATED AND WHAT WE TOLD

2752
01:43:53,727 --> 01:43:54,962
YOU ABOUT TODAY, YOU KNOW IS

2753
01:43:55,028 --> 01:43:58,098
JUST A COMPONENT OF THIS, RAS

2754
01:43:58,165 --> 01:43:58,932
AND RAF INTERACTION BUT THERE

2755
01:43:58,999 --> 01:44:03,136
ARE MANY OTHER THINGS THAT COULD

2756
01:44:03,203 --> 01:44:04,204
BE MODELS WITH PERMIAITATIONS OF

2757
01:44:04,271 --> 01:44:07,240
THIS SYSTEM AND WE LOOK FORWARD

2758
01:44:07,307 --> 01:44:09,409
TO CONTINUING TO DELVE INTO THIS

2759
01:44:09,476 --> 01:44:12,546
AND FIGURE OUT WHAT WE CAN ABOUT

2760
01:44:12,613 --> 01:44:14,214
CANCER BIOLOGY AND ONCOGENIC

2761
01:44:14,281 --> 01:44:16,350
SIGNALING, SO THANK YOU FOR YOUR

2762
01:44:16,416 --> 01:44:20,754
TAME AND I THINK WE'LL TAKE

2763
01:44:20,821 --> 01:44:23,223
QUESTIONS.

2764
01:44:23,290 --> 01:44:26,126
>> THANK YOU.

2765
01:44:26,193 --> 01:44:26,693
>> GREAT PRESENTATION.

2766
01:44:26,760 --> 01:44:29,363
DO WE HAVE QUESTIONS?

2767
01:44:29,429 --> 01:44:31,832
>> I HAVE A QUESTION.

2768
01:44:31,898 --> 01:44:33,734
ANAT HERE.

2769
01:44:33,800 --> 01:44:34,635
>> YES.

2770
01:44:34,701 --> 01:44:35,102
>> GREAT, WONDERFUL

2771
01:44:35,168 --> 01:44:35,435
PRESENTATION.

2772
01:44:35,502 --> 01:44:38,939
THIS QUESTION IS PROBABLY FOR

2773
01:44:39,006 --> 01:44:41,742
FRED, SO I GUESS 2 QUESTIONS I

2774
01:44:41,808 --> 01:44:44,611
HAD, 1 WAS WITH REGARD TO THE

2775
01:44:44,678 --> 01:44:45,879
LATENT SPACE, HOW DO YOU

2776
01:44:45,946 --> 01:44:48,415
IDENTIFY WHAT IS THE APPROPRIATE

2777
01:44:48,482 --> 01:44:49,650
DIMENSIONALITY WITHIN WHICH TO

2778
01:44:49,716 --> 01:44:53,654
DO YOUR SIMULATION OR APPLY THE

2779
01:44:53,720 --> 01:44:55,956
LEARNING AND THE SECOND QUESTION

2780
01:44:56,023 --> 01:44:57,924
IS, HOW DO YOU MEASURE SUCCESS

2781
01:44:57,991 --> 01:45:00,427
FOR THIS KIND OF SIMULATION

2782
01:45:00,494 --> 01:45:02,162
BASED EXPERIMENT, THANK YOU.

2783
01:45:02,229 --> 01:45:04,498
>> SO THE FIRST 1 I WILL GIVE A

2784
01:45:04,564 --> 01:45:06,533
HAND WAVY ANSWER, BECAUSE I

2785
01:45:06,600 --> 01:45:09,503
MYSELF DID NOT DO THAT

2786
01:45:09,569 --> 01:45:11,104
CALCULATION, BUT, THERE IS AS

2787
01:45:11,171 --> 01:45:14,508
THEY BUILD THE LATENT SPACE,

2788
01:45:14,574 --> 01:45:18,545
THEY TRY VARIOUS MODELS AND YOU

2789
01:45:18,612 --> 01:45:19,980
WANT OF COURSE THE SMALLEST

2790
01:45:20,047 --> 01:45:21,581
MODEL YOU CAN GET AWAY WITH

2791
01:45:21,648 --> 01:45:23,717
BECAUSE THE TIME FOR TRAINING

2792
01:45:23,784 --> 01:45:24,785
GOES UP SUBSTANTIALLY WITH HOW

2793
01:45:24,851 --> 01:45:26,420
LARGE A MODEL YOU HAVE, SO IF

2794
01:45:26,486 --> 01:45:28,388
IT'S TOO SMALL A MODEL, IT

2795
01:45:28,455 --> 01:45:30,490
DOESN'T CONVERGE AND YOU CAN'T

2796
01:45:30,557 --> 01:45:32,959
ACTUALLY GET, YOU KNOW--YOU

2797
01:45:33,026 --> 01:45:35,395
CAN'T GO BACK AND THE OUTER

2798
01:45:35,462 --> 01:45:36,563
DOESN'T CONVERGE, YOU CAN'T COME

2799
01:45:36,630 --> 01:45:38,398
BACK AND GET YOUR PREDICT

2800
01:45:38,465 --> 01:45:39,366
BACKWARDS WITH WHAT YOU STARTED

2801
01:45:39,433 --> 01:45:39,599
WITH.

2802
01:45:39,666 --> 01:45:42,669
IF YOU HAVE A LOT OF PARAMETERS,

2803
01:45:42,736 --> 01:45:45,472
YOU CAN GET THE RIGHT ANSWER,

2804
01:45:45,539 --> 01:45:48,508
YOU CAN IN FACT INVERT YOUR

2805
01:45:48,575 --> 01:45:49,543
AUTOENCODER BUT YOU'RE TAKING

2806
01:45:49,609 --> 01:45:50,977
TIME BUT IT'S EXPERIMENTAL

2807
01:45:51,044 --> 01:45:51,845
PROCESS, BASICALLY BUT YOU FIND

2808
01:45:51,912 --> 01:45:53,480
THE SPOT THAT WORKS, THAT IS

2809
01:45:53,547 --> 01:45:55,015
SMALL ENOUGH THAT YOU CAN DEAL

2810
01:45:55,082 --> 01:45:56,983
WITH AND THAT'S SORT OF HOW THAT

2811
01:45:57,050 --> 01:45:57,918
PROCESS IS DONE.

2812
01:45:57,984 --> 01:46:00,420
TO ANSWER YOUR OTHER QUESTION OF

2813
01:46:00,487 --> 01:46:02,189
HOW YOU CAN--HOW CAN YOU BE

2814
01:46:02,255 --> 01:46:03,890
SURE, WHAT'S YOUR CONFIDENCE

2815
01:46:03,957 --> 01:46:05,158
BASICALLY THAT YOU WILL WIND UP

2816
01:46:05,225 --> 01:46:07,060
WITH A RIGHT ANSWER, HOW DO YOU

2817
01:46:07,127 --> 01:46:08,662
VALIDATE THIS, THERE ARE 2 WAYS.

2818
01:46:08,729 --> 01:46:10,564
FIRST OF ALL WE'RE VALIDATING

2819
01:46:10,630 --> 01:46:11,965
THE CONFIRMATIONS AS WE'RE

2820
01:46:12,032 --> 01:46:13,033
DEVELOPING THEM, THAT'S PART OF

2821
01:46:13,100 --> 01:46:14,134
THAT WHOLE LOOP I DRIEBED TO

2822
01:46:14,201 --> 01:46:16,002
YOU, WE WILL DO THAT ON THE FLY.

2823
01:46:16,069 --> 01:46:20,240
AND BY THE WAY, AS WE'RE FINDING

2824
01:46:20,307 --> 01:46:21,308
THOSE SAMPLES, WE'RE RETRAINING

2825
01:46:21,374 --> 01:46:23,043
A LATENT SPACE, SO THAT LATENT

2826
01:46:23,110 --> 01:46:24,344
SPACE GETTING MORE AND MORE

2827
01:46:24,411 --> 01:46:25,545
INFORMED AS WE'RE GOING ALONG.

2828
01:46:25,612 --> 01:46:27,180
BUT THE FINAL PROOF AT THE VERY

2829
01:46:27,247 --> 01:46:29,649
END, IF WE HAVE A VALID

2830
01:46:29,716 --> 01:46:31,051
TRAJECTORY, THAT MEANS WE HAVE

2831
01:46:31,118 --> 01:46:32,986
ALSO DEFINED A VALID REACTION

2832
01:46:33,053 --> 01:46:34,988
COORDINATE AND NOW WE CAN RUN A

2833
01:46:35,055 --> 01:46:37,624
SINGLE MOLECULAR DISCIPLINARY

2834
01:46:37,691 --> 01:46:37,991
DYNAMIC

2835
01:46:38,058 --> 01:46:40,160
SINGULATION AND DRIVING THE

2836
01:46:40,227 --> 01:46:41,661
REACTION COORDINATE THAT GOES

2837
01:46:41,728 --> 01:46:43,296
ALL THE WAY ACROSS, EVEN IF

2838
01:46:43,363 --> 01:46:45,832
THAT'S SECONDS OF TIME, WE CAN

2839
01:46:45,899 --> 01:46:47,968
DO THAT, WE CAN DRIVE THE

2840
01:46:48,034 --> 01:46:49,703
DYNAMICS SIMULATION AND VALIDATE

2841
01:46:49,770 --> 01:46:52,773
IT'S A CORRECT TRAJECTORY.

2842
01:46:52,839 --> 01:46:54,374
IF THAT DOESN'T WORK, WE GO BACK

2843
01:46:54,441 --> 01:46:56,543
AND DO THE WHOLE THING AGAIN

2844
01:46:56,610 --> 01:46:58,044
BECAUSE IT'S POSSIBLE WE DO

2845
01:46:58,111 --> 01:47:00,280
SNAPSHOTS THAT ARE NOT IN FACT

2846
01:47:00,347 --> 01:47:01,047
CONNECTED TO TRANSLATIONAL

2847
01:47:01,114 --> 01:47:02,549
RESEARCH YECTRY, WE BELIEVE IT

2848
01:47:02,616 --> 01:47:03,817
WILL CONVERT BUT THAT IS THE

2849
01:47:03,884 --> 01:47:05,585
ONSLAUGHT OF THE PROJECT THAT

2850
01:47:05,652 --> 01:47:10,357
WILL DELIVER A TRAJECTORY THAT'S

2851
01:47:10,423 --> 01:47:12,993
VALID.

2852
01:47:13,059 --> 01:47:14,127
NTHANK YOU N.

2853
01:47:14,194 --> 01:47:15,262
>> CAROL?

2854
01:47:15,328 --> 01:47:17,097
>> YEAH, GREAT PRESENTATION AND

2855
01:47:17,164 --> 01:47:20,634
I'M WONDERING ABOUT THE

2856
01:47:20,700 --> 01:47:21,468
MACROMODEL PARAMETERS AND SO

2857
01:47:21,535 --> 01:47:23,003
HAVE YOU THESE PARAMETERS, YOU

2858
01:47:23,069 --> 01:47:24,304
BUILD IN THIS MODEL AND DO YOU

2859
01:47:24,371 --> 01:47:28,074
THEN GO BACK AND SEE WHICH ARE

2860
01:47:28,141 --> 01:47:29,276
THE MOST INFORMATIVE PARAMETERS,

2861
01:47:29,342 --> 01:47:31,711
I MEAN COULD YOU BUILD A MODEL

2862
01:47:31,778 --> 01:47:32,913
WITH FEWER PARAMETERS AND GET

2863
01:47:32,979 --> 01:47:37,050
THE SAME OUTPUT SO THAT CAN YOU

2864
01:47:37,117 --> 01:47:40,453
STREAMLINE THIS A LITTLE BIT

2865
01:47:40,520 --> 01:47:43,456
MORE OR HOW DO YOU GO ABOUT THE

2866
01:47:43,523 --> 01:47:44,291
MODEL PARAMETER SELECTION, I

2867
01:47:44,357 --> 01:47:48,028
GUESS, IS MY QUESTION AND CAN

2868
01:47:48,094 --> 01:47:48,829
YOU MINIMIZE IT?

2869
01:47:48,895 --> 01:47:52,833
NWE TRIED TO MINIMIZE IT BECAUSE

2870
01:47:52,899 --> 01:47:54,100
THE PARAMETERS BECOMES EXPENSIVE

2871
01:47:54,167 --> 01:47:56,536
QUICKLY, AND EVEN THOUGH WE HAVE

2872
01:47:56,603 --> 01:47:59,973
LARGE COMPUTERS IT GETS REALLY

2873
01:48:00,040 --> 01:48:00,774
EXPENSIVE.

2874
01:48:00,841 --> 01:48:03,176
SO YOU SAID MACROMODEL, SO

2875
01:48:03,243 --> 01:48:05,512
THAT'S A VERY SPECIFIC THING.

2876
01:48:05,579 --> 01:48:06,213
NYEAH, YEAH, YEAH.

2877
01:48:06,279 --> 01:48:10,951
>> THAT'S WHAT WE USE TO EQUILL

2878
01:48:11,017 --> 01:48:12,519
LIBRARY FOUNDATIONATE THE

2879
01:48:12,586 --> 01:48:14,287
LIPIDS, IT'S PUBLISHED, IT'S A

2880
01:48:14,354 --> 01:48:16,223
THEORY BASED MACROMODEL THAT IS

2881
01:48:16,289 --> 01:48:17,624
RIGOROUSLY BASED ON CORRELATION

2882
01:48:17,691 --> 01:48:23,964
FUNCTIONS THAT HAVE COME OUT OF

2883
01:48:24,030 --> 01:48:24,998
MOLECULAR DYNAMIC SIMULATIONS.

2884
01:48:25,065 --> 01:48:26,533
SO THAT'S TAKEN DIRECTLY.

2885
01:48:26,600 --> 01:48:31,471
SO WE RUN THOUSANDS OF

2886
01:48:31,538 --> 01:48:32,138
SIMULATIONS, CORRELATION,

2887
01:48:32,205 --> 01:48:33,139
COENTIOUS FICIENTS AND THOSE

2888
01:48:33,206 --> 01:48:34,941
WIND UP DRIVING A MA ROUGH ATOM

2889
01:48:35,008 --> 01:48:37,277
MODEL WHICH IS WHERE WE

2890
01:48:37,344 --> 01:48:41,281
CALIBRATE THE LIPIDS BASED ON

2891
01:48:41,348 --> 01:48:42,916
THE PROTEIN CONFIGURATIONS.

2892
01:48:42,983 --> 01:48:43,717
>> SO HOW EXTENSIBLE--ARE YOU

2893
01:48:43,783 --> 01:48:45,552
ANYTHING TO HAVE TO GO THROUGH

2894
01:48:45,619 --> 01:48:47,554
THIS WHOLE PROCESS FOR EXTENDING

2895
01:48:47,621 --> 01:48:50,957
THIS APPROACH TO LIKE ALL THAT

2896
01:48:51,024 --> 01:48:51,625
OTHER SPACE OF INTERACTION

2897
01:48:51,691 --> 01:48:52,726
THATION WERE SHOWN ON THE LAST

2898
01:48:52,792 --> 01:48:56,162
SLIDE OR THINGS THAT YOU CAN

2899
01:48:56,229 --> 01:48:56,396
BORROW.

2900
01:48:56,463 --> 01:48:58,265
>> MACHINERY CAN BE BORROWED,

2901
01:48:58,331 --> 01:48:59,900
THE PARAMETERS WOULD ALL BE

2902
01:48:59,966 --> 01:49:00,433
DIFFERENT.

2903
01:49:00,500 --> 01:49:02,269
SO THERE'S NOTHING, THERE'S

2904
01:49:02,335 --> 01:49:03,670
NOTHING--SPEAKING AS A

2905
01:49:03,737 --> 01:49:04,371
COMPUTATIONAL PHYSICIST, WHAT WE

2906
01:49:04,437 --> 01:49:06,506
HAVE BUILT IS A FRAMEWORK FOR

2907
01:49:06,573 --> 01:49:10,477
DOING A MULTISCALE MODEL ON AN

2908
01:49:10,543 --> 01:49:11,144
EXTRA SCALE COMPUTER.

2909
01:49:11,211 --> 01:49:13,280
WE CAN DO THIS ON A NUMBER OF

2910
01:49:13,346 --> 01:49:14,314
DIFFERENT BIOLOGY CONTEXT, A

2911
01:49:14,381 --> 01:49:15,482
NUMBER OF DIFFERENT PHYSICS

2912
01:49:15,548 --> 01:49:17,584
CONTEXT, IF YOU WANT A DIFFERENT

2913
01:49:17,651 --> 01:49:19,686
SET OF LIP I EDUCATIONALS, WE

2914
01:49:19,753 --> 01:49:21,454
COULD RUN SIMULATIONS, WE COULD

2915
01:49:21,521 --> 01:49:22,722
DO THAT PARAMETERIZATION AND WE

2916
01:49:22,789 --> 01:49:23,924
COULD BUILD ON A DIFFERENT SET

2917
01:49:23,990 --> 01:49:25,558
OF MODEL FOR A DIFFERENT SET OF

2918
01:49:25,625 --> 01:49:27,294
LIPIDS BUT WE HAVE THAT

2919
01:49:27,360 --> 01:49:32,999
MACHINERY IN PLACE NOW.

2920
01:49:33,066 --> 01:49:34,935
>> THANK YOU.

2921
01:49:35,001 --> 01:49:35,802
>> I BELIEVE RODNEY.

2922
01:49:35,869 --> 01:49:37,537
>> THANK YOU FRED AND DWIGHT.

2923
01:49:37,604 --> 01:49:39,873
I THINK THAT'S EXACTLY WHAT AI

2924
01:49:39,940 --> 01:49:42,475
WOULD BE VERY USEFUL FOR AND

2925
01:49:42,542 --> 01:49:44,644
THEN WITH THE COMPUTING POWER SO

2926
01:49:44,711 --> 01:49:52,752
I'M VERY FLAD --GLAD YOU HAVE AL

2927
01:49:52,819 --> 01:49:55,288
DEFINED PARAMETER YOU'RE LOOKING

2928
01:49:55,355 --> 01:49:55,522
AT.

2929
01:49:55,588 --> 01:49:56,723
IT'S COMPLICATED ENOUGH WITH

2930
01:49:56,790 --> 01:50:01,394
LIPIDS, TELL BE HUGE, RIGHT IN

2931
01:50:01,461 --> 01:50:04,197
SO THE SIMULATIONS OF ALL THE

2932
01:50:04,264 --> 01:50:05,398
SPACE, VERY SMALL FRAMEWORK IS

2933
01:50:05,465 --> 01:50:06,833
GOING TO TAKE A LOT OF

2934
01:50:06,900 --> 01:50:08,001
COMPUTING, SO THERE ARE A COUPLE

2935
01:50:08,068 --> 01:50:11,237
THINGS THAT I WAS TRYING TO

2936
01:50:11,304 --> 01:50:12,806
FIGURE IS THAT IN ADDITION TO

2937
01:50:12,872 --> 01:50:16,743
THE COMPUTING POWER, HAVE YOU

2938
01:50:16,810 --> 01:50:18,845
LOOKED AT POSSIBLITY OF QUANTUM

2939
01:50:18,912 --> 01:50:20,246
COMPUTING AS A NEXT STEP TO

2940
01:50:20,313 --> 01:50:23,516
ACCELERATE SOME OF THESE

2941
01:50:23,583 --> 01:50:24,117
PROCESS?

2942
01:50:24,184 --> 01:50:25,752
I KNOW LIVER MORE AND OTHER

2943
01:50:25,819 --> 01:50:28,188
PLACES ARE LOOKING AT IT AND

2944
01:50:28,254 --> 01:50:29,289
THAT'S 1 QUESTION.

2945
01:50:29,356 --> 01:50:34,127
ANOTHER QUESTION IS THAT JUST

2946
01:50:34,194 --> 01:50:36,429
RELATED TO US ABOUT THE

2947
01:50:36,496 --> 01:50:36,930
EXCHANGING LIPIDS.

2948
01:50:36,997 --> 01:50:38,565
SO THERE ARE SOME LIPIDS THAT

2949
01:50:38,631 --> 01:50:40,567
MAY CHAISM YOUR DYNAMICS ABOUT

2950
01:50:40,633 --> 01:50:44,070
HOW PROTEINS SIT IN THERE, AND

2951
01:50:44,137 --> 01:50:46,906
THE IN TERMS OF THE NANO OR

2952
01:50:46,973 --> 01:50:47,707
PARTICLE SECOND DIRECTIONS MAY

2953
01:50:47,774 --> 01:50:47,941
CHANGE.

2954
01:50:48,008 --> 01:50:49,309
SOPHISTICATEDY THAT IS A GOOD

2955
01:50:49,376 --> 01:50:52,479
PLACE TO BE IN, THE QUESTIONS

2956
01:50:52,545 --> 01:50:54,414
REALLY IS GOING TO COME TO IT,

2957
01:50:54,481 --> 01:50:57,784
AT LEAST IN MY MIND IS HOW DO

2958
01:50:57,851 --> 01:50:58,518
YOU VALIDATE THESE?

2959
01:50:58,585 --> 01:51:00,520
YOU KNOW ONCE YOU HAVE THESE

2960
01:51:00,587 --> 01:51:01,621
PARAMETER AND THEY WILL BE NEED

2961
01:51:01,688 --> 01:51:04,691
TO BE SOME SORT OF EXPERIMENTAL

2962
01:51:04,758 --> 01:51:07,260
VALIDATIONS TO FOLLOW UP TO TEST

2963
01:51:07,327 --> 01:51:08,094
YOUR MODEL.

2964
01:51:08,161 --> 01:51:08,495
>> ABSOLUTELY.

2965
01:51:08,561 --> 01:51:10,063
SO I WILL ANSWER THE QUANTUM

2966
01:51:10,130 --> 01:51:12,699
QUESTION AND I WILL LET DWIGHT

2967
01:51:12,766 --> 01:51:15,235
ANSWER THE VALIDATIONOT LIPIDS

2968
01:51:15,301 --> 01:51:15,502
QUESTION.

2969
01:51:15,568 --> 01:51:17,637
SO, YES, WE HAVE THOUGHT ABOUT

2970
01:51:17,704 --> 01:51:18,271
QUANTUM COMPUTING AND YOU'RE

2971
01:51:18,338 --> 01:51:19,906
RIGHT, THERE IS A FAIR AMOUNT OF

2972
01:51:19,973 --> 01:51:22,409
WORK GOING ON HERE AT LIVER

2973
01:51:22,475 --> 01:51:22,742
MORE.

2974
01:51:22,809 --> 01:51:24,611
WE ARE NOT AS PART OF THIS

2975
01:51:24,677 --> 01:51:26,713
PROJECT TRYING TO DEVELOP A

2976
01:51:26,780 --> 01:51:28,448
QUANTUM ALGORITHM THAT WE COULD

2977
01:51:28,515 --> 01:51:30,116
UTILIZE AND THAT'S REQUIRED, I

2978
01:51:30,183 --> 01:51:33,153
THINK THAT QUANTUM COMPUTING, I

2979
01:51:33,219 --> 01:51:35,288
WOULD SAY IS NOT QUITE READY FOR

2980
01:51:35,355 --> 01:51:35,855
PRIME TIME YET.

2981
01:51:35,922 --> 01:51:37,490
OT OTHER HAND I THINK IT IS

2982
01:51:37,557 --> 01:51:38,058
CLOSE.

2983
01:51:38,124 --> 01:51:38,992
IT'S A PERFECTLY REASONABLE

2984
01:51:39,059 --> 01:51:41,261
THINK TO BE EXPLORING.

2985
01:51:41,327 --> 01:51:42,462
THAT WOULD BE OUTSIDE THE SCOPE

2986
01:51:42,529 --> 01:51:43,963
OF WHAT WE'RE DOING IN THIS

2987
01:51:44,030 --> 01:51:47,133
PROJECT BUT I THINK THAT

2988
01:51:47,200 --> 01:51:48,735
POTENTIALLY SOME OF THE--BOTH

2989
01:51:48,802 --> 01:51:51,471
SOME OF THE MACHINE LEARNING,

2990
01:51:51,538 --> 01:51:52,505
OPTIMIZATION AND ACTUAL

2991
01:51:52,572 --> 01:51:55,375
SIMULATION COULD BE PROFITABLY

2992
01:51:55,442 --> 01:51:58,078
ACCELERATED WITH A FUNCTIONING

2993
01:51:58,144 --> 01:52:00,013
QUANTUM COMPUTER, THAT SHOULD BE

2994
01:52:00,080 --> 01:52:00,380
EXPLORED.

2995
01:52:00,447 --> 01:52:02,148
>> AND IN TERMS OF YOUR QUESTION

2996
01:52:02,215 --> 01:52:04,884
OF VALIDATION AND LIPID PROTEIN

2997
01:52:04,951 --> 01:52:05,585
INTERACTIONS, WE DEPARTMENT HAVE

2998
01:52:05,652 --> 01:52:08,221
TIME TO GO INTO GREAT DETAIL BUT

2999
01:52:08,288 --> 01:52:09,889
AS PART OF PREVIOUS ITERATION OF

3000
01:52:09,956 --> 01:52:14,661
THIS PROJECT WE DEFINED AN 8

3001
01:52:14,727 --> 01:52:15,462
LIPID COMPONENT MEMBRANE THAT

3002
01:52:15,528 --> 01:52:17,297
WAS BRACED ON THE PRESENCE OF

3003
01:52:17,363 --> 01:52:19,899
LIPIDS IN CELLS, LIPIDS THAT

3004
01:52:19,966 --> 01:52:20,567
WERE AVAILABLE EXPERIMENTALLY

3005
01:52:20,633 --> 01:52:22,635
AND WHICH WE COULD WORK WITH

3006
01:52:22,702 --> 01:52:23,436
COMPUTATIONALLY, RIGHT?

3007
01:52:23,503 --> 01:52:25,405
SO THAT 8 LIPID OR COMPLEX

3008
01:52:25,472 --> 01:52:26,139
MEMBRANE ENVIRONMENT THAT WE'RE

3009
01:52:26,206 --> 01:52:28,675
USING IN THE SIMULATIONS WE CAN

3010
01:52:28,741 --> 01:52:35,215
ALSO RECONSITUTE IN A MEMBRANE

3011
01:52:35,281 --> 01:52:36,783
MUMMI -ITICs IN THE LABORATORY

3012
01:52:36,850 --> 01:52:39,486
AND DOING THE EXPERIMENTS IN THE

3013
01:52:39,552 --> 01:52:41,321
LABORATORY WITH CELLS WHERE WE

3014
01:52:41,387 --> 01:52:43,089
CAN LABEL LIPIDS OR CHEMICALLY

3015
01:52:43,156 --> 01:52:44,791
WITH THE DEFINED SYSTEM TO

3016
01:52:44,858 --> 01:52:46,693
VALIDATE A LOT OF OUTPUT.

3017
01:52:46,759 --> 01:52:47,927
IT'S CORRECT.

3018
01:52:47,994 --> 01:52:50,663
THE ULTIMATE VALIDATION THAT THE

3019
01:52:50,730 --> 01:52:51,598
SIMULATIONS ARE CORRECT OR YOU

3020
01:52:51,664 --> 01:52:52,799
KNOW INFORMATION THAT CAN BE

3021
01:52:52,866 --> 01:52:54,300
USED TO FEEDBACK INTO THE

3022
01:52:54,367 --> 01:52:59,005
SIMULATIONS WILL COME FROM

3023
01:52:59,072 --> 01:52:59,506
EXPERIMENTAL APPROACHES.

3024
01:52:59,572 --> 01:53:02,509
>> IT WOULD BE VERY HELPFUL AS

3025
01:53:02,575 --> 01:53:05,145
WE'RE MOVING TOWARD LIPID

3026
01:53:05,211 --> 01:53:07,013
TRANSVEKSS FOR OTHER THINGS.

3027
01:53:07,080 --> 01:53:09,282
ADDITIONAL INSIGHT YOU GAIN

3028
01:53:09,349 --> 01:53:11,484
COULD BE FUNDAMENTALLY CHANGED

3029
01:53:11,551 --> 01:53:13,753
TO THE DYNAMIC THINKING IN THE

3030
01:53:13,820 --> 01:53:15,054
FUTURE.

3031
01:53:15,121 --> 01:53:17,157
THANK YOU.

3032
01:53:17,223 --> 01:53:19,125
>> JOHN, I BELIEVE YOU'RE NEXT.

3033
01:53:19,192 --> 01:53:20,627
>> I'M CURIOUS, YOU DIDN'T SHOW

3034
01:53:20,693 --> 01:53:23,363
US ANY DATA TO SHOW AGREEMENT

3035
01:53:23,429 --> 01:53:25,231
BETWEEN SINGLE MOLECULE FRET AND

3036
01:53:25,298 --> 01:53:27,033
WHAT THE SIMULATIONS ARE

3037
01:53:27,100 --> 01:53:27,333
PROVIDING.

3038
01:53:27,400 --> 01:53:28,835
HOW IS THAT BEING DONE AND IS

3039
01:53:28,902 --> 01:53:32,305
THAT DATA BEING USED TO HELP

3040
01:53:32,372 --> 01:53:34,140
REFINE THE MODELS IN SOME

3041
01:53:34,207 --> 01:53:35,542
MEANINGFUL WAY?

3042
01:53:35,608 --> 01:53:37,510
>> RIGHT NOW, WHAT WE'RE WORKING

3043
01:53:37,577 --> 01:53:38,444
ON VERY DILIGENTLY AND WITH A

3044
01:53:38,511 --> 01:53:43,917
LOT OF EFFORT IS TO ACTUALLY DO

3045
01:53:43,983 --> 01:53:44,751
THE PROTEIN ENGINEERING, TO

3046
01:53:44,817 --> 01:53:46,386
PLACE THE RIGHT RESIDUES IN

3047
01:53:46,452 --> 01:53:47,120
APPROPRIATE PLACES, SO THAT YOU

3048
01:53:47,187 --> 01:53:50,023
CAN HAVE A PROTEIN WHERE YOU CAN

3049
01:53:50,089 --> 01:53:51,891
ATTACH THE FRET COMPONENTS, TOO,

3050
01:53:51,958 --> 01:53:53,760
BUT NOT KILL THE ACTIVITY OF THE

3051
01:53:53,826 --> 01:53:55,962
PROTEIN AND SO, THERE'S--WE HAVE

3052
01:53:56,029 --> 01:53:57,997
A VERY STRONG PROTEIN

3053
01:53:58,064 --> 01:53:58,731
ENGINEERING TEAM HERE THAT IS

3054
01:53:58,798 --> 01:54:00,366
WORKING ON THAT AND WE ARE

3055
01:54:00,433 --> 01:54:01,234
LABELING THINGS AND STARTING TO

3056
01:54:01,301 --> 01:54:09,976
DO SOME OF THOSE INITIAL

3057
01:54:10,043 --> 01:54:11,277
MEASUREMENTS.

3058
01:54:11,344 --> 01:54:12,045
ANY OTHER QUESTIONS.

3059
01:54:12,111 --> 01:54:12,979
PERHAPS TIME WE MOVE ON.

3060
01:54:13,046 --> 01:54:15,982
THANK YOU VERY MUCH.

3061
01:54:16,049 --> 01:54:17,217
GREAT PRESENTATIONS GUYS.

3062
01:54:17,283 --> 01:54:17,817
APPRECIATE IT.

3063
01:54:17,884 --> 01:54:22,722
OUR NEXT PRESENTATION IS BY

3064
01:54:22,789 --> 01:54:24,924
DR. STEPHEN AND LEO, INNOVATIVE

3065
01:54:24,991 --> 01:54:28,228
METHODOLOGIES AND NEW DATA FOR

3066
01:54:28,294 --> 01:54:29,963
PREDICTIVE ONCOLOGY MODEL

3067
01:54:30,029 --> 01:54:30,430
EVAGZUATION.

3068
01:54:30,496 --> 01:54:33,233
>> CAN YOU HEAR ME?

3069
01:54:33,299 --> 01:54:33,499
>> YES.

3070
01:54:33,566 --> 01:54:36,469
>> I AM DR. STEVENS AND WE WILL

3071
01:54:36,536 --> 01:54:42,976
HAVE CONTRIBUTIONS BY RYAN WEIL,

3072
01:54:43,042 --> 01:54:44,811
AND JEFF'S ON, WE WILL TALK

3073
01:54:44,877 --> 01:54:46,012
ABOUT IMPROVE, THIS IS A NEW

3074
01:54:46,079 --> 01:54:47,347
PROJECT IN THE TRIO YOU'RE

3075
01:54:47,413 --> 01:54:47,914
LOOKING AT.

3076
01:54:47,981 --> 01:54:50,783
IT'S ABOUT TAKING A LOOK AT HOW

3077
01:54:50,850 --> 01:54:54,320
WE ANALYZE AND IMPROVE

3078
01:54:54,387 --> 01:54:55,922
PREDICTIVE MODELS FOR TUMOR DRUG

3079
01:54:55,989 --> 01:55:00,426
RESPONSE, SO NEXT SLIDE.

3080
01:55:00,493 --> 01:55:02,762
SO AS YOU KNOW, THERE'S HUGE

3081
01:55:02,829 --> 01:55:06,733
POTENTIAL FOR AI TO IMPACT THE

3082
01:55:06,799 --> 01:55:08,001
BIOMEDICAL COMMUNITY AND IN

3083
01:55:08,067 --> 01:55:09,502
PARTICULAR, WHAT WE'VE BEEN

3084
01:55:09,569 --> 01:55:11,037
FOCUSING ON IN THIS PROJECT IS

3085
01:55:11,104 --> 01:55:15,842
THE USE OF AI IN PREDICTING THE

3086
01:55:15,908 --> 01:55:18,678
OUTCOME OF CANCER THERAPIES,

3087
01:55:18,745 --> 01:55:20,079
PARTICULARLY CHEMO THERAPY TYPE

3088
01:55:20,146 --> 01:55:21,114
TREATMENTS AND WE THINK THIS

3089
01:55:21,180 --> 01:55:24,350
COULD HAVE A HUGE IMPACT, YET,

3090
01:55:24,417 --> 01:55:25,752
THE STATE-OF-THE-ART FOR USING

3091
01:55:25,818 --> 01:55:27,253
AI, EITHER IN A RESEARCH SETTING

3092
01:55:27,320 --> 01:55:30,323
OR EVEN IN A CLINICAL SETTING IS

3093
01:55:30,390 --> 01:55:33,893
STILL VERY MUCH AN EARLY DAYS,

3094
01:55:33,960 --> 01:55:35,161
IT'S NOVEL AND CHALLENGING TO

3095
01:55:35,228 --> 01:55:38,031
UNDERSTAND HOW WELL IT WORKS,

3096
01:55:38,097 --> 01:55:39,666
AND WE DECIDED A FEW YEARS AGO

3097
01:55:39,732 --> 01:55:41,968
THAT WE NEEDED A SYSTEMATIC

3098
01:55:42,035 --> 01:55:45,938
PROJECT TO ASSESS THE

3099
01:55:46,005 --> 01:55:46,639
TRUSTWORTHINESS AND

3100
01:55:46,706 --> 01:55:48,841
REPRODUCIBILITY OF AI BEING USED

3101
01:55:48,908 --> 01:55:51,377
IN THIS APPLICATION AND WHAT WE

3102
01:55:51,444 --> 01:55:53,179
MEAN BY REPRODUCIBILITY HERE IS

3103
01:55:53,246 --> 01:55:54,681
INTERESTING.

3104
01:55:54,747 --> 01:55:55,848
IN THE LAST 4 YEARS, THERE'S

3105
01:55:55,915 --> 01:55:58,418
BEEN CLOSE TO A HUNDRED PAPERS

3106
01:55:58,484 --> 01:56:00,620
PUBLISHED ON TUMOR DRUG RESPONSE

3107
01:56:00,687 --> 01:56:02,855
PREDICTION USING DEEP LEARNING.

3108
01:56:02,922 --> 01:56:04,590
AND MOST OF THESE PAPERS CLAIM

3109
01:56:04,657 --> 01:56:07,160
TO HAVE SOME NEW NOVEL

3110
01:56:07,226 --> 01:56:10,330
CONTRIBUTION TO START OF THE ART

3111
01:56:10,396 --> 01:56:13,166
AND WE APPROACHED THIS CHALLENGE

3112
01:56:13,232 --> 01:56:14,667
FROM THE STANDPOINT OF COULD WE

3113
01:56:14,734 --> 01:56:15,735
BUILD AN ENVIRONMENT THAT WOULD

3114
01:56:15,802 --> 01:56:18,504
ALLOW US TO ANALYZE MODELS BEING

3115
01:56:18,571 --> 01:56:21,674
PRODUCED BY THE COMMUNITY AND

3116
01:56:21,741 --> 01:56:23,743
SAY SOMETHING DEFINITIVE ABOUT

3117
01:56:23,810 --> 01:56:25,244
THEIR REPRODUCIBILITY, AND SO

3118
01:56:25,311 --> 01:56:27,280
OSO THAT'S THE HIGH LEVEL GOAL.

3119
01:56:27,347 --> 01:56:30,149
BY COMBINING NCI AND DOE

3120
01:56:30,216 --> 01:56:32,552
TOGETHER, WE'RE BRINGING UNIQUE

3121
01:56:32,618 --> 01:56:36,289
CAPABILITIES TLGT LIKE IN THE

3122
01:56:36,356 --> 01:56:37,623
PREVIOUS PRESENTATION, WE HAVE

3123
01:56:37,690 --> 01:56:39,258
LARGE SCALE COMPUTERS, ON THE

3124
01:56:39,325 --> 01:56:41,094
DOE SIDE, WE HAVE LARGE TEAMS

3125
01:56:41,160 --> 01:56:43,629
WORKING ON MACHINE LEARNING AND

3126
01:56:43,696 --> 01:56:45,631
AI METHODS AND ON THE FREDERICK

3127
01:56:45,698 --> 01:56:49,068
SIDE, ON THE NCI SIDE, WE HAVE

3128
01:56:49,135 --> 01:56:51,971
TEAMS VERY FAMILIAR WITH CANCER

3129
01:56:52,038 --> 01:56:53,106
EXPERIMENTAL CANCER DATA AND

3130
01:56:53,172 --> 01:56:54,640
TREATMENT STRATEGIES AND SO ON.

3131
01:56:54,707 --> 01:56:56,609
SO WE'RE BRINGING THOSE ASPECTS

3132
01:56:56,676 --> 01:56:59,545
TOGETHER AND THE OUTCOME OF THIS

3133
01:56:59,612 --> 01:57:01,748
IS A STANDARDIZED FRAMEWORK,

3134
01:57:01,814 --> 01:57:04,183
AGAIN, INSPIRED IN SOME WAYS,

3135
01:57:04,250 --> 01:57:05,618
SIMILAR TO WHAT FRED AND DWIGHT

3136
01:57:05,685 --> 01:57:08,988
WERE TALKING ABOUT, THAT WILL

3137
01:57:09,055 --> 01:57:11,324
ALLOW US TO STUDY AND COMPARE

3138
01:57:11,391 --> 01:57:12,725
MODELS THAT THE COMMUNITY'S

3139
01:57:12,792 --> 01:57:14,460
PRODUCING BUT NOT JUST LIMITED

3140
01:57:14,527 --> 01:57:16,562
TO THESE MODELS IN TUMOR DRUG

3141
01:57:16,629 --> 01:57:19,332
RESPONSE BUT TO BE USED TO

3142
01:57:19,399 --> 01:57:21,300
PREDICT OR ANALYZE THE

3143
01:57:21,367 --> 01:57:22,168
TRUSTWORTHINESS AND RELIABILITY

3144
01:57:22,235 --> 01:57:23,970
OF OTHER MACHINE LEARNING

3145
01:57:24,036 --> 01:57:25,471
MODELS, AND OTHER APPLICATION

3146
01:57:25,538 --> 01:57:27,607
AREAS BOTH IN BIOLOGY AND

3147
01:57:27,673 --> 01:57:33,346
OUTSIDE OF BIOLOGY.

3148
01:57:33,413 --> 01:57:33,946
NEXT SLIDE, PLEASE.

3149
01:57:34,013 --> 01:57:36,582
SO THIS IS A PROJECT STARTED IN

3150
01:57:36,649 --> 01:57:38,451
FISCAL 22, PHASED IN.

3151
01:57:38,518 --> 01:57:39,352
ONE OF THE INTERESTING THINGS

3152
01:57:39,419 --> 01:57:42,922
ABOUT IT IS THAT WE HAVE A SET

3153
01:57:42,989 --> 01:57:44,323
OF FUNDED COLLABORATORS IN

3154
01:57:44,390 --> 01:57:47,960
ADDITION TO THE CORE ACTIVITY AT

3155
01:57:48,027 --> 01:57:49,362
ARGON AND AT FREDERICK, AND RYAN

3156
01:57:49,429 --> 01:57:50,997
WILL MENTION THAT LATER.

3157
01:57:51,063 --> 01:57:53,866
THE PROJECT HAS 2 HIGH LEVEL

3158
01:57:53,933 --> 01:57:54,200
AIMS.

3159
01:57:54,267 --> 01:57:57,103
ONE IS BUILDING THIS SYSTEM FOR

3160
01:57:57,170 --> 01:57:58,571
CURATING MODELS BEING DEVELOPED

3161
01:57:58,638 --> 01:58:00,873
BY THE COMMUNITY, AND BEING ABLE

3162
01:58:00,940 --> 01:58:03,309
TO COMPARE THEM USING THE POWER

3163
01:58:03,376 --> 01:58:04,377
OF SUPER COMPUTERS TO ANALYZE

3164
01:58:04,444 --> 01:58:06,379
THEM IN VARIOUS WAYS,

3165
01:58:06,446 --> 01:58:08,781
IDENTIFYING ATTRIBUTES THAT MAKE

3166
01:58:08,848 --> 01:58:09,715
MODELS PERFORMANCE AND RELIABLE

3167
01:58:09,782 --> 01:58:13,052
AND THOSE THINGS THAT ARE LESS

3168
01:58:13,119 --> 01:58:13,619
CONTRIBUTING TO THAT.

3169
01:58:13,686 --> 01:58:18,758
SO, THINK OF THIS AS A

3170
01:58:18,825 --> 01:58:19,792
SEMIAUTOMATIC PROCESS BY WHICH

3171
01:58:19,859 --> 01:58:21,127
WE AJUST MODELS AND I WILL GIVE

3172
01:58:21,194 --> 01:58:23,229
YOU MORE DETAIL ON THE NEXT

3173
01:58:23,296 --> 01:58:24,964
SLIDE AND INCORPORATE THEM INTO

3174
01:58:25,031 --> 01:58:25,898
THIS FRAMEWORK AND THEN WE ARE

3175
01:58:25,965 --> 01:58:27,667
ABLE TO USE THE SUPER COMPUTERS

3176
01:58:27,733 --> 01:58:34,440
TO DO THIS ANALYSIS.

3177
01:58:34,507 --> 01:58:38,211
THE SECOND AIM--SORRY, NOT QUITE

3178
01:58:38,277 --> 01:58:38,945
READY--BUILDING OUT PROTOCOLS TO

3179
01:58:39,011 --> 01:58:41,113
WORK WITH US TO BELL OUT

3180
01:58:41,180 --> 01:58:43,749
PROTOCOLS FOR SPECIFYING DRUG

3181
01:58:43,816 --> 01:58:44,550
SCREENING EXPERIMENTS WHOSE

3182
01:58:44,617 --> 01:58:47,086
OUTCOME WOULD IMPROVE MODELS AND

3183
01:58:47,153 --> 01:58:49,188
THEN TO APLOY THOSE PROTOCOLS TO

3184
01:58:49,255 --> 01:58:51,524
GENERATE NOW DATA AIMED AT

3185
01:58:51,591 --> 01:58:52,558
IMPROVING MODEL PERFORMANCE AND

3186
01:58:52,625 --> 01:58:54,227
SOME SOME SENSE USING THE MODELS

3187
01:58:54,293 --> 01:58:56,295
THEMSELVES TO TELL US WHAT DATA

3188
01:58:56,362 --> 01:58:57,730
WOULD BEST IMPROVE MODELS.

3189
01:58:57,797 --> 01:59:06,873
THAT'S AIM 2.

3190
01:59:06,939 --> 01:59:07,673
NEXT SLIDE.

3191
01:59:07,740 --> 01:59:11,611
SO THIS WILL  GIVE YOU A FLAVOR

3192
01:59:11,677 --> 01:59:12,612
OF AIM 1.

3193
01:59:12,678 --> 01:59:14,947
SO WE TAKE MODELS FROM THE

3194
01:59:15,014 --> 01:59:16,916
LITERATURE AND OFTEN WITH THE

3195
01:59:16,983 --> 01:59:18,084
HELP AND ENCOURAGEMENT FROM THE

3196
01:59:18,150 --> 01:59:21,187
GROUPS THAT BUILD THOSE MODELS.

3197
01:59:21,254 --> 01:59:22,955
WE REPRODUCE THEIR BASE LINE

3198
01:59:23,022 --> 01:59:24,357
PERPORMANCE IN THE PAPER AND

3199
01:59:24,423 --> 01:59:25,725
THEN WE RESTRUCTURE THE CODE IN

3200
01:59:25,791 --> 01:59:28,828
A WAY THAT CAN PLUG INTO OUR

3201
01:59:28,895 --> 01:59:31,264
ENVIRONMENT, RECONFIRM THE BASE

3202
01:59:31,330 --> 01:59:31,898
LINE PERFORMANCE, CONSISTENT

3203
01:59:31,964 --> 01:59:34,300
WITH WHAT WAS IN THE ORIGINAL

3204
01:59:34,367 --> 01:59:35,468
PUBLISHED MODEL, AND BRING IT

3205
01:59:35,535 --> 01:59:37,270
INTO OUR WORK FLOWS WHERE YOU

3206
01:59:37,336 --> 01:59:39,005
CAN DO KETAILED ANALYSIS EMPLOY

3207
01:59:39,071 --> 01:59:40,540
SO MODEL CURATION IS A TEAM

3208
01:59:40,606 --> 01:59:42,041
EFFORT WITH QUITE A FEW PEOPLE

3209
01:59:42,108 --> 01:59:43,576
HELPING INSIDE AND OUTSIDE OF

3210
01:59:43,643 --> 01:59:45,077
THE FUNDED PROJECT MUCH THE

3211
01:59:45,144 --> 01:59:46,712
SECOND THING WE'RE DOING IS

3212
01:59:46,779 --> 01:59:54,854
KRIEWR CURATING DATA SO THE

3213
01:59:54,921 --> 01:59:57,490
COMMUNITY CORE ACTIVITY OF USING

3214
01:59:57,557 --> 01:59:58,758
VARIOUS CANCER STUDIES OVER THE

3215
01:59:58,824 --> 02:00:00,960
LAST DECADE OR SO, 1 THING WE'VE

3216
02:00:01,027 --> 02:00:02,929
BEEN DOING IS AGGREGATING THAT

3217
02:00:02,995 --> 02:00:04,196
DATA AND WE'LL IMIF YOU A NAP

3218
02:00:04,263 --> 02:00:06,632
SHOT OF THE SCOPE OF THAT SO

3219
02:00:06,699 --> 02:00:09,035
THAT WE CAN ACCOMMODATE ANY

3220
02:00:09,101 --> 02:00:11,037
COLLECTION OF DATA THAT USERS

3221
02:00:11,103 --> 02:00:12,672
INTEGRATED INTO THEIR MODELS IN

3222
02:00:12,738 --> 02:00:13,973
AN AUTOMATED WAY, WE'RE ALSO

3223
02:00:14,040 --> 02:00:16,242
MAKING THAT DATA AVAILABLE AS

3224
02:00:16,309 --> 02:00:17,977
BENCHMARK DATA TO THE BROADER

3225
02:00:18,044 --> 02:00:20,179
COMMUNITY AND THIS MAKE ITS MUCH

3226
02:00:20,246 --> 02:00:25,585
EASIER FOR TESTING MODELS IN THE

3227
02:00:25,651 --> 02:00:25,818
FUTURE.

3228
02:00:25,885 --> 02:00:28,588
SO FINALLY WHAT FRED WAS SAYING,

3229
02:00:28,654 --> 02:00:30,022
IT'S A COMPUTATIONAL FRAMEWORK

3230
02:00:30,089 --> 02:00:31,991
THAT ALLOWS 1 TO PLUG THEIR

3231
02:00:32,058 --> 02:00:35,227
MODELS IN AND ALLOWS THEM TO DO

3232
02:00:35,294 --> 02:00:37,463
THE ANALYSIS AND WE WILL GIVE

3233
02:00:37,530 --> 02:00:41,133
YOU BRIEF EXAMPLES.

3234
02:00:41,200 --> 02:00:42,034
NEXT SLIDE.

3235
02:00:42,101 --> 02:00:42,935
SO HERE'S AN EXAMPLE OF ATHAT

3236
02:00:43,002 --> 02:00:44,637
WILL SIS, THIS IS 1 TINY EXAMPLE

3237
02:00:44,704 --> 02:00:46,005
OUT OF THE HUNDREDS OF EXAMPLES

3238
02:00:46,072 --> 02:00:47,640
WE HAVE, SO THIS IS MEASURING

3239
02:00:47,707 --> 02:00:49,041
WHAT WE CALL MODEL

3240
02:00:49,108 --> 02:00:50,409
GENERALIZATION, SO THE IDEA HERE

3241
02:00:50,476 --> 02:00:51,877
IS YOU TRAIN A MODEL ON SOME

3242
02:00:51,944 --> 02:00:54,413
DATA AND THIS IS A DRUG RESPONSE

3243
02:00:54,480 --> 02:00:55,481
MODEL, TUMOR DRUG RESPONSE MODEL

3244
02:00:55,548 --> 02:00:57,116
AND YOU TEST HOW WELL DOES IT

3245
02:00:57,183 --> 02:00:59,885
WORK ON DATA IT'S NEVER SEEN

3246
02:00:59,952 --> 02:01:02,688
BEFORE, ON TUMOR PROFILES IT'S

3247
02:01:02,755 --> 02:01:04,624
NEVER SEEN BEFORE OR ON DRUG

3248
02:01:04,690 --> 02:01:05,691
DESCRIBES IT'S NEVER SEEN BEFORE

3249
02:01:05,758 --> 02:01:09,028
AND HERE'S AN EXAMPLE OF 3

3250
02:01:09,095 --> 02:01:09,562
MODELS.

3251
02:01:09,629 --> 02:01:13,566
AND WHAT THESE MATRIXES SHOW YOU

3252
02:01:13,633 --> 02:01:14,834
IS THEY'RE ESSENTIALLY ROW

3253
02:01:14,900 --> 02:01:16,602
VERSUS COLUMN SO THE ROW IS THE

3254
02:01:16,669 --> 02:01:18,237
DATE OF THE MODEL WAS TRAINED ON

3255
02:01:18,304 --> 02:01:20,973
AND THE COLUMN WAS THE DATA THE

3256
02:01:21,040 --> 02:01:24,577
MODEL IS TESTED ON AND OF COURSE

3257
02:01:24,644 --> 02:01:25,611
THE DIAGONALS WHERE IT'S TESTED

3258
02:01:25,678 --> 02:01:27,246
ON THE SAME STUDIES DATA OF

3259
02:01:27,313 --> 02:01:29,048
COURSE WITH DIFFERENT PARTITIONS

3260
02:01:29,115 --> 02:01:29,982
SO IT DOESN'T--IT'S NOT TRAINED

3261
02:01:30,049 --> 02:01:31,651
ON THE SAME DATA THAT'S TESTED

3262
02:01:31,717 --> 02:01:34,987
ON AND YOU CAN SEE, JUST BY THE

3263
02:01:35,054 --> 02:01:36,389
COLOR COATING THAT THE ABILITY

3264
02:01:36,455 --> 02:01:37,757
FOR AN AVERAGE MODEL TO BE

3265
02:01:37,823 --> 02:01:39,358
TRAINED ON 1 DATA SET AND TESTED

3266
02:01:39,425 --> 02:01:43,763
ON ANOTHER DATA SET IS QUITE

3267
02:01:43,829 --> 02:01:46,532
CHALLENGING THE GREEN IS THE

3268
02:01:46,599 --> 02:01:48,067
POSITIVE, AND THE RED IS THE

3269
02:01:48,134 --> 02:01:50,069
NEGATIVE R-QUARED AND THE YELLOW

3270
02:01:50,136 --> 02:01:51,203
IS R-QUARED AND YOU WOULD LIKE

3271
02:01:51,270 --> 02:01:53,539
TO HAVE A GREEN MATRIX AND THIS

3272
02:01:53,606 --> 02:01:54,907
SHOWS THESE MODEL VS DIFFERENT

3273
02:01:54,974 --> 02:01:56,308
RESPONSE MADERNS AND THE 1S ON

3274
02:01:56,375 --> 02:01:59,545
THE LOWER RIGHT, SHOWS THE BEST

3275
02:01:59,612 --> 02:02:00,479
GENERATEDDALLITY OF THESE 3

3276
02:02:00,546 --> 02:02:03,149
MODELS AND THESE ARE SIMILAR

3277
02:02:03,215 --> 02:02:06,552
MODELS TRAINED ON THE SAME DATA

3278
02:02:06,619 --> 02:02:06,952
SHOWING DIFFERENT

3279
02:02:07,019 --> 02:02:07,520
GENERALIZABILITY, AND WE'RE

3280
02:02:07,586 --> 02:02:08,821
TRYING TO UNDERSTAND THAT,

3281
02:02:08,888 --> 02:02:09,889
UNDERSTANDING WHAT ASPECT OF THE

3282
02:02:09,955 --> 02:02:12,558
MODEL THAT'S CONTRIBUTING TO THE

3283
02:02:12,625 --> 02:02:13,459
VARIABILITY IN GENERALIZATION,

3284
02:02:13,526 --> 02:02:14,326
IT'S THE KEY INSIGHT.

3285
02:02:14,393 --> 02:02:16,195
ONE THING WE HAVE LEARNED FROM

3286
02:02:16,262 --> 02:02:18,898
DOING THIS, ACROSS MANY STUDY

3287
02:02:18,964 --> 02:02:20,533
SYSTEM THAT MODELS OFTEN THAT

3288
02:02:20,599 --> 02:02:22,501
SHOW VERY GOOD IN-STUDY

3289
02:02:22,568 --> 02:02:24,003
GENERALIZATION ARE NOT THE BEST

3290
02:02:24,070 --> 02:02:25,538
MODELS FOR OUT OF STUDY

3291
02:02:25,604 --> 02:02:27,807
GENERALIZATION, AND THIS IS A

3292
02:02:27,873 --> 02:02:29,809
VERY INTERESTING RESULT, IT

3293
02:02:29,875 --> 02:02:31,577
MEANS THAT GROUPS THAT ARE

3294
02:02:31,644 --> 02:02:33,079
EVALUATING OR PRODUCING A NEW

3295
02:02:33,145 --> 02:02:34,380
MODEL REALLY NEED TO TRAIN THEIR

3296
02:02:34,447 --> 02:02:37,383
MODEL AND TEST IT ON VERY

3297
02:02:37,450 --> 02:02:38,818
DIFFERENT DATA SETS.

3298
02:02:38,884 --> 02:02:40,252
ONE OF THE THINGS THIS IS

3299
02:02:40,319 --> 02:02:43,155
LEADING US TO IS HOW WE WILL DO

3300
02:02:43,222 --> 02:02:46,358
THIS FOR PATIENT-DERIVED DATA,

3301
02:02:46,425 --> 02:02:48,561
PATIENT DERIVED ORGANOIDS OR

3302
02:02:48,627 --> 02:02:56,035
PATIENT DERIVED  XENOGRAPHS, AND

3303
02:02:56,102 --> 02:02:58,270
RIGHT HERE, IN THE RIGHT, IS A

3304
02:02:58,337 --> 02:02:59,438
PICTURE OF THE MODEL RUNNING ALL

3305
02:02:59,505 --> 02:02:59,839
OF THIS.

3306
02:02:59,905 --> 02:03:08,547
TO DO THIS YOU HAVE TO HAVE SERL

3307
02:03:08,614 --> 02:03:09,281
SUPER COMPUTERS.

3308
02:03:09,348 --> 02:03:15,888
NNEXT SLIDE, THIS IS  HYPER

3309
02:03:15,955 --> 02:03:16,489
PARAMETER OPTIMIZATION, YOU

3310
02:03:16,555 --> 02:03:19,225
COULD THINK OF THIS AS AN ONION,

3311
02:03:19,291 --> 02:03:20,292
THIS IS TRAIN THROUGH TRAINING

3312
02:03:20,359 --> 02:03:21,627
AND AJUST HOW THE MODEL RESPONDS

3313
02:03:21,694 --> 02:03:23,696
AND THEN YOU SET UP PARAMETERS

3314
02:03:23,763 --> 02:03:25,364
ON THE OUTSIDE CALLED HYPER

3315
02:03:25,431 --> 02:03:26,232
PARAMETERS THAT ARE THE

3316
02:03:26,298 --> 02:03:27,733
STRUCTURE OF THE MODEL, SETTINGS

3317
02:03:27,800 --> 02:03:28,601
OF LEARNING RATES AND THINGS

3318
02:03:28,667 --> 02:03:33,539
LIKE THAT AND IT'S VERY COMMON

3319
02:03:33,606 --> 02:03:36,242
TO DO A SWEEP OVER THE OUTSIDE

3320
02:03:36,308 --> 02:03:37,710
SETTINGS, THE OUTSIDE KNOBS TO

3321
02:03:37,777 --> 02:03:39,812
SEE WHICH KNOB SETTINGS PRODUCE

3322
02:03:39,879 --> 02:03:41,013
THE BEST MODEL, SO WE'VE BEEN

3323
02:03:41,080 --> 02:03:42,915
DOING THAT FOR MANY YEARS, USING

3324
02:03:42,982 --> 02:03:44,450
THE SUPER COMPUTER WE CAN RUN

3325
02:03:44,517 --> 02:03:47,686
THOUSANDS OF CASES TO GET THE

3326
02:03:47,753 --> 02:03:50,422
EXTERNAL MOBS JUST RIGHT, SO WE

3327
02:03:50,489 --> 02:03:51,590
DISCOVERED THE PARTITION BY

3328
02:03:51,657 --> 02:03:53,826
GENDER, THE MOST SETTINGS OF

3329
02:03:53,893 --> 02:03:56,529
THOSE NOBS WERE QUITE DIFFERENT

3330
02:03:56,595 --> 02:03:57,963
BYIENDER AND THIS IS NOTED

3331
02:03:58,030 --> 02:03:59,231
COMPLETELY SURPRISING BECAUSE WE

3332
02:03:59,298 --> 02:04:02,034
CAN PREDICT GENDER FROM THINGS

3333
02:04:02,101 --> 02:04:05,371
LIKE RNA-SEQ DATA AND WE KNOW

3334
02:04:05,437 --> 02:04:06,472
THAT GENDER INFLUENS LEVELS AND

3335
02:04:06,539 --> 02:04:07,406
SO ON, BUT WHAT'S INTERESTING

3336
02:04:07,473 --> 02:04:08,741
HERE IS THAT MOST ACADEMIC

3337
02:04:08,808 --> 02:04:10,376
GROUPS ARE NOT DOING HYPER

3338
02:04:10,442 --> 02:04:14,613
PARAMETER  OPTIMIZATION, WHICH

3339
02:04:14,680 --> 02:04:16,348
MEANS THAT IT'S NOT OPTIMAL FOR

3340
02:04:16,415 --> 02:04:18,551
BOTH GENDERS AND THIS IS A VERY

3341
02:04:18,617 --> 02:04:20,052
IMPORTANT RESULT, IT MAY MEAN

3342
02:04:20,119 --> 02:04:24,256
THAT IN THE FUTURE 1 WILL WANT

3343
02:04:24,323 --> 02:04:26,458
TO BUILD MODELS THAT ARE TUNED

3344
02:04:26,525 --> 02:04:28,527
SPECIFICALLY BY GENDER TO HAVE

3345
02:04:28,594 --> 02:04:30,229
THE OPTIMUM RESULTS FOR THAT

3346
02:04:30,296 --> 02:04:31,764
GENDER, IT'S TOO EARLY TO SAY

3347
02:04:31,831 --> 02:04:33,499
IT'S A POLICY WE SHOULD HAVE BUT

3348
02:04:33,566 --> 02:04:35,835
IT'S AN INTERESTING RESULT

3349
02:04:35,901 --> 02:04:37,369
IDENTIFYING THIS UNINTENDED

3350
02:04:37,436 --> 02:04:42,174
GENDER BIAS AND GENDER MODELS.

3351
02:04:42,241 --> 02:04:42,508
NEXT SLIDE.

3352
02:04:42,575 --> 02:04:46,345
SO AS I MENINGED THE AGGREGATION

3353
02:04:46,412 --> 02:04:47,913
OF DATA, THIS IS OUR DATA

3354
02:04:47,980 --> 02:04:49,415
PACKAGE WE'VE BEEN BUILDING OVER

3355
02:04:49,481 --> 02:04:53,352
THE LAST COUPLE OF YEARS CALLED

3356
02:04:53,419 --> 02:04:53,953
[INDISCERNIBLE] DATA.

3357
02:04:54,019 --> 02:04:55,354
YOU CAN SEE IT'S AGGREGATION OF

3358
02:04:55,421 --> 02:04:57,456
ALL THE TYPES OF DATA THAT THE

3359
02:04:57,523 --> 02:04:59,825
COMMUNITIES IS USING TO BUILD

3360
02:04:59,892 --> 02:05:01,493
TUMOR DRUG RESPONSES AND WE'VE

3361
02:05:01,560 --> 02:05:03,162
BEEN AGGREGATING AND CLEANING

3362
02:05:03,229 --> 02:05:04,663
THIS DATA NORMALIZING THIS DATA

3363
02:05:04,730 --> 02:05:06,198
AND PUTTING IT INTO A FORM THAT

3364
02:05:06,265 --> 02:05:07,967
DEVELOPERS CAN USE WITH A SIMPLE

3365
02:05:08,033 --> 02:05:14,707
INTERFACE THIS, IS MAKING

3366
02:05:14,773 --> 02:05:16,775
COMMUNITY DATA MORE AI READY AND

3367
02:05:16,842 --> 02:05:19,211
WE NEED IT FOR THE MORE INTERNAL

3368
02:05:19,278 --> 02:05:20,679
WORKINGS OF THE PROJECT BUT IT'S

3369
02:05:20,746 --> 02:05:21,914
A BENEFIT TO THE COMMUNITY TO

3370
02:05:21,981 --> 02:05:24,149
HAVE IT BETTER AND WE ORGANIZED

3371
02:05:24,216 --> 02:05:25,251
COMMUNITY PARTICIPANTS TO HELP

3372
02:05:25,317 --> 02:05:26,785
US CURATE THIS DATA AND THIS

3373
02:05:26,852 --> 02:05:28,387
DATA IS MADE AVAILABLE, IT WILL

3374
02:05:28,454 --> 02:05:30,322
BE LAUNCHED AT THE AACR IN THE

3375
02:05:30,389 --> 02:05:36,061
NEXT MONTH OR SO.

3376
02:05:36,128 --> 02:05:36,528
NEXT SLIDE.

3377
02:05:36,595 --> 02:05:40,766
RYAN DO YOU WANT TO TAKE THIS 1?

3378
02:05:40,833 --> 02:05:41,800
>> YEAH, THANKS RICK.

3379
02:05:41,867 --> 02:05:43,235
AS WAS DISCUSSED NOW THAT WE

3380
02:05:43,302 --> 02:05:44,536
HAVE VERSIONS READY FOR USE, WE

3381
02:05:44,603 --> 02:05:47,439
ARE BEGENERATEDDING TO GROW THAT

3382
02:05:47,506 --> 02:05:49,575
ECOSYSTEM QUITE RAPIDLY WITH IN

3383
02:05:49,642 --> 02:05:50,442
KIND COLLABORATIONS.

3384
02:05:50,509 --> 02:05:52,077
WE HAVE 15 GROUPS ACTIVELY

3385
02:05:52,144 --> 02:05:54,280
COLLABORATING IN AN ADDITIONAL

3386
02:05:54,346 --> 02:05:55,681
16 GROUPS THAT HAVE EXPRESSED

3387
02:05:55,748 --> 02:05:58,050
INTEREST IN SOME FORM OF

3388
02:05:58,117 --> 02:05:58,517
COLLABORATION.

3389
02:05:58,584 --> 02:06:01,487
WE ARE TRYING TO GROW FAIRLY

3390
02:06:01,553 --> 02:06:02,454
SUSTAINABLILY THOUGH SO AS PART

3391
02:06:02,521 --> 02:06:05,858
OF THAT WE'RE PRIORITIZING

3392
02:06:05,925 --> 02:06:08,861
STRATEGIC COLLABORATIONS SUCH AS

3393
02:06:08,928 --> 02:06:09,328
THE 1S BELOW.

3394
02:06:09,395 --> 02:06:10,362
COLLABORATIONS WITH NCI PROGRAMS

3395
02:06:10,429 --> 02:06:14,166
THAT ARE ALLOWING US TO AMPLIFY

3396
02:06:14,233 --> 02:06:17,469
INVESTMENTS AND REDUCE DUPLICATE

3397
02:06:17,536 --> 02:06:18,237
WORK.

3398
02:06:18,304 --> 02:06:20,439
OUR COLLABORATION IN HCMI, NOT

3399
02:06:20,506 --> 02:06:24,310
ONLY PROVIDES US WITH ACCESS TO

3400
02:06:24,376 --> 02:06:26,946
THE MULTIOMIC PROFILE ORGANOIDS

3401
02:06:27,012 --> 02:06:30,115
AND LINK LONGITUDINAL CLINICAL

3402
02:06:30,182 --> 02:06:31,517
DATA BUT IT'S ALSO INTRODUCED US

3403
02:06:31,583 --> 02:06:33,752
TO A NUMBER OF RESEARCHERS THAT

3404
02:06:33,819 --> 02:06:35,087
HAVE SUBSTANTIAL COLLECTIONS OF

3405
02:06:35,154 --> 02:06:39,325
RELEVANT DATA LIKE THE BROOD

3406
02:06:39,391 --> 02:06:41,593
CENTER AND DANA-FARBER, THESE

3407
02:06:41,660 --> 02:06:42,661
RELATIONSHIPS ARE BI-DIRECTIONAL

3408
02:06:42,728 --> 02:06:42,895
THOUGH.

3409
02:06:42,962 --> 02:06:44,630
THE RESPONSE DATA THAT IMPROVE

3410
02:06:44,697 --> 02:06:48,534
IS GENERATING AGAINST THE HCMI

3411
02:06:48,600 --> 02:06:49,835
SAMPLES AND INCREASING THE

3412
02:06:49,902 --> 02:06:51,370
VOLUME OF THE HCMI PROGRAM TO

3413
02:06:51,437 --> 02:06:52,404
THE COMMUNITY AT LARGE AND

3414
02:06:52,471 --> 02:06:53,472
SPECIFICALLY TO THE

3415
02:06:53,539 --> 02:06:54,873
COLLABORATORS WHO ARE HELPING

3416
02:06:54,940 --> 02:06:57,343
DRIVE THEIR SCIENCE AND THEIR

3417
02:06:57,409 --> 02:07:00,145
THOUGHT ABOUT AI AS THEY'RE

3418
02:07:00,212 --> 02:07:01,480
BEGINNING TO BRING THEIR AI INTO

3419
02:07:01,547 --> 02:07:03,849
SOME OF THESE BIGGER PROGRAMS

3420
02:07:03,916 --> 02:07:05,651
FOR EXAMPLE, WE'RE CURRENTLY IN

3421
02:07:05,718 --> 02:07:12,391
DISCUSSION WITH THE BROAD TO

3422
02:07:12,458 --> 02:07:14,159
HAVE THE MAP PORTAL IMPROVED BY

3423
02:07:14,226 --> 02:07:16,295
AI AND FOLLOW THE STANDARDS FROM

3424
02:07:16,362 --> 02:07:21,467
IMPROVE FOR THOSE AIs AS THEY

3425
02:07:21,533 --> 02:07:25,237
ADD IT TO THE MOUNT.

3426
02:07:25,304 --> 02:07:26,739
THE PSRC, THOSE RELATIONSHIPS

3427
02:07:26,805 --> 02:07:30,743
WHICH INCLUDE LANS FROM MD

3428
02:07:30,809 --> 02:07:32,845
ABDOMENNERSON, UCSD AND

3429
02:07:32,911 --> 02:07:33,145
DANA-FARBER.

3430
02:07:33,212 --> 02:07:34,380
THEY'RE BI-DIRECTIONAL.

3431
02:07:34,446 --> 02:07:35,748
THE IMPROVED DATA BEING

3432
02:07:35,814 --> 02:07:37,816
GENERATED AND THE AI BEING

3433
02:07:37,883 --> 02:07:42,755
EVALUATED IS ACTUALLY DRIVING

3434
02:07:42,821 --> 02:07:43,689
EXPERIMENTS OR WILL DRIVE

3435
02:07:43,756 --> 02:07:44,323
EXPERIMENTS FOR THOSE

3436
02:07:44,390 --> 02:07:45,924
RESEARCHERS AND THEN THEY WILL

3437
02:07:45,991 --> 02:07:47,926
FEED BA DATA BACK TO US AT

3438
02:07:47,993 --> 02:07:51,663
IMPROVE, SO THAT WE CAN GAIN A

3439
02:07:51,730 --> 02:07:54,099
BETTER UNDERSTANDING OF

3440
02:07:54,166 --> 02:07:58,837
RESISTANCE AND OF EMERGING

3441
02:07:58,904 --> 02:08:00,339
RESISTANCE AND THOSE OF THE

3442
02:08:00,406 --> 02:08:00,639
TUMOR.

3443
02:08:00,706 --> 02:08:04,143
AND SIMILARLY THIS IS OUR

3444
02:08:04,209 --> 02:08:09,915
FOUNDATION FOR THE ART NET THIS,

3445
02:08:09,982 --> 02:08:13,118
INCLUDING UCSD, MARTH LAB AND UO

3446
02:08:13,185 --> 02:08:15,087
U AND SLC, AND WE WILL TALK

3447
02:08:15,154 --> 02:08:18,223
ABOUT THE CANCERS WE'RE FOCUSED

3448
02:08:18,290 --> 02:08:20,192
ON IN A MOMENT BUT WHILE IT'S

3449
02:08:20,259 --> 02:08:21,727
BRANCHING US OUT, IT'S KEEPING

3450
02:08:21,794 --> 02:08:25,264
BOTH PROGRAMS VERY FOCUSED.

3451
02:08:25,330 --> 02:08:27,332
BEYOND JUST THE DATA

3452
02:08:27,399 --> 02:08:28,834
COLLABORATIONS AS RICK TALKED

3453
02:08:28,901 --> 02:08:30,035
ABOUT, WE ARE FUNDAMENTALLY

3454
02:08:30,102 --> 02:08:31,703
LOOKING AT ARK I MODELS SO WE'RE

3455
02:08:31,770 --> 02:08:34,239
BRINGING IN THAT COMMUNITY, THE

3456
02:08:34,306 --> 02:08:36,909
IDAKER LAB, THE MARTHLAB, THE

3457
02:08:36,975 --> 02:08:38,510
UNIVERSITY OF SALT LAKE AND THE

3458
02:08:38,577 --> 02:08:40,512
TROY LAB AT U-PITT.

3459
02:08:40,579 --> 02:08:42,848
THEY ARE DEVELOPING NOW AI

3460
02:08:42,915 --> 02:08:44,249
MODELS FOR TUMOR DRUG RESPONSE

3461
02:08:44,316 --> 02:08:47,052
AND SO BY BRINGING THEM INTO THE

3462
02:08:47,119 --> 02:08:48,320
IMPROVED FRAMEWORK, HAVING THEM

3463
02:08:48,387 --> 02:08:49,688
ADOPT THE IMPROVED FRAMEWORK,

3464
02:08:49,755 --> 02:08:52,424
AND HAVE THEIR MODELS BECOME

3465
02:08:52,491 --> 02:08:54,893
PART OF OUR ECOSYSTEM, IT'S

3466
02:08:54,960 --> 02:08:56,962
REALLY TYING US BACK TO OUR AIM

3467
02:08:57,029 --> 02:08:59,164
OF UNDERSTANDING AND IMPROVING

3468
02:08:59,231 --> 02:09:00,466
FUTURE MODELS AS AWE COMMUNITY

3469
02:09:00,532 --> 02:09:02,601
AND NOT JUST IMPROVE HAVING TO

3470
02:09:02,668 --> 02:09:09,608
BE THE 1 OUT THERE DOING IT ALL.

3471
02:09:09,675 --> 02:09:10,442
NEXT SLIDE, PLEASE.

3472
02:09:10,509 --> 02:09:13,645
ONE BACK.

3473
02:09:13,712 --> 02:09:14,279
THANK YOU.

3474
02:09:14,346 --> 02:09:16,482
AS RICK MENTIONED IN THE

3475
02:09:16,548 --> 02:09:18,050
INTRODUCTION, THE SECOND AIM OF

3476
02:09:18,117 --> 02:09:19,685
IMPROVE IS ACTUALLY VERY NOVEL

3477
02:09:19,751 --> 02:09:21,220
FOR AN AI EVALUATION PROJECT

3478
02:09:21,286 --> 02:09:22,721
SUCH AS THIS BECAUSE WE'RE

3479
02:09:22,788 --> 02:09:26,492
GENERATING NEW DATA SETS TO HELP

3480
02:09:26,558 --> 02:09:28,694
US EVALUATE THE CURRENT MODELS

3481
02:09:28,760 --> 02:09:30,596
AND IMPROVE FUTURE MODELS AND AS

3482
02:09:30,662 --> 02:09:32,698
RICK ALLUDED TO, WE'RE USING THE

3483
02:09:32,764 --> 02:09:35,868
GAPS AND BIASES THAT WE SEE IN

3484
02:09:35,934 --> 02:09:38,270
THOSE MODELS AND THE AI

3485
02:09:38,337 --> 02:09:40,372
PREDICTIVE POWER, TO GUIDE THAT

3486
02:09:40,439 --> 02:09:41,740
EXPERIMENTAL DESIGN, AND THEN ON

3487
02:09:41,807 --> 02:09:42,941
TOP OF THAT, WE'RE TRYING TO DO

3488
02:09:43,008 --> 02:09:45,277
IT IN A WAY THAT'S BRINGING US

3489
02:09:45,344 --> 02:09:49,214
CLOSER TO PATIENTS, SO MOVING

3490
02:09:49,281 --> 02:09:51,316
AWAY FROM IMMORTALIZED CELL

3491
02:09:51,383 --> 02:09:52,117
LINES TO PDOs.

3492
02:09:52,184 --> 02:09:53,986
OUR COLLABORATION WITH THE HCMI

3493
02:09:54,052 --> 02:09:55,721
IS ONLY 1 PART OF THIS AND THEIR

3494
02:09:55,787 --> 02:09:57,089
COLLECTION IS VERY IMPORTANT

3495
02:09:57,156 --> 02:10:01,093
BECAUSE IT GIVES US THOSE

3496
02:10:01,160 --> 02:10:02,294
MULTIOMICLY PROFILED ORGANOIDS

3497
02:10:02,361 --> 02:10:04,296
SO WE CAN COST EFFECTIVELY DO

3498
02:10:04,363 --> 02:10:06,865
OUR RESPONSE DATA ANALYSIS AT

3499
02:10:06,932 --> 02:10:08,834
SCALE BUT WE'RE ALSO LOOKING AT

3500
02:10:08,901 --> 02:10:09,134
THE FUTURE.

3501
02:10:09,201 --> 02:10:11,670
AND AS PART OF THIS, WE'RE

3502
02:10:11,737 --> 02:10:13,338
GATHERING RESPONSE DATA FOR

3503
02:10:13,405 --> 02:10:15,374
THINGS LIKE ADVANCED IMAGING

3504
02:10:15,440 --> 02:10:16,208
MODALITIES, WE'RE NOT JUST GOING

3505
02:10:16,275 --> 02:10:18,410
TO LOOK AT ARE THE CELLS ALIVE

3506
02:10:18,477 --> 02:10:21,079
OR DEAD, AND WHILE NO CURRENT

3507
02:10:21,146 --> 02:10:25,417
MODELS USE THESE IMAGING

3508
02:10:25,484 --> 02:10:26,552
MODALITIES BY GATHERING THEM, WE

3509
02:10:26,618 --> 02:10:28,654
CAN PUT THAT DATA OUT THERE, AS

3510
02:10:28,720 --> 02:10:31,323
OUR DATA BEING MADE PUBLIC, AND

3511
02:10:31,390 --> 02:10:34,393
FUTURE MODELS CAN USE IT,

3512
02:10:34,459 --> 02:10:35,794
BECAUSE UNDERSTANDING, YOU KNOW

3513
02:10:35,861 --> 02:10:37,129
HOW HEALTHY WERE THE CELLS AT

3514
02:10:37,196 --> 02:10:39,097
THE END OF THE THERAPY, OR THE

3515
02:10:39,164 --> 02:10:39,965
TREATMENT, THAT'S INTERESTING

3516
02:10:40,032 --> 02:10:42,367
AND CAN DRIVE THINGS LIKE THE

3517
02:10:42,434 --> 02:10:45,437
SELECTION OF COMBINATION

3518
02:10:45,504 --> 02:10:47,139
THERAPIES, AND PENDING WHO YOU

3519
02:10:47,206 --> 02:10:49,441
BELIEVE, SOME SAY THESE IMCANCER

3520
02:10:49,508 --> 02:10:50,943
CENTERRINGLY MODALITIES CAN EVEN

3521
02:10:51,009 --> 02:10:54,913
SUBSTITUTE FOR MORE EXPENSIVE OR

3522
02:10:54,980 --> 02:11:00,652
SENSITIVE OMICS ANALYSIS, LIKE

3523
02:11:00,719 --> 02:11:01,253
EXPRESSION ANALYSIS.

3524
02:11:01,320 --> 02:11:02,988
IT IS FEARED THAT AMPLIFYING

3525
02:11:03,055 --> 02:11:04,323
EFFORTS AND READINESS OF DATA

3526
02:11:04,389 --> 02:11:06,458
WERE COLLABORATING WITH A NUMBER

3527
02:11:06,525 --> 02:11:09,695
OF LABS AND MD ANDERSON, YOU CSD

3528
02:11:09,761 --> 02:11:13,332
AS WELL AS CHICAGO, THAT HAVE

3529
02:11:13,398 --> 02:11:16,635
COLLECTIONS OF EITHER LARGE OR

3530
02:11:16,702 --> 02:11:18,237
UNIQUE CANCER DATA AND BY

3531
02:11:18,303 --> 02:11:20,405
WORKING WITH THEM AND DOING

3532
02:11:20,472 --> 02:11:21,807
CROSS VALIDATION STUDIES WITH

3533
02:11:21,873 --> 02:11:24,443
THEM, WE'RE ACTUALLY ABLE TO

3534
02:11:24,509 --> 02:11:25,844
CREATE LENGTHS BETWEEN THEIR

3535
02:11:25,911 --> 02:11:27,579
DATA, OUR DATA AND EXISTING DATA

3536
02:11:27,646 --> 02:11:29,915
SETS SO THAT WE CAN COMPARE,

3537
02:11:29,982 --> 02:11:35,621
CROSS THEM AND USE THEM.

3538
02:11:35,687 --> 02:11:39,057
RIGHT NOW WE'RE DOING INITIAL

3539
02:11:39,124 --> 02:11:40,359
PILOTS THAT ARE FOCUSED ON

3540
02:11:40,425 --> 02:11:42,127
COLORECTAL CANCER BECAUSE IT'S A

3541
02:11:42,194 --> 02:11:44,329
HIGH INVENTORY CANCER AND OUR

3542
02:11:44,396 --> 02:11:46,331
INITIAL STUDIES SHOWED THAT IT'S

3543
02:11:46,398 --> 02:11:47,833
EXTREMELY POORLY PREDICTED BY

3544
02:11:47,899 --> 02:11:52,337
EXISTING AI MODELS BUT OVER THE

3545
02:11:52,404 --> 02:11:54,773
SUMMER, AND EVEN SOONER IF THE

3546
02:11:54,840 --> 02:11:57,409
DATA GOES QUICKLY, WE'RE ADDING

3547
02:11:57,476 --> 02:12:05,651
ADDITIONAL CANCERS SUCH AS

3548
02:12:05,717 --> 02:12:07,286
ADENOMA, AND SARCOMA AS WELL AS

3549
02:12:07,352 --> 02:12:08,453
EXPABDING DRUGS FROM THE INITIAL

3550
02:12:08,520 --> 02:12:14,459
SET OF DRUGS WE USED.

3551
02:12:14,526 --> 02:12:15,360
NEXT SLIDE.

3552
02:12:15,427 --> 02:12:17,629
IMPROVE IS AN OPEN COMMUNITY.

3553
02:12:17,696 --> 02:12:19,164
IMPROVE WAS CONCEIVED OF FROM

3554
02:12:19,231 --> 02:12:21,700
THE BEGINNING TO BE OUTWARD

3555
02:12:21,767 --> 02:12:22,801
FACING.

3556
02:12:22,868 --> 02:12:24,136
AND THE RESOURCES BEING

3557
02:12:24,202 --> 02:12:26,371
GENERATED WERE BEING GENERATED

3558
02:12:26,438 --> 02:12:27,773
TO SUPPORT COMMUNITY NEEDS.

3559
02:12:27,839 --> 02:12:31,076
WE SAY WE'RE TRYING TO LEFT ALL

3560
02:12:31,143 --> 02:12:31,843
THE BOATS.

3561
02:12:31,910 --> 02:12:35,781
SO IN ADDITION AS RICK MENTIONED

3562
02:12:35,847 --> 02:12:40,552
TO NCI, D. O. E. AND ARGON

3563
02:12:40,619 --> 02:12:42,054
FREDERICK NATIONAL LABS WE HAVE

3564
02:12:42,120 --> 02:12:44,222
OUR CORE MODELING GROUP WHICH

3565
02:12:44,289 --> 02:12:48,727
COMPRISES OF MAY O CLINIC, WANG

3566
02:12:48,794 --> 02:12:50,228
LAB, TEXT PARTICULAR TECH

3567
02:12:50,295 --> 02:12:52,631
UNIVERSITY, WITH THE PAL LAB AND

3568
02:12:52,698 --> 02:12:54,566
PACIFIC NORTHWEST NATIONAL LAB

3569
02:12:54,633 --> 02:12:59,071
ARRA TOY AND AS WELL AS PACIFIC

3570
02:12:59,137 --> 02:12:59,671
NORTHWEST NATIONAL LABORATORY.

3571
02:12:59,738 --> 02:13:04,876
AS CAN YOU SEE, ON THE RIGHT, ON

3572
02:13:04,943 --> 02:13:06,812
THE BOTTOM, SORRY CAN'T DO THE

3573
02:13:06,878 --> 02:13:08,880
POINTER, THIS IS OUR INITIAL

3574
02:13:08,947 --> 02:13:10,749
KICKOFF, THIS IS AT ARGON WHEN

3575
02:13:10,816 --> 02:13:13,618
WHEN WE KICKS OFF CCMKB SIN IN

3576
02:13:13,685 --> 02:13:14,319
JANUARY OF 23.

3577
02:13:14,386 --> 02:13:19,624
AND THEN, ON THE TOP RIGHT WE

3578
02:13:19,691 --> 02:13:22,361
HAVE OUR YEAR ENDING JAMBOREE,

3579
02:13:22,427 --> 02:13:23,795
THAT WAS AT UCSD WHEN WE MET

3580
02:13:23,862 --> 02:13:26,665
WITH THE LAB AND OTHERS THERE TO

3581
02:13:26,732 --> 02:13:28,967
DO AN INITIAL ROLL OUT.

3582
02:13:29,034 --> 02:13:31,069
WE ADDITIONALLY HEALTH EVENTS AT

3583
02:13:31,136 --> 02:13:32,671
THE UNIVERSITY OF UTAH SALT LAKE

3584
02:13:32,738 --> 02:13:34,973
AND A VIRTUAL EVENT WITH THE

3585
02:13:35,040 --> 02:13:35,507
UNIVERSITY OF PITTSBURGH.

3586
02:13:35,574 --> 02:13:39,478
WE HAVE A HACKATHON STARTING

3587
02:13:39,544 --> 02:13:41,313
TOMORROW AT ARGON AND THEN OUR

3588
02:13:41,380 --> 02:13:44,316
NEXT HACKATHON IS IN BOSTON IN

3589
02:13:44,383 --> 02:13:47,686
MAY IN 2024 AND THE THEME FOR

3590
02:13:47,753 --> 02:13:50,222
THAT IS AI DATA READINESS.

3591
02:13:50,288 --> 02:13:52,023
AND THAT'S BEING HELD IN

3592
02:13:52,090 --> 02:14:00,065
CONJUNCTION WITH THE BROAD JUST

3593
02:14:00,132 --> 02:14:01,533
TO PREVENT QUESTIONS, THIS EVENT

3594
02:14:01,600 --> 02:14:07,139
AND AN IMPROVE EVENT BUT WE'RE

3595
02:14:07,205 --> 02:14:10,409
COORDINATING WITH THE AI LAB AND

3596
02:14:10,475 --> 02:14:14,913
ARGON LAB AND THEY'RE PROVIDING

3597
02:14:14,980 --> 02:14:16,081
THROW A FOOTBALL TO FURNISH

3598
02:14:16,148 --> 02:14:16,314
JUDGES.

3599
02:14:16,381 --> 02:14:18,283
AND THEN THE NEXT SLIDE AND RICK

3600
02:14:18,350 --> 02:14:19,785
WILL FINISH US OUT.

3601
02:14:19,851 --> 02:14:23,021
>> LIKE THE PREVIOUS PROJECT

3602
02:14:23,088 --> 02:14:24,990
EVERYTHING IS OPEN, WE HAVE A

3603
02:14:25,056 --> 02:14:26,291
GITHUB WHERE THE COMMUNITY

3604
02:14:26,358 --> 02:14:28,827
SHARES CODE AND TUTORIALS AND

3605
02:14:28,894 --> 02:14:30,195
EXAMPLES, TOITORIAL ANDS SO

3606
02:14:30,262 --> 02:14:32,297
FORTH, SO THERE'S OUR GITHUB

3607
02:14:32,364 --> 02:14:33,331
LINK.

3608
02:14:33,398 --> 02:14:35,333
ALL THE DATA AND CURATED MODELS

3609
02:14:35,400 --> 02:14:38,937
ARE ALSO BEING HOSTED IN THE

3610
02:14:39,004 --> 02:14:40,539
MODAC REPOSITORY THAT YOU HEARD

3611
02:14:40,605 --> 02:14:46,044
ABOUT BEFORE AT CANCER .GOV AND

3612
02:14:46,111 --> 02:14:47,779
WE HAVE A PROJECT WEBSITE THAT

3613
02:14:47,846 --> 02:14:49,181
HAS A DESCRIPTION OF WHAT WE DO

3614
02:14:49,247 --> 02:14:51,149
AND HOW PEOPLE CAN GET MORE

3615
02:14:51,216 --> 02:14:52,250
ENGAGED AND WITH THAT WE ARE

3616
02:14:52,317 --> 02:14:54,786
HAPPY TO ANSWER QUESTIONS.

3617
02:14:54,853 --> 02:14:56,555
THANK YOU.

3618
02:14:56,621 --> 02:14:57,823
>> OKAY.

3619
02:14:57,889 --> 02:15:03,061
QUESTIONS?

3620
02:15:03,128 --> 02:15:04,496
CAROL?

3621
02:15:04,563 --> 02:15:05,030
>> YEAH, THANK YOU.

3622
02:15:05,096 --> 02:15:08,400
SO I WAS INTERESTED IN A BUNCH

3623
02:15:08,467 --> 02:15:11,937
OF THINGS, BUT INTERESTING TALK.

3624
02:15:12,003 --> 02:15:14,139
BUT THE SEX DATA THAT WAS FOUND

3625
02:15:14,206 --> 02:15:15,340
IN THERE, BECAUSE MOST OF THESE

3626
02:15:15,407 --> 02:15:17,709
DATA ARE FROM PEOPLE OF EUROPEAN

3627
02:15:17,776 --> 02:15:18,944
ANCESTRY, DO YOU THINK THAT

3628
02:15:19,010 --> 02:15:23,048
THERE'S GOING TO BE BIAS THERE

3629
02:15:23,114 --> 02:15:26,551
AS WELL AS DATA FROM MORE

3630
02:15:26,618 --> 02:15:27,953
DIVERSE ETHNIC BACKGROUNDS GETS

3631
02:15:28,019 --> 02:15:29,354
GENERATED FOR THESE STUDIES.

3632
02:15:29,421 --> 02:15:31,022
>> THE SIMPLE ANSWER IS YES, WE

3633
02:15:31,089 --> 02:15:32,190
BELIEVE THAT THERE'S RACIAL BIAS

3634
02:15:32,257 --> 02:15:34,893
IN THE DATA AS WELL.

3635
02:15:34,960 --> 02:15:37,095
WE'VE ACTUALLY DONE THE SLICES,

3636
02:15:37,162 --> 02:15:39,197
WE BUILT A TOOL THAT ARK LOWS US

3637
02:15:39,264 --> 02:15:41,633
TO SLICE THE DATA BY GENDER OR

3638
02:15:41,700 --> 02:15:43,668
SOME OTHER MEASURE AND RACIAL

3639
02:15:43,735 --> 02:15:46,371
BACKGROUND IS ANOTHER 1 THAT

3640
02:15:46,438 --> 02:15:47,873
WE'VE CONE THE EXPERIMENTS ON

3641
02:15:47,939 --> 02:15:50,242
AND OF IT DOES ALSO SEEM TO HAVE

3642
02:15:50,308 --> 02:15:51,042
THE SIMILAR CHALLENGES.

3643
02:15:51,109 --> 02:15:52,244
WE'RE NOT QUITE READY TO PUBLISH

3644
02:15:52,310 --> 02:15:54,079
ON THAT YET BUT I THINK THE WAY

3645
02:15:54,145 --> 02:15:56,481
TO THINK ABOUT THIS IS THAT SOME

3646
02:15:56,548 --> 02:15:59,518
OF THIS IS CAUSED BY SAMPLE

3647
02:15:59,584 --> 02:16:01,353
IMBALANCE, THERE TENDS TO BE

3648
02:16:01,419 --> 02:16:03,522
MORE SAMPLES OF CERTAIN SUBCLASS

3649
02:16:03,588 --> 02:16:06,057
ASKS THAT HAS AN EFFECT ON IT

3650
02:16:06,124 --> 02:16:08,493
AND BECAUSE AI WANTS TO OPTIMIZE

3651
02:16:08,560 --> 02:16:09,961
FOR THE MOST ABUNDANT CLASSES.

3652
02:16:10,028 --> 02:16:12,230
SO IF YOU HAVE A MINORITY CLASS

3653
02:16:12,297 --> 02:16:14,733
THAT GETS LEFT OUT, SO THERE MAY

3654
02:16:14,799 --> 02:16:17,435
BE WAYS TO MITIGATE THIS WITH

3655
02:16:17,502 --> 02:16:19,271
ADJUSTMENTS IN THE MODELS WHERE

3656
02:16:19,337 --> 02:16:21,239
WE CAN COMPENSATE FOR CLASS

3657
02:16:21,306 --> 02:16:22,541
IMBALANCE AND WE CAN DO OTHER

3658
02:16:22,607 --> 02:16:24,743
THINGS BUT I THINK IT'S STILL A

3659
02:16:24,809 --> 02:16:26,711
BIT EARLY IN UNDERSTANDING THE

3660
02:16:26,778 --> 02:16:29,447
IMPLICATIONS OF BOTH WHERE THE

3661
02:16:29,514 --> 02:16:31,550
DATA IS NOT BALANCED BUT ALSO

3662
02:16:31,616 --> 02:16:32,384
WHAT THE COMPUTATIONAL

3663
02:16:32,450 --> 02:16:34,986
TECHNIQUES ARE THAT MIGHT

3664
02:16:35,053 --> 02:16:35,554
MITIGATE THAT.

3665
02:16:35,620 --> 02:16:37,255
>> THANK YOU.

3666
02:16:37,322 --> 02:16:41,459
SO MY OTHER QUESTION IS MORE

3667
02:16:41,526 --> 02:16:45,997
SELF-SERVING BECAUSE I'M PART OF

3668
02:16:46,064 --> 02:16:47,265
THE NCI'S PEDIATRIC PRECLINICAL

3669
02:16:47,332 --> 02:16:48,166
IN VIVO TESTING PROGRAM AND SO

3670
02:16:48,233 --> 02:16:52,537
WE HAVE A LOT OF TREATMENT

3671
02:16:52,604 --> 02:16:56,608
RESPONSE DATA UPON FOR PDX

3672
02:16:56,675 --> 02:16:59,644
MODELS, NOT PDOs BUT PDX SO WE

3673
02:16:59,711 --> 02:17:02,380
HAVE THE MODELS, GENOMICS,

3674
02:17:02,447 --> 02:17:02,881
TREATMENT RESPONSE DATA.

3675
02:17:02,948 --> 02:17:04,316
ARE THOSE THE DATA THAT IF WE

3676
02:17:04,382 --> 02:17:06,017
MADE THEM AI READY WOULD BE

3677
02:17:06,084 --> 02:17:08,386
USEFUL FOR THIS ENDEAVOR AS

3678
02:17:08,453 --> 02:17:09,854
WELL?

3679
02:17:09,921 --> 02:17:10,221
>> ABSOLUTELY.

3680
02:17:10,288 --> 02:17:10,522
ABSOLUTELY.

3681
02:17:10,589 --> 02:17:11,523
WE WOULD LOVE TO HAVE THAT DAT

3682
02:17:11,590 --> 02:17:13,458
AND THAT'S THE KIND OF DATA

3683
02:17:13,525 --> 02:17:14,292
WE'RE HUNTING FOR BECAUSE WE

3684
02:17:14,359 --> 02:17:16,494
WANT TO MOVE CLOSER TO THE

3685
02:17:16,561 --> 02:17:19,397
PATIENT WHETHER IT'S PDXs OR

3686
02:17:19,464 --> 02:17:22,000
PDOs BUT AWAY FROM TRADITIONAL

3687
02:17:22,067 --> 02:17:22,734
CELL LINE.

3688
02:17:22,801 --> 02:17:24,035
NIT'S OKAY, YOU ARE HEAR FROM ME

3689
02:17:24,102 --> 02:17:28,540
LATER IN THE WEEK.

3690
02:17:28,607 --> 02:17:30,041
>> OH YEAH, ABSOLUTELY.

3691
02:17:30,108 --> 02:17:31,576
I'VE WRITTEN DOWN THE MAY

3692
02:17:31,643 --> 02:17:32,978
HACKATHON AND I WILL LOOK UP

3693
02:17:33,044 --> 02:17:34,613
YOUR WEBSITE, THIS WOULD BE

3694
02:17:34,679 --> 02:17:35,580
FANTASTIC TO LEVERAGE THESE DATA

3695
02:17:35,647 --> 02:17:43,788
FOR SOMETHING LIKE THIS.

3696
02:17:43,855 --> 02:17:45,457
NTHANK YOU.

3697
02:17:45,523 --> 02:17:45,757
>> ANANT.

3698
02:17:45,824 --> 02:17:46,358
>> THANK YOU.

3699
02:17:46,424 --> 02:17:49,094
REEL KEEPSAKESLY ENJOYED THE

3700
02:17:49,160 --> 02:17:49,427
PRESENTATION.

3701
02:17:49,494 --> 02:17:52,097
MY QUESTION FOLLOWS ON THE BACK

3702
02:17:52,163 --> 02:17:53,264
OF THE PREVIOUS QUESTION.

3703
02:17:53,331 --> 02:17:54,332
YOU SAID SOMETHING REALLY

3704
02:17:54,399 --> 02:17:57,869
INTERESTING WITH REGARD TO THE

3705
02:17:57,936 --> 02:17:58,770
SAMPLE IMBALANCE RESULTING IN

3706
02:17:58,837 --> 02:18:00,639
SOME OF THOSE ISSUES THAT YOU

3707
02:18:00,705 --> 02:18:03,041
WERE SEEING WITH REGARD TO

3708
02:18:03,108 --> 02:18:05,477
GENDER SPECIFIC DIFFERENCES AND

3709
02:18:05,543 --> 02:18:07,912
ALSO POTENTIALLY RACE AND

3710
02:18:07,979 --> 02:18:13,284
ETHNICITY SPECIFIC DIFFERENCES.

3711
02:18:13,351 --> 02:18:17,255
EXCUSE ME--WHICH BEGS THE

3712
02:18:17,322 --> 02:18:21,760
QUESTION ABOUT WHETHER WITH

3713
02:18:21,826 --> 02:18:23,862
THESE MORE, BIG KIND OF MODELS

3714
02:18:23,928 --> 02:18:25,230
WHETHER THERE'S CONCERN ABOUT

3715
02:18:25,296 --> 02:18:33,204
BATCH EFFECTS AND WHETHER YOU

3716
02:18:33,271 --> 02:18:34,472
EVALUATED WHETHER TECHNICAL

3717
02:18:34,539 --> 02:18:35,540
FACTORS CAN PLAY A ROLE.

3718
02:18:35,607 --> 02:18:37,308
AND I GUESS THE BROADER QUESTION

3719
02:18:37,375 --> 02:18:38,910
ABOUT WHETHER THERE IS A SENSE

3720
02:18:38,977 --> 02:18:40,712
OF LOOKING AT MORE EXPLAINABLE

3721
02:18:40,779 --> 02:18:42,180
MODELS BECAUSE 1 OF THE

3722
02:18:42,247 --> 02:18:44,816
CHALLENGES WE KNOW WITH DEEP

3723
02:18:44,883 --> 02:18:45,884
LEARNING FOCUSED MODELS IS THE

3724
02:18:45,950 --> 02:18:46,584
OPACITY.

3725
02:18:46,651 --> 02:18:48,453
SO I GUESS THE FOLLOW-ON

3726
02:18:48,520 --> 02:18:50,722
QUESTION IS ABOUT TRYING TO LOOK

3727
02:18:50,789 --> 02:18:52,357
AT MORE EXPLAINABLE MODELS TO

3728
02:18:52,424 --> 02:18:54,225
TRY TO SORT OF GET AWAY FROM

3729
02:18:54,292 --> 02:18:57,128
SOME OF THAT REPRODUCIBILITY

3730
02:18:57,195 --> 02:18:58,363
OPACITY ISSUE.

3731
02:18:58,430 --> 02:19:06,071
NYES, YOU HAVE SEVERAL POINTS IN

3732
02:19:06,137 --> 02:19:06,271
THERE.

3733
02:19:06,337 --> 02:19:07,772
NSO EXPLAINABILITY IS █SOMETIMES

3734
02:19:07,839 --> 02:19:08,273
A CHALLENGE.

3735
02:19:08,339 --> 02:19:09,841
YOU KNOW IT WAS VERY COMMONLY

3736
02:19:09,908 --> 02:19:11,910
TALKED ABOUT A FEW YEARS AGO BUT

3737
02:19:11,976 --> 02:19:13,411
SINCE THEN THERE'S BEEN A LARGE

3738
02:19:13,478 --> 02:19:17,949
NUMBER OF TECHNIQUES DEVELOPED

3739
02:19:18,016 --> 02:19:19,584
TO HELP INTERPRET WHAT DEEP

3740
02:19:19,651 --> 02:19:22,420
NEURAL NETWORKS ARE DOING AND I

3741
02:19:22,487 --> 02:19:23,455
WOULD SAY EXPLAINABILITY IS

3742
02:19:23,521 --> 02:19:24,856
PROBABLY LESS OF AN ISSUE NOW

3743
02:19:24,923 --> 02:19:27,092
THAN IT WAS A FEW YEARS AGO.

3744
02:19:27,158 --> 02:19:29,527
WE CAN FOR EXAMPLE, BUILD MODELS

3745
02:19:29,594 --> 02:19:31,029
THAT HELP EXPLAIN THE DECISION

3746
02:19:31,096 --> 02:19:34,199
MAKING OF THE PRIMARY MODEL.

3747
02:19:34,265 --> 02:19:37,302
WE CAN DO THINGS THAT EXPLAIN

3748
02:19:37,368 --> 02:19:39,537
THE FUTURES THAT THE MODEL IS

3749
02:19:39,604 --> 02:19:41,740
USING AND SO FORTH, SO I THINK

3750
02:19:41,806 --> 02:19:43,708
EXPLAINABILITY IS LESS OF A

3751
02:19:43,775 --> 02:19:44,342
CONCERN.

3752
02:19:44,409 --> 02:19:45,543
WE CAN ALMOST USE THESE MODELS

3753
02:19:45,610 --> 02:19:47,412
TO TELL US WHAT FEATURES ARE

3754
02:19:47,479 --> 02:19:49,948
MOST IMPORTANT AND SO FORTH.

3755
02:19:50,014 --> 02:19:52,050
IN TERMS OF BATCH EFFECTS, THE

3756
02:19:52,117 --> 02:19:55,086
DATA AND NORMALIZATION WE DO, WE

3757
02:19:55,153 --> 02:19:58,690
HAVE VERY SOPHISTICATED

3758
02:19:58,757 --> 02:19:59,891
PROCEDURES FOR NORMALIZING AND

3759
02:19:59,958 --> 02:20:01,126
RESAMPLING THE DAILY BASIS THEA

3760
02:20:01,192 --> 02:20:05,697
AND SO ON TO TRY TO SMOOTH OUT

3761
02:20:05,764 --> 02:20:06,698
BATCH EFFECTS AND AT A IN THE

3762
02:20:06,765 --> 02:20:08,066
GOOD PART OF THE SPACE, HAVING

3763
02:20:08,133 --> 02:20:09,934
SAID THAT IT'S STILL A CONCERN,

3764
02:20:10,001 --> 02:20:12,003
WE CAN OFTEN EASILY DETECT WHICH

3765
02:20:12,070 --> 02:20:14,873
LABS DATA CAME FROM, THAT

3766
02:20:14,939 --> 02:20:16,174
THERE'S A SIGNAL IMPRINT ON THEM

3767
02:20:16,241 --> 02:20:17,809
AND EVEN THE TIME OF YEAR THAT

3768
02:20:17,876 --> 02:20:20,378
THE DATA WAS PRODUCED SO THAT'S

3769
02:20:20,445 --> 02:20:22,447
ALSO A CHALLENGE.

3770
02:20:22,514 --> 02:20:26,618
THERE ARE, AGAIN, 5 YEARS AGO, I

3771
02:20:26,684 --> 02:20:29,654
THINK SOME OF THESE WERE MOAF

3772
02:20:29,721 --> 02:20:31,389
CHALLENGING PROBLEMS BECAUSE THE

3773
02:20:31,456 --> 02:20:33,258
COMMUNITY HADN'T BUILT AS MUCH

3774
02:20:33,324 --> 02:20:34,392
TECHNOLOGY FOR DIRECTING CLASS

3775
02:20:34,459 --> 02:20:36,394
BALANCE OR BATCH EFFECTS OR

3776
02:20:36,461 --> 02:20:37,328
THINGS LIKE THAT.

3777
02:20:37,395 --> 02:20:38,630
ONE TECHNIQUE THAT'S VERY

3778
02:20:38,696 --> 02:20:42,300
HELPFUL, THESE DAYS IS DATA

3779
02:20:42,367 --> 02:20:43,301
AUGMENTATION AND SYNTHETIC DATA

3780
02:20:43,368 --> 02:20:44,636
AND AND WE'RE ALSO EXPLORING HOW

3781
02:20:44,702 --> 02:20:46,037
THAT CAN BE USED TO MITIGATE

3782
02:20:46,104 --> 02:20:52,677
SOME OF THESE EEIVETS.

3783
02:20:52,744 --> 02:20:53,945
WE CAN OF COURSE COMPARE THE

3784
02:20:54,012 --> 02:20:56,014
DEEP LEARNING MODELS TO MODELS

3785
02:20:56,080 --> 02:20:58,783
THAT ARE MORE BASED ON MECHANISM

3786
02:20:58,850 --> 02:21:01,486
AND THAT'S BEEN AN ONGOING

3787
02:21:01,553 --> 02:21:03,121
PROGRAM FOR MANY YEARS IS TRYING

3788
02:21:03,188 --> 02:21:05,757
TO FIND MORE MECHANISTIC MODELS

3789
02:21:05,824 --> 02:21:07,225
AND WORK THAT INTO THE

3790
02:21:07,292 --> 02:21:08,793
FRAMEWORK, SO ALL THESE ARE

3791
02:21:08,860 --> 02:21:10,995
IMPORTANT POINTS THAT YOU RAISE

3792
02:21:11,062 --> 02:21:13,665
IN IT AND I AGREE THAT THERE ARE

3793
02:21:13,731 --> 02:21:14,799
ALL CHALLENGES BUT WE'RE TRYING

3794
02:21:14,866 --> 02:21:17,368
TO MANAGE THEM THE BEST WE CAN.

3795
02:21:17,435 --> 02:21:17,735
>> THANK YOU.

3796
02:21:17,802 --> 02:21:19,137
I'M JUST GOING TO PUSH BACK A

3797
02:21:19,204 --> 02:21:20,972
LITTLE BIT THERE WITH THE

3798
02:21:21,039 --> 02:21:21,773
EXPLAINABILITY, I THINK WE STILL

3799
02:21:21,840 --> 02:21:26,110
HAVE A WAY TO GO WITH TRUE

3800
02:21:26,177 --> 02:21:27,278
EXPLAINABILITY AND I THINK THE

3801
02:21:27,345 --> 02:21:28,913
CHAL EVENLG WITH SOME OF THE

3802
02:21:28,980 --> 02:21:31,616
APPROACHES THAT EXIST WOULD

3803
02:21:31,683 --> 02:21:32,750
SUGGEST EXPLAINABILITY BEYOND

3804
02:21:32,817 --> 02:21:33,384
EXPLAINABILITY, PARTICULARLY

3805
02:21:33,451 --> 02:21:35,353
WITH THE VISUAL ATTENTION MAPS

3806
02:21:35,420 --> 02:21:36,020
AND SO ON.

3807
02:21:36,087 --> 02:21:37,522
BUT I UNDERSTAND IT IS

3808
02:21:37,589 --> 02:21:38,356
CHALLENGING AND COMMEND YOU FOR

3809
02:21:38,423 --> 02:21:41,693
THE WORK YOU'RE DOING.

3810
02:21:41,759 --> 02:21:42,026
THANK YOU.

3811
02:21:42,093 --> 02:21:43,061
>> THANK YOU.

3812
02:21:43,127 --> 02:21:44,596
>> SO WE'RE RUNNING A LITTLE

3813
02:21:44,662 --> 02:21:46,564
OVER, SO, MARY DID YOU HAVE

3814
02:21:46,631 --> 02:21:48,867
SOMETHING YOU WOULD LIKE TO ASK?

3815
02:21:48,933 --> 02:21:50,935
>> I JUST PUT IT IN THE CHAT.

3816
02:21:51,002 --> 02:21:51,336
ALL RIGHT, FINE.

3817
02:21:51,402 --> 02:21:52,370
THANK YOU AND I THINK WE WILL

3818
02:21:52,437 --> 02:21:54,806
MOVE ON EMPLOY THE NEXT

3819
02:21:54,873 --> 02:21:56,541
PRESENTATION IS ENTITLED MA

3820
02:21:56,608 --> 02:22:00,511
SWRAIIC, ACHIEVING NEAR REALTIME

3821
02:22:00,578 --> 02:22:03,114
CANCER SURVEILLANCE WITH

3822
02:22:03,181 --> 02:22:05,617
AUTOMATIC RECORD ABSTRACTION.

3823
02:22:05,683 --> 02:22:06,584
DRS. HANSON AND SHIS U.

3824
02:22:06,651 --> 02:22:08,219
>> SO HEIDI AND I WILL CLOSE OUT

3825
02:22:08,286 --> 02:22:11,990
THE PRESENTATION ON THE NCI

3826
02:22:12,056 --> 02:22:14,325
COLLABORATION SYSTEM MOSAIC, OR

3827
02:22:14,392 --> 02:22:16,160
MODELING OUTCOMES USING

3828
02:22:16,227 --> 02:22:17,562
ARTIFICIAL AND SCALABLE

3829
02:22:17,629 --> 02:22:18,162
INTELLIGENCE FOR CANCER.

3830
02:22:18,229 --> 02:22:18,496
NEXT SLIDE.

3831
02:22:18,563 --> 02:22:21,366
SO I WANT TO START WITH A LITTLE

3832
02:22:21,432 --> 02:22:22,901
BACKGROUND ON THE SEER CENTRAL

3833
02:22:22,967 --> 02:22:25,370
REGISTRIES THAT ARE SUPPORTED BY

3834
02:22:25,436 --> 02:22:25,770
THE NCI.

3835
02:22:25,837 --> 02:22:28,740
STEER ROUGH ATOM VIEDS THE

3836
02:22:28,806 --> 02:22:29,908
FRAMEWORK FOR MOSAIC'S

3837
02:22:29,974 --> 02:22:31,609
FRAMEWORK, IT WAS A MISSION TO

3838
02:22:31,676 --> 02:22:32,610
SUPPORT RESEARCH.

3839
02:22:32,677 --> 02:22:35,947
AND THE REGISTRY IS TO IDENTIFY

3840
02:22:36,014 --> 02:22:38,616
DATA, TO MAKE IT THROUGH

3841
02:22:38,683 --> 02:22:41,786
APPROPRIATE AUTHENTICATION AND

3842
02:22:41,853 --> 02:22:42,287
AUTHORIZATION PROCESSES.

3843
02:22:42,353 --> 02:22:43,421
SEER CONSISTS OF 18 REG TREES

3844
02:22:43,488 --> 02:22:45,323
AND 85% OF THE INCIDENT CASES

3845
02:22:45,390 --> 02:22:47,525
RECEIVED BY THE SEER REG TREES

3846
02:22:47,592 --> 02:22:48,593
HAVE ASSOCIATED ELECTRONIC

3847
02:22:48,660 --> 02:22:49,894
PATHOLOGY REPORTING WHICH IS

3848
02:22:49,961 --> 02:22:52,196
CRITICAL IN ORDER TO ACHIEVE

3849
02:22:52,263 --> 02:22:53,131
NEAR REALTIME INSTANCE REPORTING

3850
02:22:53,197 --> 02:22:54,999
AS WELL AS WORK WE'RE DOING

3851
02:22:55,066 --> 02:22:56,501
UNDER MOSAIC.

3852
02:22:56,567 --> 02:22:58,436
A CANCER ABSTRACT IN A REGISTRY

3853
02:22:58,503 --> 02:23:01,239
IS CONSOLIDATED FROM A NUMBER OF

3854
02:23:01,306 --> 02:23:02,407
HOSPITAL ABSTRACTS AND PATHOLOGY

3855
02:23:02,473 --> 02:23:03,441
REPORTS AND DEATH CERTIFICATE

3856
02:23:03,508 --> 02:23:05,176
ANDS THIS INFORMATION IS

3857
02:23:05,243 --> 02:23:06,978
BECOMING MORE COMPLEX AND

3858
02:23:07,045 --> 02:23:08,012
HETEROGENIUS AND INCLUDES NEW

3859
02:23:08,079 --> 02:23:09,447
DATA SOURCES SUCH AS FRANCIS

3860
02:23:09,514 --> 02:23:11,115
COLLINS PHARMACIES AND CLAIMS

3861
02:23:11,182 --> 02:23:12,517
AND GENOMIC TESTING RESULTS AND

3862
02:23:12,583 --> 02:23:15,486
AS WELL AS REALTIME DATA FIELDS

3863
02:23:15,553 --> 02:23:17,121
BUT THIS LARGELY EMANUEL PROCESS

3864
02:23:17,188 --> 02:23:18,323
FOR SCREENING AND ABSTRACTION.

3865
02:23:18,389 --> 02:23:19,991
THE LAST THING I WANT TO

3866
02:23:20,058 --> 02:23:23,628
HIGHLIGHT, IS THE SIERRA DATA

3867
02:23:23,695 --> 02:23:25,163
MANAGEMENT SYSTEM OR SEER IMS,

3868
02:23:25,229 --> 02:23:29,801
USED BY THE REG TREE.

3869
02:23:29,867 --> 02:23:37,909
SEER DMS UTILIZES LINKAGES AS

3870
02:23:37,976 --> 02:23:40,445
WELL AS SIMULTANEOUS PROGRAMS TO

3871
02:23:40,511 --> 02:23:43,247
SUPPORT A WORK FLOW FOR THE

3872
02:23:43,314 --> 02:23:43,548
REGISTRIES.

3873
02:23:43,614 --> 02:23:44,248
NEXT SLIDE.

3874
02:23:44,315 --> 02:23:46,250
SO THE KEY COMPONENT TO ENHANCES

3875
02:23:46,317 --> 02:23:47,485
SEER INFRASTRUCTURE TO SUPPORT A

3876
02:23:47,552 --> 02:23:48,753
BROADER SET OF CANCER RESEARCH

3877
02:23:48,820 --> 02:23:50,621
ACTIVITY SYSTEM THE WORK WITH

3878
02:23:50,688 --> 02:23:50,955
MOSAIC.

3879
02:23:51,022 --> 02:23:52,490
THE ACTIVITIES IN MOSAIC ARE

3880
02:23:52,557 --> 02:23:55,093
CENTERED ARK ROUND THE REAL

3881
02:23:55,159 --> 02:23:56,260
WORLD INFORMATION PIPELINE TO

3882
02:23:56,327 --> 02:23:58,296
EXTRACT FREVERGZ IN AN AUTOMATED

3883
02:23:58,363 --> 02:24:00,999
FASHION TO SUPPORT NEAR REALTIME

3884
02:24:01,065 --> 02:24:01,666
CANCER INITANCE REPORTING AS

3885
02:24:01,733 --> 02:24:03,001
WELL AS INFORMATION THAT WILL

3886
02:24:03,067 --> 02:24:04,702
SUPPORT BETTER UNDERSTANDING OF

3887
02:24:04,769 --> 02:24:07,972
PATIENT TRAJECTORY AT THE

3888
02:24:08,039 --> 02:24:09,007
POPULATION LEVEL.

3889
02:24:09,073 --> 02:24:12,176
WITH REGARD TO DIAGNOSIS AND

3890
02:24:12,243 --> 02:24:13,344
TREATMENT, BEDDING DNCHS AND

3891
02:24:13,411 --> 02:24:15,480
OUTCOMES IN REAL WORLD CANCER

3892
02:24:15,546 --> 02:24:18,016
PATIENTS SUCH AS SUBSEQUENT

3893
02:24:18,082 --> 02:24:19,717
TREATMENT OR METASTASIS IS

3894
02:24:19,784 --> 02:24:20,618
INCREASINGLY DIFFICULT.

3895
02:24:20,685 --> 02:24:23,187
WE WILL HIGH LIE THE WORK IN

3896
02:24:23,254 --> 02:24:24,355
NEAR REALTIME INSTANCE

3897
02:24:24,422 --> 02:24:25,289
RESPORTING THROUGH AUTOMATED

3898
02:24:25,356 --> 02:24:26,491
ACTION TRACTION FROM

3899
02:24:26,557 --> 02:24:27,625
CHARACTERISTICS FROM PATHOLOGY

3900
02:24:27,692 --> 02:24:29,961
REPORTS AND NEAR REALTIME CASE

3901
02:24:30,028 --> 02:24:30,928
ATTAINMENT FOR CANCER RELATED

3902
02:24:30,995 --> 02:24:32,196
REPORT ANDS BETTER UNDERSTANDING

3903
02:24:32,263 --> 02:24:39,370
OF OUTCOMES THROUGH PREDICTION

3904
02:24:39,437 --> 02:24:40,204
HETAFT SIS.

3905
02:24:40,271 --> 02:24:41,906
NEW MANAGES DEVELOPED REPRESENT

3906
02:24:41,973 --> 02:24:43,908
AN TRUANT TO CLOSE CRITICAL

3907
02:24:43,975 --> 02:24:44,942
INFORMATION GAPS AND CREATE A

3908
02:24:45,009 --> 02:24:47,178
TOOL BOX FOR RAPID PHENOTYPES OF

3909
02:24:47,245 --> 02:24:48,546
CANCER DATA TO IMPROVE OUTCOMES.

3910
02:24:48,613 --> 02:24:50,248
AND THE TOOL BOX CAN BE EXPANDED

3911
02:24:50,314 --> 02:24:52,650
TO INCLUDE OTHER INFORMATION FOR

3912
02:24:52,717 --> 02:24:53,918
HEALTH OUTCOMES SUCH AS EXPO

3913
02:24:53,985 --> 02:24:54,852
STUDIES OF MULTIPLE ENDOCRINIC

3914
02:24:54,919 --> 02:24:56,120
MEASURES WHICH IS NEW WORK THAT

3915
02:24:56,187 --> 02:25:01,759
WE ARE ALSO GOING TO HIGHLIGHT.

3916
02:25:01,826 --> 02:25:02,293
NEXT SLIDE.

3917
02:25:02,360 --> 02:25:07,198
ON SO IN THE INNERI SHALL AREAS,

3918
02:25:07,265 --> 02:25:08,366
THAT EXTRACT THE INFORMATION

3919
02:25:08,433 --> 02:25:10,635
FROM THE REPORS AS THIS

3920
02:25:10,701 --> 02:25:13,805
INFORMATION IS CRITICAL FOR

3921
02:25:13,871 --> 02:25:15,006
INDENSE REPORTING.

3922
02:25:15,073 --> 02:25:17,675
SO THE REPORT AT THE ACCURACY

3923
02:25:17,742 --> 02:25:19,277
THRESHOLD REPRESENTING A TIME

3924
02:25:19,343 --> 02:25:20,878
SAVINGS OF 14,000 PERSON HOURS

3925
02:25:20,945 --> 02:25:23,181
PER YEAR.

3926
02:25:23,247 --> 02:25:24,048
THIS PATHOLOGY EXTRACTION API IS

3927
02:25:24,115 --> 02:25:27,585
PART OF THE DEFAULT INSTALLATION

3928
02:25:27,652 --> 02:25:30,455
OF CRDMS AND CURRENTLY USED WITH

3929
02:25:30,521 --> 02:25:32,623
UP TO 19 REGISTRIES AND

3930
02:25:32,690 --> 02:25:34,358
EXPANSION IN THE NEXT FEW YEARS.

3931
02:25:34,425 --> 02:25:36,127
THEY ALSO FOUND RESULTS FROM THE

3932
02:25:36,194 --> 02:25:37,395
APECULIARS I CAN CREATE

3933
02:25:37,462 --> 02:25:38,696
EFFICIENCIES IN WAYS WE DIDN'T

3934
02:25:38,763 --> 02:25:39,130
ANTICIPATE.

3935
02:25:39,197 --> 02:25:41,132
FOR EXAMPLE, THROUGHOUT THE CASE

3936
02:25:41,199 --> 02:25:41,966
AS ASCERTAINMENT FOR RESEARCH

3937
02:25:42,033 --> 02:25:52,510
STUDIES AND TRAIN XG STAFF.

3938
02:25:53,678 --> 02:25:54,345
NEXT SLIDE.

3939
02:25:54,412 --> 02:25:55,746
I THINK HEIDI WILL TAKE IT FROM

3940
02:25:55,813 --> 02:25:56,080
HERE.

3941
02:25:56,147 --> 02:26:00,451
>> I WILL TALK ABOUT HOW WE'RE

3942
02:26:00,518 --> 02:26:03,421
USING AI FECNOLOGYS.

3943
02:26:03,488 --> 02:26:05,289
I MOSAIC PARTNERSHIP HAS BEEN

3944
02:26:05,356 --> 02:26:06,591
SINNER GESTIC BRINGING HIGH

3945
02:26:06,657 --> 02:26:07,959
QUALITY SUBJECT MATTER EXPERT

3946
02:26:08,025 --> 02:26:09,927
ANDS HIGH PERFORMANCE COMPUTING

3947
02:26:09,994 --> 02:26:12,130
EXPERTS AS WELL AS SOFTWARE

3948
02:26:12,196 --> 02:26:13,731
ENGINEERS TO DEVELOP INNOVATIVE

3949
02:26:13,798 --> 02:26:16,868
SOLUTIONS FOR NEAR REALTIME

3950
02:26:16,934 --> 02:26:18,769
DISEASE, SURVEILLANCE IN THE

3951
02:26:18,836 --> 02:26:20,271
CANCER COMMUNITY, OVER THE PAST

3952
02:26:20,338 --> 02:26:22,340
2 YEARS WE HAVE BROADEN OUR

3953
02:26:22,406 --> 02:26:25,243
FOCUS AIMING TO DEVELOP TOOLS

3954
02:26:25,309 --> 02:26:26,177
USED BY THE BROADER ONCOLOGY

3955
02:26:26,244 --> 02:26:27,845
COMMUNITY AND WE HAVE BEEN DO

3956
02:26:27,912 --> 02:26:29,814
THANKSGIVING BY COUPLING

3957
02:26:29,881 --> 02:26:31,649
INNOVATIVE RESEARCH AND THE

3958
02:26:31,716 --> 02:26:40,258
DEVELOPMENT OF MODULAR SOFTWARE

3959
02:26:40,324 --> 02:26:40,491
DESIGN.

3960
02:26:40,558 --> 02:26:42,226
MODULAR DESIGN AND COMPONENTS OR

3961
02:26:42,293 --> 02:26:52,837
MODULES ARE DESIGNED TO BE INTER

3962
02:26:53,471 --> 02:26:54,272
CHANGEABLE, ACCELERATING THE

3963
02:26:54,338 --> 02:26:55,773
DEVELOPMENT AND RESEARCH PROCESS

3964
02:26:55,840 --> 02:26:57,275
LEADING TO FASTER BREAK THROUGHS

3965
02:26:57,341 --> 02:26:58,743
AND QUICKER IMPLEMENTATION OF

3966
02:26:58,809 --> 02:26:59,343
RESEARCH OUTCOMES.

3967
02:26:59,410 --> 02:27:02,880
WHAT I'M GOING TO TALK ABOUT

3968
02:27:02,947 --> 02:27:05,082
NEXT IS OUR MODULAR SOFTWARE

3969
02:27:05,149 --> 02:27:06,751
PACKAGE WHICH IS FRESK CO, WE'VE

3970
02:27:06,817 --> 02:27:09,053
BEEN FOCUSING ON TRANSLATIONAL

3971
02:27:09,120 --> 02:27:10,555
SCIENCE AND HOW WE CAN BRING

3972
02:27:10,621 --> 02:27:12,623
EVERYTHING THAT WE'RE DEVELOPING

3973
02:27:12,690 --> 02:27:13,424
TO THE BROADER ONCOLOGY

3974
02:27:13,491 --> 02:27:14,659
COMMUNITY, SO I'M GOING TO WALK

3975
02:27:14,725 --> 02:27:16,294
YOU THROUGH A FEW EXAMPLES OF

3976
02:27:16,360 --> 02:27:18,663
HOW WE WE'VE DONE THAT WITH OUR

3977
02:27:18,729 --> 02:27:19,397
CURRENT PRODUCTION ALGORITHMS

3978
02:27:19,463 --> 02:27:23,067
WHICH ARE OPERATING IN THE SEER

3979
02:27:23,134 --> 02:27:24,001
REGISTRY AND AFTER THAT I WILL

3980
02:27:24,068 --> 02:27:25,403
WALK YOU THROUGH THE NEW

3981
02:27:25,469 --> 02:27:26,370
SCIENTIFIC DEVELOPMENT THAT

3982
02:27:26,437 --> 02:27:29,106
WE'RE INCORPORATING INTO THE

3983
02:27:29,173 --> 02:27:39,617
MODULAR SOFTWARE DESIGN.

3984
02:27:40,051 --> 02:27:41,185
NEXT SLIDE, PLEASE.

3985
02:27:41,252 --> 02:27:43,854
BARI IS OUR TOOL FOR CLINICAL

3986
02:27:43,921 --> 02:27:45,690
DATA RADIENESS AND WHEN TAKING

3987
02:27:45,756 --> 02:27:47,625
CLINICAL NO NOTES AND GETTING

3988
02:27:47,692 --> 02:27:50,261
THEM READY--SORRY, LET ME PAUSE

3989
02:27:50,328 --> 02:27:52,330
PER A SECOND.

3990
02:27:52,396 --> 02:27:53,197
TAKING AI, TAKING CLINICAL NOTES

3991
02:27:53,264 --> 02:27:55,533
AND GETTING IT READY IS A

3992
02:27:55,600 --> 02:27:56,133
COMPLICATED TASK.

3993
02:27:56,200 --> 02:28:01,372
WE HAVE TO TAKE TEXT INPUT

3994
02:28:01,439 --> 02:28:02,406
THAT'S HETEROGENERATED AOUS,

3995
02:28:02,473 --> 02:28:05,009
FULL OF ERONS AND GET READY FOR

3996
02:28:05,076 --> 02:28:10,047
THE AI ALLEGOR RYTH RHYTHMS

3997
02:28:10,114 --> 02:28:11,515
REQUIRING TOKENNIZED INPUT.

3998
02:28:11,582 --> 02:28:15,419
SO WE HAVE WORKED WITH BARDI,

3999
02:28:15,486 --> 02:28:17,655
USING COMMON DATA PREPROCESSING

4000
02:28:17,722 --> 02:28:21,025
OPERATIONS INTO THE MODULAR

4001
02:28:21,092 --> 02:28:21,459
COMPONENTS.

4002
02:28:21,525 --> 02:28:22,960
BARDI SIMPLIFYS DEVELOPMENT AND

4003
02:28:23,027 --> 02:28:25,196
UPKEEP OF COMPLEX DATA PIPELINES

4004
02:28:25,263 --> 02:28:26,631
MAKING ITENTIOUS FICIENT TO USE

4005
02:28:26,697 --> 02:28:28,432
FOR BOTH UROLOGYST PROJECT AND

4006
02:28:28,499 --> 02:28:31,035
OTHERS AS WELL.

4007
02:28:31,102 --> 02:28:33,104
THE BRITISH COLUMBIA REGISTRY

4008
02:28:33,170 --> 02:28:36,707
HAS UTILIZED THIS PACKAGE FOR

4009
02:28:36,774 --> 02:28:37,308
PREPROCESSING ALL THE DATA

4010
02:28:37,375 --> 02:28:38,242
MENTORSHIP SKILLS PRIOR TO

4011
02:28:38,309 --> 02:28:42,680
FEEDING IT INTO THE DOWN STREAM

4012
02:28:42,747 --> 02:28:43,581
ALGORITHMS FOR USE.

4013
02:28:43,648 --> 02:28:46,117
SO WHAT THIS PACKAGE CAME BACK

4014
02:28:46,183 --> 02:28:48,119
AND A SYSTEMATIC DEVELOPMENT

4015
02:28:48,185 --> 02:28:50,021
PIPELINE FOR GETTING DATA TO BE

4016
02:28:50,087 --> 02:28:51,989
AI READY.

4017
02:28:52,056 --> 02:28:54,625
NEXT SLIDE, PLEASE EMPLOY THE

4018
02:28:54,692 --> 02:28:57,628
FRAMEWORK FOR EXPLORING SCALABLE

4019
02:28:57,695 --> 02:28:59,063
COMPUTATIONAL ONCOLOGY OR

4020
02:28:59,130 --> 02:29:00,131
FRRESCO, IS THE PACKAGE THAT

4021
02:29:00,197 --> 02:29:01,799
TAKES THE DAILY BASIS THEA THAT

4022
02:29:01,866 --> 02:29:05,036
HAS BEEN FOLKENNIZED AND THEN

4023
02:29:05,102 --> 02:29:06,003
CREATES PREDICTION ALGORITHMS

4024
02:29:06,070 --> 02:29:10,741
FOR SEVERAL DIFFERENT TASKS

4025
02:29:10,808 --> 02:29:11,776
INCLUDING REPORTABILITY, SITE,

4026
02:29:11,842 --> 02:29:12,643
SUBSITE, THE END BEHAVIOR, AND I

4027
02:29:12,710 --> 02:29:16,380
WILL TALK ABOUT A FEW OTHER

4028
02:29:16,447 --> 02:29:17,214
TASKS AS WELL.

4029
02:29:17,281 --> 02:29:18,516
OUR PARTNERRINGS AT THE VA WERE

4030
02:29:18,582 --> 02:29:21,152
ABLE TO PICK UP OUR FRSK O

4031
02:29:21,218 --> 02:29:22,586
PACKAGE AND PRETRAIN A MODEL ON

4032
02:29:22,653 --> 02:29:25,256
THEIR DATA WITHIN A COUPLE

4033
02:29:25,323 --> 02:29:25,990
MONTHS TIMELINE AND HAVE SCALED

4034
02:29:26,057 --> 02:29:29,593
THAT UP TO THE ENTIRE VA

4035
02:29:29,660 --> 02:29:29,894
POPULATION.

4036
02:29:29,960 --> 02:29:32,163
AND THEY HAVE FOUND THAT BY

4037
02:29:32,229 --> 02:29:34,165
DOING THIS, IT ALLOWS THEM TO

4038
02:29:34,231 --> 02:29:36,934
HAVE HIGHER ACCURACY AND

4039
02:29:37,001 --> 02:29:37,768
PREDICTING REPORTABLE REPORTS,

4040
02:29:37,835 --> 02:29:41,138
AND THEN TYPICAL MODELS THAT ARE

4041
02:29:41,205 --> 02:29:42,106
AVAILABLE OFF THE SHELF.

4042
02:29:42,173 --> 02:29:45,309
I BELIEVE THEY USED A ROBERTA

4043
02:29:45,376 --> 02:29:46,477
MODEL TO TEST THIS AGAINST,

4044
02:29:46,544 --> 02:29:48,679
THEY'RE ALSO ABLE TO PREDICT

4045
02:29:48,746 --> 02:29:51,349
BREAST CANCER OR DIFFERENT SITES

4046
02:29:51,415 --> 02:29:52,516
RELIABLY AND HIGHER ACCURACY

4047
02:29:52,583 --> 02:29:55,152
THAN OTHER TYPES OF MODELS.

4048
02:29:55,219 --> 02:29:58,589
SO THIS IS EVIDENCE THAT THE

4049
02:29:58,656 --> 02:29:59,824
ALGORITHMS THAT WE'RE DEVELOPING

4050
02:29:59,890 --> 02:30:01,826
ARE NOT ONLY BENEFICIAL TO THE

4051
02:30:01,892 --> 02:30:03,861
SEER REGISTRIES BUT CAN BE USED

4052
02:30:03,928 --> 02:30:04,862
FOR CANCER SURVEILLANCE ACROSS

4053
02:30:04,929 --> 02:30:08,332
THE U.S. AND NEAR REALTIME

4054
02:30:08,399 --> 02:30:10,234
IDENTIFICATION OF CANCER

4055
02:30:10,301 --> 02:30:13,371
PATIENTS.

4056
02:30:13,437 --> 02:30:14,038
NEXT SLIDE, PREEZ.

4057
02:30:14,105 --> 02:30:15,806
NOW I'M GOING TO TALK ABOUT THE

4058
02:30:15,873 --> 02:30:16,507
SCIENTIFIC DEVELOPMENT THAT

4059
02:30:16,574 --> 02:30:18,142
WE'VE BEEN WORKING ON OVER THE

4060
02:30:18,209 --> 02:30:20,511
PAST YEAR TO IMPROVE OUR

4061
02:30:20,578 --> 02:30:23,647
AUTOCODING ACCURACY.

4062
02:30:23,714 --> 02:30:24,648
NEXT SLIDE.

4063
02:30:24,715 --> 02:30:26,150
BETSY MENTIONED WE ARE

4064
02:30:26,217 --> 02:30:27,351
AUTOCODING 27% OF ALL SEER

4065
02:30:27,418 --> 02:30:30,221
RECORDS AND WE HOPE TO INCREASE

4066
02:30:30,287 --> 02:30:31,489
THE AUTOCODING RATE BY 50% BY

4067
02:30:31,555 --> 02:30:34,525
THE END OF THIS CALENDAR YEAR.

4068
02:30:34,592 --> 02:30:36,727
WE ARE DOING THAT BY EXPANDING

4069
02:30:36,794 --> 02:30:38,929
OUR CURRENT MODELS IN A COUPLE

4070
02:30:38,996 --> 02:30:39,997
DIFFERENT WAYS.

4071
02:30:40,064 --> 02:30:44,702
FIRST WE'RE--WE HAVE DEVELOPED

4072
02:30:44,769 --> 02:30:47,037
AND RELEASED A PATH BIG BIRD

4073
02:30:47,104 --> 02:30:48,072
MODEL THAT WAS CHANGE FRIDAY

4074
02:30:48,139 --> 02:30:50,708
SCRATCH USING OUR OWN REPORTS.

4075
02:30:50,775 --> 02:30:52,076
THIS IS IMPORTANT BECAUSE OUR

4076
02:30:52,143 --> 02:30:54,612
PURPOSE OR THE LANGUAGE AND

4077
02:30:54,678 --> 02:30:55,980
PATHOLOGY REPORTS IS DIFFERENT

4078
02:30:56,046 --> 02:30:57,615
THAN THE LANGUAGE GENERALLY USED

4079
02:30:57,681 --> 02:30:59,917
IN SCIENTIFIC REPORTING AND

4080
02:30:59,984 --> 02:31:01,051
THEREFORE HAVING A MODEL TRAINED

4081
02:31:01,118 --> 02:31:03,120
SPECIFIC TO THAT TYPE OF

4082
02:31:03,187 --> 02:31:06,223
LANGUAGE YIELDS TO BETTER

4083
02:31:06,290 --> 02:31:07,258
PREDICTION ACCURACYENTIOUS

4084
02:31:07,324 --> 02:31:10,161
SPECIALLY THE HARDEST PROPREDICT

4085
02:31:10,227 --> 02:31:12,730
SUCH SUCH AS HISTOLOGY, WE SEE A

4086
02:31:12,797 --> 02:31:13,864
4-POINT IMPROVEMENT USING THE

4087
02:31:13,931 --> 02:31:16,167
MODEL OVER OUR CURRENT

4088
02:31:16,233 --> 02:31:16,834
HIERARCHICAL SELF-ATTENTION

4089
02:31:16,901 --> 02:31:19,370
MODEL THAT WE HAVE IN PRODUCTION

4090
02:31:19,437 --> 02:31:20,905
AT THE SEER REGISTRIES.

4091
02:31:20,971 --> 02:31:23,174
WE ARE ALSO DEVELOPING A LEVEL

4092
02:31:23,240 --> 02:31:25,142
ATTENTION MODEL WHICH FOCUSES ON

4093
02:31:25,209 --> 02:31:27,211
THE PHRASES RATHER THAN JUST THE

4094
02:31:27,278 --> 02:31:29,246
SPECIFIC WORDS WHICH IS

4095
02:31:29,313 --> 02:31:31,615
IMPORTANT IN ONCOLOGY

4096
02:31:31,682 --> 02:31:32,049
PREDICTIONS.

4097
02:31:32,116 --> 02:31:35,853
AND WE SEE A BIG IMPROVEMENT

4098
02:31:35,920 --> 02:31:39,356
BETWEEN OUR CURRENT

4099
02:31:39,423 --> 02:31:41,592
IMPLEMENTATION OF THE HISSAN

4100
02:31:41,659 --> 02:31:43,794
LEVEL AND THE ALSO THE ACCURACY

4101
02:31:43,861 --> 02:31:45,095
IN THE OTHER MODELS.

4102
02:31:45,162 --> 02:31:46,730
IN ADDITION, WE ARE DEVELOPING

4103
02:31:46,797 --> 02:31:48,132
NEW MODELS THAT INCLUDE MIXTURE

4104
02:31:48,199 --> 02:31:50,000
OF EXPERT WHICH IS ALLOWS US TO

4105
02:31:50,067 --> 02:31:51,535
DEVELOP MULTIPLE DIFFERENT TYPES

4106
02:31:51,602 --> 02:31:54,305
OF MODELS TO IMPROVE THE

4107
02:31:54,371 --> 02:31:59,376
PREDICTIONS, HIERARCHICAL MODELS

4108
02:31:59,443 --> 02:32:01,545
AND HETEROGENIUS ENSEMBLING

4109
02:32:01,612 --> 02:32:02,713
MODELS.

4110
02:32:02,780 --> 02:32:04,815
THE TAKE AWAY FROM THIS SLIDE,

4111
02:32:04,882 --> 02:32:07,251
IS THAT WE HAVE SEVERAL DEVELOPS

4112
02:32:07,318 --> 02:32:08,419
THAT WILL LEAD US TO BELIEVE WE

4113
02:32:08,486 --> 02:32:10,955
WILL GET TO THIS 50% AUTOCODING

4114
02:32:11,021 --> 02:32:15,593
RATE IN THE NEAR FUTURE.

4115
02:32:15,659 --> 02:32:16,760
NEXT SLIDE.

4116
02:32:16,827 --> 02:32:19,530
NSO IDENTIFICATION OF PATHOLOGY

4117
02:32:19,597 --> 02:32:20,798
REPORTS RELATE TO CANCER IS THE

4118
02:32:20,865 --> 02:32:23,234
OTHER CRITICAL KEY TO ACHIEVING

4119
02:32:23,300 --> 02:32:24,068
REALTIME INSTANCE REPORTING

4120
02:32:24,134 --> 02:32:25,469
SINCE CANCER REG TREES ARE

4121
02:32:25,536 --> 02:32:26,670
AUTHORIZED TO HOLD THE

4122
02:32:26,737 --> 02:32:27,938
INFORMATION ON CANCER CASES AND

4123
02:32:28,005 --> 02:32:29,707
MOSAIC IS HOPING TO ACHIEVE

4124
02:32:29,773 --> 02:32:31,308
THIS, THE QUEPMENT OF

4125
02:32:31,375 --> 02:32:32,076
REPORTABILITY API.

4126
02:32:32,142 --> 02:32:33,511
CURRENTLY A MIX OF METHODS ARE

4127
02:32:33,577 --> 02:32:36,480
USED TO FILTER CANCER RELATED

4128
02:32:36,547 --> 02:32:38,282
REPORTS FROM FACILITIES BEFORE

4129
02:32:38,349 --> 02:32:39,650
THEY'RE REPORTED AND THESE ARE

4130
02:32:39,717 --> 02:32:41,719
LED TO A LARGE NUMBER OF

4131
02:32:41,785 --> 02:32:43,153
FALSE-POSITIVES THAT MUST BE

4132
02:32:43,220 --> 02:32:44,421
MANUELLY REVIEWED BY THE

4133
02:32:44,488 --> 02:32:46,657
REGISTRIES TO CONFIRM A

4134
02:32:46,724 --> 02:32:47,691
REPORTABLE CASE.

4135
02:32:47,758 --> 02:32:48,526
IMPROVING TO AUTOMATICALLY

4136
02:32:48,592 --> 02:32:50,594
SCREEN FOR CANCER RELATED PORTS

4137
02:32:50,661 --> 02:32:52,563
IS EXCEPTIONAL FOR OUR GOAL OF

4138
02:32:52,630 --> 02:32:54,565
RAPID CASE ASCERTAIN AM AS WELL

4139
02:32:54,632 --> 02:32:56,534
AS ACHIEVING REALTIME INCIDENCE

4140
02:32:56,600 --> 02:32:56,834
REPORTING.

4141
02:32:56,901 --> 02:32:58,702
SO CURRENTLY ON THE PROCESS OF

4142
02:32:58,769 --> 02:32:59,470
VALIDATING THE   PERFOR THE

4143
02:32:59,537 --> 02:33:01,472
PURPOSANCE OF THIS API ACROSS

4144
02:33:01,539 --> 02:33:03,240
THE BOUGHTER BROADER SET OF

4145
02:33:03,307 --> 02:33:04,508
REGISTRIES BUT HEIDI WILL

4146
02:33:04,575 --> 02:33:05,376
PRESENT RESULTS FROM THE

4147
02:33:05,442 --> 02:33:06,544
NATIONAL WORK THAT WE'VE DONE

4148
02:33:06,610 --> 02:33:08,979
WITH THE SEATTLE REGISTRY.

4149
02:33:09,046 --> 02:33:09,446
NEXT SLIDE.

4150
02:33:09,513 --> 02:33:10,381
>> AS I MENTIONED BEFORE, PART

4151
02:33:10,447 --> 02:33:13,017
OF WHAT WE DEVELOPED IS THIS

4152
02:33:13,083 --> 02:33:14,752
ABILITY TO RAPIDLY DEVELOP

4153
02:33:14,818 --> 02:33:16,787
MODELS AND THIS IS DONE BECAUSE

4154
02:33:16,854 --> 02:33:18,155
OF OUR FRESK O FRAMEWORK.

4155
02:33:18,222 --> 02:33:20,758
SO IN THE CASE OF NEAR REALTIME

4156
02:33:20,824 --> 02:33:22,126
CANCER CASE IDENT IIVES, WITHIN

4157
02:33:22,192 --> 02:33:23,894
A MATTER OF MONTHS WE WILL BE

4158
02:33:23,961 --> 02:33:27,932
ABLE TO DEVELOP A MODEL USING

4159
02:33:27,998 --> 02:33:29,767
SEATTLE REPORTS, PATHOLOGY

4160
02:33:29,833 --> 02:33:34,204
REPORTS FROM OVER 4000 OR SORRY

4161
02:33:34,271 --> 02:33:35,339
NEARLY 4 MILLION CANCER

4162
02:33:35,406 --> 02:33:36,941
PATHOLOGY RESPORTS AND THIS

4163
02:33:37,007 --> 02:33:38,342
ALGORITHM WAS ABLE TO HAVE HIGH

4164
02:33:38,409 --> 02:33:40,945
ACRASE MODEL EXPE PREDICTING

4165
02:33:41,011 --> 02:33:41,779
IDENTIFYING REPORTABLE OR

4166
02:33:41,845 --> 02:33:44,915
NONREPORTABLE REPORTS AND WE

4167
02:33:44,982 --> 02:33:49,687
TESTED THIS MODEL FOR BY

4168
02:33:49,753 --> 02:33:51,121
ASSISTANCES, BIASES ACROSS

4169
02:33:51,188 --> 02:33:51,755
SOCIOLOGICAL DEMOGRAPHIC MODELS

4170
02:33:51,822 --> 02:33:53,090
AS WELL AND BECAUSE OF THE

4171
02:33:53,157 --> 02:33:54,191
MODULAR DESIGN WE WERE ABLE TO

4172
02:33:54,258 --> 02:33:55,926
DO THIS ALL RAPIDLY WITHIN A

4173
02:33:55,993 --> 02:33:57,127
COUPLE MONTH PERIOD OF TIME.

4174
02:33:57,194 --> 02:33:58,896
WHEN WE'RE THINKING ABOUT NEAR

4175
02:33:58,963 --> 02:34:01,031
REALTIME SURVEILLANCE, THIS

4176
02:34:01,098 --> 02:34:04,501
RAPID RESPONSE IS HIGHLY

4177
02:34:04,568 --> 02:34:05,669
NECESSARY AND SOMETHING WE HAVE

4178
02:34:05,736 --> 02:34:06,870
BEEN ABLE DO BECAUSE OF THE

4179
02:34:06,937 --> 02:34:11,308
MODELS THAT WE HAVE DESIGNED.

4180
02:34:11,375 --> 02:34:12,009
NEXT SLIDE, PLEASE.

4181
02:34:12,076 --> 02:34:22,586
IN ARK DITION TO NEAR REALTIME

4182
02:34:26,957 --> 02:34:27,558
REPORTABILITY--WHICH MAKE ITS

4183
02:34:27,625 --> 02:34:30,294
VERY DIFFICULT TO ASSESS RISK

4184
02:34:30,361 --> 02:34:31,362
AND FOLLOW PATIENTS

4185
02:34:31,428 --> 02:34:31,729
LONGITUDINALLY.

4186
02:34:31,795 --> 02:34:32,529
THE SOLUTION THAT WE HAVE COME

4187
02:34:32,596 --> 02:34:34,999
UP WITH IN THE MOSAIC PROJECT IS

4188
02:34:35,065 --> 02:34:37,001
TO DEVELOP AN ALGORITHM THAT

4189
02:34:37,067 --> 02:34:38,636
CLASSIFIES PATHOLOGY REPORTS FOR

4190
02:34:38,702 --> 02:34:39,937
BOTH RECURNESS IN METASTASIS, IN

4191
02:34:40,004 --> 02:34:42,806
ORDER TO DO THIS, WE NEEDED HIGH

4192
02:34:42,873 --> 02:34:45,042
QUALITY DATA THAT HAD BEENAN

4193
02:34:45,109 --> 02:34:47,578
OITATED BY EXPERTS, BECAUSE OF

4194
02:34:47,645 --> 02:34:49,279
OUR PARTNERSHIP WITH SEER, WE

4195
02:34:49,346 --> 02:34:51,315
WERE ABLE TO COLLECT INFORMATION

4196
02:34:51,382 --> 02:34:52,683
ON OVER 67,000 REPORTS ALLOWING

4197
02:34:52,750 --> 02:34:55,052
US TO TRAIN HIGHLY ACCURATE

4198
02:34:55,119 --> 02:34:57,454
MODEL FOR BOTH RECURRENCE AND

4199
02:34:57,521 --> 02:34:59,023
METASTASIS, AND WE ARE CURRENTLY

4200
02:34:59,089 --> 02:35:00,524
TESTING THAT MODEL FOR

4201
02:35:00,591 --> 02:35:02,493
DEPLOYMENT AT THE SEER

4202
02:35:02,559 --> 02:35:02,893
REGISTRIES.

4203
02:35:02,960 --> 02:35:04,695
WE CAN SEE HERE THAT FOR

4204
02:35:04,762 --> 02:35:05,963
METASTASIS, WE'RE ABLE TO

4205
02:35:06,030 --> 02:35:10,834
PREDICT WHETHER OR NOT A REPORT

4206
02:35:10,901 --> 02:35:12,569
INDICATES METASTASIS AT .9

4207
02:35:12,636 --> 02:35:13,303
ACCURACY LEVEL OF .9.

4208
02:35:13,370 --> 02:35:14,905
MAKING IT SOMETHING THAT WOULD

4209
02:35:14,972 --> 02:35:17,574
BE VERY USEFUL IN POPULATION

4210
02:35:17,641 --> 02:35:19,276
SURVEILLANCE OF RECURRENCE IN

4211
02:35:19,343 --> 02:35:24,615
METASTATIC DISEASE.

4212
02:35:24,682 --> 02:35:25,449
NEXT SLIDE, PLEASE.

4213
02:35:25,516 --> 02:35:27,384
NWE HAVE ALSO BEEN DEVELOPING

4214
02:35:27,451 --> 02:35:30,220
REAL WORLD PRIVACY PRESENTED

4215
02:35:30,287 --> 02:35:33,257
FEDERATED LEARNING DEVELOPMENTS.

4216
02:35:33,323 --> 02:35:33,824
NEXT SLIDE.

4217
02:35:33,891 --> 02:35:36,393
SO A HOT TOPIC RIGHT NOW IS

4218
02:35:36,460 --> 02:35:37,227
FEDERATED LEARNING, EVERYBODY'S

4219
02:35:37,294 --> 02:35:39,396
VERY EXCITED ABOUT IT AND FOR

4220
02:35:39,463 --> 02:35:42,099
IMD REASON, IT'S A SOLUTION TO

4221
02:35:42,166 --> 02:35:44,635
THE ISSUE WITH DATA STYLING THAT

4222
02:35:44,702 --> 02:35:45,903
EXISTS WITHIN HEALTHCARE

4223
02:35:45,969 --> 02:35:46,303
RESEARCH.

4224
02:35:46,370 --> 02:35:48,405
SILOS MAKE IT NEARLY IMPOSSIBLE

4225
02:35:48,472 --> 02:35:50,174
TO DEVELOP MODELS THAT ARE

4226
02:35:50,240 --> 02:35:52,342
REPRESENTATIVE OF AN INTIRE

4227
02:35:52,409 --> 02:35:56,146
POPULATION AND CAN BE IMPORTED

4228
02:35:56,213 --> 02:35:57,214
ACROSS DIFFERENT LOCATIONS,

4229
02:35:57,281 --> 02:35:58,415
FEDERATED OFFERS A SOLUTION TO

4230
02:35:58,482 --> 02:35:59,717
THAT, HOWEVER, WHAT IS LESS

4231
02:35:59,783 --> 02:36:02,419
TALKED ABOUT IN THIS SPACE, ARE

4232
02:36:02,486 --> 02:36:04,455
THE BIG SCIENTIFIC CHALLENGES

4233
02:36:04,521 --> 02:36:06,657
THAT STILL EXIST WITH CROSS SILO

4234
02:36:06,724 --> 02:36:09,226
FEDERATED LEARNING, 1 OF THOSE

4235
02:36:09,293 --> 02:36:11,995
BIGGEST CHALLENGES, BEING THE

4236
02:36:12,062 --> 02:36:13,030
PRIVACY ACCURACY TRADE-OFF.

4237
02:36:13,097 --> 02:36:13,964
BASICALLY, YOU CAN DEVELOP A

4238
02:36:14,031 --> 02:36:15,966
MODEL THAT IS HIGHLY ACCURATE,

4239
02:36:16,033 --> 02:36:18,602
IN ORDER TO DO THAT, YOU NEED TO

4240
02:36:18,669 --> 02:36:22,673
BE MUCH MORE LENIENTOT PRIVACY

4241
02:36:22,740 --> 02:36:25,008
SIDE OF THINGS AND SO THOSE

4242
02:36:25,075 --> 02:36:26,176
HIGHLY ACCURATE MODELS,

4243
02:36:26,243 --> 02:36:27,578
TYPICALLY DON'T HAVE THE LEVEL

4244
02:36:27,644 --> 02:36:30,013
OF PRIVACY THAT WE NEED IN

4245
02:36:30,080 --> 02:36:30,848
HEALTH SPACE, ALTERNATIVELY, YOU

4246
02:36:30,914 --> 02:36:33,250
CAN DEVELOP A MODEL THAT IS

4247
02:36:33,317 --> 02:36:36,353
HIGHLY PRIVATE, BUT YOU'RE GOING

4248
02:36:36,420 --> 02:36:37,888
TO SACRIFICE ACCURACY BY DOING

4249
02:36:37,955 --> 02:36:38,589
SO, BASICALLY BECAUSE WHAT

4250
02:36:38,655 --> 02:36:40,224
YOU'RE HAVING TO DO IS INJECT

4251
02:36:40,290 --> 02:36:42,526
NOISE INTO THE MODEL, AND YOU

4252
02:36:42,593 --> 02:36:44,628
ARE MAKING IT MORE DIFFICULT TO

4253
02:36:44,695 --> 02:36:46,130
PREDICT WITH HIGH ACCURACY.

4254
02:36:46,196 --> 02:36:47,197
THIS BECOMES EVEN MORE

4255
02:36:47,264 --> 02:36:48,499
PROBLEMATIC IN THE HEALTHCARE

4256
02:36:48,565 --> 02:36:52,236
SPACE BECAUSE WE HAVE VERY

4257
02:36:52,302 --> 02:36:53,170
HETEROGENIUS DATA.

4258
02:36:53,237 --> 02:36:56,907
WE UPDATE THAD JUST BY NATURE

4259
02:36:56,974 --> 02:36:58,509
VARIOUSYS BETWEEN DIFFERENT

4260
02:36:58,575 --> 02:36:59,610
SPACES, IT'S AKIN TO BATCH

4261
02:36:59,676 --> 02:37:00,778
EFFECTS IN THE GENETICS WORLD

4262
02:37:00,844 --> 02:37:01,979
WHERE WE HAVE A LOT OF

4263
02:37:02,045 --> 02:37:03,514
DIFFERENCES WE COULD PICK UP

4264
02:37:03,580 --> 02:37:04,782
THAT WOULD BE PURELY FOR THE

4265
02:37:04,848 --> 02:37:06,383
FACT THAT DAT APPROVAL FROM SBA

4266
02:37:06,450 --> 02:37:07,885
COLLECT INDEED UTAH AS OPPOSE TO

4267
02:37:07,951 --> 02:37:09,186
KENTUCKY AND HAVE NOTHING TO DO

4268
02:37:09,253 --> 02:37:11,188
WITH THE DIAGNOSE ITSELF.

4269
02:37:11,255 --> 02:37:12,923
SO, THESE--WE HAVE BEEN WORKING

4270
02:37:12,990 --> 02:37:14,424
ON OVERCOMING OR DEVELOPING NEW

4271
02:37:14,491 --> 02:37:16,059
METHODS TO OVERCOME THESE

4272
02:37:16,126 --> 02:37:18,328
CHALLENGES, AND I BELIEVE THAT

4273
02:37:18,395 --> 02:37:19,730
THERE'S A HUGE POTENTIAL FOR

4274
02:37:19,797 --> 02:37:21,398
THOSE MODELS IN THE FUTURE, BUT

4275
02:37:21,465 --> 02:37:24,735
THERE'S STILL A LOT OF THINGS TO

4276
02:37:24,802 --> 02:37:26,670
DO, THE 1 OPPORTUNITY THAT WE

4277
02:37:26,737 --> 02:37:28,405
HAVE IS UTILIZATION OF THE SEER

4278
02:37:28,472 --> 02:37:29,072
DATA.

4279
02:37:29,139 --> 02:37:31,275
BECAUSE WE CAN TEST WHAT THESE

4280
02:37:31,341 --> 02:37:33,577
MODELS DO, IN REAL DATA, WE'RE

4281
02:37:33,644 --> 02:37:35,879
ABLE TO COME UP WITH REAL WORLD

4282
02:37:35,946 --> 02:37:37,681
SOLUTIONS AND SOMETHING THAT IS

4283
02:37:37,748 --> 02:37:39,449
TRULY TRANSLATIONAL.

4284
02:37:39,516 --> 02:37:40,517
IN ORDER--IN ADDITION TO THE

4285
02:37:40,584 --> 02:37:43,053
WORK WE'VE BEEN CURRENTLY DOING,

4286
02:37:43,120 --> 02:37:46,924
WE ARE ALSO HOLING A PRIVACY

4287
02:37:46,990 --> 02:37:47,858
PRESERVING HACKATHON THAT WILL

4288
02:37:47,925 --> 02:37:50,460
BE HELD IN JUNE OF 2024, THIS

4289
02:37:50,527 --> 02:37:52,062
HACKATHON WILL BE FOCUSED ON

4290
02:37:52,129 --> 02:37:54,464
IDENTIFYING SPACES WHERE WE

4291
02:37:54,531 --> 02:37:58,569
REALLY MAY BE OPEN TO

4292
02:37:58,635 --> 02:37:59,169
IDENTIFYING, REIDENTIFYING

4293
02:37:59,236 --> 02:38:01,371
INFORMATION AS WE'RE SHARING

4294
02:38:01,438 --> 02:38:02,206
GRADIENTS BETWEEN THE MODEL ANDS

4295
02:38:02,272 --> 02:38:04,007
THIS IS SOMETHING THAT'S REALLY

4296
02:38:04,074 --> 02:38:04,675
EXCITING.

4297
02:38:04,741 --> 02:38:06,777
SOMING THAT HASN'T BEEN

4298
02:38:06,844 --> 02:38:08,946
QUANTIFIED REALLY WELL, IN THE

4299
02:38:09,012 --> 02:38:10,347
NLP COMMUNITY OR IN THE

4300
02:38:10,414 --> 02:38:11,415
MULTIMODAL COMMUNITY AND WE'RE

4301
02:38:11,481 --> 02:38:12,583
LOOKING FORWARD TO THIS

4302
02:38:12,649 --> 02:38:15,652
SCIENTIFIC DISCOVERIES THAT WE

4303
02:38:15,719 --> 02:38:17,054
WILL HAVE DURING THAT HACKATHON

4304
02:38:17,120 --> 02:38:23,594
IN THE YEARS TO COME.

4305
02:38:23,660 --> 02:38:24,962
NEXT SLIDE, PLEASE.

4306
02:38:25,028 --> 02:38:26,263
AS BETSY MENTIONED WE ARE

4307
02:38:26,330 --> 02:38:28,799
CURRENTLY WORKING ON A PROJECT

4308
02:38:28,866 --> 02:38:32,236
WHERE WE ARE LINKING THE

4309
02:38:32,302 --> 02:38:32,736
EXTERNAL EXPOETICSOME.

4310
02:38:32,803 --> 02:38:33,403
NEXT SLIDE, PLEASE.

4311
02:38:33,470 --> 02:38:38,375
WE HAVE THE  BENEFIT OF UTILIZIG

4312
02:38:38,442 --> 02:38:41,111
THE SEER DATA WHICH GIVES US AN

4313
02:38:41,178 --> 02:38:42,279
OPPORTUNITY THAT HAS NOT BEEN

4314
02:38:42,346 --> 02:38:43,213
AVAILABLE TO ANYBODY IN THE

4315
02:38:43,280 --> 02:38:45,449
CANCER COMMUNITY UP TO DATE.

4316
02:38:45,515 --> 02:38:46,617
ESSENTIALLY WHAT WE'RE ABLE TO

4317
02:38:46,683 --> 02:38:49,920
DO IS TAKE THE SEER LINKAGES,

4318
02:38:49,987 --> 02:38:54,191
THAT HAVE BEEN   PERFORMED

4319
02:38:54,258 --> 02:38:56,927
BETWEEN SEER INCIDENCE CASES AND

4320
02:38:56,994 --> 02:38:57,861
LEXUS NEXUS RESIDENTIAL HISTORY

4321
02:38:57,928 --> 02:39:01,398
DATA FOR ALL DIAGNOSIS FROM 2005

4322
02:39:01,465 --> 02:39:01,665
FORWARD.

4323
02:39:01,732 --> 02:39:03,500
WHAT THAT ALLOWS US TO DO IS FOR

4324
02:39:03,567 --> 02:39:04,902
EVERY DIAGNOSE IN THAT SEER REG

4325
02:39:04,968 --> 02:39:07,204
STRO THAT HAPPENS AFTER 2005, WE

4326
02:39:07,271 --> 02:39:10,540
ARE ABLE TO PULL THEIR

4327
02:39:10,607 --> 02:39:11,541
RESIDENTIAL HISTORY FROM 1995 TO

4328
02:39:11,608 --> 02:39:12,309
THE PRESENT.

4329
02:39:12,376 --> 02:39:14,344
THIS ALLOWS US TO TAKE AN

4330
02:39:14,411 --> 02:39:15,646
INDEPTH LOOK INTO EXPOSURES THAT

4331
02:39:15,712 --> 02:39:17,347
A PATIENT HAS EXPERIENCED PRIOR

4332
02:39:17,414 --> 02:39:19,650
TO THEIR TIME OF DIAGNOSIS, BUT

4333
02:39:19,716 --> 02:39:21,051
ALSO DURING THE TIME OF

4334
02:39:21,118 --> 02:39:22,552
TREATMENT AND IN THEIR

4335
02:39:22,619 --> 02:39:24,488
SURVIVORSHIP YEARS AS WELL.

4336
02:39:24,554 --> 02:39:25,689
THIS IS EXTREMELY IMPORTANT IF

4337
02:39:25,756 --> 02:39:28,225
WE'RE THINKING ABOUT THINGS LIKE

4338
02:39:28,292 --> 02:39:29,159
INDOOR RADON EXPOSURE, WHICH

4339
02:39:29,226 --> 02:39:31,428
COULD HAVE A LATENCY PERIOD OF

4340
02:39:31,495 --> 02:39:33,964
UP TO 30 YEARS.

4341
02:39:34,031 --> 02:39:36,066
UNDER THAT SCENARIO, LINKING

4342
02:39:36,133 --> 02:39:38,335
INDOOR RADON EXPOSURE AT TIME OF

4343
02:39:38,402 --> 02:39:39,403
DIAGNOSIS JUST ISN'T GOOD ENOUGH

4344
02:39:39,469 --> 02:39:42,339
IF WE TRULY WANT TO UNDERSTAND

4345
02:39:42,406 --> 02:39:43,807
THE ASSOCIATION BETWEEN RADON

4346
02:39:43,874 --> 02:39:44,574
EXPOSURE AND OUTCOME.

4347
02:39:44,641 --> 02:39:47,244
AND THIS IS TRUE FOR MANY

4348
02:39:47,311 --> 02:39:48,612
DIFFERENT EXPOSURE TYPES

4349
02:39:48,679 --> 02:39:51,114
INCLUDING AIR POLLUTION

4350
02:39:51,181 --> 02:39:53,317
EXPOSURE, SMOKE, WILDFIRE SMOKE,

4351
02:39:53,383 --> 02:39:55,819
WATER DATA, TOXIC RELEASES,

4352
02:39:55,886 --> 02:39:57,020
BUILT ENVIRONMENT, SOCIAL

4353
02:39:57,087 --> 02:39:57,554
DETERMINANTS OF HEALTH.

4354
02:39:57,621 --> 02:40:00,223
SO WHAT WE HAVE BEEN DOING OVER

4355
02:40:00,290 --> 02:40:03,894
THE PAST YEAR, AND WILL CONTINUE

4356
02:40:03,961 --> 02:40:05,796
TO EXPAND OVER THE NEXT YEAR IS

4357
02:40:05,862 --> 02:40:08,598
WE HAVE BEEN COMBINING

4358
02:40:08,665 --> 02:40:09,566
INFORMATION ACROSS MANY DEFINITE

4359
02:40:09,633 --> 02:40:10,600
SOCIAL AND ENVIRONMENTAL

4360
02:40:10,667 --> 02:40:10,867
MEASURES.

4361
02:40:10,934 --> 02:40:14,304
WE HAVE BEEN CREATING A DATABASE

4362
02:40:14,371 --> 02:40:16,039
THAT SPATIALLY LINKS ALL THIS

4363
02:40:16,106 --> 02:40:17,808
INFORMATION AND CAN BE UTILIZED

4364
02:40:17,874 --> 02:40:19,676
TO ASSIGN AN EXPOSURE PROFILE TO

4365
02:40:19,743 --> 02:40:21,812
A CANCER PATIENT OVER SPACE AND

4366
02:40:21,878 --> 02:40:22,012
TIME.

4367
02:40:22,079 --> 02:40:24,948
THIS IS A BROADER EFFORT THAT

4368
02:40:25,015 --> 02:40:26,850
INCLUDES PARTNERS FROM THE VA,

4369
02:40:26,917 --> 02:40:29,720
AND ALSO FUNDING FROM OUR OSCAR

4370
02:40:29,786 --> 02:40:38,128
BIOPREPAREDNESS GRANT AS WELL.

4371
02:40:38,195 --> 02:40:38,762
NEXT SLIDE, PLEASE.

4372
02:40:38,829 --> 02:40:39,896
SO TO BRING ALL THIS BACK TO

4373
02:40:39,963 --> 02:40:42,199
TELL YOU WHAT THE SEEMINGLY

4374
02:40:42,265 --> 02:40:46,136
THRUST DISLIKE WHEN THEY COME

4375
02:40:46,203 --> 02:40:47,337
TOGETHER, I WILL WALK YOU 32

4376
02:40:47,404 --> 02:40:48,638
WHAT WE'RE DOING, WHAT WE ARE

4377
02:40:48,705 --> 02:40:50,774
TRYING TO DO IS DEVELOP REAL

4378
02:40:50,841 --> 02:40:53,744
WORLD AI SOLUTIONS FOR

4379
02:40:53,810 --> 02:40:54,611
POPULATION SURVEILLANCE AND

4380
02:40:54,678 --> 02:40:55,545
THESE SOLUTIONS WILL ALLOW FOLKS

4381
02:40:55,612 --> 02:40:58,882
TO USE IT EITHER IN A SILOED

4382
02:40:58,949 --> 02:41:00,283
WORLD OR IN A [INDISCERNIBLE]

4383
02:41:00,350 --> 02:41:03,053
WORLD TO BE ABLE TO SPEED UP OUR

4384
02:41:03,120 --> 02:41:06,123
TIME FROM DEC OCCURRENCE TO

4385
02:41:06,189 --> 02:41:07,157
POPULATION LEVEL DEC STATISTICS

4386
02:41:07,224 --> 02:41:09,092
AND THIS IS NOT ONLY IMPORTANT

4387
02:41:09,159 --> 02:41:11,928
FOR POPULATION HEALTH

4388
02:41:11,995 --> 02:41:13,663
SURVEILLANCE, BUT IT ALSO YIELDS

4389
02:41:13,730 --> 02:41:15,832
REAL WORLD SOLUTIONS FOR

4390
02:41:15,899 --> 02:41:17,200
PRECISION HEALTH AS WELL BECAUSE

4391
02:41:17,267 --> 02:41:21,405
I'M ABLE TO LINK INDIVIDUAL RISK

4392
02:41:21,471 --> 02:41:22,439
FACTORS TO INDIVIDUALS AND THEN

4393
02:41:22,506 --> 02:41:25,842
LOOK AT HOW THAT AFFECTS

4394
02:41:25,909 --> 02:41:26,576
PROGNOSIS, PATIENT'S

4395
02:41:26,643 --> 02:41:31,114
TRANSLATIONAL R

4396
02:41:31,181 --> 02:41:32,215
ESEARCH--TRAJECTORIES AND

4397
02:41:32,282 --> 02:41:33,884
UTILIZE THOSE PORPOPPULATION

4398
02:41:33,950 --> 02:41:35,152
HEALTH SURVEILLANCE AS WELL, ALL

4399
02:41:35,218 --> 02:41:36,520
OUR SOLUTIONS ARE AVAILABLE,

4400
02:41:36,586 --> 02:41:38,855
THEY ARE AVAILABLE FROM GIT-HUB,

4401
02:41:38,922 --> 02:41:40,824
REPOE AND THE LINK IS RIGHT

4402
02:41:40,891 --> 02:41:42,359
THERE AND WE--AS WE CONTINUE TO

4403
02:41:42,426 --> 02:41:43,727
DEVELOP, WE WILL CONTINUE TO

4404
02:41:43,794 --> 02:41:47,864
BRING IN OTHER PARTNERS AS WE GO

4405
02:41:47,931 --> 02:41:48,131
FORWARD.

4406
02:41:48,198 --> 02:41:50,367
BETSY DO HAVE YOU ANYTHING TO

4407
02:41:50,434 --> 02:41:50,534
ADD?

4408
02:41:50,600 --> 02:41:50,934
>> NO, THANKS.

4409
02:41:51,001 --> 02:41:56,673
I THINK WE CAN TAKE QUESTIONS.

4410
02:41:56,740 --> 02:41:58,275
NOKAY, QUESTIONS.

4411
02:41:58,341 --> 02:42:00,243
GREAT PRESENTATION, THANK YOU

4412
02:42:00,310 --> 02:42:03,680
VERY MUCH.

4413
02:42:03,747 --> 02:42:04,881
YES, ANANT.

4414
02:42:04,948 --> 02:42:05,549
>> FABULOUS PRESENTATION, WHAT

4415
02:42:05,615 --> 02:42:07,918
ARE THE PLANS TO TRY TO

4416
02:42:07,984 --> 02:42:08,752
INCORNERATE ADDITIONAL KINDS OF

4417
02:42:08,819 --> 02:42:11,288
DATA SUCH AS IMAGING OR

4418
02:42:11,354 --> 02:42:12,622
ADDITIONAL PATHOLOGY AS PART OF

4419
02:42:12,689 --> 02:42:15,725
THE SEER DATABASE?

4420
02:42:15,792 --> 02:42:17,227
>> SURE I DON'T KNOW IF ANYONE

4421
02:42:17,294 --> 02:42:18,628
WANTS TO ADD ANYTHING BUT SEER

4422
02:42:18,695 --> 02:42:19,830
HAS BEEN WORKING OVER THE PAST,

4423
02:42:19,896 --> 02:42:21,498
I DON'T KNOW HOW MANY YEARS NOW,

4424
02:42:21,565 --> 02:42:24,267
IT'S BEEN TO BRING IN ADDITIONAL

4425
02:42:24,334 --> 02:42:26,136
IMAGES THROUGH PARTNERSHIP WITH

4426
02:42:26,203 --> 02:42:28,105
OUTSIDE DATA VENDORS SO FOR

4427
02:42:28,171 --> 02:42:31,541
EXAMPLE, WE HAVE AGREEMENTS WITH

4428
02:42:31,608 --> 02:42:33,210
CVS AND WALGREEN'S TO BRING IN

4429
02:42:33,276 --> 02:42:34,678
PHARMACY DATA, WE'VE BEEN

4430
02:42:34,744 --> 02:42:38,081
WORKING ON A WHOLE SITE IMAGES

4431
02:42:38,148 --> 02:42:40,350
PROJECT TO BRING IN DIGITAL

4432
02:42:40,417 --> 02:42:41,651
PATHOLOGY IMAGES WHERE WE HAVE

4433
02:42:41,718 --> 02:42:44,387
PARTNERSHIPS TO BRING IN CLAIMS

4434
02:42:44,454 --> 02:42:45,822
INFORMATION FOR EXAMPLE, FROM

4435
02:42:45,889 --> 02:42:46,656
HEALTHCARE AND UNLIMITED SYSTEM,

4436
02:42:46,723 --> 02:42:50,760
SO I THINK, YOU KNOW AS SEER

4437
02:42:50,827 --> 02:42:51,828
EXPANDS, THE KIND OF INFORMATION

4438
02:42:51,895 --> 02:42:53,730
WE HAVE AND PROVIDES ADDITIONAL

4439
02:42:53,797 --> 02:42:55,465
DATA THAT CAN BE USED FOR SOME

4440
02:42:55,532 --> 02:42:59,035
OF THE MODELS THAT WE'RE ALSO

4441
02:42:59,102 --> 02:42:59,970
DOING WITHIN MOSAIC.

4442
02:43:00,036 --> 02:43:02,906
>> YEAH, YEAH, I WOULD JUST LIKE

4443
02:43:02,973 --> 02:43:04,774
TO EXPAND, SO OUTSIDE OF JUST

4444
02:43:04,841 --> 02:43:09,846
THE DAT SETS FROM SEER, FROM A

4445
02:43:09,913 --> 02:43:11,114
MOSAIC PERSPECTIVE, WE REALLY

4446
02:43:11,181 --> 02:43:12,215
ARE DESIGNING EVERYTHING SO IT

4447
02:43:12,282 --> 02:43:13,483
CAN BE USED JUST OUTSIDE OF THE

4448
02:43:13,550 --> 02:43:13,984
SEER DATA.

4449
02:43:14,050 --> 02:43:15,752
SO THE FRESK O FRAMEWORK IS USED

4450
02:43:15,819 --> 02:43:17,420
AS A FOUNDATION FOR WORK THAT

4451
02:43:17,487 --> 02:43:19,189
WE'RE DOING FOR BIOSURVEILLANCE,

4452
02:43:19,256 --> 02:43:21,024
AGAIN, BECAUSE THESE MODELS CAN

4453
02:43:21,091 --> 02:43:24,094
BE USED ACROSS DIFFERENT

4454
02:43:24,161 --> 02:43:25,729
MODALITIES, OR NOT JUST

4455
02:43:25,795 --> 02:43:27,397
PATHOLOGY REPORTS ALONE BUT

4456
02:43:27,464 --> 02:43:29,099
CLINICAL NOTES, TOO, AND THEN

4457
02:43:29,166 --> 02:43:31,735
WE'RE ALSO WITHIN THE RECURRENCE

4458
02:43:31,801 --> 02:43:34,137
WORK, WE ARE ALSO DEVELOPING

4459
02:43:34,204 --> 02:43:36,273
MULTIMODAL MODELS, SO MODELS

4460
02:43:36,339 --> 02:43:38,675
THAT INCLUDE TABULAR

4461
02:43:38,742 --> 02:43:39,309
INFORMATION, TEXT INFORMATION,

4462
02:43:39,376 --> 02:43:41,611
AND WE HOPE TO EXPAND NOW INTO

4463
02:43:41,678 --> 02:43:42,612
OTHER MODALITIES AS WELL.

4464
02:43:42,679 --> 02:43:44,915
SO WHAT WE'RE DEVELOPING HERE IS

4465
02:43:44,981 --> 02:43:46,516
NOT JUST SPECIFIC TO SEER, BUT

4466
02:43:46,583 --> 02:43:48,018
IT'S BECAUSE OF OUR SEER

4467
02:43:48,084 --> 02:43:49,986
PARTNERSHIP THAT WE CAN REALLY

4468
02:43:50,053 --> 02:43:51,955
DEVELOP TOOLS THAT ARE AVAILABLE

4469
02:43:52,022 --> 02:43:56,059
TO THE WIDER ONCOLOGIC

4470
02:43:56,126 --> 02:43:56,326
COMMUNITY.

4471
02:43:56,393 --> 02:43:57,294
>> THANK YOU.

4472
02:43:57,360 --> 02:43:58,395
>> THANK YOU.

4473
02:43:58,461 --> 02:44:01,398
>> CAROL?

4474
02:44:01,464 --> 02:44:03,800
>> YEAH, SO, I THINK IT WAS

4475
02:44:03,867 --> 02:44:05,569
HEIDI HA MENTIONED THE

4476
02:44:05,635 --> 02:44:09,105
TOKENNIZATION OF CLINICAL NOTES

4477
02:44:09,172 --> 02:44:10,373
FOR BARDI.

4478
02:44:10,440 --> 02:44:12,475
I'M WONDERING HOW YOU DEAL WITH

4479
02:44:12,542 --> 02:44:14,644
VARIATION IN LIKE NOMENCLATURE

4480
02:44:14,711 --> 02:44:15,712
SO SOMEBODY CALLING SOMETHING A

4481
02:44:15,779 --> 02:44:18,582
FATTY MASS AND ANOTHER 1 CALLING

4482
02:44:18,648 --> 02:44:20,016
IT A LIPOMA, DO YOU JUST

4483
02:44:20,083 --> 02:44:21,618
TOKENNIZE ALL THE WORDS OR DO

4484
02:44:21,685 --> 02:44:26,489
YOU TRY TO DO MAPPINGS OF

4485
02:44:26,556 --> 02:44:27,357
EQUIVALENT?

4486
02:44:27,424 --> 02:44:30,026
>> DON'T DO RULE BASED MAPPING

4487
02:44:30,093 --> 02:44:30,760
AT ALL.

4488
02:44:30,827 --> 02:44:31,928
BASICALLY WHAT WE'RE DOING IS WE

4489
02:44:31,995 --> 02:44:33,663
HAVE RULES THAT CLEAN THE DATA.

4490
02:44:33,730 --> 02:44:34,831
SO WE FOUND THAT THERE ARE

4491
02:44:34,898 --> 02:44:37,801
CERTAIN THINGS THAT YOU NEED TO

4492
02:44:37,867 --> 02:44:39,703
HAPPEN FOR THE PREPROCESSING,

4493
02:44:39,769 --> 02:44:42,872
YOU NEED TO REMOVE ADDRESSES,

4494
02:44:42,939 --> 02:44:43,974
IDENTIFIABLE INFORMATION, ALL

4495
02:44:44,040 --> 02:44:45,942
THAT HAPPENS, AND THOSE RULES

4496
02:44:46,009 --> 02:44:47,944
CAN BE BASICALLY TAILORED TO THE

4497
02:44:48,011 --> 02:44:48,979
TASK AT HAND.

4498
02:44:49,045 --> 02:44:51,448
SO SOMETIMES FOR BIOMARKERS WE

4499
02:44:51,514 --> 02:44:52,015
USE DIFFERENT PREPROCESSING

4500
02:44:52,082 --> 02:44:53,250
RULES THAN WE DO ARE IF THE

4501
02:44:53,316 --> 02:44:55,752
OTHER TASK, BECAUSE WE WANT TO

4502
02:44:55,819 --> 02:44:57,721
MAKE SURE THAT WE'RE KEEPING

4503
02:44:57,787 --> 02:44:59,055
CERTAIN INFORMATION.

4504
02:44:59,122 --> 02:45:00,624
ONCE WE PREPROCESS THE DATA,

4505
02:45:00,690 --> 02:45:01,691
THEN WE TOKENNIZE THE DAILY

4506
02:45:01,758 --> 02:45:03,560
BASIS AT, WE DON'T DO ANY RULE

4507
02:45:03,627 --> 02:45:05,428
BASED SORTS OF SWITCHES,

4508
02:45:05,495 --> 02:45:06,696
MAPPING, ET CETERA.

4509
02:45:06,763 --> 02:45:08,231
AND THE TOKENNIZATIONS THAT WE

4510
02:45:08,298 --> 02:45:11,635
USE CAN BE DONE EITHER WORD PEEZ

4511
02:45:11,701 --> 02:45:14,070
TOKENNIZATION, WE ALSO HAVE

4512
02:45:14,137 --> 02:45:14,904
SUBWORK TOKENNIZATION AS WELL

4513
02:45:14,971 --> 02:45:17,240
AND WE'RE BUILDING ON OTHER

4514
02:45:17,307 --> 02:45:18,074
TOKENNIZATION MODULES THAT ALLOW

4515
02:45:18,141 --> 02:45:19,376
US TO CONNECT TO WHAT'S

4516
02:45:19,442 --> 02:45:21,611
HAPPENING IN THE BROADER SPACE

4517
02:45:21,678 --> 02:45:25,115
IN THE TRANSFORMER AI WORLD.

4518
02:45:25,181 --> 02:45:34,891
>> THANK YOU.

4519
02:45:34,958 --> 02:45:35,225
>> RODNEY?

4520
02:45:35,292 --> 02:45:36,926
>> YOU'RE MUTED.

4521
02:45:36,993 --> 02:45:40,563
>> ALL RIGHT.

4522
02:45:40,630 --> 02:45:43,566
VERY GLAD TO SEE THE DATABASE

4523
02:45:43,633 --> 02:45:45,268
TRANSCRIBING TO SPLG YOU CAN

4524
02:45:45,335 --> 02:45:49,172
MODEL WITH THE COLLABORATION

4525
02:45:49,239 --> 02:45:51,541
BETWEEN 1 AND THE DIGITAL FOLKS

4526
02:45:51,608 --> 02:45:54,678
WITH THAT, SO 1 OF MY QUESTIONS

4527
02:45:54,744 --> 02:45:58,348
FOR YOU IS THAT, YOU TALK ABOUT

4528
02:45:58,415 --> 02:46:00,617
THIS REALTIME METASTATICS AND

4529
02:46:00,684 --> 02:46:04,854
OCCURRENCE ANALYSIS, RIGHT, SO

4530
02:46:04,921 --> 02:46:10,994
THIS IS WONDERFUL, SO 1 OF MY

4531
02:46:11,061 --> 02:46:12,862
QUESTIONS, IS THAT METASTATICS

4532
02:46:12,929 --> 02:46:15,899
PREDICTIONS IS PRETTY IMD,

4533
02:46:15,965 --> 02:46:16,599
CORRELATIONS OF 1.9.

4534
02:46:16,666 --> 02:46:20,870
HAVE YOU LOOKED AT THE

4535
02:46:20,937 --> 02:46:21,471
RECURRENCE PREDICTIONS?

4536
02:46:21,538 --> 02:46:25,442
IS THAT AS GOOD OR IS IT STILL

4537
02:46:25,508 --> 02:46:27,010
SOMETHING TO WORK ON?

4538
02:46:27,077 --> 02:46:28,244
>> WE'RE STILL WORKING ON IT.

4539
02:46:28,311 --> 02:46:30,113
WE HAVE LOOKED AT IT.

4540
02:46:30,180 --> 02:46:31,281
WE HAVE RECURRENCE PREDICTIONS

4541
02:46:31,348 --> 02:46:32,615
AS WELL.

4542
02:46:32,682 --> 02:46:34,084
WE'RE USING THE MULTIMODAL

4543
02:46:34,150 --> 02:46:35,385
RECURRENCE MODEL SO ESSENTIALLY

4544
02:46:35,452 --> 02:46:36,586
WHAT IT DOES IS TAKE INFORMATION

4545
02:46:36,653 --> 02:46:39,422
FROM TIME OF DIAGNOSIS, ALL OF

4546
02:46:39,489 --> 02:46:40,323
THAT TABULAR INFORMATION,

4547
02:46:40,390 --> 02:46:42,525
COMBINES IT WITH A PATHOLOGY

4548
02:46:42,592 --> 02:46:44,294
REPORTS THAT ARE COMING AT A

4549
02:46:44,361 --> 02:46:47,197
LATER POINT IN TIME AND THEN

4550
02:46:47,263 --> 02:46:47,931
WE'RE PREDICTING REOCCURRENCE,

4551
02:46:47,997 --> 02:46:50,467
RIGHT NOW FOR NAMODEL, WE'RE

4552
02:46:50,533 --> 02:46:52,736
GETTING SLIGHTLY LOWER ACCURACY,

4553
02:46:52,802 --> 02:46:55,972
SO SOMEWHERE IN THE .75 RANGE.

4554
02:46:56,039 --> 02:46:56,806
WE'VE GONE THROUGH MULTILE

4555
02:46:56,873 --> 02:46:58,775
DIFFERENT TESTS IN ORDER TO TRY

4556
02:46:58,842 --> 02:47:00,377
TO IMPROVE THAT, AND THERE ARE

4557
02:47:00,443 --> 02:47:02,812
OTHER SORTS OF THINGS THAT WE'RE

4558
02:47:02,879 --> 02:47:04,080
TESTING CURRENTLY TESTING RIGHT

4559
02:47:04,147 --> 02:47:06,149
NOW TO BRING BACK THE ACCURACY

4560
02:47:06,216 --> 02:47:06,616
UP.

4561
02:47:06,683 --> 02:47:10,487
WE ALSO ARE A BUILT-IN

4562
02:47:10,553 --> 02:47:11,054
ABSTENTION WHICH ESSENTIALLY

4563
02:47:11,121 --> 02:47:12,622
ALLOWS US TO PREDICT ON THE

4564
02:47:12,689 --> 02:47:13,323
THINGS WE'RE VERY CONFIELD

4565
02:47:13,390 --> 02:47:14,624
FUNCTIONS KENT IN BUT ABSTAIN ON

4566
02:47:14,691 --> 02:47:16,593
THOSE THINGS THAT WE ARE NOT

4567
02:47:16,659 --> 02:47:19,596
CONFIDENT IN WHICH IS A NICE

4568
02:47:19,662 --> 02:47:20,363
ADDITION BECAUSE, WE CAN'T

4569
02:47:20,430 --> 02:47:23,967
PREDICT SOME OF THE RECURRENCE,

4570
02:47:24,033 --> 02:47:26,236
OR SOME PATIENTS RECURRENCE WITH

4571
02:47:26,302 --> 02:47:27,303
HIGH ACCURACY AND THEN BASICALLY

4572
02:47:27,370 --> 02:47:28,838
FOR THOSE THAT WERE NOT QUITE

4573
02:47:28,905 --> 02:47:31,141
SURE ABOUT, WE CAN JUST CALL

4574
02:47:31,207 --> 02:47:32,342
ABSTAIN, AND HAVE AN INDIVIDUAL

4575
02:47:32,409 --> 02:47:35,011
LOOK AT THEM TO GET MORE

4576
02:47:35,078 --> 02:47:35,311
INFORMATION.

4577
02:47:35,378 --> 02:47:37,280
>> IF I COULD JUST ADD, THIS IS

4578
02:47:37,347 --> 02:47:39,149
LYNN, IF I COULD ADD 1 COMMENT

4579
02:47:39,215 --> 02:47:40,283
TO THAT, 1 OF THE CHALLENGES

4580
02:47:40,350 --> 02:47:42,886
THAT WE HAD IS THAT, YOU KNOW

4581
02:47:42,952 --> 02:47:44,320
CURRENT METASTATIC DEC IS AN

4582
02:47:44,387 --> 02:47:45,922
EASIER END POINT TO IDENTIFY AND

4583
02:47:45,989 --> 02:47:47,357
WHEN WE DEVELOPED OUR GOLD

4584
02:47:47,424 --> 02:47:48,792
STANDARD DATA SET, THERE WAS

4585
02:47:48,858 --> 02:47:50,160
SOME CONFUSION, EVEN BY THE

4586
02:47:50,226 --> 02:47:52,595
EXPERTS WHO WERE CODING THE

4587
02:47:52,662 --> 02:47:53,897
RECURRENCE FROM THE--FROM AN

4588
02:47:53,963 --> 02:47:55,965
INDIVIDUAL PATH REPORT, SO I

4589
02:47:56,032 --> 02:47:57,367
THINK THAT IS RELATED TO THE

4590
02:47:57,434 --> 02:48:00,670
LOWER SCORE AS WELL.

4591
02:48:00,737 --> 02:48:01,938
>> YEAH, THERE'S QUITE A BIT OF

4592
02:48:02,005 --> 02:48:03,139
LABEL NOISE AND THAT'S 1 OF THE

4593
02:48:03,206 --> 02:48:05,175
THINGS THAT WE'RE TRYING TO

4594
02:48:05,241 --> 02:48:09,078
SOLVE FOR, IS HOW DO WE DEVELOP

4595
02:48:09,145 --> 02:48:10,613
A MODEL WHEN THERE'S QUITE A BIT

4596
02:48:10,680 --> 02:48:13,516
OF LABEL NOISE IN WHAT'S BEENAN

4597
02:48:13,583 --> 02:48:13,750
OITATED.

4598
02:48:13,817 --> 02:48:15,952
>> SO WE'VE RUN OVER BUT WE HAVE

4599
02:48:16,019 --> 02:48:18,521
TIME FOR LINDA, 1 LAST QUESTION.

4600
02:48:18,588 --> 02:48:20,123
OR COMMENT SMRKS SO THIS

4601
02:48:20,190 --> 02:48:22,525
QUESTION IS BASED ON, SO THE

4602
02:48:22,592 --> 02:48:24,294
SEER COMMUNITIES AND THE DATA

4603
02:48:24,360 --> 02:48:24,561
COLLECTED.

4604
02:48:24,627 --> 02:48:26,596
SO YOU MENTIONED THAT THE CANCER

4605
02:48:26,663 --> 02:48:28,665
REG TREE CAN ONLY RETAIN THE

4606
02:48:28,731 --> 02:48:29,933
INFORMATION THAT OUR CANCER

4607
02:48:29,999 --> 02:48:32,936
CASES, BUT I'M CURIOUS WHETHER

4608
02:48:33,002 --> 02:48:35,138
THERE'S MECHANISM FOR HANDOFF IF

4609
02:48:35,205 --> 02:48:38,575
FOR INSTANCE, IT CAME INTO THIS

4610
02:48:38,641 --> 02:48:39,108
PIPELINE, THROUGH CANCER

4611
02:48:39,175 --> 02:48:42,612
SUSPICION BUT IT LOOKS VERY MUCH

4612
02:48:42,679 --> 02:48:43,513
LIKE INFLAMMATORY OR AUTOIMMUNE

4613
02:48:43,580 --> 02:48:44,881
DISEASE, IS THERE A MECHANISM TO

4614
02:48:44,948 --> 02:48:47,083
HAND IT TO 1 OF THE OTHER SEER

4615
02:48:47,150 --> 02:48:49,686
COMMUNITIES FOR THEIR REGISTRY,

4616
02:48:49,752 --> 02:49:00,096
AND/OR WHAT HAPPENS WITH

4617
02:49:00,163 --> 02:49:00,864
POTENTIAL PREMALIGNANCY DATA?

4618
02:49:00,930 --> 02:49:02,265
>> SO CERTAINLY THE REG TREES

4619
02:49:02,332 --> 02:49:04,701
CAN OLD ANY INFORMATION ABOUT A

4620
02:49:04,767 --> 02:49:06,469
CANCER PATIENT INCLUDING

4621
02:49:06,536 --> 02:49:07,170
FOLLOW-UP PATHOLOGY REPORTS, I

4622
02:49:07,237 --> 02:49:08,438
DON'T KNOW THERE IS SOMETHING,

4623
02:49:08,505 --> 02:49:10,006
IF THERE WAS A REPORT THAT WAS

4624
02:49:10,073 --> 02:49:12,542
NOT RELATED TO A CANCER PATIENT

4625
02:49:12,609 --> 02:49:13,009
AT ALL.

4626
02:49:13,076 --> 02:49:15,378
SO, YOU KNOW PATHOLOGY, YOU KNOW

4627
02:49:15,445 --> 02:49:16,779
LABORATORY FACILITIES ARE GOING

4628
02:49:16,846 --> 02:49:18,081
TO PROCESS PATHOLOGY REPORTS FOR

4629
02:49:18,147 --> 02:49:19,282
NOT JUST CANCER PATIENTS BUT

4630
02:49:19,349 --> 02:49:22,852
LOTS OF OTHER DISEASES, WHILE

4631
02:49:22,919 --> 02:49:24,153
THE REGISTRY--WHILE THE

4632
02:49:24,220 --> 02:49:24,988
FACILITIES MAINTAIN THOSE

4633
02:49:25,054 --> 02:49:26,623
REPORTS, I DON'T KNOW IF THERE'S

4634
02:49:26,689 --> 02:49:28,124
ANY MECHANISM TO HAND IT OFF TO

4635
02:49:28,191 --> 02:49:30,593
ANOTHER LIKE FOR EXAMPLE, CDC,

4636
02:49:30,660 --> 02:49:31,661
INFECT YOWZ DEC REGISTRY OR

4637
02:49:31,728 --> 02:49:33,396
WHATEVER, ARE YOU AWARE OF

4638
02:49:33,463 --> 02:49:34,464
ANYTHING LIKE THAT?

4639
02:49:34,531 --> 02:49:35,498
THERE'S CERTAINLY MECHANISMS IN

4640
02:49:35,565 --> 02:49:37,367
PLACE FOR CANCER REGISTRIES TO

4641
02:49:37,433 --> 02:49:38,601
EXCHANGE INFORMATION WITH EACH

4642
02:49:38,668 --> 02:49:39,769
OTHER WHETHER IT'S A SEER

4643
02:49:39,836 --> 02:49:41,771
REGISTRY OR A C, DID C REG TREE,

4644
02:49:41,838 --> 02:49:44,541
THEY CAN EXCHAIRVELG INFORMATION

4645
02:49:44,607 --> 02:49:44,974
ON CANCER PATIENTS.

4646
02:49:45,041 --> 02:49:48,578
BUT I'M NOT SURE ABOUT TO OTHER

4647
02:49:48,645 --> 02:49:50,046
NONCANCKER REG TREES.

4648
02:49:50,113 --> 02:49:51,314
>> THAT'S AN INTERESTING IDEA

4649
02:49:51,381 --> 02:49:52,048
BECAUSE WHAT'S HAPPENING RIGHT

4650
02:49:52,115 --> 02:49:54,317
NOW IS MANY OF OUR REGISTRIES

4651
02:49:54,384 --> 02:49:55,552
ARE ACTUALLY CHANGING THE RULES,

4652
02:49:55,618 --> 02:50:00,423
SO THAT THEY CAN RECEIVE

4653
02:50:00,490 --> 02:50:01,724
INFORMATION ON NONCANCKER PAST

4654
02:50:01,791 --> 02:50:01,958
REPORTS.

4655
02:50:02,025 --> 02:50:03,359
SO THEY CAN'T MAINTAIN IT

4656
02:50:03,426 --> 02:50:04,861
OVERTIME BUT THEY CAN USE THAT

4657
02:50:04,928 --> 02:50:07,230
AS PART OF THEIR SCREENING

4658
02:50:07,297 --> 02:50:07,463
PROCESS.

4659
02:50:07,530 --> 02:50:09,265
AND YOU KNOW THAT'S A REALLY

4660
02:50:09,332 --> 02:50:10,767
INTRIGUING IDEA TO SEE IF THEY

4661
02:50:10,833 --> 02:50:11,968
FOUND SOME OTHER DIAGNOSIS THAT

4662
02:50:12,035 --> 02:50:14,704
THEY CAN SHARE THAT WITH OTHER

4663
02:50:14,771 --> 02:50:16,239
REG TREES, I HADN'T REALLY

4664
02:50:16,306 --> 02:50:17,540
THOUGHT ABOUT THAT BUT IT'S A

4665
02:50:17,607 --> 02:50:19,409
COOL IDEA AND AN EFFICIENT WAY

4666
02:50:19,475 --> 02:50:21,477
TO MOVE THINGS FORWARD.

4667
02:50:21,544 --> 02:50:21,711
THANKS.

4668
02:50:21,778 --> 02:50:22,679
>> AND THEN I THINK THE OTHER

4669
02:50:22,745 --> 02:50:25,982
PART OF YOUR QUESTION WAS AROUND

4670
02:50:26,049 --> 02:50:27,283
PRECANCKER INFORMATION, IF

4671
02:50:27,350 --> 02:50:29,786
THERE'S ANYTHING HELD THERE AND

4672
02:50:29,852 --> 02:50:30,853
CERTAINLY OBVIOUSLY A REG TREE

4673
02:50:30,920 --> 02:50:31,421
WILL NONAPOPTOTIC THE

4674
02:50:31,487 --> 02:50:32,722
INFORMATION UNTIL A PERSON IS

4675
02:50:32,789 --> 02:50:34,624
DIAGNOSED WITH CANCER BUT WITH

4676
02:50:34,691 --> 02:50:35,291
THINGS LIKE RESIDENTIAL HISTORY

4677
02:50:35,358 --> 02:50:37,293
ONCE THEY'RE A PATIENT IN THE

4678
02:50:37,360 --> 02:50:38,861
REG TREE, RESIDENTIAL HISTORY

4679
02:50:38,928 --> 02:50:41,464
YOU COULD LISTEN IT TO PREVIOUS

4680
02:50:41,531 --> 02:50:43,399
EXPOSURES LIKE EXPOSE ORDER OF

4681
02:50:43,466 --> 02:50:44,367
MICRONSIC PROJECT THAT HEIDI

4682
02:50:44,434 --> 02:50:45,935
MENTIONED SO YOU COULD LOOK AT

4683
02:50:46,002 --> 02:50:47,303
POTENTIAL RISK TBACTORS THAT

4684
02:50:47,370 --> 02:50:50,139
THEY HAD BEEN EXPOSED TO EVEN

4685
02:50:50,206 --> 02:50:52,275
BEFORE CANCER DIAGNOSIS WITH THE

4686
02:50:52,342 --> 02:50:56,646
CONFIRMATION NSOME REGISTRIES TO

4687
02:50:56,713 --> 02:50:58,014
CAPTURE INFORMATION ON

4688
02:50:58,081 --> 02:50:59,616
PREMALIGNANT LESIONS SO LIKE

4689
02:50:59,682 --> 02:51:03,953
CINs 1, 2, 3, I THINK SOME OF

4690
02:51:04,020 --> 02:51:04,520
THE PROSTRATE PREMALIGNANT

4691
02:51:04,587 --> 02:51:05,588
LESION ANDS THEN OTHER THINGS

4692
02:51:05,655 --> 02:51:06,723
THAT SPECIFIC REG STROKINGS

4693
02:51:06,789 --> 02:51:08,625
COLLECT, BUT IT'S NOT--IT'S NOT

4694
02:51:08,691 --> 02:51:15,164
CONSISTENT ACROSS ALL THE

4695
02:51:15,231 --> 02:51:15,465
REGISTRIES.

4696
02:51:15,531 --> 02:51:15,765
>> OKAY.

4697
02:51:15,832 --> 02:51:16,199
THANK YOU VERY MUCH.

4698
02:51:16,265 --> 02:51:18,301
THIS HAS BEEN AN INCREDIBLE DAY

4699
02:51:18,368 --> 02:51:20,136
WITH SO MANY OUTSTANDING

4700
02:51:20,203 --> 02:51:21,871
PRESENTATIONS SO I THINK SO

4701
02:51:21,938 --> 02:51:23,306
MANY, SO MUCH INFORMATION HAS

4702
02:51:23,373 --> 02:51:25,742
BEEN PUT FORTH, SO, WE THANK ALL

4703
02:51:25,808 --> 02:51:27,477
THE PRESENTERS, IS THERE ANY

4704
02:51:27,543 --> 02:51:28,645
OTHER BUSINESS TO COME BEFORE

4705
02:51:28,711 --> 02:51:30,980
THE MEETING BEFORE I CALL FOR A

4706
02:51:31,047 --> 02:51:35,018
MOTION TO ADJOURN?

4707
02:51:35,084 --> 02:51:38,821
OKAY, MAY I HAVE A MOTION TO

4708
02:51:38,888 --> 02:51:39,956
ADJOURN?

4709
02:51:40,023 --> 02:51:45,695
NSO MOVED N--

4710
02:51:45,762 --> 02:51:47,030
>> RODNEY AND SECOND WAS MARY.

4711
02:51:47,096
OKAY, THANK YOU VERY MUCH.